Gefitinib or Chemotherapy for Nonâ€“Small-Cell Lung C

New England Journal of Medicine
362, 2380-2388
DOI: 10.1056/nejmoa0909530

Citation Report

#	Article	IF	Citations
1	Molecular Markers Help Characterize Neuroendocrine Lung Tumors. Annals of Thoracic Surgery, 1996, 62, 798-810.	0.7	118
2	Atrophy of the putamen in dementia with Lewy bodies but not Alzheimerâ€™s disease. Neurology, 2003, 61, 1191-1195.	1.5	108
3	Mesenchymal Stem Cells Derived from Bone Marrow of Diabetic Patients Portrait Unique Markers Influenced by the Diabetic Microenvironment. Review of Diabetic Studies, 2009, 6, 260-270.	0.5	48
4	Evolving Therapies and FAK Inhibitors for the Treatment of Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 722-734.	0.9	40
5	Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology, 2010, 5, 1706-1713.	0.5	273
6	ILD during Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1877-1878.	0.5	5
7	The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. Genes and Cancer, 2010, 1, 1200-1210.	0.6	88
8	Recent Development of Molecular-Targeted Drugs in Lung Cancer. Internal Medicine, 2010, 49, 1923-1934.	0.3	6
9	1. Basic and Clinical Practice of Molecular Target Therapy for Lung Cancers.. The Journal of the Japanese Society of Internal Medicine, 2010, 99, 2035-2051.	0.0	0
10	ILD during Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1878.	0.5	0
11	Lung Adenocarcinoma: Lessons in Translation from Bench to Bedside. Mount Sinai Journal of Medicine, 2010, 77, 597-605.	1.9	36
12	Personalized Medicine in Nonâ€“Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptorâ€“Targeted Therapy?. Journal of Clinical Oncology, 2010, 28, 4769-4777.	0.8	243
13	Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Human Genetics, 2010, 128, 567-575.	1.8	12
14	Soins spÃ©cifiques, soins de support â€” mÃªme combat !. Oncologie, 2010, 12, 555-557.	0.2	0
15	Personalized medicine in lung adenocarcinoma: no longer a hope or a passing fashion, but a new reality. Targeted Oncology, 2010, 5, 229-230.	1.7	0
16	Response to â€˜Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysisâ€™â€˜(Pazâ€Ares et al., J Cell Mol Med. 2010; 14: 51â€“69). Journal of Cellular and Molecular Medicine, 2010, 14, 2693-2694.	1.6	0
17	Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy. BMC Medical Genetics, 2010, 11, 167.	2.1	31
18	Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. British Journal of Cancer, 2010, 103, 796-801.	2.9	26

#	Article	IF	Citations
19	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer, 2010, 10, 760-774.	12.8	943
20	EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 2010, 1, 497-514.	0.8	159
21	Interstitial Lung Disease and Gefitinib. New England Journal of Medicine, 2010, 363, 1578-1580.	13.9	15
22	Development of Central Nervous System Metastases in Patients with Advanced Nonâ€“Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib. Clinical Cancer Research, 2010, 16, 5873-5882.	3.2	209
23	The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. European Respiratory Review, 2010, 19, 186-196.	3.0	35
24	Update on nonsmall cell lung cancer. European Respiratory Review, 2010, 19, 173-185.	3.0	20
25	HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2010, 14, 1047-1057.	1.5	63
26	Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Nonâ€“Small Cell Lung Adenocarcinoma. Clinical Cancer Research, 2010, 16, 4616-4624.	3.2	71
27	The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 4909-4911.	3.2	69
28	TGF-Î² IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15535-15540.	3.3	356
29	Strategies for Prolonged Therapy in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 5116-5123.	0.8	64
30	Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma. Oncologist, 2010, 15, 1320-1328.	1.9	109
31	Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib. Oncology, 2010, 79, 423-429.	0.9	43
32	New Results Will Change the Paradigm for Phase I Trials and Drug Approval. Oncologist, 2010, 15, 1023-1025.	1.9	5
33	Lung cancer therapeutics that target signaling pathways: an update. Expert Review of Respiratory Medicine, 2010, 4, 631-645.	1.0	29
34	Novel Agents in the Management of Lung Cancer. Current Medicinal Chemistry, 2010, 17, 4291-4325.	1.2	21
37	Les nouveautÃ©s en matiÃ¨re de traitements biologiques des CBNPC. Revue Des Maladies Respiratoires Actualites, 2010, 2, 275-281.	0.0	1
39	Tyrosine-kinase inhibitorsâ€”new standard for NSCLC therapy. Nature Reviews Clinical Oncology, 2010, 7, 618-619.	12.5	13

#	Article	IF	Citations
40	Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resistance Updates, 2010, 13, 196-204.	6.5	15
41	Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 4953-4960.	0.8	331
42	â€œPersonalizingâ€•Therapy for Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2010, 22, 118-120.	0.4	1
43	First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2010, 29, 126.	3.5	12
44	EGFR Mutations, Gene Amplification, and Protein Expression and KRAS Mutations in Primary and Metastatic Tumors of Nonsmall Cell Lung Cancers and Their Clinical Implications: A Meta-Analysis. Cancer Investigation, 2011, 29, 626-634.	0.6	16
45	Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics, 2011, 11, 171-182.	1.5	124
46	American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Nonâ€“Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology, 2011, 29, 2121-2127.	0.8	476
47	A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 1553-1560.	3.2	117
48	Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Nonâ€“Small-Cell Lung Cancer in Asia (IPASS). Journal of Clinical Oncology, 2011, 29, 2866-2874.	0.8	1,368
49	Front-line therapy in lung cancer with mutations in EGFR. Nature Reviews Clinical Oncology, 2011, 8, 571-573.	12.5	15
50	¹⁸F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. Journal of Nuclear Medicine, 2011, 52, 1684-1689.	2.8	94
51	9122 POSTER Efficacy of Gefitinib in Patients With Epidermal Growth Factor Receptor Mutation Positive Advanced Non-Small-Cell Lung Cancer -a Metaanalysis of Randomized Controlled Trials. European Journal of Cancer, 2011, 47, S630.	1.3	0
53	Diagnostic Workup of Lung Cancer. Surgical Oncology Clinics of North America, 2011, 20, 667-679.	0.6	9
55	Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for BRCA1/2-Associated Cancers. Cancer Discovery, 2011, 1, 29-34.	7.7	43
56	Evaluation and Treatment of Patients with Nonâ€“Small Cell Lung Cancer. Medical Clinics of North America, 2011, 95, 1041-1054.	1.1	24
57	9121 POSTER A Multi-center, Open, Randomized, Phase II Study to Investigate the Sequential Administration of Docetaxel and Intermittent Erlotinib Versus Erlotinib as a Second-line Therapy for Advanced Non-small Cell Lung Cancer (NSCLC). European Journal of Cancer, 2011, 47, S630.	1.3	0
58	ActualitÃ©s en oncologie thoracique. Revue Des Maladies Respiratoires Actualites, 2011, 3, 515-518.	0.0	0
61	A Decade of Advances in Treatment for Advanced Nonâ€“Small Cell Lung Cancer. Clinics in Chest Medicine, 2011, 32, 839-851.	0.8	58

#	Article	IF	Citations
63	Treatment of Nonâ€“Small-Cell Lung Cancer with Erlotinib or Gefitinib. New England Journal of Medicine, 2011, 364, 947-955.	13.9	375
64	Pemetrexed in advanced non-small cell lung cancer. Expert Opinion on Drug Safety, 2011, 10, 311-317.	1.0	14
65	Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology, 2011, 8, 492-503.	12.5	132
66	Pathology of Lung Cancer. Clinics in Chest Medicine, 2011, 32, 669-692.	0.8	436
67	One size does not fit all. Nature Reviews Clinical Oncology, 2011, 8, 68-70.	12.5	48
68	Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer. Expert Opinion on Biological Therapy, 2011, 11, 1131-1133.	1.4	3
69	Recomendaciones para la determinaciÃ³n de las mutaciones del gen EGFR en el carcinoma de pulmÃ³n no microcÃ‡tico. Revista Espanola De Patologia, 2011, 44, 17-31.	0.6	2
70	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer, 2011, 71, 249-257.	0.9	113
71	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues. Lung Cancer, 2011, 72, 3-8.	0.9	43
72	Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer, 2011, 74, 98-102.	0.9	28
73	The search for improved systemic therapy of non-small cell lung cancerâ€”What are today's options?. Lung Cancer, 2011, 72, 265-270.	0.9	19
74	Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer, 2011, 74, 293-299.	0.9	24
75	Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer, 2011, 73, 1-10.	0.9	28
76	Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer, 2011, 74, 457-461.	0.9	80
77	Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials. Lung Cancer, 2011, 74, 469-473.	0.9	70
78	EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer, 2011, 73, 249-255.	0.9	15
79	Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung. Lung Cancer, 2011, 73, 379-380.	0.9	21
80	Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer, 2011, 74, 355-363.	0.9	22

#	Article	IF	Citations
81	What is the true prevalence of EGFR mutations in India?. Lung Cancer, 2011, 74, 549.	0.9	0
83	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond. Drug Design, Development and Therapy, 2011, 5, 471.	2.0	165
84	Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology, 2011, 8, 661-668.	12.5	145
85	Surface engineering on mesoporous silica chips for enriching low molecular weight phosphorylated proteins. Nanoscale, 2011, 3, 421-428.	2.8	32
86	Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations. Drugs, 2011, 71, 79-88.	4.9	6
87	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. Drugs, 2011, 71, 2231-2246.	4.9	23
88	Case 21-2011. New England Journal of Medicine, 2011, 365, 158-167.	13.9	10
89	Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1410-1426.	0.6	408
90	The potential for crizotinib in non-small cell lung cancer: a perspective review. Therapeutic Advances in Medical Oncology, 2011, 3, 279-291.	1.4	72
94	Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Nonâ€“Small Cell Lung Cancers. Cancer Discovery, 2011, 1, 608-625.	7.7	122
95	Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1591-603.	1.4	49
96	Optimization of Dosing for EGFR-Mutant Nonâ€“Small Cell Lung Cancer with Evolutionary Cancer Modeling. Science Translational Medicine, 2011, 3, 90ra59.	5.8	457
97	A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes. Nanotechnology, 2011, 22, 265105.	1.3	19
100	9123 POSTER Final Results of a Phase II Study of Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Non-small Cell Lung Cancer â€“ Gefitinib for Elderly Patients With Lung Adenocarcinoma. European Journal of Cancer, 2011, 47, S630.	1.3	0
101	The Changing Pathology of Lung Cancer. Surgical Oncology Clinics of North America, 2011, 20, 637-653.	0.6	10
102	Importance of Molecular Features of Nonâ€“Small Cell Lung Cancer for Choice of Treatment. American Journal of Pathology, 2011, 178, 1940-1948.	1.9	42
103	Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treatment Reviews, 2011, 37, 456-64.	3.4	69
104	Skin manifestations of gefitinib and the association with survival of advanced non-small-cell lung cancer in Taiwan. Dermatologica Sinica, 2011, 29, 13-18.	0.2	4

#	Article	IF	Citations
105	Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. European Journal of Cancer, 2011, 47, 2603-2606.	1.3	104
106	The inverted pyramid of biomarker-driven trials. Nature Reviews Clinical Oncology, 2011, 8, 562-566.	12.5	17
107	Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. European Respiratory Journal, 2011, 38, 903-910.	3.1	28
109	Mutation and copy number detection in human cancers using a custom genotyping assay. Genomics, 2011, 98, 296-301.	1.3	1
110	The Challenges of Oral Agents as Antineoplastic Treatments. Seminars in Oncology Nursing, 2011, 27, 93-103.	0.7	79
111	2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment â€" First-line therapy. European Journal of Cancer, 2011, 47, S248-S257.	1.3	5
112	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2011, 12, 735-742.	5.1	3,758
113	Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?. Lancet Oncology, The, 2011, 12, 710-711.	5.1	34
114	Neoadjuvant chemotherapy in lung cancer. Therapy: Open Access in Clinical Medicine, 2011, 8, 23-31.	0.2	3
115	The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 673-682.	1.1	44
116	Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer, 2011, 73, 361-365.	0.9	76
117	Epidermal growth factor receptor mutationâ€guided treatment for lung cancers: Where are we now?. Thoracic Cancer, 2011, 2, 1-6.	0.8	5
118	Use of a comprehensive panel of biomarkers to predict response to a fluorouracilâ€"oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics, 2011, 12, 433-442.	0.6	40
119	Therapeutic advances in non-small cell lung cancer: Highlights from the annual clinical cancer conferences. Community Oncology, 2011, 8, 5-16.	0.2	0
120	Early Prediction of Nonprogression in Advanced Nonâ€"Small-Cell Lung Cancer Treated With Erlotinib By Using [¹⁸F]Fluorodeoxyglucose and [¹⁸F]Fluorothymidine Positron Emission Tomography. Journal of Clinical Oncology, 2011, 29, 1701-1708.	0.8	170
121	First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer â€" A Review. Journal of Experimental and Clinical Medicine, 2011, 3, 116-120.	0.2	7
122	Sex and Gender Differences in Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2011, 23, 137-145.	0.4	57
123	Personalized Therapy for Non-Small Cell Lung Cancer: Which Drug for Which Patient?. Seminars in Thoracic and Cardiovascular Surgery, 2011, 23, 281-290.	0.4	11

#	Article	IF	Citations
124	Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. Frontiers in Bioscience - Landmark, 2011, 16, 1714.	3.0	8
125	Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib. BMJ Case Reports, 2011, 2011, bcr0820114586-bcr0820114586.	0.2	5
126	Significance, Mechanisms, and Progress of Anticancer Drugs Targeting HGF-Met. , 2011, , .		0
127	Systemic Therapy for Lung Cancer for the Radiation Oncologist. Medical Radiology, 2011, , 247-266.	0.0	0
128	Pathology of Lung Cancer. Medical Radiology, 2011, , 53-62.	0.0	0
129	Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2011, 71, 15.	0.7	4
130	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. Pharmacogenomics and Personalized Medicine, 2011, Volume 4, 1-9.	0.4	4
131	Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy. Journal of Lung Cancer, 2011, 10, 1.	0.2	2
132	The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases. Pulmonary Medicine, 2011, 2011, 1-5.	0.5	25
133	Protease addiction and synthetic lethality in cancer. Frontiers in Oncology, 2011, 1, 25.	1.3	17
134	Non-Small Cell Lung Cancer: The Challenges of the Next Decade. Frontiers in Oncology, 2011, 1, 29.	1.3	5
135	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. PLoS ONE, 2011, 6, e22769.	1.1	174
136	Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction. PLoS ONE, 2011, 6, e23303.	1.1	50
137	Targeting the Hedgehog and Notch Signaling Pathways. Journal of Thoracic Oncology, 2011, 6, S1820-S1821.	0.5	0
138	Maintenance Therapy in Advanced Non-small Cell Lung Cancer: Current Status and Future Implications. Journal of Thoracic Oncology, 2011, 6, 174-182.	0.5	35
139	Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 1889-1894.	0.5	7
140	Safe and Successful Treatment With Erlotinib After Gefitinib-Induced Hepatotoxicity: Difference in Metabolism As a Possible Mechanism. Journal of Clinical Oncology, 2011, 29, e588-e590.	0.8	47
141	First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?. Current Opinion in Oncology, 2011, 23, 131-132.	1.1	1

#	Article	IF	Citations
142	Increasing the Odds of: â€œIs This Treatment Going to Work?â€• Proceedings of Singapore Healthcare, 2011, 20, 1-2.	0.2	0
143	HER-1, 2, and 3. Journal of Thoracic Oncology, 2011, 6, S1793-S1796.	0.5	0
144	Novel Therapeutic Targets in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1601-1612.	0.5	127
145	New discoveries in lung cancer biology: paving the road of personalized medicine. Therapy: Open Access in Clinical Medicine, 2011, 8, 1-4.	0.2	0
146	Whatâ€™s new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 2011, 43, 103-115.	0.3	54
147	Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America. Journal of Thoracic Oncology, 2011, 6, 1955-1959.	0.5	113
148	Gefitinib or Chemotherapy for Nonâ€“Small-Cell Lung Cancer with Mutated EGFR. Yearbook of Pulmonary Disease, 2011, 2011, 93-95.	0.4	2
149	Multigene Mutation Analysis of Metastatic Lymph Nodes in Non-small Cell Lung Cancer Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. Chest, 2011, 140, 1319-1324.	0.4	115
150	Breathe contributes to the ERS Action Plan for Thoracic Oncology. Breathe, 2011, 7, 219-220.	0.6	0
151	A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA. Journal of Thoracic Oncology, 2011, 6, 1639-1648.	0.5	71
152	Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib. Journal of Thoracic Oncology, 2011, 6, 1152-1161.	0.5	233
153	Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations. Journal of Thoracic Oncology, 2011, 6, 569-575.	0.5	124
154	Anticancer treatment for advanced non-small cell lung cancer. Breathe, 2011, 8, 124-133.	0.6	2
155	Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach. Journal of Thoracic Oncology, 2011, 6, 1663-1669.	0.5	37
156	Diagnostic Factors of Standard Bronchoscopy for Small (.LEQ.15 mm) Peripheral Pulmonary Lesions: A Multivariate Analysis. Internal Medicine, 2011, 50, 557-561.	0.3	9
157	Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome. Journal of Thoracic Oncology, 2011, 6, 1763-1773.	0.5	70
158	Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial. Journal of Thoracic Oncology, 2011, 6, 2112-2119.	0.5	27
159	Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1474-1480.	0.5	148

#	Article	IF	Citations
160	A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1379-1391.	0.5	89
161	A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age â‰¥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1569-1577.	0.5	34
165	18F-Fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts. Oncology Reports, 2011, 26, 725-30.	1.2	10
167	Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors. Oncology Letters, 2011, 2, 1059-1064.	0.8	1
168	Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology, 2011, 6, 1413-1417.	0.5	53
169	The Diverse Diversity. Journal of Thoracic Oncology, 2011, 6, 842-843.	0.5	1
170	Annual Review of Advances in Non-small Cell Lung Cancer Research: A Report for the Year 2010. Journal of Thoracic Oncology, 2011, 6, 1443-1450.	0.5	10
171	Complete Pathologic Response in Lung Tumors in Two Patients with Metastatic Non-small Cell Lung Cancer Treated with Erlotinib. Journal of Thoracic Oncology, 2011, 6, 1946-1949.	0.5	12
172	NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-32.	2.3	227
173	Novel Targeted Agents and Radiopharmaceuticals in Lung Cancer. Medical Radiology, 2011, , 773-790.	0.0	0
174	Efficacy of gefitinib for nonâ€adenocarcinoma nonâ€smallâ€cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports. Cancer Science, 2011, 102, 1032-1037.	1.7	128
175	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nature Medicine, 2011, 17, 304-312.	15.2	94
176	Towards systematic functional characterization of cancer genomes. Nature Reviews Genetics, 2011, 12, 487-498.	7.7	77
177	Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1. Oncogene, 2011, 30, 3821-3832.	2.6	26
178	Bevacizumab in the treatment of nonâ€small cell lung cancer: focus on East Asia. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 1-3.	0.7	0
179	Classification of Lung Cancer. Seminars in Roentgenology, 2011, 46, 178-186.	0.2	42
180	Personalized Treatment of Lung Cancer. Seminars in Oncology, 2011, 38, 274-283.	0.8	35
181	Molecular Profiling of Cancerâ€"The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. Seminars in Oncology, 2011, 38, 173-185.	0.8	61

#	Article	IF	Citations
182	A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients. Journal of Experimental and Clinical Cancer Research, 2011, 30, 111.	3.5	74
183	Lung cancer: New biological insights and recent therapeutic advances. Ca-A Cancer Journal for Clinicians, 2011, 61, 91-112.	157.7	413
184	Clinical Evidence on the Undertreatment of Older and Poor Performance Patients Who Have Advanced Non-Small-Cell Lung Cancer: Is There a Role for Targeted Therapy in These Cohorts?. Clinical Lung Cancer, 2011, 12, 272-279.	1.1	22
185	Biomarkers, Prediction, and Prognosis in Nonâ€"Small-Cell Lung Cancer: A Platform for Personalized Treatment. Clinical Lung Cancer, 2011, 12, 360-368.	1.1	28
186	Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study. Clinical Lung Cancer, 2011, 12, 387-392.	1.1	50
187	EGFR Mutation Status in Primary Lung Adenocarcinomas and Corresponding Metastatic Lesions: Discordance in Pleural Metastases. Clinical Lung Cancer, 2011, 12, 380-386.	1.1	111
188	Costs and Ethical Issues Related to First-Line Treatment of Metastatic Nonâ€"Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective. Clinical Lung Cancer, 2011, 12, 335-340.	1.1	2
189	Monoclonal antibodies against EGFR in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2011, 80, 1-9.	2.0	42
190	Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). Critical Reviews in Oncology/Hematology, 2011, 81, 49-57.	2.0	24
191	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Review of Respiratory Medicine, 2011, 5, 413-424.	1.0	24
192	Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design. Clinical Cancer Research, 2011, 17, 6298-6303.	3.2	383
193	Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature Reviews Clinical Oncology, 2011, 8, 587-596.	12.5	259
194	Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine, 2011, 3, 75ra26.	5.8	2,938
195	Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer. Clinical Oncology and Cancer Research, 2011, 8, 235-241.	0.1	0
196	Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs. Pharmacogenomics, 2011, 12, 827-843.	0.6	13
197	MED19 promotes proliferation and tumorigenesis of lung cancer. Molecular and Cellular Biochemistry, 2011, 355, 27-33.	1.4	24
198	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human nonâ€"small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1397-1408.	1.2	17
199	Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1849-1857.	1.2	18

#	Article	IF	Citations
202	The PCR-invader method (structure-specific 5â€² nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. International Journal of Clinical Oncology, 2011, 16, 335-344.	1.0	47
203	Lung cancers unrelated to smoking: characterized by single oncogene addiction?. International Journal of Clinical Oncology, 2011, 16, 294-305.	1.0	23
205	Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemotherapy and Pharmacology, 2011, 68, 1-15.	1.1	47
206	Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemotherapy and Pharmacology, 2011, 68, 1099-1109.	1.1	86
207	Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases. Medical Oncology, 2011, 28, 570-576.	1.2	5
208	Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clinical and Translational Oncology, 2011, 13, 460-471.	1.2	28
209	SEOM clinical guidelines for using molecular markers in clinical practice. Clinical and Translational Oncology, 2011, 13, 587-591.	1.2	0
210	Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Clinical and Translational Oncology, 2011, 13, 812-818.	1.2	7
211	Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib. Advances in Therapy, 2011, 28, 126-133.	1.3	11
213	Targetable â€œDriverâ€•Mutations in Non Small Cell Lung Cancer. Indian Journal of Surgical Oncology, 2011, 2, 178-188.	0.3	22
214	Pulmonary toxicities from targeted therapies: a review. Targeted Oncology, 2011, 6, 235-243.	1.7	94
215	How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?. Current Treatment Options in Oncology, 2011, 12, 1-11.	1.3	12
216	The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer. Current Oncology Reports, 2011, 13, 280-289.	1.8	7
217	Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer, 2011, 11, 1.	1.1	260
218	Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. Journal of Hematology and Oncology, 2011, 4, 5.	6.9	30
219	Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. Respiratory Research, 2011, 12, 97.	1.4	29
220	Genetically informed lung cancer medicine. Journal of Pathology, 2011, 223, 231-241.	2.1	59
221	Personalized medicine in rheumatoid arthritis: Miles to go before we sleep. Arthritis and Rheumatism, 2011, 63, 590-593.	6.7	14

#	Article	IF	Citations
222	Update in Lung Cancer and Oncological Disorders 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 297-302.	2.5	6
223	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer. Current Drug Targets, 2011, 12, 922-933.	1.0	25
224	Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy, 2011, 3, 213-227.	1.0	53
225	Treatment of Advanced Lung Cancer in the Elderly. Hospital Practice (1995), 2011, 39, 107-115.	0.5	11
226	Case 31-2011. New England Journal of Medicine, 2011, 365, 1426-1435.	13.9	6
227	Pathological Diagnosis and Classification of Lung Cancer in Small Biopsies and Cytology: Strategic Management of Tissue for Molecular Testing. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 022-031.	0.8	140
229	Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations. Current Medicinal Chemistry, 2011, 18, 1613-1628.	1.2	32
232	Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Nonâ€“Small-Cell Lung Cancer Patients with EGFR Mutations. Clinical Cancer Research, 2011, 17, 1160-1168.	3.2	292
233	Gefitinib for non-small-cell lung cancer treatment. Expert Opinion on Drug Safety, 2011, 10, 987-996.	1.0	13
234	Knockdown of Oncogenic KRAS in Nonâ€“Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy. Molecular Cancer Therapeutics, 2011, 10, 336-346.	1.9	151
235	Targeted Therapies for Lung Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 512-527.	1.0	91
236	EGFR Mutant Lung Cancer. Current Topics in Microbiology and Immunology, 2011, 355, 59-81.	0.7	8
237	Extraction of RNA Using Fine-Needle Aspiration Samples Stored Under Different Conditions. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 218-222.	0.8	5
238	Simultaneous Isolation of Total RNA, DNA, and Protein Using Samples Obtained by EBUS-TBNA. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 301-305.	0.8	23
239	Cotargeting Cyclin D1 Starts a New Chapter in Lung Cancer Prevention and Therapy. Cancer Prevention Research, 2011, 4, 779-782.	0.7	15
240	Customizing systemic therapy in patients with advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2011, 3, 207-218.	1.4	11
241	Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. Journal of Thoracic Oncology, 2011, 6, 2011-2017.	0.5	196
242	Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Therapeutic Advances in Medical Oncology, 2011, 3, 113-125.	1.4	96

#	Article	IF	Citations
243	Targeting the Phosphatidylinositol 3-Kinase, Akt, and Mammalian Target of Rapamycin Pathway in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, S1805-S1807.	0.5	3
244	Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas. Journal of Clinical Oncology, 2011, 29, 2066-2070.	0.8	247
245	Plasma Isoflavones and the Risk of Lung Cancer in Women: A Nested Caseâ€“Control Study in Japan. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 419-427.	1.1	49
246	E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor. Molecular Cancer Therapeutics, 2011, 10, 1218-1228.	1.9	14
247	Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation. Clinical Cancer Research, 2011, 17, 1616-1622.	3.2	556
248	Outcomes After Combined Modality Therapy forEGFR-Mutant and Wild-Type Locally Advanced NSCLC. Oncologist, 2011, 16, 886-895.	1.9	59
249	CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib. Journal of Clinical Oncology, 2011, 29, e443-e445.	0.8	546
250	EGFR Protein Expression in Nonâ€“Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitorâ€”A Novel Antibody for Immunohistochemistry or AQUA Technology. Clinical Cancer Research, 2011, 17, 7796-7807.	3.2	37
251	ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice. Journal of Oncology Practice, 2011, 7, 202-204.	2.5	24
252	Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Annals of Oncology, 2011, 22, 2277-2285.	0.6	86
253	Gefitinib in Non Small Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-14.	3.0	19
254	Role of 18 Fâ€Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Nonâ€Small Cell Lung Cancer. Oncologist, 2011, 16, 319-326.	1.9	77
255	Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S6252.	0.6	28
256	Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma WithEGFR-Activating Mutations. Journal of Clinical Oncology, 2011, 29, 3435-3442.	0.8	33
257	Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib. Clinical Cancer Research, 2011, 17, 2521-2527.	3.2	116
258	Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. Annals of Oncology, 2011, 22, 376-382.	0.6	13
259	Is FISH floating or still swimming in the lung cancer ocean?. Annals of Oncology, 2011, 22, 493-499.	0.6	6
260	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. Annals of Oncology, 2011, 22, 1507-1519.	0.6	117

#	Article	IF	Citations
261	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib. Clinical Cancer Research, 2011, 17, 6322-6328.	3.2	57
262	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	0.5	4,127
263	Phase II Study of Gefitinib as a First-line Therapy in Elderly Patients with Pulmonary Adenocarcinoma: West Japan Thoracic Oncology Group Study 0402. Japanese Journal of Clinical Oncology, 2011, 41, 948-952.	0.6	15
264	Histopathologic Characteristics of Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification. Archives of Pathology and Laboratory Medicine, 2011, 135, 1329-1334.	1.2	90
265	Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biology and Therapy, 2011, 11, 50-57.	1.5	44
266	The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clinical Investigation, 2011, 1, 1119-1126.	0.0	19
267	Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer. Therapy: Open Access in Clinical Medicine, 2011, 8, 15-22.	0.2	6
268	Non-Small Cell Lung Cancer in Never-Smokers: A New Disease Entity?. Onkologie, 2011, 34, 202-207.	1.1	3
269	Three Cheers for Targeted Therapy in Non-Small Cell Lung Cancerâ€¦ When We Hit the Target!. Journal of Chemotherapy, 2011, 23, 245-246.	0.7	3
270	The Potential Benefits of BIM in the Further Pursuit of Biomarker Discovery in Cancer Therapeutics: Figure 1.. Cancer Discovery, 2011, 1, 289-290.	7.7	5
271	Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma. Journal of Clinical Oncology, 2011, 29, 2972-2977.	0.8	218
272	Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. Journal of Clinical Pathology, 2011, 64, 947-952.	1.0	68
273	Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy. Clinical Cancer Research, 2011, 17, 5179-5187.	3.2	67
274	Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs. Journal of Clinical Oncology, 2011, 29, 2543-2549.	0.8	64
275	PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. British Journal of Cancer, 2011, 105, 1920-1926.	2.9	18
276	Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. British Journal of Cancer, 2011, 105, 1131-1136.	2.9	10
277	Liposomal Delivery of MicroRNA-7â€“Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 1720-1727.	1.9	128
278	Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. British Journal of Cancer, 2011, 105, 1-8.	2.9	52

#	Article	IF	Citations
279	Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. British Journal of Cancer, 2011, 105, 760-765.	2.9	72
280	The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients. Expert Opinion on Investigational Drugs, 2011, 20, 305-307.	1.9	7
281	Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. European Respiratory Journal, 2011, 38, 239-243.	3.1	54
282	Rare subtypes of adenocarcinoma of the lung. Expert Review of Anticancer Therapy, 2011, 11, 1535-1542.	1.1	16
283	A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 3567-3573.	0.8	77
284	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology, 2011, 22, 2616-2624.	0.6	326
286	Aberrant Signaling Pathways in Squamous Cell Lung Carcinoma. Cancer Informatics, 2011, 10, CIN.S8283.	0.9	41
287	Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2011, 3, 163-170.	1.4	13
288	Genetic Testing for Lung Cancer: Reflex Versus Clinical Selection. Journal of Clinical Oncology, 2011, 29, 1943-1945.	0.8	14
289	Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-7.	3.0	108
290	Effectiveness of Tyrosine Kinase Inhibitors on â€œUncommonâ€•Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 3812-3821.	3.2	413
291	Large-Cell Neuroendocrine Carcinoma of the Lung HarboringEGFRMutation and Responding to Gefitinib. Journal of Clinical Oncology, 2011, 29, e819-e822.	0.8	70
292	Erlotinib for Pretreated Squamous Cell Carcinoma of the Lung in Japanese Patients. Japanese Journal of Clinical Oncology, 2011, 41, 1366-1372.	0.6	14
293	Target Therapies in Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-5.	3.0	9
294	The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer. Cancers, 2011, 3, 2667-2678.	1.7	7
295	The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer. Oncologist, 2011, 16, 1498-1507.	1.9	44
296	Class III Î²-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial. Clinical Cancer Research, 2011, 17, 5205-5214.	3.2	41
297	Proposal for a Novel Methodology to Screen And Score Cost Versus Survival for Anticancer Drugs in Metastatic Disease: Could Cost Weigh in Evaluation?. Journal of Oncology Practice, 2012, 8, 224-230.	2.5	6

#	Article	IF	Citations
299	Personalized medicine of esophageal cancer. Journal of Cancer Research and Therapeutics, 2012, 8, 343.	0.3	6
300	Treatment Paradigms for Patients with Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line. Current Oncology, 2012, 19, 52-58.	0.9	114
301	Molecular Imaging in Therapeutic Efficacy Assessment of Targeted Therapy for Nonsmall Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-10.	3.0	2
302	A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Current Oncology, 2012, 19, 78-90.	0.9	9
303	The Role of Molecular Pathology in Non-Small-Cell Lung Carcinomaâ€"Now and in the Future. Current Oncology, 2012, 19, 24-32.	0.9	25
304	Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmacogenomics and Personalized Medicine, 2012, 5, 113.	0.4	18
305	Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S7340.	0.6	32
306	KRAS Wild-Type Lung Cancer: A Moving Target in an Era of Genotype Migration. Journal of Clinical Oncology, 2012, 30, 3322-3324.	0.8	9
307	Development of a Novel, Fully-Automated Genotyping System: Principle and Applications. Sensors, 2012, 12, 16614-16627.	2.1	26
308	First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients. Indian Journal of Medical and Paediatric Oncology, 2012, 33, 146.	0.1	9
309	Non-Small-Cell Lung Carcinoma Subtyping on Cytology without the Use of Immunohistochemistry â€“ Can We Meet the Challenge?. Acta Cytologica, 2012, 56, 413-418.	0.7	6
310	EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia. Case Reports in Pulmonology, 2012, 2012, 1-2.	0.2	3
311	Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Annals of Oncology, 2012, 23, 1010-1016.	0.6	20
312	Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 394-400.	0.8	491
313	MicroRNA-214 Regulates the Acquired Resistance to Gefitinib via the PTEN/AKT Pathway in EGFR-mutant Cell Lines. Asian Pacific Journal of Cancer Prevention, 2012, 13, 255-260.	0.5	110
314	Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity. Journal of Thoracic Oncology, 2012, 7, 355-364.	0.5	73
315	Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung. Clinical Cancer Research, 2012, 18, 220-228.	3.2	88
316	Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. European Respiratory Journal, 2012, 39, 366-372.	3.1	106

#	Article	IF	Citations
317	Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Annals of Oncology, 2012, 23, 2931-2936.	0.6	35
318	IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Imaging, 2012, 27, 340-353.	0.8	69
319	Human Correlates of Provocative Questions in Pancreatic Pathology. Advances in Anatomic Pathology, 2012, 19, 351-362.	2.4	29
320	Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung. Journal of Oncology Practice, 2012, 8, 267-274.	2.5	75
321	Patterns of Care for Nonâ€“Small-Cell Lung Cancer at an Academic Institution Affiliated With a National Cancer Instituteâ€“Designated Cancer Center. Journal of Oncology Practice, 2012, 8, 57-62.	2.5	4
322	Novel Approaches of Chemoradiotherapy in Unresectable Stage IIIA and Stage IIIB Non-Small Cell Lung Cancer. Oncologist, 2012, 17, 682-693.	1.9	35
323	ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung Adenocarcinoma. Journal of Clinical Oncology, 2012, 30, 878-879.	0.8	42
324	Differential diagnosis of lung carcinoma with three-dimensional quantitative molecular vibrational imaging. Journal of Biomedical Optics, 2012, 17, 066017.	1.4	10
325	MiR-23a regulates TGF-Î²-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. International Journal of Oncology, 2012, 41, 869-875.	1.4	154
326	Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers. Clinical Cancer Research, 2012, 18, 6169-6177.	3.2	503
327	Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology. Journal of Clinical Oncology, 2012, 30, 2025-2027.	0.8	4
328	Validation of a Radiosensitivity Molecular Signature in Breast Cancer. Clinical Cancer Research, 2012, 18, 5134-5143.	3.2	174
329	The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Nonâ€“Small Cell Lung Cancer with EGFR Mutations. Clinical Cancer Research, 2012, 18, 4406-4414.	3.2	166
330	Prognostic and predictive factors for lung cancer. Breathe, 2012, 9, 112-121.	0.6	37
331	Clinical Outcomes in Nonâ€“Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR. Clinical Cancer Research, 2012, 18, 3470-3477.	3.2	62
332	Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment. Archives of Pathology and Laboratory Medicine, 2012, 136, 1478-1481.	1.2	58
333	The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation. Current Medicinal Chemistry, 2012, 19, 3337-3352.	1.2	35
334	Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells. Clinical Cancer Research, 2012, 18, 3592-3602.	3.2	104

#	Article	IF	Citations
335	Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S55-S60.	1.5	5
336	A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. Personalized Medicine, 2012, 9, 547-557.	0.8	71
337	Targeted therapy for squamous cell lung cancer. Lung Cancer Management, 2012, 1, 293-300.	1.5	41
338	Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2012, 12, 237-246.	0.8	12
339	Management of advanced lung cancer in resource-constrained settings: a perspective from India. Expert Review of Anticancer Therapy, 2012, 12, 1479-1495.	1.1	37
340	Targeted Therapy at the End of Life in Advanced Cancer Patients. Journal of Palliative Medicine, 2012, 15, 991-997.	0.6	20
341	Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. Current Medical Research and Opinion, 2012, 28, 1699-1708.	0.9	10
342	Leveraging informatics, mobile health technologies and biobanks to treat each patient right. Personalized Medicine, 2012, 9, 849-857.	0.8	4
343	An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Annals of Oncology, 2012, 23, 2914-2919.	0.6	94
344	Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. Blood Cancer Journal, 2012, 2, e67-e67.	2.8	11
345	Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules. British Journal of Cancer, 2012, 106, 867-875.	2.9	16
346	Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601). British Journal of Cancer, 2012, 107, 1474-1480.	2.9	7
347	Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factorâ€“Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer. Clinical Cancer Research, 2012, 18, 1663-1671.	3.2	81
348	Development of Targeted Agents and Companion Diagnostics. Drug Information Journal, 2012, 46, 405-419.	0.5	1
349	Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Therapeutic Advances in Medical Oncology, 2012, 4, 19-29.	1.4	87
350	Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases. Journal of Medical Economics, 2012, 15, 195-204.	1.0	11
351	Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity. Cancer Biology and Therapy, 2012, 13, 369-378.	1.5	22
352	Quality of Life with Gefitinib in Patients with EGFR â€Mutated Nonâ€Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. Oncologist, 2012, 17, 863-870.	1.9	98

#	Article	IF	Citations
353	EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC. Journal of Oncology Pharmacy Practice, 2012, 18, 245-249.	0.5	6
354	Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. Chemotherapy, 2012, 58, 84-88.	0.8	22
355	Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. European Respiratory Journal, 2012, 39, 9-28.	3.1	38
356	Therapeutic advances in non-small cell lung cancer. Thorax, 2012, 67, 1097-1101.	2.7	22
357	Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Nonâ€“Small Cell Lung Cancer Published between 2000 and 2009. Clinical Cancer Research, 2012, 18, 6356-6363.	3.2	21
358	Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma?. Frontiers in Oncology, 2012, 2, 49.	1.3	22
359	The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S5127.	0.6	4
360	Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies. Expert Review of Anticancer Therapy, 2012, 12, 1299-1312.	1.1	4
361	Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. OncoTargets and Therapy, 2012, 5, 439.	1.0	35
362	Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases. Lung Cancer International, 2012, 2012, 1-6.	1.2	6
363	The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors. Chemotherapy, 2012, 58, 60-69.	0.8	14
364	Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC. Japanese Journal of Clinical Oncology, 2012, 42, 528-533.	0.6	28
365	Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review. Oncologist, 2012, 17, 555-568.	1.9	44
366	Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 856-865.	0.5	39
367	EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy. Journal of Thoracic Oncology, 2012, 7, 672-680.	0.5	28
368	EGFR Gene Mutation Study in Cytology Specimens. Acta Cytologica, 2012, 56, 661-668.	0.7	17
369	CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib. Case Reports in Oncology, 2012, 5, 546-553.	0.3	9
370	Gastroesphageal Variceal Hemorrhage Induced by Metastatic Liver Tumor of Lung Cancer. Case Reports in Oncology, 2012, 5, 644-650.	0.3	5

#	Article	IF	Citations
371	Treatment of elderly patients with stage IV non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2012, 12, 111-120.	1.1	6
372	Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1807-1814.	0.5	585
373	Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 272-280.	0.5	37
375	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations. Journal of Thoracic Oncology, 2012, 7, 1722-1727.	0.5	103
376	Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 118-131.	0.8	29
377	Encouragement to Submit Data of Clinical Response to EGFR-TKIs in Patients With Uncommon EGFR Mutations. Journal of Thoracic Oncology, 2012, 7, 775-776.	0.5	21
378	New driver mutations in non-small-cell lung cancer. Yearbook of Pulmonary Disease, 2012, 2012, 108-110.	0.4	619
379	Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis. Journal of Thoracic Oncology, 2012, 7, 1078-1085.	0.5	34
380	Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation. Journal of Thoracic Oncology, 2012, 7, 1640-1644.	0.5	107
381	Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1522-1527.	0.5	26
383	EGFR Gene Mutations: Is it Prognostic or Predictive in Surgically Resected Lung Cancer?. Journal of Thoracic Oncology, 2012, 7, 1739-1741.	0.5	4
384	Demographic profile of lung cancer patients at the Universitas Academic Hospital Bronchoscopy Unit in Bloemfontein. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2012, 27, 130-132.	0.2	0
385	Targeted therapy in non-small cell lung cancer. Breathe, 2012, 8, 206-215.	0.6	6
386	Targeted therapy for lung cancer. Anti-Cancer Drugs, 2012, 23, 1016-1021.	0.7	27
387	Addition of vandetanib to chemotherapy in advanced solid cancers. Anti-Cancer Drugs, 2012, 23, 731-738.	0.7	8
388	Crizotinib for the treatment of non-small-cell lung cancer withALKgene rearrangements. Clinical Investigation, 2012, 2, 895-907.	0.0	1
389	Translational informatics in personalized medicine. Personalized Medicine, 2012, 9, 39-45.	0.8	2
390	Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains. Journal of Thoracic Oncology, 2012, 7, 85-89.	0.5	82

#	Article	IF	Citations
391	Update on HER1â€“3 in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, S369-S371.	0.5	4
393	Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1236-1271.	2.3	312
395	Successful Treatment of Non-small Cell Lung Cancer with Gefitinib after Severe Erlotinib-related Hepatotoxicity. Internal Medicine, 2012, 51, 431-434.	0.3	24
396	MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 459-467.	0.5	86
397	Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC. Oncology Letters, 2012, 3, 1064-1068.	0.8	4
398	Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2012, 7, 40-48.	0.5	40
399	Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncology Letters, 2012, 3, 1288-1292.	0.8	18
400	Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer. Oncology Letters, 2012, 4, 89-93.	0.8	33
401	Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib. Journal of Thoracic Oncology, 2012, 7, 1815-1822.	0.5	160
402	HIV-associated lung cancer. Aids, 2012, 26, 1031-1033.	1.0	3
403	First- and second-line treatment of non-small-cell lung cancer patients withEGFRmutation-positive tumors. Lung Cancer Management, 2012, 1, 201-217.	1.5	0
404	Clinical Significance of Thyroid Transcription Factor-1 in Advanced Lung Adenocarcinoma Under Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment. Chest, 2012, 141, 420-428.	0.4	42
405	Molecular-Based Decision Making for Personalized Cancer Management. , 2012, , .		0
406	Presence of EGFR mutation in pathologically non-malignant specimens from computed tomography-guided lung needle biopsies. Oncology Letters, 2012, 3, 401-404.	0.8	2
407	EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib. Journal of Thoracic Oncology, 2012, 7, 434-442.	0.5	17
408	Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans. Yearbook of Pulmonary Disease, 2012, 2012, 110-111.	0.4	0
409	Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment. Journal of Thoracic Oncology, 2012, 7, 122-127.	0.5	31
410	Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation. Journal of Thoracic Oncology, 2012, 7, 49-56.	0.5	38

#	Article	IF	Citations
411	Bevacizumab Maintenance in Patients with Advanced Nonâ€“Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis. Journal of Thoracic Oncology, 2012, 7, 1707-1712.	0.5	54
412	Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors. Oncology Letters, 2012, 4, 865-867.	0.8	13
413	A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1602-1608.	0.5	143
414	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1830-1844.	0.5	23
415	Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA. Journal of Thoracic Oncology, 2012, 7, 1369-1381.	0.5	68
416	Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology, 2012, 7, 993-1000.	0.5	32
417	Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Nonâ€“Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Projectâ€”Part 2). Journal of Thoracic Oncology, 2012, 7, 1490-1502.	0.5	69
418	XL647â€”A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib. Journal of Thoracic Oncology, 2012, 7, 219-226.	0.5	51
419	Targeted therapies in small cell lung cancer (Review). Oncology Letters, 2012, 5, 3-11.	0.8	25
420	First-Line Gefitinib in Patients Aged 75 or Older With Advanced Nonâ€“Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study. Journal of Thoracic Oncology, 2012, 7, 1417-1422.	0.5	140
421	The Long-term Survival of a Patient with Adenosquamous Lung Carcinoma Harboring EGFR-activating Mutations Who was Treated with Gefitinib. Internal Medicine, 2012, 51, 2771-2774.	0.3	14
422	Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma. Medical Oncology, 2012, 29, 3169-3175.	1.2	4
423	Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology. Oncologist, 2012, 17, 1351-1375.	1.9	206
424	Crizotinib for ALK-Rearranged Nonâ€“Small Cell Lung Cancer: A New Targeted Therapy for a New Target. Clinical Cancer Research, 2012, 18, 3737-3742.	3.2	82
425	Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer, 2012, 78, 201-206.	0.9	32
426	Nonâ€small cell lung cancer: One size doesn't fit all. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 211-212.	0.7	0
427	Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer, 2012, 78, 207-211.	0.9	35
428	The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer, 2012, 76, 131-137.	0.9	26

#	Article	IF	Citations
429	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cancer Chemotherapy and Pharmacology, 2012, 70, 315-320.	1.1	17
430	The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets, 2012, 16, S7-S16.	1.5	17
431	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. Tumor Biology, 2012, 33, 2061-2068.	0.8	30
432	Hypoxia induces gefitinib resistance in nonâ€smallâ€cell lung cancer with both mutant and wildâ€type epidermal growth factor receptors. Cancer Science, 2012, 103, 1946-1954.	1.7	61
433	Largeâ€scale comparative analyses of immunomarkers for diagnostic subtyping of nonâ€smallâ€cell lung cancer biopsies. Histopathology, 2012, 61, 1017-1025.	1.6	102
434	Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future. Archives of Pathology and Laboratory Medicine, 2012, 136, 1482-1491.	1.2	40
436	Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. British Journal of Cancer, 2012, 107, 1745-1753.	2.9	23
437	The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Research, 2012, 22, 2109-2119.	2.4	524
438	Clinical and economic review of erlotinib in non-small-cell lung cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 411-423.	0.7	9
439	Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Nonâ€“Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models. Clinical Cancer Research, 2012, 18, 6658-6667.	3.2	149
440	EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. Future Oncology, 2012, 8, 1015-1029.	1.1	21
441	Role of molecular studies in the diagnosis of lung adenocarcinoma. Modern Pathology, 2012, 25, S11-S17.	2.9	22
442	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncology, The, 2012, 13, e23-e31.	5.1	505
443	Genetic heterogeneity and cancer drug resistance. Lancet Oncology, The, 2012, 13, e178-e185.	5.1	386
444	Mind over menopausal symptoms in women with breast cancer. Lancet Oncology, The, 2012, 13, 227-229.	5.1	1
445	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 239-246.	5.1	4,943
446	Beyond first-line NSCLC therapy: chemotherapy or erlotinib?. Lancet Oncology, The, 2012, 13, 225-227.	5.1	11
447	Optimising therapy for EGFR-addicted NSCLC: just the start. Lancet Oncology, The, 2012, 13, 216-217.	5.1	2

#	Article	IF	Citations
448	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncology, The, 2012, 13, 539-548.	5.1	390
449	Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 466-475.	5.1	236
450	Cancer-Associated Fibroblasts Induce Matrix Metalloproteinaseâ€“Mediated Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cells. Molecular Cancer Research, 2012, 10, 1158-1168.	1.5	99
451	Direct Comparison of 3 PCR Methods in Detecting EGFR Mutations in Patients with Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 369-374.	1.1	10
452	Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection. International Journal of Clinical Oncology, 2012, 17, 462-469.	1.0	8
453	Directed Therapies in Lung Cancer: New Hope?. Archivos De Bronconeumologia, 2012, 48, 367-371.	0.4	5
454	Terapias dirigidas en el cÃ¡ncer de pulmÃ³n: Â¿una nueva esperanza?. Archivos De Bronconeumologia, 2012, 48, 367-371.	0.4	6
455	MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-Î² Receptor Signaling. Cell, 2012, 151, 937-950.	13.5	371
456	SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. Journal of Proteomics, 2012, 76, 91-101.	1.2	67
457	Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA Journal, 2012, 3, 1.	3.3	18
458	Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a caseâ€“control study. Tumor Biology, 2012, 33, 1341-1348.	0.8	17
459	Terapie molecolari mirate e antiangiogeniche nel trattamento dei glioblastomi. EMC - Neurologia, 2012, 12, 1-14.	0.0	0
461	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2012, 58, 263-268.	0.3	6
463	Prise en charge thÃ©rapeutique des cancers bronchiques non Ã petites cellules mÃ©tastatiques mutÃ©s pour l'EGFR. Revue Des Maladies Respiratoires Actualites, 2012, 4, 583-598.	0.0	2
464	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira (English Edition), 2012, 58, 263-268.	0.1	0
465	Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. American Journal of Pathology, 2012, 181, 1034-1043.	1.9	55
466	Vandetanib for the treatment of lung cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1211-1221.	1.9	6
467	The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. British Journal of Cancer, 2012, 106, 1100-1106.	2.9	95

#	Article	IF	Citations
468	Targeted therapy of non-small-cell lung carcinoma. Therapeutic Advances in Respiratory Disease, 2012, 6, 41-56.	1.0	4
469	Disparities in subgroup populations enrolled in lung cancer trials. Expert Review of Respiratory Medicine, 2012, 6, 163-172.	1.0	0
470	Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas. Annals of Surgical Oncology, 2012, 19, 347-354.	0.7	49
471	Expression of IGF1R Is Associated with Tumor Differentiation and Survival in Patients with Lung Adenocarcinoma. Annals of Surgical Oncology, 2012, 19, 412-420.	0.7	15
472	Clinical trials and biomarker research on lung cancer in China. Expert Opinion on Therapeutic Targets, 2012, 16, S45-S50.	1.5	20
473	Translating genomic information into clinical medicine: Lung cancer as a paradigm. Genome Research, 2012, 22, 2101-2108.	2.4	74
474	Detecting the effect of targeted anti-cancer medicines on single cancer cells using a poly-silicon wire ion sensor integrated with a confined sensitive window. Biomedical Microdevices, 2012, 14, 839-848.	1.4	4
475	Acquisition and Processing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Specimens in the Era of Targeted Lung Cancer Chemotherapy. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 606-611.	2.5	69
476	Prodigiosin downâ€regulates SKP2 to induce p27^{KIP1} stabilization and antiproliferation in human lung adenocarcinoma cells. British Journal of Pharmacology, 2012, 166, 2095-2108.	2.7	39
477	A ROSy future for metabolic regulation of HSC division. Nature Medicine, 2012, 18, 1334-1336.	15.2	3
478	HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation. Cancer Discovery, 2012, 2, 922-933.	7.7	613
479	Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Review of Molecular Diagnostics, 2012, 12, 593-602.	1.5	87
480	Hotspot oncomutations: implications for personalized cancer treatment. Expert Review of Molecular Diagnostics, 2012, 12, 603-620.	1.5	13
481	Sec62 Bridges the Gap from 3q Amplification to Molecular Cell Biology in Nonâ€“Small Cell Lung Cancer. American Journal of Pathology, 2012, 180, 473-483.	1.9	66
482	Elevated Expression of Fn14 in Non-Small Cell Lung Cancer Correlates with Activated EGFR and Promotes Tumor Cell Migration and Invasion. American Journal of Pathology, 2012, 181, 111-120.	1.9	52
483	Dynamics of targeted cancer therapy. Trends in Molecular Medicine, 2012, 18, 311-316.	3.5	78
484	EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis. Cancer Letters, 2012, 314, 63-72.	3.2	33
485	Problems involved in the clinical trials for non-small cell lung carcinoma. Cancer Treatment Reviews, 2012, 38, 194-202.	3.4	6

#	Article	IF	Citations
486	EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treatment Reviews, 2012, 38, 416-430.	3.4	114
487	Systemic Issues in Small Cell Lung Cancer. Current Problems in Cancer, 2012, 36, 131-155.	1.0	4
488	Establishing an EGFR mutation screening service for non-small cell lung cancer â€“ Sample quality criteria and candidate histological predictors. European Journal of Cancer, 2012, 48, 61-67.	1.3	34
489	Influence of Chemotherapy on EGFR Mutation Status Among Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3077-3083.	0.8	188
490	Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. Journal of Clinical Oncology, 2012, 30, 3330-3336.	0.8	39
491	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer: The TORCH Randomized Trial. Journal of Clinical Oncology, 2012, 30, 3002-3011.	0.8	229
492	The tumor microenvironment controls drug sensitivity. Nature Medicine, 2012, 18, 1332-1334.	15.2	112
493	Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG) Tj ETQq1 1 0.784314 rgBT /Overloc	3.4	40
494	Customized chemotherapy based on epidermal growth factor receptormutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial. BMC Cancer, 2012, 12, 185.	1.1	16
495	Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors. BMC Cancer, 2012, 12, 241.	1.1	73
496	Expression of Bim, Noxa, and Puma in non-small cell lung cancer. BMC Cancer, 2012, 12, 286.	1.1	12
497	A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene. BMC Cancer, 2012, 12, 558.	1.1	39
498	Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. BMC Cancer, 2012, 12, 568.	1.1	33
499	Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands. Health and Quality of Life Outcomes, 2012, 10, 108.	1.0	10
500	Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. Journal of Translational Medicine, 2012, 10, 180.	1.8	41
501	Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer. Diagnostic Pathology, 2012, 7, 146.	0.9	16
502	Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? – A literature-based meta-analysis. Journal of Hematology and Oncology, 2012, 5, 62.	6.9	25
503	Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. EPMA Journal, 2012, 3, 6.	3.3	2

#	Article	IF	Citations
504	Oncology Endpoints. , 2012, , 213-236.		0
505	Role of randomized phase III trials in an era of effective targeted therapies. Nature Reviews Clinical Oncology, 2012, 9, 208-214.	12.5	46
506	Treatment of Lung Cancer. Radiologic Clinics of North America, 2012, 50, 961-974.	0.9	90
507	Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 15-31.	1.5	688
508	Cancer treatment according to BRCA1 and BRCA2 mutations. Nature Reviews Clinical Oncology, 2012, 9, 520-528.	12.5	69
509	First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naÃ¯ve patients. Expert Opinion on Pharmacotherapy, 2012, 13, 1389-1396.	0.9	9
510	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics: Targets and Therapy, 2012, 6, 337.	3.0	46
511	Discordance of epidermal growth factor receptor mutations between primary tumors and corresponding mediastinal nodal metastases in patients operated on for stage N2 nonâ€small cell lung cancer. Thoracic Cancer, 2012, 3, 313-319.	0.8	6
512	Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene, 2012, 31, 4768-4777.	2.6	140
513	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature, 2012, 483, 613-617.	13.7	430
515	Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene, 2012, 31, 4811-4814.	2.6	29
517	Personalized Medicine for Nonâ€“Small-Cell Lung Cancer: Implications of Recent Advances in Tissue Acquisition for Molecular and Histologic Testing. Clinical Lung Cancer, 2012, 13, 334-339.	1.1	47
518	Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Who Previously Responded to Gefitinib. Clinical Lung Cancer, 2012, 13, 458-463.	1.1	25
519	A Phase Ib, Dose-Finding Study of Erlotinib in Combination With a Fixed Dose of Pertuzumab in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 432-441.	1.1	19
520	EGFR inhibition and other targeted therapies in NSCLC. Community Oncology, 2012, 9, S30-S34.	0.2	0
521	Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Critical Reviews in Oncology/Hematology, 2012, 83, 407-421.	2.0	151
522	Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: Current status and future challenges. Cancer Treatment Reviews, 2012, 38, 861-867.	3.4	19
523	Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials. Cancer Treatment Reviews, 2012, 38, 807-814.	3.4	25

#	Article	IF	Citations
524	Ethnic variation in response to EGFR inhibitors. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e61-e66.	0.5	1
526	Recomendaciones para la determinaciÃ³n de biomarcadores en el carcinoma de pulmÃ³n no microcÃtico avanzado. Consenso nacional de la Sociedad EspaÃ±ola de AnatomÃa PatolÃ³gica y de la Sociedad EspaÃ±ola de OncologÃa MÃ©dica. Revista Espanola De Patologia, 2012, 45, 14-28.	0.6	9
527	Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment. Respiratory Investigation, 2012, 50, 117-121.	0.9	11
528	Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer, 2012, 75, 89-94.	0.9	57
529	Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. Lung Cancer, 2012, 75, 313-320.	0.9	73
530	Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care. Lung Cancer, 2012, 75, 269-274.	0.9	11
531	Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 2012, 76, 177-182.	0.9	119
532	Conversion from the â€œoncogene addictionâ€•to â€œdrug addictionâ€•by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer, 2012, 76, 292-299.	0.9	56
533	Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer, 2012, 76, 387-392.	0.9	152
534	Characteristics of lung cancer in women: Importance of hormonal and growth factors. Lung Cancer, 2012, 76, 280-285.	0.9	48
535	Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer, 2012, 76, 362-367.	0.9	186
536	A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905. Lung Cancer, 2012, 77, 110-115.	0.9	1
537	Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study. Lung Cancer, 2012, 77, 121-127.	0.9	73
538	Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer, 2012, 77, 299-305.	0.9	49
539	Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature. Lung Cancer, 2012, 77, 464-468.	0.9	28
540	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer, 2012, 77, 556-560.	0.9	308
541	Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials. Lung Cancer, 2012, 78, 8-15.	0.9	120
542	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Molecular Oncology, 2012, 6, 15-26.	2.1	66

#	Article	IF	Citations
543	Biomarkers That Currently Affect Clinical Practice: EGFR, ALK, MET, KRAS. Current Oncology, 2012, 19, 33-44.	0.9	46
544	Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer. Drugs, 2012, 72, 28-36.	4.9	61
545	Growth factor signaling in metastasis: current understanding and future opportunities. Cancer and Metastasis Reviews, 2012, 31, 479-491.	2.7	27
546	Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutationâ€"diversity, ductility, and destiny. Cancer and Metastasis Reviews, 2012, 31, 807-814.	2.7	132
547	Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Review of Anticancer Therapy, 2012, 12, 1537-1543.	1.1	6
548	Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC. Current Treatment Options in Oncology, 2012, 13, 516-526.	1.3	12
549	Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma. Cell Biochemistry and Biophysics, 2012, 64, 155-160.	0.9	52
550	Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy. Medical Oncology, 2012, 29, 1629-1637.	1.2	3
551	Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. Medical Oncology, 2012, 29, 1599-1605.	1.2	3
553	Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2012, 12, 151-162.	1.1	20
556	Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation. Drugs, 2012, 72, 3-10.	4.9	6
557	Molecular Signatures of Lung Cancer. Molecular Diagnosis and Therapy, 2012, 16, 1-6.	1.6	3
558	The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer. Oncology, 2012, 82, 341-346.	0.9	11
559	First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung. Journal of Clinical Oncology, 2012, 30, 1122-1128.	0.8	694
560	Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 433-440.	0.8	471
561	Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. Oncology Letters, 2012, 3, 713-717.	0.8	13
562	Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 173-181.	1.4	15
563	Molecular Pathology of Lung Cancer. Molecular Pathology Library, 2012, , .	0.1	6

#	Article	IF	Citations
564	Identifying the status of genetic lesions in cancer clinical trial documents using machine learning. BMC Genomics, 2012, 13, S21.	1.2	11
565	Tyrosine Kinase Inhibitors in Lung Cancer. Hematology/Oncology Clinics of North America, 2012, 26, 589-605.	0.9	32
566	DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2012, 31, 80.	3.5	39
567	Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer. Journal of Experimental and Clinical Cancer Research, 2012, 31, 77.	3.5	23
568	A Novel Classification of Lung Cancer into Molecular Subtypes. PLoS ONE, 2012, 7, e31906.	1.1	99
569	Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e40178.	1.1	10
570	Have Mutation, Will Travel: Utilizing Online Patient Communities and New Trial Strategies to Optimize Clinical Research in the Era of Molecularly Diverse Oncology. Journal of Thoracic Oncology, 2012, 7, 482-484.	0.5	10
571	Non-small cell lung cancer: the era of targeted therapy. Lung Cancer: Targets and Therapy, 2012, 3, 31.	1.3	8
572	Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer. Journal of Personalized Medicine, 2012, 2, 35-49.	1.1	6
573	Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System. Journal of Personalized Medicine, 2012, 2, 77-92.	1.1	2
574	New EGFR-TKI: A case report of recurrent lung adenocarcinoma successfully treated with icotinib. Tumori, 2012, 98, e102-e104.	0.6	3
575	Braf and erbB2 mutations correlate with smoking status in lung cancer patients. Experimental and Therapeutic Medicine, 2012, 3, 771-775.	0.8	20
576	Gefitinib, but Not Erlotinib, is a Possible Inducer of Fra-1-mediated Interstitial Lung Disease. Keio Journal of Medicine, 2012, 61, 120-127.	0.5	5
577	The Clinical Significance of the Serum Cross-Linked N-Telopeptide of Type I Collagen as a Prognostic Marker for Non-Small-Cell Lung Cancer. Annals of Oncology, 2012, 23, xi158.	0.6	0
578	Analysis of EGFR mutation frequency and coexistence of KRAS and EGFR mutations using RT-PCR in lung adenocarcinoma: may a clinical and pathological model of a patientâ€™s qualification for targeted therapy have an impact on time to obtain genetic results?. Kardiochirurgia I Torakochirurgia Polska, 2012, 4, 443-451.	0.1	4
579	The place of TKI in the treatment of EGFR mutation-positive lung cancer. Journal of Solid Tumors, 2012, 2, .	0.1	0
581	Final Analysis of Overall Survival (OS) in the IPASS, an International Multicenter Phase III Study on Gefitinib and Carboplatin/Paclitaxel for Treatment-na^|^iuml;ve NSCLC Patients. Japanese Journal of Lung Cancer, 2012, 52, 153-160.	0.0	2
582	Genetic Testing for Respiratory Disease: Are We There Yet?. Canadian Respiratory Journal, 2012, 19, 246-248.	0.8	1

#	Article	IF	Citations
583	K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. , 2012, 2012, 1-8.		23
584	Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. Journal of Cancer, 2012, 3, 7-13.	1.2	29
585	MET targeted therapy for lung cancer: clinical development and future directions. Lung Cancer: Targets and Therapy, 2012, 3, 53.	1.3	4
586	Crizotinib in the treatment of non-small-cell lung cancer [Polish version: Kryzotynib w leczeniu chorych na niedrobno komÃ³rkowego raka pÅ‚uca p. 485]. Wspolczesna Onkologia, 2012, 6, 480-490.	0.7	5
587	Cetuximab and biomarkers in non-small-cell lung carcinoma. Biologics: Targets and Therapy, 2012, 6, 221.	3.0	10
588	Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. International Journal of Nanomedicine, 2012, 7, 1449.	3.3	24
589	Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial. Journal of Clinical Oncology, 2012, 30, 2063-2069.	0.8	225
590	Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology, 2012, 25, 347-369.	2.9	215
591	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2127-33.	3.3	410
592	Respiratory cytology in the era of molecular diagnostics: A review. Diagnostic Cytopathology, 2012, 40, 556-563.	0.5	10
593	Epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy is effective as firstâ€line treatment of advanced nonâ€smallâ€cell lung cancer with mutated EGFR: A metaâ€analysis from six phase III randomized controlled trials. International Journal of Cancer, 2012, 131, E822-9.	2.3	119
594	Tumorâ€associated macrophages correlate with response to epidermal growth factor receptorâ€tyrosine kinase inhibitors in advanced nonâ€small cell lung cancer. International Journal of Cancer, 2012, 131, E227-35.	2.3	81
595	Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in neverâ€smoker women with pulmonary adenocarcinoma. Cancer, 2012, 118, 5588-5594.	2.0	52
596	Gefitinib versus pemetrexed as secondâ€line treatment in patients with nonsmall cell lung cancer previously treated with platinumâ€based chemotherapy (KCSGâ€LU08â€01). Cancer, 2012, 118, 6234-6242.	2.0	89
597	Driver mutations determine survival in smokers and neverâ€smokers with stage IIIB/IV lung adenocarcinomas. Cancer, 2012, 118, 5840-5847.	2.0	55
598	Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update. Cancer Investigation, 2012, 30, 433-446.	0.6	58
599	Targeting embryonic signaling pathways in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 131-145.	1.5	36
600	Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. Pharmacogenomics, 2012, 13, 789-802.	0.6	38

#	Article	IF	Citations
601	Driver mutations as predictive biomarkers in lung cancer. Current Respiratory Care Reports, 2012, 1, 21-29.	0.6	0
602	A review on various targeted anticancer therapies. Targeted Oncology, 2012, 7, 69-85.	1.7	62
603	Management of Non-Small Cell Lung Cancer with Oligometastasis. Current Oncology Reports, 2012, 14, 333-341.	1.8	40
604	Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer. Medical Oncology, 2012, 29, 595-599.	1.2	4
605	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clinical and Translational Oncology, 2012, 14, 338-349.	1.2	35
606	A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 1241-1246.	1.1	44
607	The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Cancer Chemotherapy and Pharmacology, 2012, 69, 1407-1412.	1.1	9
608	Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 407-414.	1.4	64
609	EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1421-1425.	1.2	28
612	Personalized medicine for lung cancer: new challenges for pathology. Histopathology, 2012, 60, 531-546.	1.6	84
613	EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cellular Signalling, 2012, 24, 296-301.	1.7	27
614	Smoking History as a Predictive Factor of Treatment Response in Advanced Nonâ€“Small-Cell Lung Cancer: A Systematic Review. Clinical Lung Cancer, 2012, 13, 239-251.	1.1	27
615	A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 129-135.	1.1	8
616	Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Nonâ€“Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials. Clinical Lung Cancer, 2012, 13, 107-114.	1.1	122
617	Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2012, 13, 267-279.	1.1	21
618	Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Nonâ€“Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2012, 13, 252-266.	1.1	113
619	Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Nonâ€“Small-Cell Lung Cancer, A Phase II Trial. Clinical Lung Cancer, 2012, 13, 123-128.	1.1	10
620	Gefitinib Compared with Systemic Chemotherapy as First-line Treatment for Chemotherapy-naive Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of Randomised Controlled Trials. Clinical Oncology, 2012, 24, 396-401.	0.6	10

#	Article	IF	Citations
621	Strategies for maintenance therapy in advanced non-small cell lung cancer: Current status, unanswered questions and future directions. Critical Reviews in Oncology/Hematology, 2012, 82, 338-360.	2.0	13
622	Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges. Critical Reviews in Oncology/Hematology, 2012, 83, 130-144.	2.0	24
623	Mixed micelles of PEG2000-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: Enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines. European Journal of Pharmaceutical Sciences, 2012, 46, 64-71.	1.9	90
624	Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 267-274.	0.7	3
625	Phase III, randomized, openâ€label, firstâ€line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonâ€smallâ€cell lung cancer: evaluation of patients recruited from mainland China. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 232-243.	0.7	42
626	Efficacy of erlotinib in patients with advanced Nonâ€smallâ€cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 248-254.	0.7	6
627	Ligandâ€triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Science, 2012, 103, 1189-1194.	1.7	64
628	The positive impact of cytological specimens for EGFR mutation testing in nonâ€small cell lung cancer: a single South East Asian laboratoryâ€™s analysis of 670 cases. Cytopathology, 2012, 23, 229-236.	0.4	48
629	RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations. Pathology International, 2012, 62, 324-330.	0.6	25
630	A retrospective analysis comparing the safety and efficacy of chemotherapy in elderly and nonâ€elderly nonâ€smallâ€cell lung cancer patients. Geriatrics and Gerontology International, 2012, 12, 499-505.	0.7	2
631	Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma. BMC Cancer, 2012, 12, 87.	1.1	26
632	Cell surface receptor expression patterns in osteosarcoma. Cancer, 2012, 118, 740-749.	2.0	85
633	Costâ€effectiveness of epidermal growth factor receptor mutation testing and firstâ€line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer, 2012, 118, 1032-1039.	2.0	58
634	Oncogenic KRASâ€induced interleukinâ€8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of nonâ€small cell lung cancer. International Journal of Cancer, 2012, 130, 1733-1744.	2.3	80
635	Authors' reply to Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. International Journal of Cancer, 2012, 130, 2217-2218.	2.3	2
636	Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. International Journal of Cancer, 2012, 130, 2215-2217.	2.3	7
637	Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemotherapy and Pharmacology, 2012, 69, 273-280.	1.1	13
638	Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. Molecular Biology Reports, 2012, 39, 4971-4979.	1.0	36

#	Article	IF	Citations
639	Personalized cancer medicine and the future of pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 3-8.	1.4	36
640	Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2012, 138, 285-291.	1.2	1
641	Evaluation of EGFR mutation status in cytology specimens: An institutional experience. Diagnostic Cytopathology, 2013, 41, 316-323.	0.5	58
642	High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR. Journal of Translational Medicine, 2013, 11, 90.	1.8	31
644	Volumetric tumor growth in advanced nonâ€small cell lung cancer patients with EGFR mutations during EGFRâ€tyrosine kinase inhibitor therapy. Cancer, 2013, 119, 3761-3768.	2.0	40
645	EGFR mutations in malignant pleural effusions from lung cancer. Current Respiratory Care Reports, 2013, 2, 79-87.	0.6	9
646	Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Cancer, 2013, 119, 3043-3051.	2.0	19
647	Management of Lung Cancer in Older People. , 2013, , .		1
648	EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncology, 2013, 9, 991-1003.	1.1	8
649	Prognostic impact of serum CYFRA 21â€“1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer, 2013, 13, 354.	1.1	42
650	Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4â€“ALK-rearranged nonâ€“smallâ€“cell lung cancer harbored coexisting EGFRmutation. BMC Cancer, 2013, 13, 262.	1.1	46
651	Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, 2013, 779, v-vi.	0.8	1
652	Cisplatin influences acquisition of resistance to molecularâ€targeted agents through epithelialâ€“mesenchymal transitionâ€like changes. Cancer Science, 2013, 104, 904-911.	1.7	48
653	Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18â€“21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes. Lung, 2013, 191, 491-499.	1.4	37
654	Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Medical Oncology, 2013, 30, 645.	1.2	64
655	Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib. Clinical and Translational Oncology, 2013, 15, 384-390.	1.2	6
656	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Supportive Care in Cancer, 2013, 21, 3243-3254.	1.0	46
657	Identification of the NEDD4L Gene as a Prognostic Marker by Integrated Microarray Analysis of Copy Number and Gene Expression Profiling in Non-small Cell Lung Cancer. Annals of Surgical Oncology, 2013, 20, 590-598.	0.7	34

#	Article	IF	Citations
658	Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naÃ¯ve patients with advanced nonsquamous non-small-cell lung cancer. Investigational New Drugs, 2013, 31, 1275-1282.	1.2	38
659	DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies. American Journal of Human Genetics, 2013, 93, 439-451.	2.6	67
660	Management of non-small-cell lung cancer: recent developments. Lancet, The, 2013, 382, 709-719.	6.3	658
661	Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Targeted Oncology, 2013, 8, 27-33.	1.7	89
662	Clinical meta-analyses of targeted therapies in adenocarcinoma. Targeted Oncology, 2013, 8, 35-45.	1.7	4
663	Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. Cancer Chemotherapy and Pharmacology, 2013, 71, 859-865.	1.1	7
664	New Advances in the Precision Medicine of Lung Cancer. Current Pathobiology Reports, 2013, 1, 1-8.	1.6	4
665	Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer. Clinical Pharmacokinetics, 2013, 52, 593-609.	1.6	77
666	First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments. Drugs, 2013, 73, 357-369.	4.9	12
667	EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. British Journal of Cancer, 2013, 109, 1821-1828.	2.9	118
668	Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR). Journal of Medicinal Chemistry, 2013, 56, 7025-7048.	2.9	201
669	Molecular Surgical Pathology. , 2013, , .		23
670	Oncogenic driver mutations in lung cancer. Translational Respiratory Medicine, 2013, 1, 6.	3.8	49
671	Pemetrexed versus erlotinib in pretreated patients with advanced nonâ€“small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer, 2013, 119, 2754-2764.	2.0	106
672	A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. Lung Cancer, 2013, 82, 299-304.	0.9	28
673	Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma. Lung Cancer, 2013, 80, 159-164.	0.9	28
674	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer, 2013, 80, 120-130.	0.9	43
675	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treatment Reviews, 2013, 39, 839-850.	3.4	100

#	Article	IF	Citations
676	The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature Medicine, 2013, 19, 1389-1400.	15.2	883
677	CNS metastases in non-small-cell lung cancer: Current role of EGFR-TKI therapy and future perspectives. Lung Cancer, 2013, 80, 242-248.	0.9	66
679	Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. Biochemical and Biophysical Research Communications, 2013, 436, 319-324.	1.0	248
680	Targeted therapy for NSCLC with driver mutations. Expert Opinion on Biological Therapy, 2013, 13, 1401-1412.	1.4	42
681	Crizotinib in the Treatment of Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 473-480.	1.1	36
682	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Review of Anticancer Therapy, 2013, 13, 1207-1218.	1.1	13
683	Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Annals of Oncology, 2013, 24, 2080-2087.	0.6	111
684	Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial. Clinical Cancer Research, 2013, 19, 2646-2656.	3.2	23
685	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. Clinical and Translational Oncology, 2013, 15, 977-984.	1.2	18
686	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Science Translational Medicine, 2013, 5, 216ra177.	5.8	438
687	Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. Journal of Clinical Pathology, 2013, 66, 839-846.	1.0	27
688	Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell, 2013, 155, 1309-1322.	13.5	801
689	Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clinical Cancer Research, 2013, 19, 2240-2247.	3.2	2,097
690	Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. Cancer Research, 2013, 73, 5195-5205.	0.4	153
691	A phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703. Respiratory Investigation, 2013, 51, 28-34.	0.9	10
692	Is EGF receptorâ€“tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?. Lung Cancer Management, 2013, 2, 441-443.	1.5	1
693	Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung Cancer, 2013, 82, 431-435.	0.9	61
694	Lung Cancer Imaging. , 2013, , .		2

#	Article	IF	Citations
695	Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Nonâ€“Small-Cell Lung Cancer: Implications for Personalized Medicine. Clinical Lung Cancer, 2013, 14, 609-626.	1.1	15
696	Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Critical Reviews in Oncology/Hematology, 2013, 88, 477-493.	2.0	71
697	Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer, 2013, 13, 472.	1.1	11
698	HER2 and lung cancer. Expert Review of Anticancer Therapy, 2013, 13, 1219-1228.	1.1	63
699	Characteristics of Lung Cancers Harboring NRAS Mutations. Clinical Cancer Research, 2013, 19, 2584-2591.	3.2	134
700	KRAS Mutations in Lung Cancer. Clinical Lung Cancer, 2013, 14, 205-214.	1.1	182
701	Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. Journal of Translational Medicine, 2013, 11, 186.	1.8	61
702	CT-guided needle lung biopsy is possible during apneic oxygenation: a case series. Multidisciplinary Respiratory Medicine, 2013, 8, 73.	0.6	2
703	Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. European Journal of Cancer, 2013, 49, 2116-2125.	1.3	38
705	Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene, 2013, 32, 4427-4435.	2.6	23
706	Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. Future Oncology, 2013, 9, 377-386.	1.1	18
707	Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline. Clinical Therapeutics, 2013, 35, 1282-1303.	1.1	81
708	Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Lineâ€”Is There a Difference?. Journal of Clinical Oncology, 2013, 31, 1081-1088.	0.8	101
709	Lung Cancer Biomarkers: Present Status and Future Developments. Archives of Pathology and Laboratory Medicine, 2013, 137, 1191-1198.	1.2	105
710	An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1037-1051.	1.5	10
711	Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and metaâ€analysis of clinical trials. British Journal of Clinical Pharmacology, 2013, 75, 919-930.	1.1	69
712	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitorâ€“Resistant Disease. Journal of Clinical Oncology, 2013, 31, 1070-1080.	0.8	425
714	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology, 2013, 31, 3327-3334.	0.8	2,854

#	Article	IF	Citations
715	LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both. Journal of Clinical Oncology, 2013, 31, 3335-3341.	0.8	303
716	Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology, 2013, 31, 3342-3350.	0.8	285
717	EGFRmutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. Journal of Clinical Pathology, 2013, 66, 79-89.	1.0	267
718	The role of afatinib in the management of non-small cell lung carcinoma. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1529-1539.	1.5	4
719	Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years. European Journal of Cancer, 2013, 49, 1216-1225.	1.3	87
720	Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage IÂ–IV Non-Small Cell Lung Cancer Patients. Respiration, 2013, 85, 119-125.	1.2	100
721	Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer. Advances in Experimental Medicine and Biology, 2013, 779, 145-164.	0.8	7
722	Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Annals of Oncology, 2013, 24, 59-66.	0.6	103
723	Diagnostic Applications of High-Throughput DNA Sequencing. Annual Review of Pathology: Mechanisms of Disease, 2013, 8, 381-410.	9.6	58
724	New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials. Journal of Clinical Oncology, 2013, 31, 992-1001.	0.8	458
725	Genotyping and Genomic Profiling of Nonâ€“Small-Cell Lung Cancer: Implications for Current and Future Therapies. Journal of Clinical Oncology, 2013, 31, 1039-1049.	0.8	438
726	Nonâ€“Small-Cell Lung Cancer: Then and Now. Journal of Clinical Oncology, 2013, 31, 981-983.	0.8	28
727	ALK in Lung Cancer: Past, Present, and Future. Journal of Clinical Oncology, 2013, 31, 1105-1111.	0.8	387
728	Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer. European Journal of Cancer, Supplement, 2013, 11, 307-309.	2.2	1
729	Molecular profile of lung cancer in never smokers. European Journal of Cancer, Supplement, 2013, 11, 248-253.	2.2	30
730	Les mÃ©tastases osseuses au cours des cancers broncho-pulmonaires. Revue Des Maladies Respiratoires Actualites, 2013, 5, 538-546.	0.0	0
731	A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer, 2013, 82, 109-114.	0.9	84
732	The Efficacy of EBUS-Guided Transbronchial Needle Aspiration for Molecular Testing in Lung Adenocarcinoma. Annals of Thoracic Surgery, 2013, 96, 1196-1202.	0.7	80

#	Article	IF	Citations
733	Tumor Burden is Predictive of Survival in Patients With Nonâ€“Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib. Clinical Lung Cancer, 2013, 14, 383-389.	1.1	63
734	Mutation de lâ€™EGFR, de lâ€™Ã©tude du gÃ¨ne Ã la pratique clinique : exemplaritÃ© ou exception ?. Revue Des Maladies Respiratoires Actualites, 2013, 5, 519-537.	0.0	1
735	Requirement for Interaction of PI3-Kinase p110Î± with RAS in Lung Tumor Maintenance. Cancer Cell, 2013, 24, 617-630.	7.7	148
736	Epidermal Growth Factor Receptor Exon 20 Mutation Increased inPost-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Patients' Blood Samples. Translational Oncology, 2013, 6, 504-510.	1.7	9
737	The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Nonâ€“Small-Cell Lung Cancer: Focus on Clinical Trial Results. Clinical Lung Cancer, 2013, 14, 311-321.	1.1	11
738	Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study. Lung Cancer, 2013, 82, 231-237.	0.9	83
739	Adenocarcinoma de pulmÃ³n diseminado con mutaciones activadoras de EGFR. Medicine, 2013, 11, 1504.e1-1504.e3.	0.0	0
740	Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. Gynecologic Oncology, 2013, 128, 461-469.	0.6	29
741	Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma. Lung Cancer, 2013, 80, 289-292.	0.9	16
742	Polymorphisms of CYP2D6 Gene and Gefitinib-Induced Hepatotoxicity. Clinical Lung Cancer, 2013, 14, 502-507.	1.1	50
743	Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer, 2013, 81, 53-59.	0.9	53
744	Subsolid Pulmonary Nodule Management and Lung Adenocarcinoma Classification: State of the Art and Future Trends. Seminars in Roentgenology, 2013, 48, 295-307.	0.2	19
745	Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. Journal of the Chinese Medical Association, 2013, 76, 249-257.	0.6	42
746	Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2013, 69, 708-720.	0.6	94
747	Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer, 2013, 82, 294-298.	0.9	101
748	Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. Journal of Clinical Oncology, 2013, 31, 3987-3996.	0.8	299
749	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics, 2013, 14, 1765-1777.	0.6	38
750	Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer, 2013, 79, 242-247.	0.9	62

#	Article	IF	Citations
751	Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer, 2013, 81, 328-336.	0.9	49
752	The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer. Journal of the Chinese Medical Association, 2013, 76, 682-685.	0.6	8
753	Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist?. Lung Cancer, 2013, 81, 347-353.	0.9	81
754	Analysis of Intratumor Heterogeneity of EGFR Mutations in Mixed Type Lung Adenocarcinoma. Clinical Lung Cancer, 2013, 14, 521-526.	1.1	32
755	Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer. Lung Cancer, 2013, 80, 191-196.	0.9	11
756	Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 2013, 79, 283-288.	0.9	68
757	Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer, 2013, 81, 435-439.	0.9	28
758	Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progression. Biochemical Pharmacology, 2013, 86, 1664-1672.	2.0	10
759	Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study. Lung Cancer, 2013, 81, 280-287.	0.9	44
760	Incidence and consequences of bone metastases in lung cancer patients. Journal of Bone Oncology, 2013, 2, 22-29.	1.0	78
761	A Sequential Method of Epidermal Growth Factor Receptor Mutation Detection Reduces False Negatives: A New Case With Doublet Mutations of L833V and H835L in China. Clinical Lung Cancer, 2013, 14, 295-300.	1.1	9
762	EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung. Lung Cancer, 2013, 81, 440-444.	0.9	41
763	Cancer Concepts and Principles: Primer for the Interventional Oncologistâ€”Part II. Journal of Vascular and Interventional Radiology, 2013, 24, 1167-1188.	0.2	26
764	A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer, 2013, 79, 307-311.	0.9	23
765	The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. Seminars in Diagnostic Pathology, 2013, 30, 298-312.	1.0	13
766	Suitability of Computed Tomography-Guided Biopsy Specimens for Subtyping and Genotyping of Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 719-725.	1.1	19
768	Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy. Lung Cancer, 2013, 79, 167-172.	0.9	31
769	A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. European Journal of Cancer, 2013, 49, 2512-2521.	1.3	11

#	Article	IF	Citations
770	Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer. Lung Cancer, 2013, 80, 344-346.	0.9	4
771	Targeting MET: why, where and how?. Current Opinion in Pharmacology, 2013, 13, 511-518.	1.7	41
772	Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?. Medical Oncology, 2013, 30, 328.	1.2	33
773	Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis. Medical Oncology, 2013, 30, 349.	1.2	38
774	Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study. Medical Oncology, 2013, 30, 450.	1.2	33
775	Surgery for NSCLC in the era of personalized medicine. Nature Reviews Clinical Oncology, 2013, 10, 235-244.	12.5	85
776	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. Nature Reviews Cancer, 2013, 13, 365-376.	12.8	242
777	Novel therapeutic targets in non-small cell lung cancer. Current Opinion in Pharmacology, 2013, 13, 394-401.	1.7	70
778	Identification of driver mutations in lung cancer: first step in personalized cancer. Targeted Oncology, 2013, 8, 3-14.	1.7	26
779	Erlotinib in the first-line treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2013, 13, 523-533.	1.1	17
780	Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cellular Oncology (Dordrecht), 2013, 36, 277-288.	2.1	80
781	EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A caseâ€“control study of overall survival. Lung Cancer, 2013, 80, 306-312.	0.9	44
782	Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?. Cancer Treatment Reviews, 2013, 39, 489-497.	3.4	26
783	High-Dose Cytarabine (HD araC) in the Treatment of Leukemias: a Review. Current Hematologic Malignancy Reports, 2013, 8, 141-148.	1.2	65
784	Incorporating Pharmacogenomics in Drug Development. , 2013, , 343-366.		0
785	Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394.	13.9	3,181
786	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncology, The, 2013, 14, 777-786.	5.1	280
787	Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer. Targeted Oncology, 2013, 8, 237-242.	1.7	25

#	Article	IF	Citations
788	Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations. Lung Cancer, 2013, 79, 276-282.	0.9	38
789	Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Review of Anticancer Therapy, 2013, 13, 745-758.	1.1	100
790	Point: Should Epidermal Growth Factor Receptor Mutations Be Routinely Tested for in Patients With Lung Cancer? Yes. Chest, 2013, 143, 597-600.	0.4	2
791	Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout. Drug Discovery Today, 2013, 18, 11-24.	3.2	10
792	Companion Diagnostic Testing for Targeted Cancer Therapies: An Overview. Genetic Testing and Molecular Biomarkers, 2013, 17, 515-523.	0.3	14
793	The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer. Clinical Investigation, 2013, 3, 369-383.	0.0	3
794	EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance. Current Oncology Reports, 2013, 15, 396-404.	1.8	25
795	Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer. Journal of Pathology, 2013, 230, 194-204.	2.1	52
796	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2013, 15, 415-453.	1.2	397
797	Clinical Significance of the Serum Crosslinked N-Telopeptide of Type I Collagen as a Prognostic Marker for Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 50-54.	1.1	14
798	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer, 2013, 79, 33-39.	0.9	156
799	Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer, 2013, 79, 20-26.	0.9	39
800	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2013, 137, 828-860.	1.2	415
801	Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing â€œwax-and-waneâ€•transformation. BMC Cancer, 2013, 13, 529.	1.1	15
802	Plasma fibrinogen levels are associated with epidermal growth factor receptor gene mutation in Chinese patients with non-small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2013, 12, 203-209.	0.1	1
803	A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 409-416.	1.2	33
804	Successful EGFR-TKI Rechallenge of Leptomeningeal Carcinomatosis after Gefitinib-induced Interstitial Lung Disease. Japanese Journal of Clinical Oncology, 2013, 43, 422-425.	0.6	20
805	PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. Expert Opinion on Pharmacotherapy, 2013, 14, 597-608.	0.9	6

#	Article	IF	Citations
806	Personalised cancer management: closer, but not here yet. Annals of Oncology, 2013, 24, 1951-1955.	0.6	5
807	Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation. Chemotherapy, 2013, 59, 414-419.	0.8	7
808	Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1691-1700.	1.2	29
810	Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Investigational New Drugs, 2013, 31, 1158-1168.	1.2	22
811	Severe Acute Interstitial Lung Disease After Crizotinib Therapy in a Patient With EML4-ALKâ€“Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, e15-e17.	0.8	66
812	Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance. Annual Review of Pharmacology and Toxicology, 2013, 53, 161-185.	4.2	170
813	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 2013, 8, 823-859.	0.5	792
815	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2013, 19, 818-832.	0.9	24
816	Advances in personalized therapy for lung cancer. Expert Opinion on Medical Diagnostics, 2013, 7, 475-485.	1.6	9
818	RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0. American Journal of Roentgenology, 2013, 201, W64-W71.	1.0	39
819	The future of Connected Health in preventive medicine. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 791-794.	0.2	13
823	Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. European Respiratory Review, 2013, 22, 565-576.	3.0	23
824	Afatinib in advanced non-small-cell lung cancer. Lung Cancer Management, 2013, 2, 493-504.	1.5	0
826	Targeted Therapy for Nonâ€“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 907-912.	2.5	25
827	Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung. Modern Pathology, 2013, 26, 239-246.	2.9	18
828	Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. Future Oncology, 2013, 9, 327-345.	1.1	8
829	An economic model to value companion diagnostics in non-small-cell lung cancer. Personalized Medicine, 2013, 10, 139-147.	0.8	10
830	Personalizing Therapy in Advanced Nonâ€“Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 822-836.	0.8	20

#	Article	IF	Citations
831	Results of the First Italian External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 773-778.	0.5	19
832	Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Archives of Pathology and Laboratory Medicine, 2013, 137, 668-684.	1.2	359
833	Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes. Radiology, 2013, 268, 254-264.	3.6	156
834	EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition. Cancer Research, 2013, 73, 2428-2434.	0.4	151
835	Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?. Journal of Carcinogenesis, 2013, 12, 7.	2.5	10
836	Treatment of Lung Cancer in the Elderly Patient. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 802-809.	0.8	7
837	Surgical Pathology of Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 770-786.	0.8	10
838	Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-9.	0.5	44
839	Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers. Seminars in Interventional Radiology, 2013, 30, 191-198.	0.3	67
840	Verifying the Role of Surgical Pathologists in the Precision Medicine of Lung Cancer. Archives of Pathology and Laboratory Medicine, 2013, 137, 1176-1178.	1.2	2
841	A Preclinical Evaluation of Antimycin A as a Potential Antilung Cancer Stem Cell Agent. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-13.	0.5	20
842	Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: A retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. Indian Journal of Cancer, 2013, 50, 87.	0.2	23
843	Identification of Somatic Genomic Alterations in Circulating Tumors Cells: Another Step Forward in Nonâ€“Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2013, 31, 2236-2239.	0.8	15
844	Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405). Japanese Journal of Clinical Oncology, 2013, 43, 664-668.	0.6	38
845	Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Oncologist, 2013, 18, 1214-1220.	1.9	119
846	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Annals of Oncology, 2013, 24, 2371-2376.	0.6	510
847	Combination of Pyrosequencing^{Â®} and Sanger sequencing reveals alleged novel mutation in exon 18 of EGFR. Personalized Medicine, 2013, 10, 201-209.	0.8	4
848	ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas. American Journal of Surgical Pathology, 2013, 37, 1441-1449.	2.1	168

#	Article	IF	Citations
849	PharmGKB summary. Pharmacogenetics and Genomics, 2013, 23, 636-642.	0.7	13
850	The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2013, 25, 121-129.	1.1	10
851	Histologic and Molecular Characterization of Lung Cancer With Tissue Obtained by Electromagnetic Navigation Bronchoscopy. Journal of Bronchology and Interventional Pulmonology, 2013, 20, 10-15.	0.8	18
852	Current questions in HIV-associated lung cancer. Current Opinion in Oncology, 2013, 25, 511-517.	1.1	20
853	Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Annals of Oncology, 2013, 24, 1615-1622.	0.6	112
854	Can Serum be Used for Analyzing the EGFR Mutation Status in Patients with Advanced Non-small Cell Lung Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 57-63.	0.6	23
855	Evaluation of 2 Real-Time PCR Assays for In Vitro Diagnostic Use in the Rapid and Multiplex Detection of EGFR Gene Mutations in NSCLC. Diagnostic Molecular Pathology, 2013, 22, 138-143.	2.1	14
856	How and when to use genetic markers for nonsmall cell lung cancer. Current Opinion in Pulmonary Medicine, 2013, 19, 1.	1.2	13
857	Evaluation of 2-Year Experience With EGFR Mutation Analysis of Small Diagnostic Samples. Diagnostic Molecular Pathology, 2013, 22, 70-75.	2.1	17
858	Cisplatin Resistance Associated with PARP Hyperactivation. Cancer Research, 2013, 73, 2271-2280.	0.4	143
859	Personalized Treatment of Lung Adenocarcinoma. Clinical Pulmonary Medicine, 2013, 20, 309-314.	0.3	1
860	The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. Pathology, 2013, 45, 553-558.	0.3	37
861	Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review. Onkologie, 2013, 36, 5-5.	1.1	77
862	Unintentional Weakness of Cancers: The MEKâ€“ERK Pathway as a Double-Edged Sword. Molecular Cancer Research, 2013, 11, 1125-1128.	1.5	2
863	Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments. Pharmacogenomics, 2013, 14, 195-203.	0.6	9
864	Personalized Medicine: Hype or Reality. Oncologist, 2013, 18, 640-643.	1.9	11
865	Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Frontiers in Oncology, 2013, 3, 86.	1.3	64
866	Phase II Trial of Erlotinib for Japanese Patients With Previously Treated Non-small-cell Lung Cancer Harboring EGFR Mutations: Results of Lung Oncology Group in Kyushu (LOGiK0803). Japanese Journal of Clinical Oncology, 2013, 43, 629-635.	0.6	16

#	Article	IF	Citations
867	Key issues affecting the development and implementation of personalised medicine: a foresight exercise. Drug Discovery Today: Therapeutic Strategies, 2013, 10, e189-e194.	0.5	1
868	The Role of MET Receptor Tyrosine Kinase in Non-Small Cell Lung Cancer and Clinical Development of Targeted Anti-MET Agents. Oncologist, 2013, 18, 115-122.	1.9	62
869	What Lies Within: Novel Strategies in Immunotherapy for Nonâ€Small Cell Lung Cancer. Oncologist, 2013, 18, 1203-1213.	1.9	35
870	EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women. Carcinogenesis, 2013, 34, 612-619.	1.3	15
871	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Nonâ€“Small-Cell Lung Cancer: The Never-Ending Story. Journal of Clinical Oncology, 2013, 31, 3291-3293.	0.8	16
872	Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Annals of Oncology, 2013, 24, 1326-1331.	0.6	59
873	Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Therapeutic Advances in Medical Oncology, 2013, 5, 249-270.	1.4	38
874	Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets and Therapy, 2013, 6, 135.	1.0	66
875	Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 2171-2182.	0.9	16
876	Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Nonâ€“Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer?. Journal of Clinical Oncology, 2013, 31, 3303-3306.	0.8	63
877	Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: A retrospective, observational, multicentric study. Journal of Oncology Pharmacy Practice, 2013, 19, 246-253.	0.5	11
878	Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cellâ€“like Properties in Cancer Cells. Cancer Research, 2013, 73, 3051-3061.	0.4	241
879	Novel cancer therapies: treatments driven by tumour biology. Postgraduate Medical Journal, 2013, 89, 652-658.	0.9	16
880	Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Research, 2013, 23, 1434-1445.	2.4	48
881	Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer. Cancer Biomarkers, 2013, 13, 329-336.	0.8	24
882	Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib. Molecular and Clinical Oncology, 2013, 1, 875-878.	0.4	4
883	Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery. Molecular and Clinical Oncology, 2013, 1, 949-952.	0.4	6
884	Efficacy of tyrosine kinase inhibitors in routine clinical practice: Epidermal growth factor mutations and their implications. Journal of Cancer Research and Therapeutics, 2013, 9, 261.	0.3	5

#	Article	IF	Citations
885	Emerging Options for the Management of Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S10269.	0.6	16
886	Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung Cancer. Chemotherapy, 2013, 59, 99-105.	0.8	6
887	Biochemical Basis and Therapeutic Implications of Angiogenesis. , 2013, , .		5
888	Salvage Therapy beyond Targeted Therapy in Lung Adenocarcinoma. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 837-844.	0.8	5
889	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptorâ€mutated lung cancer model. Cancer Science, 2013, 104, 1440-1446.	1.7	34
890	Analysis ofEGFR,EML4-ALK,KRAS, andc-METmutations in Chinese lung adenocarcinoma patients. Experimental Lung Research, 2013, 39, 328-335.	0.5	53
891	Rebiopsy of nonâ€“small cell lung cancer patients with acquired resistance to epidermal growth factor receptorâ€tyrosine kinase inhibitor. Cancer, 2013, 119, 4325-4332.	2.0	169
892	Cancer stemâ€like cell properties are regulated by <scp>EGFR</scp>/<scp>AKT</scp>/Î²â€“catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. FEBS Journal, 2013, 280, 2027-2041.	2.2	81
893	Diagnostic yield of combined bronchoscopy and endobronchial ultrasonography, under <scp>L</scp>ung<scp>P</scp>oint guidance for small peripheral pulmonary lesions. Respirology, 2013, 18, 834-839.	1.3	72
894	Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for nonâ€small cell lung cancer. Cancer Science, 2013, 104, 291-297.	1.7	41
895	<scp>RET</scp> fusion gene: Translation to personalized lung cancer therapy. Cancer Science, 2013, 104, 1396-1400.	1.7	106
896	The current and future role of sequence-based analysis in prostate cancer treatment. Personalized Medicine, 2013, 10, 257-273.	0.8	0
897	Inhibiting the RASâ€“PI3K Pathway in Cancer Therapy. The Enzymes, 2013, 34 Pt. B, 107-136.	0.7	20
898	The role of palliative chemotherapy for terminally ill patients with advanced NSCLC. Thoracic Cancer, 2013, 4, 153-160.	0.8	4
899	Clinicians' views on introducing epidermal growth factor receptor testing in New Zealand. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 249-256.	0.7	2
900	Impact of EGFR Inhibitor in Nonâ€“Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 595-605.	3.0	469
901	Model Pharmacoeconomic Study on IressaÂ® (Gefitinib) as a First Line Treatment of Non-Small Cell Lung Cancer at Stage IIIB/IV in EGFR Mutation Positive Bulgarian Patients. Biotechnology and Biotechnological Equipment, 2013, 27, 3586-3594.	0.5	0
902	Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review. Journal of Clinical Oncology, 2013, 31, 3957-3963.	0.8	87

#	Article	IF	Citations
903	Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1148-1155.	0.5	97
904	A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis, 2013, 2, e39-e39.	2.1	211
905	Rare mutations in non-small-cell lung cancer. Future Oncology, 2013, 9, 699-711.	1.1	23
906	Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model. Molecular Cancer Therapeutics, 2013, 12, 589-597.	1.9	62
907	Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatinâ€“paclitaxel for chemo-naÃ¯ve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology, 2013, 24, 54-59.	0.6	484
908	New treatment strategy for patients withEGFR-mutant lung cancer. Lung Cancer Management, 2013, 2, 505-516.	1.5	0
909	Clinical Classification of Targeted Agents Used for Anticancer Treatment. Tohoku Journal of Experimental Medicine, 2013, 230, 1-5.	0.5	1
910	Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. Oncology Reports, 2013, 30, 1463-1472.	1.2	6
911	Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer. Lung Cancer Management, 2013, 2, 75-85.	1.5	0
912	Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials. Oncology Research and Treatment, 2013, 36, 357-362.	0.8	1
913	Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients. Journal of Thoracic Oncology, 2013, 8, 52-61.	0.5	374
914	Chemotherapy: still an essential player in non-small-cell lung cancer treatment?. Lung Cancer Management, 2013, 2, 381-390.	1.5	0
915	Chemotherapy of advanced non-small-cell lung cancer: current landscape. Clinical Investigation, 2013, 3, 265-279.	0.0	0
916	The role of meta-analysis in defining clinical practice in advanced non-small-cell lung cancer. Clinical Investigation, 2013, 3, 523-530.	0.0	0
917	Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Nonâ€“Small-Cell Lung Cancer in a Publicly Funded Health Care System. Journal of Thoracic Oncology, 2013, 8, 1136-1141.	0.5	42
918	Combined Treatment with Erlotinib and a Transforming Growth Factor-Î² Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Nonâ€“Small-Cell Lung Cancer Cells. Journal of Thoracic Oncology, 2013, 8, 259-269.	0.5	39
919	KRAS mutations predict sensitivity to pemetrexed-based chemotherapy. Lung Cancer Management, 2013, 2, 275-280.	1.5	5
920	Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. Oncology Letters, 2013, 5, 271-276.	0.8	31

#	Article	IF	Citations
921	Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitor in Nonâ€“Small-Cell Lung Cancer Harboring EGFR Mutation. Journal of Thoracic Oncology, 2013, 8, 892-898.	0.5	44
922	Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation. Journal of Thoracic Oncology, 2013, 8, 131-139.	0.5	86
923	Detection of EGFR gene mutations in non-small cell lung cancer: Lessons from a single-institution routine analysis of 1,403 tumor samples. International Journal of Oncology, 2013, 43, 1045-1051.	1.4	32
924	Gefitinib: re-emerging from the shadows. Lung Cancer Management, 2013, 2, 423-437.	1.5	0
925	Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Nonâ€“Small-Cell Lung Cancer Patients Treated with EGFR TKI. Journal of Thoracic Oncology, 2013, 8, 1059-1068.	0.5	48
926	Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas. Journal of Thoracic Oncology, 2013, 8, 322-328.	0.5	145
927	A Patient With Anaplastic Lymphoma Kinaseâ€“Positive Nonâ€“Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 389-394.	2.3	14
928	Clinician Perceptions of Care Difficulty, Quality of Life, and Symptom Reports for Lung Cancer Patients: An Analysis from the Symptom Outcomes and Practice Patterns (SOAPP) Study. Journal of Thoracic Oncology, 2013, 8, 1474-1483.	0.5	29
929	Treatment of Stage IV Non-small Cell Lung Cancer. Chest, 2013, 143, e341S-e368S.	0.4	180
930	Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status. Clinical Cancer Research, 2013, 19, 183-193.	3.2	117
931	Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors. Lung Cancer Management, 2013, 2, 89-92.	1.5	0
932	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. Journal of Thoracic Oncology, 2013, 8, 373-384.	0.5	113
933	Targeting HER Receptors in Cancer. Current Pharmaceutical Design, 2013, 19, 808-817.	0.9	39
934	Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. Oncology Letters, 2013, 5, 68-72.	0.8	5
935	Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed. Journal of Thoracic Oncology, 2013, 8, 96-101.	0.5	56
936	Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. International Journal of Oncology, 2013, 42, 1151-1158.	1.4	80
937	Establishing the Diagnosis of Lung Cancer. Chest, 2013, 143, e142S-e165S.	0.4	825
938	Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2013, 8, 346-351.	0.5	313

#	Article	IF	Citations
939	Prognostic Factors and the Significance of Treatment After Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer. Chest, 2013, 143, 1626-1634.	0.4	65
940	Molecular Biology of Lung Cancer. Chest, 2013, 143, e30S-e39S.	0.4	65
941	Personalized medicine for radiation therapy. Personalized Medicine, 2013, 10, 107-110.	0.8	0
942	Wnt Pathway Activation Predicts Increased Risk of Tumor Recurrence in Patients With Stage I Nonsmall Cell Lung Cancer. Annals of Surgery, 2013, 257, 548-554.	2.1	40
943	Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma. Annals of Surgery, 2013, 258, 1079-1086.	2.1	175
944	BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Nonâ€“Small-Cell Lung Cancer Patients with EGFR Mutations. Journal of Thoracic Oncology, 2013, 8, 295-300.	0.5	17
945	How Sensitive Are Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Geneâ€“Sensitive Mutations?. Journal of Thoracic Oncology, 2013, 8, 89-95.	0.5	68
946	Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested. Case Reports in Oncology, 2013, 6, 263-268.	0.3	7
947	Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung. Journal of Thoracic Oncology, 2013, 8, 1012-1018.	0.5	33
948	Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines. Oncology Letters, 2013, 5, 440-446.	0.8	14
950	Histology and Smoking Status Predict Survival of Patients with Advanced Nonâ€“Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L. Journal of Thoracic Oncology, 2013, 8, 753-758.	0.5	42
951	Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 161-169.	2.3	64
952	17. Characteristics of Lung Cancer in Japanese Patients and Therapy. The Journal of the Japanese Society of Internal Medicine, 2013, 102, 137b-138a.	0.0	0
954	Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. OncoTargets and Therapy, 2013, 6, 155.	1.0	6
955	Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. OncoTargets and Therapy, 2013, 6, 1771.	1.0	7
956	Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. Cancer Management and Research, 2013, 5, 15.	0.9	4
957	Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. Cancer Management and Research, 2013, 5, 91.	0.9	15
958	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. Journal of Cancer, 2013, 4, 736-754.	1.2	77

#	Article	IF	Citations
959	Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib. Journal of Korean Medical Science, 2013, 28, 1595.	1.1	4
960	The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology. Yonsei Medical Journal, 2013, 54, 1.	0.9	18
962	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. OncoTargets and Therapy, 2013, 6, 563.	1.0	22
963	MET overexpression and gene amplification in NSCLC: a clinical perspective. Lung Cancer: Targets and Therapy, 2013, 4, 15.	1.3	9
964	Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond. Lung Cancer: Targets and Therapy, 2013, 4, 43.	1.3	3
965	Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Males, Smokers, and Non-adenocarcinoma Lung Cancer in Patients with EGFR Mutations. International Journal of Biological Markers, 2013, 28, 249-258.	0.7	9
966	The economic evaluation of personalised oncology medicines: ethical challenges. Medical Journal of Australia, 2013, 199, 471-473.	0.8	17
967	Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy. Lung Cancer: Targets and Therapy, 2013, 4, 9.	1.3	8
968	Research biopsies in the context of early phase oncology studies: clinical and ethical considerations. Oncology Reviews, 2013, 7, 5.	0.8	16
969	EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?. Lung Cancer: Targets and Therapy, 2013, 4, 27.	1.3	4
970	The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations. Chinese Journal of Cancer, 2013, 32, 136-140.	4.9	5
971	Three Cases of Lung Cancer Treated Safely and Effectively with Erlotinib Following Gefitinib-induced Hepatotoxicity. Japanese Journal of Lung Cancer, 2013, 53, 793-798.	0.0	1
972	Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e51021.	1.1	7
973	A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Nonâ€“Small-Cell Lung Cancer. PLoS ONE, 2013, 8, e55917.	1.1	46
974	EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital. PLoS ONE, 2013, 8, e56011.	1.1	65
975	Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System. PLoS ONE, 2013, 8, e67466.	1.1	151
976	Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome. PLoS ONE, 2013, 8, e70346.	1.1	32
977	Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan. PLoS ONE, 2013, 8, e70839.	1.1	92

#	Article	IF	Citations
978	Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis. PLoS ONE, 2013, 8, e79000.	1.1	17
979	Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer. PLoS ONE, 2013, 8, e59183.	1.1	30
980	Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. Biologics: Targets and Therapy, 2013, 7, 61.	3.0	34
981	Lung Cancer in 2013: State of the Art Therapy for Metastatic Disease. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 339-346.	1.8	8
982	Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. OncoTargets and Therapy, 2014, 7, 799.	1.0	14
983	Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Brazilian Journal of Medical and Biological Research, 2014, 47, 929-939.	0.7	94
984	Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. OncoTargets and Therapy, 2014, 7, 253.	1.0	2
985	Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics: Targets and Therapy, 2014, 8, 183.	3.0	25
986	Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. PLoS ONE, 2014, 9, e85245.	1.1	125
987	Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib. PLoS ONE, 2014, 9, e86667.	1.1	5
988	The Relationship between TTF-1 Expression and EGFR Mutations in Lung Adenocarcinomas. PLoS ONE, 2014, 9, e95479.	1.1	48
989	Real-Time Bidirectional Pyrophosphorolysis-Activated Polymerization for Quantitative Detection of Somatic Mutations. PLoS ONE, 2014, 9, e96420.	1.1	3
990	Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e103305.	1.1	98
991	Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS ONE, 2014, 9, e107161.	1.1	142
992	Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC. PLoS ONE, 2014, 9, e110780.	1.1	121
993	Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. OncoTargets and Therapy, 2014, 7, 841.	1.0	14
994	Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. Journal of Personalized Medicine, 2014, 4, 297-310.	1.1	16
995	Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 1048.	0.9	61

#	Article	IF	Citations
996	Molecular pathways and therapeutic targets in lung cancer. Oncotarget, 2014, 5, 1392-1433.	0.8	171
997	Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Drug Design, Development and Therapy, 2014, 8, 1037.	2.0	9
998	The new concepts on overcoming drug resistance in lung cancer. Drug Design, Development and Therapy, 2014, 8, 735.	2.0	21
999	EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Design, Development and Therapy, 2014, 8, 1595.	2.0	36
1000	Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. OncoTargets and Therapy, 2014, 7, 375.	1.0	22
1001	Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus. OncoTargets and Therapy, 2015, 8, 111.	1.0	9
1002	Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reverse transcriptase expression in human lung cancer cells. Oncotarget, 2014, 5, 11909-11923.	0.8	14
1003	Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics. Lung Cancer: Targets and Therapy, 2014, 5, 73.	1.3	3
1004	Phase II Clinical Trial of Gefitinib for the Treatment of ChemonaÃ¨ve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status. Clinical Medicine Insights: Oncology, 2014, 8, CMO.S15172.	0.6	4
1005	Effects of Targeted Anticancer Medicines on Post-Cell Removal Surface Morphology of Cancer Cells Cultivated on 3-Aminopropyltriethoxysilane Surface. , 2014, S, .		0
1006	Advantages and Disadvantages of Targeting the C-erbB Family of Receptors in Cancer Treatment: A Review. Biology and Medicine (Aligarh), 2014, 06, .	0.3	1
1007	Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis. Oncology Letters, 2014, 8, 327-334.	0.8	8
1008	Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer HarboringEGFRMutation. Tuberculosis and Respiratory Diseases, 2014, 76, 8.	0.7	6
1009	PGx/Biomarker Utilization for Regulatory Decision Making. , 2014, , 951-967.		1
1010	Interstitial Lung Disease Induced by Targeted Therapy for Non-Small Cell Lung Cancer: A Review of Diagnosis, Workup, and Management. Journal of Palliative Care & Medicine, 2014, 05, .	0.1	1
1011	The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer. Chinese Journal of Cancer, 2014, 33, 105-114.	4.9	6
1012	Clinical Significance of Disease Flares in Patients with Non-small Cell Lung Cancer with Positive EGFR Mutations Following the Suspension of Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Japanese Journal of Lung Cancer, 2014, 54, 1-5.	0.0	1
1013	Chronic Nicotine Exposure Mediates Resistance to Egfr-Tki in Egfr-Mutated Lung Cancer Via Egfr Signal. Annals of Oncology, 2014, 25, v73.	0.6	0

#	Article	IF	Citations
1014	Molecular Targeted Therapy in Lung Cancer. Hanyang Medical Reviews, 2014, 34, 37.	0.4	1
1015	A Case of Lung Adenocarcinoma with Postoperative Recurrence of Multiple Bone Metastases that Showed a Gradual Complete Response to Combined Administration of Erlotinib and Zoledronic Acid. Tumori, 2014, 100, e45-e48.	0.6	0
1016	Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e353-e365.	1.8	75
1017	50 Years of Progress in the Systemic Therapy of Nonâ€“Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 177-189.	1.8	92
1018	Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Investigational New Drugs, 2014, 32, 1311-1315.	1.2	28
1019	PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. The Cochrane Library, 2016, 2016, CD009519.	1.5	118
1020	A current perspective on treatment of adrenocortical carcinoma. Expert Opinion on Orphan Drugs, 2014, 2, 911-921.	0.5	2
1021	First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901. Cancer Chemotherapy and Pharmacology, 2014, 74, 721-727.	1.1	36
1022	Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: A retrospective caseâ€“control study. Complementary Therapies in Medicine, 2014, 22, 1010-1018.	1.3	42
1023	A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. Journal of Neuro-Oncology, 2014, 120, 423-430.	1.4	36
1024	Overcoming resistance to EGF receptor tyrosine kinase inhibitors inEGFR-mutated NSCLC. Lung Cancer Management, 2014, 3, 459-476.	1.5	1
1025	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitorâ€“Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. Cancer Discovery, 2014, 4, 1036-1045.	7.7	348
1026	Phase <scp>II</scp> trial of paclitaxelâ€carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown nonâ€small cell lung cancer. Thoracic Cancer, 2014, 5, 149-154.	0.8	4
1027	Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. Cancer Chemotherapy and Pharmacology, 2014, 74, 939-946.	1.1	10
1028	Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?. Cancer Chemotherapy and Pharmacology, 2014, 74, 661-665.	1.1	22
1029	Risk factors of recurrence for resected T1aN0M0 invasive lung adenocarcinoma: a clinicopathologic study of 177 patients. World Journal of Surgical Oncology, 2014, 12, 285.	0.8	10
1030	Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer. BMC Cancer, 2014, 14, 848.	1.1	14
1031	Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActiveÂ®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer, 2014, 14, 748.	1.1	101

#	Article	IF	Citations
1032	Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2. BMC Pulmonary Medicine, 2014, 14, 174.	0.8	47
1033	Challenges in the Management of <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors. Oncology, 2014, 87, 83-94.	0.9	4
1034	PIK3CA Activating Mutations: A Discordant Role in Early Versus Advanced Hormone-Dependent Estrogen Receptorâ€"Positive Breast Cancer?. Journal of Clinical Oncology, 2014, 32, 2932-2934.	0.8	32
1035	Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 74, 1191-1198.	1.1	23
1036	Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. Annals of Pharmacotherapy, 2014, 48, 1159-1165.	0.9	23
1037	A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors. Clinical Cancer Research, 2014, 20, 1644-1655.	3.2	51
1038	Management of NSCLC: focus on crizotinib. Expert Opinion on Pharmacotherapy, 2014, 15, 2587-2597.	0.9	15
1039	Evaluating the utility of local therapy for oligometastatic lung cancer. Lung Cancer Management, 2014, 3, 373-381.	1.5	0
1040	Successes and Limitations of Targeted Cancer Therapy in Lung Cancer. Progress in Tumor Research, 2014, 41, 62-77.	0.1	34
1041	Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH. Modern Pathology, 2014, 27, 1621-1631.	2.9	15
1042	Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. Future Oncology, 2014, 10, 2081-2096.	1.1	16
1043	First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. European Respiratory Review, 2014, 23, 92-105.	3.0	43
1044	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. British Journal of Cancer, 2014, 110, 55-62.	2.9	351
1046	Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. Neuro-Oncology, 2014, 16, viii7-viii13.	0.6	85
1047	Republished: Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. Postgraduate Medical Journal, 2014, 90, 228-235.	0.9	4
1048	Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China. Lung Cancer: Targets and Therapy, 2014, 5, 1.	1.3	44
1049	Amplification of TRIM44: Pairing a Prognostic Target With Potential Therapeutic Strategy. Journal of the National Cancer Institute, 2014, 106, .	3.0	38
1050	Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Current Medical Research and Opinion, 2014, 30, 447-461.	0.9	33

#	Article	IF	Citations
1051	Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review. Oncology Letters, 2014, 7, 878-880.	0.8	13
1052	Relationship of Thyroid Transcription Factor 1 to EGFR Status in Non-Small-Cell Lung Cancer. Current Oncology, 2014, 21, 305-308.	0.9	8
1053	Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy. Cancers, 2014, 6, 2035-2048.	1.7	10
1054	Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naÃ¯ve patient: A report of three cases. Oncology Letters, 2014, 7, 357-360.	0.8	33
1055	Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. Frontiers in Oncology, 2014, 4, 258.	1.3	4
1056	Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib. Oncology Letters, 2014, 8, 2699-2704.	0.8	6
1057	Prognosis of recurrent non-small cell lung cancer following complete resection. Oncology Letters, 2014, 7, 1300-1304.	0.8	38
1058	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Frontiers in Oncology, 2014, 4, 204.	1.3	137
1059	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Nonâ€“Small Cell Carcinoma of the Lung. Archives of Pathology and Laboratory Medicine, 2014, 138, 171-174.	1.2	20
1060	New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. European Respiratory Review, 2014, 23, 367-378.	3.0	78
1061	Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Molecular Medicine Reports, 2014, 10, 931-938.	1.1	26
1062	Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion. Journal of Thoracic Oncology, 2014, 9, 1048-1052.	0.5	36
1063	RETand other genes: therapeutic targets in lung adenocarcinoma. Lung Cancer Management, 2014, 3, 219-226.	1.5	0
1064	Phase I/II Study of Amrubicin and Nedaplatin in Patients with Untreated, Advanced, Non-Small Cell Lung Cancer. Chemotherapy, 2014, 60, 180-184.	0.8	3
1065	A review of economic impact of targeted oral anticancer medications. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 45-69.	0.7	15
1066	Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer. Future Oncology, 2014, 10, 813-822.	1.1	10
1067	First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. Future Oncology, 2014, 10, 1081-1093.	1.1	5
1068	Management of EGFR-mutant non-small-cell lung cancer patients afterÂfirst-line reversible EGF receptor-tyrosine kinaseÂinhibitors. Lung Cancer Management, 2014, 3, 77-84.	1.5	0

#	Article	IF	Citations
1069	Targeted nextâ€generation sequencing using fineâ€needle aspirates from adenocarcinomas of the lung. Cancer Cytopathology, 2014, 122, 104-113.	1.4	103
1070	Echinoderm microtubuleâ€associated proteinâ€like 4â€anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in <scp>C</scp>hinese patients with lung adenocarcinoma. Thoracic Cancer, 2014, 5, 411-416.	0.8	7
1072	Personalized oncology: genomic screening in phase 1. Apmis, 2014, 122, 723-733.	0.9	18
1073	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 2014, 25, 1475-1484.	0.6	210
1074	Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opinion on Pharmacotherapy, 2014, 15, 2693-2708.	0.9	20
1075	miR-27a suppresses EV71 replication by directly targeting EGFR. Virus Genes, 2014, 49, 373-382.	0.7	32
1076	Assessment of MAGE-A Expression in Resected Nonâ€“Small Cell Lung Cancer in Relation to Clinicopathologic Features and Mutational Status of EGFR and KRAS. Cancer Immunology Research, 2014, 2, 943-948.	1.6	20
1077	Antitumor effects of bevacizumab in a microenvironmentâ€dependent human adult <scp>T</scp>â€cell leukemia/lymphoma mouse model. European Journal of Haematology, 2014, 92, 219-228.	1.1	6
1078	Patients harboring epidermal growth factor receptor (<scp>EGFR)</scp> double mutations had a lower objective response rate than those with a single mutation in nonâ€small cell lung cancer when treated with <scp>EGFR</scp>â€tyrosine kinase inhibitors. Thoracic Cancer, 2014, 5, 126-132.	0.8	21
1079	First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine, 2014, 371, 2167-2177.	13.9	2,808
1080	RAC 1 inhibition as a therapeutic target for gefitinibâ€resistant nonâ€smallâ€cell lung cancer. Cancer Science, 2014, 105, 788-794.	1.7	42
1081	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score. Lung Cancer, 2014, 86, 363-368.	0.9	17
1082	Current status and future perspectives of cooperative study groups for lung cancer in Japan. Respiratory Investigation, 2014, 52, 339-347.	0.9	3
1083	Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer. Lung Cancer, 2014, 86, 339-343.	0.9	3
1084	A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles. Journal of Medicinal Chemistry, 2014, 57, 9889-9900.	2.9	55
1085	AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discovery, 2014, 4, 1046-1061.	7.7	1,655
1086	Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation. Clinical Cancer Research, 2014, 20, 1383-1392.	3.2	153
1087	Molecular alterations in nonâ€smallâ€cell lung cancer: Perspective for targeted therapy and specimen management for the bronchoscopist. Respirology, 2014, 19, 1117-1125.	1.3	15

#	Article	IF	Citations
1088	A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization. Advances in Experimental Medicine and Biology, 2014, 799, 85-117.	0.8	98
1089	Preparing for tomorrow: Molecular diagnostics and the changing nonsmall cell lung cancer landscape. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 2-10.	0.7	4
1090	Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib. Oncologist, 2014, 19, 1100-1109.	1.9	27
1091	Factors associated with early progression of nonâ€smallâ€cell lung cancer treated by epidermal growth factor receptor tyrosineâ€kinase inhibitors. Cancer Medicine, 2014, 3, 61-69.	1.3	6
1092	Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling. Biochemical and Biophysical Research Communications, 2014, 455, 269-276.	1.0	25
1093	Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer. Medical Oncology, 2014, 31, 220.	1.2	6
1094	Pooled analysis of clinical outcome for <scp>EGFR TKI</scp>â€treated patients with <scp>EGFR</scp> mutationâ€positive <scp>NSCLC</scp>. Journal of Cellular and Molecular Medicine, 2014, 18, 1519-1539.	1.6	33
1095	Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opinion on Pharmacotherapy, 2014, 15, 2293-2305.	0.9	16
1096	Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Oncology, 2014, 86, 86-93.	0.9	19
1097	Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Annals of Oncology, 2014, 25, 423-428.	0.6	170
1098	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Nonâ€“Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor. JAMA - Journal of the American Medical Association, 2014, 311, 1430.	3.8	136
1099	Efficacy of S-1 in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1927-1942.	0.9	7
1100	Do anti-angiogenic cancer therapies increase risk of significant weight loss?. Expert Opinion on Drug Safety, 2014, 13, 473-482.	1.0	1
1101	Advances in the Diagnosis and Treatment of Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2014, 13, 557-564.	1.9	18
1102	Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage. Clinical Cancer Research, 2014, 20, 3496-3506.	3.2	28
1103	Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. BMC Cancer, 2014, 14, 786.	1.1	35
1104	Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma. Diagnostic Pathology, 2014, 9, 103.	0.9	6
1105	Effectiveness of Gefitinib against Nonâ€“Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q. Journal of Thoracic Oncology, 2014, 9, 189-194.	0.5	182

#	Article	IF	Citations
1106	An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators. Journal of Thoracic Oncology, 2014, 9, 631-638.	0.5	148
1107	Clinical Characteristics and Treatment Outcomes of Lung Adenocarcinomas with Discrepant EGFR Mutation Testing Results Derived from PCR-Direct Sequencing and Real-Time PCR-Based Assays. Journal of Thoracic Oncology, 2014, 9, 91-96.	0.5	14
1108	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opinion on Drug Safety, 2014, 13, 535-549.	1.0	30
1109	Novel drugs against non-small-cell lung cancer. Current Opinion in Oncology, 2014, 26, 145-151.	1.1	22
1110	EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinoma. Pathology, 2014, 46, 32-36.	0.3	0
1111	Comparison of the Yield of Different Diagnostic Procedures for Cellular Differentiation and Genetic Profiling of Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1120-1125.	0.5	10
1112	EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas. Journal of Thoracic Oncology, 2014, 9, 195-199.	0.5	245
1113	Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib. Journal of Thoracic Oncology, 2014, 9, 200-204.	0.5	57
1114	Meta-Analysis of First-Line Therapies in Advanced Nonâ€“Small-Cell Lung Cancer Harboring EGFR-Activating Mutations. Journal of Thoracic Oncology, 2014, 9, 805-811.	0.5	78
1115	Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Nonâ€“Small Cell Lung Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 343-349.	0.6	20
1116	Mirror Mirror on the Wall, Who Is the Fairest of Them All. Journal of Thoracic Oncology, 2014, 9, 431-432.	0.5	0
1117	Routine implementation of EGFR mutation testing in clinical practice in Flanders: â€˜HERMESâ€™ project. Acta Clinica Belgica, 2014, 69, 92-97.	0.5	12
1118	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 1495-1513.	1.1	8
1119	Label-Free Molecular Vibrational Imaging for Cancer Diagnosis. , 2014, , 187-199.		0
1120	Convex Probe Endobronchial Ultrasound. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 636-644.	0.8	5
1122	Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 646.	0.9	21
1123	Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo. Molecular Medicine Reports, 2014, 9, 2265-2272.	1.1	89
1124	Review of EGFRÃ¢â‚¬â€°TKIs in Metastatic NSCLC, Including Ongoing Trials. Frontiers in Oncology, 2014, 4, 244.	1.3	55

#	Article	IF	Citations
1125	Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small-cell lung cancer. Molecular and Clinical Oncology, 2014, 2, 252-258.	0.4	11
1126	Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System. Molecular and Clinical Oncology, 2014, 2, 991-996.	0.4	8
1127	The Relationship Between Common EGFR, BRAF, KRAS Mutations and Prognosis in Advanced Stage Non-Small Cell Lung Cancer with Response to the Treatment in Turkey.. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2014, 24, 1-10.	0.1	3
1128	Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. European Respiratory Review, 2014, 23, 356-366.	3.0	139
1129	Therapeutic Use of MicroRNAs in Lung Cancer. BioMed Research International, 2014, 2014, 1-8.	0.9	44
1130	The Role of microRNAs in the Regulation of Apoptosis in Lung Cancer and Its Application in Cancer Treatment. BioMed Research International, 2014, 2014, 1-19.	0.9	53
1131	Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. European Respiratory Journal, 2014, 44, 513-522.	3.1	99
1132	Flex-rigid Pleuroscopy Under Local Anesthesia in Patients with Dry Pleural Dissemination on Radiography. Japanese Journal of Clinical Oncology, 2014, 44, 749-755.	0.6	6
1133	U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations. Oncologist, 2014, 19, 774-779.	1.9	113
1134	Relapsed small cell lung cancer: treatment options and latest developments. Therapeutic Advances in Medical Oncology, 2014, 6, 69-82.	1.4	73
1135	TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-Î¹B and Regresses Mutant EGFR-Associated Human Nonâ€“Small Cell Lung Cancers. Molecular Cancer Therapeutics, 2014, 13, 617-629.	1.9	76
1136	Response to Chemotherapy, Reexposure to Crizotinib and Treatment with a Novel ALK Inhibitor in a Patient with Acquired Crizotinib Resistance. Respiration, 2014, 88, 262-264.	1.2	10
1137	Overall Response to First-Line Tyrosine Kinase Inhibitor and Second-Line Chemotherapy Is Predictive of Survival Outcome in Epidermal Growth Factor Receptor-Mutated Adenocarcinoma. Chemotherapy, 2014, 60, 201-210.	0.8	4
1138	The Impact of Clinical Outcomes According to EGFR Mutation Status in Patients with Locally Advanced Lung Adenocarcinoma Who Recieved Concurrent Chemoradiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 144-147.	0.6	41
1139	Transbronchial Biopsy Needle Rinse Solution Used for Comprehensive Biomarker Testing in Patients with Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 26-32.	0.5	15
1140	A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Nonâ€“Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 2014, 9, 154-162.	0.5	1,131
1141	Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Nonâ€“Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21. Journal of Thoracic Oncology, 2014, 9, 506-511.	0.5	44
1142	Clinical Significance of BIM Deletion Polymorphism in Nonâ€“Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation. Journal of Thoracic Oncology, 2014, 9, 483-487.	0.5	67

#	Article	IF	Citations
1143	Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma. Journal of Thoracic Imaging, 2014, 29, 357-363.	0.8	61
1144	High proportion of rare and compound epidermal growth factor receptor mutations in an ‹scp›A‹/scp›ustralian population of nonâ€squamous nonâ€smallâ€cell lung cancer. Internal Medicine Journal, 2014, 44, 1188-1192.	0.5	15
1145	Biomarkers in Oncology and Nephrology. , 2014, , 21-38.		5
1146	Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer, 2014, 83, 329-333.	0.9	45
1147	Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer. Seminars in Oncology, 2014, 41, 101-109.	0.8	19
1148	Epidermal Growth Factor Receptor Mutation Testing in Thailand: A Cost-Utility Analysis. Value in Health Regional Issues, 2014, 3, 39-43.	0.5	5
1149	Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials. Lung Cancer, 2014, 85, 66-73.	0.9	55
1150	Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Lung Cancer, 2014, 84, 196-202.	0.9	53
1151	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. Critical Reviews in Oncology/Hematology, 2014, 90, 135-145.	2.0	12
1152	Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer, 2014, 83, 174-181.	0.9	43
1153	Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients withpostoperative recurrence following platinum-based chemotherapy. Respiratory Investigation, 2014, 52, 121-128.	0.9	5
1154	Extending Survival of Stage IV Non-Small Cell Lung Cancer. Seminars in Oncology, 2014, 41, 69-92.	0.8	34
1155	The mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. Surgery Today, 2014, 44, 478-486.	0.7	27
1156	Diacylglycerol kinase Î· modulates oncogenic properties of lung cancer cells. Clinical and Translational Oncology, 2014, 16, 29-35.	1.2	19
1157	Application of Translational Science to Clinical Development. , 2014, , 1-21.		1
1158	Personalized Health Care (PHC) in Cancer. , 2014, , 23-49.		0
1159	Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 906-914.	3.3	60
1160	Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. Translational Respiratory Medicine, 2014, 2, 2.	3.8	23

#	Article	IF	Citations
1161	Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance. Medical Oncology, 2014, 31, 810.	1.2	20
1162	FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 89-98.	1.2	88
1163	Administration of gefitinib via nasogastric tube effectively improved the performance status of a patient with lung adenocarcinoma-derived meningeal carcinomatosis. International Cancer Conference Journal, 2014, 3, 211-214.	0.2	3
1164	Suppression of Dicer Increases Sensitivity to Gefitinib in Human Lung Cancer Cells. Annals of Surgical Oncology, 2014, 21, 555-563.	0.7	25
1165	Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome. Cancer Treatment Reviews, 2014, 40, 723-729.	3.4	19
1166	How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?. Lung Cancer, 2014, 83, 117-125.	0.9	35
1167	EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. Lung Cancer, 2014, 83, 224-230.	0.9	41
1169	Changes of CD4+CD25+FOXP3+ and CD8+CD28â^' regulatory T cells in non-small cell lung cancer patients undergoing surgery. International Immunopharmacology, 2014, 18, 255-261.	1.7	69
1170	Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials. Lung Cancer, 2014, 83, 231-239.	0.9	99
1171	Clinical Significance of Heterogeneity in Response to Retreatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Cancer Acquiring Secondary Resistance to the Drug. Clinical Lung Cancer, 2014, 15, 145-151.	1.1	19
1172	Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders. Cancer Treatment Reviews, 2014, 40, 197-203.	3.4	36
1173	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 213-222.	5.1	1,740
1174	Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized, Phase II Study. Annals of Surgical Oncology, 2014, 21, 2091-2096.	0.7	83
1175	Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer. Medical Oncology, 2014, 31, 893.	1.2	6
1176	The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 849-857.	1.2	14
1177	Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 839-848.	1.2	6
1178	Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 427-433.	1.2	8
1179	Management of adrenal cancer: a 2013 update. Journal of Endocrinological Investigation, 2014, 37, 207-217.	1.8	89

#	Article	IF	Citations
1180	Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. International Journal of Clinical Oncology, 2014, 19, 594-600.	1.0	92
1181	Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer. Clinical Cancer Research, 2014, 20, 1428-1444.	3.2	81
1182	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Critical Reviews in Oncology/Hematology, 2014, 89, 300-313.	2.0	68
1184	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced nonâ€small cell lung cancer. Cancer, 2014, 120, 2289-2298.	2.0	30
1185	Molecular profiling of small cell lung cancer in a Japanese cohort. Lung Cancer, 2014, 84, 139-144.	0.9	32
1186	Systems Analysis of Human Multigene Disorders. Advances in Experimental Medicine and Biology, 2014, 799, v - viii.	0.8	4
1187	Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies. Clinical Cancer Research, 2014, 20, 2264-2275.	3.2	60
1188	Molecular Testing in Cancer. , 2014, , .		2
1189	Pharmacogenomics and Personalized Medicines in Cancer Treatment. , 2014, , 55-90.		0
1190	Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1203-1213.	0.9	17
1191	Recent Clinical Advances in Lung Cancer Management. Journal of Clinical Oncology, 2014, 32, 973-982.	0.8	203
1192	The impact of personalized medicine on survival: Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. Cancer Treatment Reviews, 2014, 40, 485-494.	3.4	21
1193	Targeted therapy-induced diarrhea: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 165-179.	2.0	47
1194	Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation. Journal of Oncology Pharmacy Practice, 2014, 20, 11-28.	0.5	54
1195	Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients. Journal of Clinical Oncology, 2014, 32, 121-128.	0.8	176
1196	A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease. Lung Cancer, 2014, 83, 73-77.	0.9	9
1197	New Treatment Options for Lung Adenocarcinoma - in View of Molecular Background. Pathology and Oncology Research, 2014, 20, 11-25.	0.9	44
1198	Efficiency of the TherascreenÂ® RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas. Clinica Chimica Acta, 2014, 429, 8-11.	0.5	43

#	Article	IF	Citations
1199	MiR-134/487b/655 Cluster Regulates TGF-Î²â€“Induced Epithelialâ€“Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells. Molecular Cancer Therapeutics, 2014, 13, 444-453.	1.9	181
1200	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 1433-1441.	5.1	114
1202	Aspects biologiques des cancers bronchiques. Revue Des Maladies Respiratoires Actualites, 2014, 6, 311-319.	0.0	0
1204	Carcinome bronchique non Ã petites cellules : quelle chimiothÃ©rapie de rattrapage ?. Revue Des Maladies Respiratoires Actualites, 2014, 6, 442-452.	0.0	0
1205	Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance. Respiratory Investigation, 2014, 52, 330-338.	0.9	18
1206	Evolutionary triage governs fitness in driver and passenger mutations and suggests targeting never mutations. Nature Communications, 2014, 5, 5499.	5.8	71
1207	Diagnostic Impact of Color Doppler Ultrasound-Guided Core Biopsy on Fine-Needle Aspiration of Anterior Mediastinal Masses. Ultrasound in Medicine and Biology, 2014, 40, 2768-2776.	0.7	12
1208	The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 2135-2142.	1.2	18
1209	Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. Cancer Chemotherapy and Pharmacology, 2014, 74, 1149-1157.	1.1	11
1210	Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15964-15968.	3.3	100
1211	LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. Future Oncology, 2014, 10, 533-540.	1.1	6
1212	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2014, 15, 1369-1378.	5.1	124
1213	A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2014, 86, 207-212.	0.9	47
1214	Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor. Lung Cancer, 2014, 86, 219-224.	0.9	17
1215	A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung Cancer, 2014, 86, 195-200.	0.9	8
1216	Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer. Lung Cancer, 2014, 86, 213-218.	0.9	26
1217	Physicians' Attitudes About Multiplex Tumor Genomic Testing. Journal of Clinical Oncology, 2014, 32, 1317-1323.	0.8	203
1218	Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2014, 15, 411-417.e4.	1.1	32

#	Article	IF	Citations
1219	Novel agents in development for advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2014, 6, 240-253.	1.4	33
1220	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Expert Review of Molecular Diagnostics, 2014, 14, 453-468.	1.5	17
1221	Advancing clinical oncology through genome biology and technology. Genome Biology, 2014, 15, 427.	3.8	9
1222	Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers. Clinical Cancer Research, 2014, 20, 4193-4199.	3.2	24
1223	Erlotinib in African Americans With Advanced Nonâ€“Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses. Clinical Pharmacology and Therapeutics, 2014, 96, 182-191.	2.3	21
1224	Prognostic Significance of Genotype and Number of Metastatic Sites in Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 441-447.	1.1	35
1225	EGFR Blockade Enriches for Lung Cancer Stemâ€“like Cells through Notch3-Dependent Signaling. Cancer Research, 2014, 74, 5572-5584.	0.4	105
1226	Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Annals of Oncology, 2014, 25, 2385-2391.	0.6	64
1227	Update on systemic therapy of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 1189-1203.	1.1	31
1228	Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1333-1348.	1.9	48
1230	MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Letters, 2014, 351, 265-271.	3.2	75
1231	The Correlation of the International Association forÂthe Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) Classification With Prognosis and EGFR Mutation in Lung Adenocarcinoma. Annals of Thoracic Surgery, 2014, 98, 453-458.	0.7	92
1232	Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drugâ€“drug interactions. Cancer Treatment Reviews, 2014, 40, 917-926.	3.4	134
1233	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncology, The, 2014, 15, 1236-1244.	5.1	678
1234	Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2014, 20, 5898-5907.	3.2	72
1235	Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?. Medical Oncology, 2014, 31, 78.	1.2	4
1236	M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma. Medical Oncology, 2014, 31, 127.	1.2	32
1237	Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. Medical Oncology, 2014, 31, 228.	1.2	23

#	Article	IF	Citations
1238	The impact of rescue or maintenance therapy with EGFR TKIs for Stage IIIb-IV non-squamous non-small-cell lung cancer patients requiring mechanical ventilation. BMC Anesthesiology, 2014, 14, 55.	0.7	9
1239	Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study. BMC Cancer, 2014, 14, 491.	1.1	11
1240	Differential knockdown of TGF-Î² ligands in a three-dimensional co-culture tumor- stromal interaction model of lung cancer. BMC Cancer, 2014, 14, 580.	1.1	20
1241	Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World Journal of Surgical Oncology, 2014, 12, 148.	0.8	28
1242	Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor. Journal of Medicinal Chemistry, 2014, 57, 8249-8267.	2.9	454
1243	Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Nonâ€“Small-Cell Lung Cancer andEGFRMutations?. Journal of Clinical Oncology, 2014, 32, 859-863.	0.8	3
1244	Combination of stereotactic ablative body radiation with targeted therapies. Lancet Oncology, The, 2014, 15, e426-e434.	5.1	32
1245	Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Annals of Oncology, 2014, 25, 126-131.	0.6	270
1246	Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). Journal of Clinical Oncology, 2014, 32, 1902-1908.	0.8	238
1247	Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 2097-2105.	1.2	7
1248	Recent advances in personalized lung cancer medicine. Personalized Medicine, 2014, 11, 309-321.	0.8	22
1249	A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer. Journal of Molecular Medicine, 2014, 92, 969-981.	1.7	16
1250	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. Journal of Molecular Medicine, 2014, 92, 697-707.	1.7	58
1251	Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemotherapy and Pharmacology, 2014, 73, 943-950.	1.1	8
1252	A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology, 2014, 74, 37-43.	1.1	17
1253	Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1087-1095.	1.2	6
1254	Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1901-1909.	1.2	40
1255	miR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1661-1670.	1.2	31

#	Article	IF	Citations
1256	Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis. Clinical and Experimental Metastasis, 2014, 31, 543-551.	1.7	49
1257	Cytoplasmic YAP Expression is Associated with Prolonged Survival in Patients with Lung Adenocarcinomas and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment. Annals of Surgical Oncology, 2014, 21, 610-618.	0.7	15
1258	Clinical trials: More trials, fewer tribulations. Nature, 2014, 509, S55-S57.	13.7	4
1259	Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes. Cell Biochemistry and Biophysics, 2014, 70, 553-558.	0.9	12
1260	A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib. Medical Oncology, 2014, 31, 36.	1.2	7
1261	Autoclustering of Non-small Cell Lung Carcinoma Subtypes on 18F-FDG PET Using Texture Analysis: A Preliminary Result. Nuclear Medicine and Molecular Imaging, 2014, 48, 278-286.	0.6	60
1262	Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity. BMC Cancer, 2014, 14, 312.	1.1	14
1263	MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab. Molecular Cancer, 2014, 13, 63.	7.9	38
1264	A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood. Journal of Translational Medicine, 2014, 12, 143.	1.8	34
1265	Treatment algorithm in 2014 for advanced non-small cell lung cancer: Therapy selection by tumour histology and molecular biology. Advances in Medical Sciences, 2014, 59, 308-313.	0.9	21
1266	Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. British Journal of Cancer, 2014, 111, 413-420.	2.9	41
1267	Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends in Biochemical Sciences, 2014, 39, 465-474.	3.7	134
1268	State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine. Radiology, 2014, 271, 6-27.	3.6	114
1269	Tilting the Balance of Dose Modification for Oral Anticancer Drugs?. Journal of Clinical Oncology, 2014, 32, 1537-1539.	0.8	10
1270	Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptorâ€“Mutated Lung Adenocarcinoma: A Case-Control Study. Translational Oncology, 2014, 7, 508-512.	1.7	5
1272	Acquired Resistance to Targeted Therapies Against Oncogene-Driven Nonâ€“Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications. Clinical Lung Cancer, 2014, 15, 1-6.	1.1	79
1273	Pathologie avancÃ©e et dÃ©faillances dâ€™organesÂ: outil dâ€™aide Ã la dÃ©cision. Medecine Palliative, 2014, 13, 150-154.	0.0	1
1274	Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?. Lung Cancer, 2014, 84, 97-100.	0.9	19

#	Article	IF	Citations
1275	Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib. Cancer Treatment Communications, 2014, 2, 4-7.	0.4	3
1276	Association of Merkel cell polyomavirus infection with EGFR mutation status in Chinese non-small cell lung cancer patients. Lung Cancer, 2014, 83, 341-346.	0.9	16
1277	Treatment of Advanced Nonâ€“Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2014, 15, 173-181.	1.1	56
1278	Management of Italian Patients With Advanced Nonâ€“Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study. Clinical Lung Cancer, 2014, 15, 338-345.e1.	1.1	7
1279	An effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer. Respiratory Investigation, 2014, 52, 49-56.	0.9	6
1280	Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 36-40.	0.4	10
1281	PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[Î±]indene Derivative in Lung Cancer Cells. Translational Oncology, 2014, 7, 256-266.e5.	1.7	1
1282	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer, 2014, 84, 161-167.	0.9	81
1283	The State of the Art in Nonâ€“Small Cell Lung Cancer Immunotherapy. Seminars in Thoracic and Cardiovascular Surgery, 2014, 26, 26-35.	0.4	11
1284	An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 346-355.	1.1	377
1285	Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Lung Cancer, 2014, 83, 374-382.	0.9	40
1286	Differential drug responses of circulating tumor cells within patient blood. Cancer Letters, 2014, 352, 28-35.	3.2	20
1287	Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. Experimental Cell Research, 2014, 326, 201-209.	1.2	6
1288	Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Lung Cancer, 2014, 85, 161-167.	0.9	43
1289	Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. Cancer Research, 2014, 74, 3146-3156.	0.4	69
1290	Ten lessons from EGFR. Respiratory Investigation, 2014, 52, 151-152.	0.9	0
1291	The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with nonâ€“small cell lung cancer. Cancer, 2014, 120, 2299-2307.	2.0	84
1292	Drug resistance to targeted therapies: DÃ©jÃ vu all over again. Molecular Oncology, 2014, 8, 1067-1083.	2.1	187

#	Article	IF	Citations
1293	Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: Retrospective clinical observation. International Immunopharmacology, 2014, 21, 396-405.	1.7	16
1294	Afatinib in the treatment of EGFR mutation-positive NSCLC â€“ A network meta-analysis. Lung Cancer, 2014, 85, 230-238.	0.9	47
1295	Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 322-329.	0.4	91
1296	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treatment Reviews, 2014, 40, 990-1004.	3.4	70
1297	BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer, 2014, 85, 326-330.	0.9	82
1301	Review of the current targeted therapies for non-small-cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 576.	0.9	59
1302	Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients with/without EGFR-Mutation: Evidence Based on Recent Phase III Randomized Trials. Medical Science Monitor, 2014, 20, 2666-2676.	0.5	18
1303	Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmacogenomics and Personalized Medicine, 2014, 7, 285.	0.4	30
1304	Adenomatous polyposis coli determines sensitivity to the EGFR tyrosine kinase inhibitor gefitinib in colorectal cancer cells. Oncology Reports, 2014, 31, 1811-1817.	1.2	8
1305	Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment. Case Reports in Oncology, 2014, 7, 126-131.	0.3	2
1307	Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation. Oncology, 2014, 87, 215-223.	0.9	15
1311	SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification. Oncology Reports, 2014, 32, 2612-2618.	1.2	10
1312	A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy. Oncology Letters, 2014, 8, 1563-1566.	0.8	4
1313	A Complex Deletion/Insertion on Exon 19 of the EGFR Gene Predicts Response to Gefitinib. Journal of Thoracic Oncology, 2014, 9, e47-e48.	0.5	0
1314	Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design. International Journal of Endocrine Oncology, 2014, 1, 31-34.	0.4	1
1315	Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1385-1392.	0.5	45
1316	Analysis of <scp>BIM</scp> (<scp>BCL</scp>â€2 like 11 gene) deletion polymorphism in <scp>C</scp>hinese nonâ€small cell lung cancer patients. Thoracic Cancer, 2014, 5, 509-516.	0.8	13
1317	Tumor <scp>MET</scp> expression profile predicts the outcome of nonâ€small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Thoracic Cancer, 2014, 5, 517-524.	0.8	5

#	Article	IF	Citations
1318	The Presence of EGFR Mutations Predicts the Response in Chinese Non-Small Cell Lung Cancer Patients Treated with Erlotinib. International Journal of Biological Markers, 2014, 29, 112-119.	0.7	2
1319	Successful Chemotherapy with Nab-Paclitaxel in a Heavily Treated Non-Small Cell Lung Cancer Patient: A Case Report. Case Reports in Oncology, 2014, 7, 401-406.	0.3	4
1320	Advanced EGFR Mutation-Positive Nonâ€“Small-Cell Lung Cancer: Case Report, Literature Review, and Treatment Recommendations. Cancer Control, 2014, 21, 67-73.	0.7	16
1321	Quality of Care of Patients with Nonâ€“Small-Cell Lung Cancer: A Report of a Performance Improvement Initiative. Cancer Control, 2014, 21, 90-97.	0.7	6
1322	A Survey of Japanese Thoracic Oncologists' Perception of Diagnostic and Treatment Strategies for EGFR Mutant or EML4-ALK Fusion Non-small Cell Lung Cancer. Chest, 2014, 146, e222-e225.	0.4	4
1323	Third-line systemic treatment for non-small cell lung cancer. The Cochrane Library, 0, , .	1.5	0
1324	Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. Molecular and Clinical Oncology, 2014, 2, 731-736.	0.4	20
1325	High efficacy of gefitinib in the treatment of EGFR mutation-positive advanced non-small cell lung adenocarcinoma: A case report. Oncology Letters, 2014, 8, 1320-1322.	0.8	2
1326	Nestin regulates proliferation, migration, invasion and stemness of lung adenocarcinoma. International Journal of Oncology, 2014, 44, 1118-1130.	1.4	69
1327	The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Nonâ€“Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2015, 10, 903-909.	0.5	36
1328	Towards manageable toxicities from targeted lung cancer treatment. Lung Cancer Management, 2015, 4, 279-287.	1.5	0
1329	Clinical significance of expanded Foxp3+ Heliosâ" regulatory T cells in patients with non-small cell lung cancer. International Journal of Oncology, 2015, 47, 2082-2090.	1.4	22
1330	In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non-small cell lung cancer cell lines. Oncology Reports, 2015, 33, 239-249.	1.2	21
1331	Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib. Molecular and Clinical Oncology, 2015, 3, 802-806.	0.4	12
1332	Detection of epidermal growth factor receptor (EGFR) exon 19 E746-A750 deletion and EGFR exon 21 point mutations in lung adenocarcinoma by immunohistochemistry: a comparative study to EGFR exons 19 and 21 mutations analysis using PCR followed by high-resolution melting and pyrosequencing. Journal of Histotechnology, 2015, 38, 56-62.	0.2	3
1333	Novel targeted agents for the treatment of lung cancer in China. Cancer, 2015, 121, 3089-3096.	2.0	10
1334	Epidermal growth factor receptor variant <scp>III</scp> mutation in <scp>C</scp>hinese patients with squamous cell cancer of the lung. Thoracic Cancer, 2015, 6, 319-326.	0.8	10
1335	Implementation of modern therapy approaches and research for nonâ€small cell lung cancer in <scp>J</scp>apan. Respirology, 2015, 20, 199-208.	1.3	4

#	Article	IF	Citations
1336	Subsequent treatment of epidermal growth factor receptorâ€tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma. Thoracic Cancer, 2015, 6, 678-686.	0.8	3
1337	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. Journal of Internal Medicine, 2015, 278, 545-570.	2.7	46
1338	Surgical Intervention for Nonâ€“Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004. Journal of Thoracic Oncology, 2015, 10, 1076-1082.	0.5	46
1339	Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. International Journal of Oncology, 2015, 46, 505-512.	1.4	12
1340	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Nonâ€“Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. Journal of Thoracic Oncology, 2015, 10, 1754-1761.	0.5	145
1341	Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Oncology Reports, 2015, 33, 391-396.	1.2	17
1342	Targeted therapies in oncology: perspectives on trial designs and practical considerations. Clinical Investigation, 2015, 5, 117-119.	0.0	0
1343	A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer. International Journal of Oncology, 2015, 46, 1473-1480.	1.4	9
1344	Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement. Thoracic Cancer, 2015, 6, 216-219.	0.8	13
1346	Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. Scientific Reports, 2015, 5, 14237.	1.6	51
1348	EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, 1720-1725.	0.5	58
1349	Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. Experimental Hematology and Oncology, 2015, 5, 24.	2.0	20
1350	Do we understand the personalized medicine paradigm?. EMBO Reports, 2015, 16, 133-136.	2.0	19
1351	Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine in EGFR-mutated lung adenocarcinoma: Retrospective and in vitro studies. International Journal of Oncology, 2015, 46, 989-998.	1.4	3
1352	A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncology Reports, 2015, 33, 1040-1048.	1.2	7
1354	Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology. Scientific Reports, 2015, 5, 11317.	1.6	33
1355	Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma. Internal Medicine, 2015, 54, 3185-3188.	0.3	7
1356	2. Preemptive Medicine from the Perspective of Physicians: Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2015, 104, 1808-1811.	0.0	0

#	Article	IF	Citations
1357	Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Nonâ€“Small-Cell Lung Cancer with Activating EGFR Mutation. Journal of Thoracic Oncology, 2015, 10, 1189-1194.	0.5	26
1358	A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer. International Journal of Oncology, 2015, 46, 497-504.	1.4	29
1359	FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1131-1132.	0.5	0
1360	QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports, 2015, 5, 11934.	1.6	9
1362	ERÎ² localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations. Scientific Reports, 2015, 5, 11392.	1.6	19
1363	More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. Biomarker Insights, 2015, 10s3, BMI.S22436.	1.0	7
1364	Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis. Cancer Treatment Communications, 2015, 4, 169-171.	0.4	5
1365	Heterogeneity of EGFR mutations in a patient treated with gefitinib as neo-adjuvant chemotherapy. Cancer Treatment Communications, 2015, 4, 117-120.	0.4	0
1366	Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Nonâ€“Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI. Journal of Thoracic Oncology, 2015, 10, 1553-1559.	0.5	137
1367	Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: whatâ€™s new and whatâ€™s enough. Chinese Journal of Cancer, 2015, 34, 310-9.	4.9	13
1368	Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naÃ¯ve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. BMC Cancer, 2015, 15, 763.	1.1	18
1369	Overview of KRASâ€Driven Genetically Engineered Mouse Models of Nonâ€Small Cell Lung Cancer. Current Protocols in Pharmacology, 2015, 70, 14.35.1-14.35.16.	4.0	12
1370	Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. Journal of Translational Medicine, 2015, 13, 257.	1.8	26
1371	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer, 2015, 121, 3212-3220.	2.0	160
1372	Decision to adopt medical technology under the <scp>N</scp>ational <scp>H</scp>ealth <scp>I</scp>nsurance <scp>S</scp>ystem in <scp>T</scp>aiwan: case study of new molecular targeted drugs among nonâ€small cell lung cancer patients. Journal of Evaluation in Clinical Practice, 2015, 21, 808-816.	0.9	6
1373	Primary TKI Resistance in Advanced Non-small Cell Lung Cancer with EGFR Mutation: An Open Question. Tumori, 2015, 101, e115-e117.	0.6	5
1374	Anterior Gradient 2 is Correlated with EGFR Mutation in Lung Adenocarcinoma Tissues. International Journal of Biological Markers, 2015, 30, 234-242.	0.7	4
1375	Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine. Proteomics - Clinical Applications, 2015, 9, 928-937.	0.8	32

#	Article	IF	Citations
1376	Keap1â€“Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics. Chronic Diseases and Translational Medicine, 2015, 1, 175-186.	0.9	36
1377	Adequacy of Malignant Pleural Effusion for Epidermal Growth Factor Receptor Mutation Analysis Using the Pyrosequencing Method. Pleura (Thousand Oaks, Ventura County, Calif), 2015, 2, 237399751561658.	0.2	2
1378	IMPRESS is impressing. Lung Cancer Management, 2015, 4, 51-53.	1.5	1
1379	Epidermal Growth Factor Receptorâ€“Mutant Lung Cancer. Cancer Journal (Sudbury, Mass), 2015, 21, 371-377.	1.0	40
1380	Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. Anti-Cancer Drugs, 2015, 26, 995-1003.	0.7	15
1381	The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers, 2015, 7, 1815-1846.	1.7	107
1382	Anti-HER3 Antibody Patritumab Overcomes Resistance to EGFR Inhibitor in Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2015, 55, 948-955.	0.0	0
1383	Prognostic impact of initial maximum standardized uptake value of 18F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib. OncoTargets and Therapy, 2015, 8, 3749.	1.0	6
1384	The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis. Oncotarget, 2015, 6, 25696-25700.	0.8	24
1385	Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget, 2015, 6, 30850-30858.	0.8	72
1386	Clinical development of nintedanib for advanced non-small-cell lung cancer. Therapeutics and Clinical Risk Management, 2015, 11, 1701.	0.9	10
1387	Thyroid transcription factor-1 expression is significantly associated with mutations in exon 21 of the epidermal growth factor receptor gene in Chinese patients with lung adenocarcinoma. OncoTargets and Therapy, 2015, 8, 2469.	1.0	9
1388	Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer. OncoTargets and Therapy, 2015, 9, 13.	1.0	3
1389	Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer. OncoTargets and Therapy, 2015, 8, 893.	1.0	15
1390	Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Management and Research, 2015, 7, 75.	0.9	31
1391	EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma. OncoTargets and Therapy, 2015, 8, 3017.	1.0	12
1392	The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011. Einstein (Sao Paulo, Brazil), 2015, 13, 215-220.	0.3	2
1393	Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget, 2015, 6, 34300-34308.	0.8	70

#	Article	IF	Citations
1394	miRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: beyond â€˜traditional mechanismsâ€™ of resistance. Ecancermedicalscience, 2015, 9, 569.	0.6	12
1395	Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer. Oncology Letters, 2015, 10, 1135-1140.	0.8	6
1396	Combating Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e165-e173.	1.8	16
1397	The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib. Tuberculosis and Respiratory Diseases, 2015, 78, 315.	0.7	3
1398	Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers, 2015, 7, 763-783.	1.7	59
1399	Epiregulin as a therapeutic target in non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2015, 6, 91.	1.3	24
1400	Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?. Drug Design, Development and Therapy, 2015, 9, 5641.	2.0	24
1401	Diagnosing Lung Cancer in the 21st Century: Are We Ready to Meet the Challenge of Individualized Care?. Current Oncology, 2015, 22, 272-278.	0.9	8
1402	Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer. OncoTargets and Therapy, 2015, 8, 3289.	1.0	22
1403	Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. PLoS ONE, 2015, 10, e0121211.	1.1	16
1404	Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib. PLoS ONE, 2015, 10, e0123901.	1.1	12
1405	Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma. PLoS ONE, 2015, 10, e0127092.	1.1	45
1406	Crizotinib-Induced Abnormal Signal Processing in the Retina. PLoS ONE, 2015, 10, e0135521.	1.1	17
1407	The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis. PLoS ONE, 2015, 10, e0135829.	1.1	15
1408	Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC. OncoTargets and Therapy, 2015, 8, 3227.	1.0	13
1409	Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors. OncoTargets and Therapy, 2015, 8, 1137.	1.0	21
1410	Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. Jornal Brasileiro De Pneumologia, 2015, 41, 365-375.	0.4	31
1411	The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on DifferentEGFRMutation Lung Adenocarcinoma. BioMed Research International, 2015, 2015, 1-8.	0.9	0

#	Article	IF	Citations
1412	Combination of EGFR-TKI and Platinum-based Therapy for EGFR-mutated Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2015, 55, 871-878.	0.0	0
1413	Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget, 2015, 6, 5465-5474.	0.8	116
1415	A Phase III Study Comparing Gefitinib and Inserted Platinum-doublet Chemotherapy with Gefitinib as a First-line Treatment for Patients with Advanced Non-squamous Non-small Cell Lung Cancer Harboring <i>EGFR</i> Activating Mutations. Japanese Journal of Lung Cancer, 2015, 55, 879-884.	0.0	1
1416	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget, 2015, 6, 26814-26825.	0.8	152
1417	The Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic Testing. Journal of Pathology and Translational Medicine, 2015, 49, 300-309.	0.4	39
1418	Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy. Critical Reviews in Oncogenesis, 2015, 20, 357-371.	0.2	8
1419	Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World Journal of Clinical Oncology, 2015, 6, 133.	0.9	83
1420	Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer--data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Japanese Journal of Clinical Oncology, 2015, 45, 670-676.	0.6	33
1421	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications, 2015, 6, 6377.	5.8	498
1422	Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Drug Resistance Updates, 2015, 20, 12-28.	6.5	103
1423	EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clinical Cancer Research, 2015, 21, 2221-2226.	3.2	72
1424	Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations. International Journal of Clinical Oncology, 2015, 20, 1122-1129.	1.0	12
1426	Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?. Lung Cancer, 2015, 89, 19-26.	0.9	7
1427	Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Future Oncology, 2015, 11, 1109-1122.	1.1	18
1428	Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer, 2015, 88, 187-194.	0.9	68
1429	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clinical Cancer Research, 2015, 21, 3924-3933.	3.2	459
1430	Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target. Oncogene, 2015, 34, 4834-4844.	2.6	70
1431	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncology, The, 2015, 16, 830-838.	5.1	786

#	Article	IF	Citations
1432	The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma. Journal of Neuro-Oncology, 2015, 124, 79-85.	1.4	32
1433	EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncology, 2015, 11, 1611-1623.	1.1	82
1434	New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material. , 2015, , 129-154.		0
1435	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Archives of Toxicology, 2015, 89, 1227-1240.	1.9	42
1436	A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test. Cancer Chemotherapy and Pharmacology, 2015, 75, 1229-1236.	1.1	7
1437	Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Cancer Chemotherapy and Pharmacology, 2015, 76, 155-161.	1.1	34
1438	Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1427-1439.	1.2	12
1439	Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations. Clinical and Translational Oncology, 2015, 17, 702-709.	1.2	12
1440	Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival. Lung Cancer, 2015, 88, 139-146.	0.9	31
1441	A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Annals of Oncology, 2015, 26, 1401-1408.	0.6	77
1442	Crizotinib in the management of advanced-stage non-small-cell lung cancer. Future Oncology, 2015, 11, 735-745.	1.1	16
1443	Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. Therapeutic Advances in Respiratory Disease, 2015, 9, 242-250.	1.0	42
1444	MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation. BMC Cancer, 2015, 15, 31.	1.1	29
1445	The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer. BMC Cancer, 2015, 15, 386.	1.1	27
1446	Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Molecular Cancer, 2015, 14, 100.	7.9	75
1447	Pretreatment levels of the serum biomarkers CEA, CYFRA 21â€“1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients. SpringerPlus, 2015, 4, 171.	1.2	30
1448	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clinical Cancer Research, 2015, 21, 3913-3923.	3.2	318
1449	Targeting EGFR in lung cancer: Lessons learned and future perspectives. Molecular Aspects of Medicine, 2015, 45, 67-73.	2.7	42

#	Article	IF	Citations
1450	Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases. JAMA Oncology, 2015, 1, 457.	3.4	190
1451	Integrating biomarkers in colorectal cancer trials in the West and China. Nature Reviews Clinical Oncology, 2015, 12, 553-560.	12.5	11
1452	Induction of PD-L1 Expression by the EML4â€“ALK Oncoprotein and Downstream Signaling Pathways in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 4014-4021.	3.2	392
1453	Variation in pre-PCR processing of FFPE samples leads to discrepancies inBRAFandEGFRmutation detection: a diagnostic RING trial. Journal of Clinical Pathology, 2015, 68, 111-118.	1.0	34
1454	Experience with erlotinib in the treatment of non-small cell lung cancer. Therapeutic Advances in Respiratory Disease, 2015, 9, 146-163.	1.0	25
1455	Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe. Journal of Thoracic Oncology, 2015, 10, 1370-1374.	0.5	25
1456	Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Annals of Oncology, 2015, 26, vii83.	0.6	0
1457	Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced nonâ€small cell lung cancer harboring activating <scp>EGFR</scp> mutations: Subgroup analysis of <scp>LUX</scp>â€Lung 3. Cancer Science, 2015, 106, 1202-1211.	1.7	99
1458	New insights into the molecular profile of lung adenocarcinoma and implications for therapy. Expert Review of Anticancer Therapy, 2015, 15, 361-364.	1.1	1
1459	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 5439-5444.	3.2	104
1460	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). OncoImmunology, 2015, 4, e1049804.	2.1	51
1461	Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis. BMJ Open Respiratory Research, 2015, 2, e000075.	1.2	5
1462	Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1421-1429.	0.5	2
1463	Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer. Medicine (United States), 2015, 94, e2303.	0.4	5
1464	Cancers bronchiques non Ã petites cellules mutÃ©s ou rÃ©arrangÃ©s : de la premiere Ã¡ la Ã©niÃ¨me ligne. Revue Des Maladies Respiratoires Actualites, 2015, 7, 497-505.	0.0	0
1465	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. Journal of Thoracic Oncology, 2015, 10, 793-799.	0.5	199
1466	BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations. Medicine (United States), 2015, 94, e1263.	0.4	18
1467	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. Journal of Thoracic Oncology, 2015, 10, 1341-1348.	0.5	18

#	Article	IF	Citations
1468	Indications de rÃ©animation en oncologie thoracique. Revue Des Maladies Respiratoires Actualites, 2015, 7, 545-553.	0.0	1
1469	Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. International Journal of Oncology, 2015, 46, 1039-1050.	1.4	40
1470	Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3. International Journal of Oncology, 2015, 46, 2083-2095.	1.4	22
1471	Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells. Oncology Reports, 2015, 34, 3187-3195.	1.2	13
1472	Advances in Molecular Biology of Lung Disease. Chest, 2015, 148, 1063-1072.	0.4	18
1473	The Challenges of Precision Oncology Drug Development and Implementation. Public Health Genomics, 2015, 18, 338-348.	0.6	15
1474	Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations. Oncology, 2015, 89, 275-280.	0.9	14
1475	Clinical potential of gene mutations in lung cancer. Clinical and Translational Medicine, 2015, 4, 33.	1.7	36
1476	Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC. Oncology, 2015, 89, 53-59.	0.9	13
1477	Selection criteria for intensive care unit referral of lung cancer patients: a pilot study. European Respiratory Journal, 2015, 45, 491-500.	3.1	26
1478	Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Nonâ€“Small-Cell Lung Cancer. AÂRandomized Phase II Clinical Trial. Clinical Lung Cancer, 2015, 16, 193-199.	1.1	13
1479	Histologic Evolution From Adenocarcinoma to Squamous Cell Carcinoma After Gefitinib Treatment. Annals of Thoracic Surgery, 2015, 99, 316-319.	0.7	32
1480	EGFR T790M resistance mutation in non small-cell lung carcinoma. Clinica Chimica Acta, 2015, 444, 81-85.	0.5	61
1481	Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. Targeted Oncology, 2015, 10, 153-170.	1.7	51
1482	Somatic Diseases (Cancer). , 2015, , 343-360.		0
1483	Genomic profiling of small-cell lung cancer: the era of targeted therapies. Japanese Journal of Clinical Oncology, 2015, 45, 513-9.	0.6	17
1484	Emerging drugs for squamous cell lung cancer. Expert Opinion on Emerging Drugs, 2015, 20, 149-160.	1.0	18
1485	Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Annals of Oncology, 2015, 26, 888-894.	0.6	97

#	Article	IF	Citations
1486	Chimeric ubiquitin ligases inhibit non-small cell lung cancer via negative modulation of EGFR signaling. Cancer Letters, 2015, 359, 57-64.	3.2	11
1487	Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer, 2015, 88, 63-69.	0.9	78
1488	Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations. Medical Oncology, 2015, 32, 40.	1.2	16
1489	Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced nonâ€small cell lung cancer: A comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. Cancer Cytopathology, 2015, 123, 117-122.	1.4	58
1490	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Reports, 2015, 16, 280-296.	2.0	200
1491	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Nonâ€“Small-Cell Lung Cancer and Brain Metastases. Journal of Clinical Oncology, 2015, 33, 1881-1888.	0.8	555
1492	EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer. Medical Oncology, 2015, 32, 420.	1.2	3
1493	Current and Future Approaches in the Management of Nonâ€“Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. Clinical Lung Cancer, 2015, 16, 252-261.	1.1	27
1494	The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer, 2015, 87, 169-175.	0.9	81
1495	Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): A feasibility study. Experimental and Molecular Pathology, 2015, 98, 113-118.	0.9	9
1496	A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). Lung Cancer, 2015, 87, 136-140.	0.9	16
1497	Comparison of Gefitinib Versus VMP in the Combination with Radiotherapy for Multiple Brain Metastases from Non-small Cell Lung Cancer. Cell Biochemistry and Biophysics, 2015, 71, 1261-1265.	0.9	18
1498	The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer, 2015, 121, E1-6.	2.0	55
1499	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, The, 2015, 16, 141-151.	5.1	1,369
1500	A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax, 2015, 70, 359-367.	2.7	104
1501	Adaptive stress signaling in targeted cancer therapy resistance. Oncogene, 2015, 34, 5599-5606.	2.6	57
1502	The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials. Oncologist, 2015, 20, 307-315.	1.9	51
1503	The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). Tumor Biology, 2015, 36, 2491-2499.	0.8	7

#	Article	IF	Citations
1504	Molecular histology of lung cancer: From targets to treatments. Cancer Treatment Reviews, 2015, 41, 361-375.	3.4	142
1505	Can <scp>EGFR</scp> mutation status be reliably determined in preâ€operative needle biopsies from adenocarcinomas of the lung?. Apmis, 2015, 123, 289-297.	0.9	1
1506	Complex Decisions for Firstâ€Line and Maintenance Treatment of Advanced Wildâ€Type Nonâ€Small Cell Lung Cancer. Oncologist, 2015, 20, 299-306.	1.9	11
1507	First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies. Expert Opinion on Pharmacotherapy, 2015, 16, 465-472.	0.9	29
1508	Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. Tumor Biology, 2015, 36, 5505-5513.	0.8	7
1509	Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. Targeted Oncology, 2015, 10, 247-253.	1.7	54
1510	Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients. Annals of Surgical Oncology, 2015, 22, 2593-2598.	0.7	14
1511	Update in lung cancer: Prologue to a modern review series. Respirology, 2015, 20, 183-184.	1.3	12
1512	The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. International Journal of Clinical Oncology, 2015, 20, 668-673.	1.0	13
1513	EGFRâ€"TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. Cancer Chemotherapy and Pharmacology, 2015, 75, 197-206.	1.1	26
1514	Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naÃ¯ve patients with advanced non-squamous non-small cell lung cancer. International Journal of Clinical Oncology, 2015, 20, 659-667.	1.0	2
1515	Role of FDG PET/CT in assessing response to targeted therapy in metastatic lung cancers: Morphological versus metabolic criteria. Indian Journal of Nuclear Medicine, 2015, 30, 21.	0.1	12
1516	Advances in target therapy in lung cancer. European Respiratory Review, 2015, 24, 23-29.	3.0	28
1517	The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells. Scientific Reports, 2015, 5, 8629.	1.6	20
1518	Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9990-9995.	3.3	31
1519	Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer Chemotherapy and Pharmacology, 2015, 76, 251-256.	1.1	11
1520	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clinical Cancer Research, 2015, 21, 5305-5313.	3.2	164
1521	Comprehensive detection of diverse exon 19 deletion mutations of EGFR in lung Cancer by a single probe set. Biosensors and Bioelectronics, 2015, 74, 849-855.	5.3	11

#	Article	IF	Citations
1522	Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Lung Cancer, 2015, 89, 337-342.	0.9	43
1523	Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges. Pharmacogenomics, 2015, 16, 1149-1160.	0.6	15
1524	First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation. Clinical Lung Cancer, 2015, 16, e259-e261.	1.1	5
1525	Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Critical Reviews in Oncology/Hematology, 2015, 94, 213-227.	2.0	51
1526	Relevance of EGFR gene mutation with pathological features and prognosis in patients with nonâ€“smallâ€“cell lung carcinoma. Asian Pacific Journal of Tropical Medicine, 2015, 8, 249-252.	0.4	2
1527	Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Scientific Reports, 2015, 5, 8477.	1.6	111
1528	EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Nonâ€“Small Cell Lung Cancer in Germany: An Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1254-1261.	1.1	38
1529	Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma. Molecular Cancer Therapeutics, 2015, 14, 2238-2248.	1.9	19
1530	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA. Clinical Chemistry, 2015, 61, 1191-1196.	1.5	99
1531	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. Journal of Clinical Oncology, 2015, 33, 2472-2480.	0.8	94
1532	Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 337	0.6	406
1533	EGFRMutations in Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2015, 1, 146.	3.4	33
1534	Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection. European Journal of Cardio-thoracic Surgery, 2015, 47, 556-562.	0.6	37
1535	Shorter EGFR Dinucleotide Repeat Length Predicts Better Response of Patients with Advanced Non-small Cell Lung Cancer to EGFR Tyrosine Kinase Inhibitor. Cell Biochemistry and Biophysics, 2015, 73, 799-804.	0.9	1
1536	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review. Current Oncology, 2015, 22, 183-215.	0.9	59
1537	EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models. Medical Oncology, 2015, 32, 205.	1.2	27
1538	Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy. Lung Cancer: Targets and Therapy, 2015, 6, 1.	1.3	7
1539	Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma. Lung Cancer, 2015, 90, 199-204.	0.9	66

#	Article	IF	Citations
1540	Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs, 2015, 75, 1335-1348.	4.9	104
1541	A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. European Journal of Cancer, 2015, 51, 1904-1910.	1.3	14
1542	Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs, 2015, 29, 167-183.	2.2	59
1543	Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. Lung Cancer, 2015, 90, 65-70.	0.9	42
1544	First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Annals of Oncology, 2015, 26, 1883-1889.	0.6	616
1545	Cancer modelling in the NGS era â€“ Part I: Emerging technology and initial modelling. Critical Reviews in Oncology/Hematology, 2015, 96, 274-307.	2.0	9
1546	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clinical Cancer Research, 2015, 21, 3196-3203.	3.2	427
1547	Emerging treatment for advanced lung cancer withEGFRmutation. Expert Opinion on Emerging Drugs, 2015, 20, 597-612.	1.0	22
1548	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology, The, 2015, 16, 990-998.	5.1	353
1549	Chemotherapy for lung cancer: still alive!. Japanese Journal of Clinical Oncology, 2015, 45, 609-610.	0.6	1
1550	Small Molecule Inhibition of MERTK Is Efficacious in Nonâ€“Small Cell Lung Cancer Models Independent of Driver Oncogene Status. Molecular Cancer Therapeutics, 2015, 14, 2014-2022.	1.9	45
1551	Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany. Pharmacoeconomics, 2015, 33, 1215-1228.	1.7	23
1552	Genomic alterations in lung adenocarcinoma. Lancet Oncology, The, 2015, 16, e342-e351.	5.1	302
1553	Biomarkers in Lung Adenocarcinoma: A Decade of Progress. Archives of Pathology and Laboratory Medicine, 2015, 139, 469-480.	1.2	66
1554	DUSP1 Expression Induced by HDAC1 Inhibition Mediates Gefitinib Sensitivity in Nonâ€“Small Cell Lung Cancers. Clinical Cancer Research, 2015, 21, 428-438.	3.2	35
1555	Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 2015, 88, 74-79.	0.9	157
1556	The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discovery, 2015, 5, 475-487.	7.7	501
1557	Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials. Oncologist, 2015, 20, 400-410.	1.9	123

#	Article	IF	Citations
1558	AZD9291 in EGFR Inhibitorâ€“Resistant Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 1689-1699.	13.9	1,802
1559	Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. Thoracic Cancer, 2015, 6, 224-226.	0.8	1
1560	Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients WithÂEpidermal Growth Factor Receptor MutantÂLung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorÂTherapy. Clinical Lung Cancer, 2015, 16, 228-236.	1.1	23
1561	Disease flare after gefitinib discontinuation. Respiratory Investigation, 2015, 53, 68-72.	0.9	10
1562	Cross-reactivity of EGFR L858R mutation-specific antibody in HER2 positive gastric adenocarcinomas. Revista Espanola De Patologia, 2015, 48, 75-79.	0.6	1
1564	Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. Seminars in Thoracic and Cardiovascular Surgery, 2015, 27, 36-48.	0.4	8
1565	Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal. Lung Cancer, 2015, 88, 16-23.	0.9	31
1566	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 1958-1965.	0.8	280
1567	Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System. Clinical Lung Cancer, 2015, 16, e213-e221.	1.1	18
1568	Phase I/II study of gefitinib (IressaÂ®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 475-483.	1.1	62
1569	Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemotherapy and Pharmacology, 2015, 75, 521-526.	1.1	62
1570	Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. European Radiology, 2015, 25, 1257-1266.	2.3	72
1571	A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1669-1678.	1.2	9
1572	Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. Tumor Biology, 2015, 36, 861-869.	0.8	8
1573	Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiology, 2015, 39, 291-297.	0.8	39
1574	Fuzheng Kangâ€™ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Trials, 2015, 16, 146.	0.7	18
1575	The epidermal growth factor receptor (EGRF) in lung cancer. Translational Respiratory Medicine, 2015, 3, 1.	3.8	34
1576	Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Cancer Treatment Reviews, 2015, 41, 401-411.	3.4	40

#	Article	IF	Citations
1577	Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. Expert Opinion on Drug Safety, 2015, 14, 97-110.	1.0	7
1578	Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors. Future Oncology, 2015, 11, 1259-1274.	1.1	10
1579	Addressing the unmet need in lung cancer: The potential of immuno-oncology. Cancer Treatment Reviews, 2015, 41, 465-475.	3.4	30
1580	Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation. Clinical Cancer Research, 2015, 21, 642-651.	3.2	98
1581	Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncology, 2015, 1, 149.	3.4	224
1582	Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. Annals of Oncology, 2015, 26, 1500-1504.	0.6	24
1583	Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer. Cancer and Metastasis Reviews, 2015, 34, 173-182.	2.7	6
1584	EPMA position paper in cancer: current overview and future perspectives. EPMA Journal, 2015, 6, 9.	3.3	86
1585	Emerging paradigms in targeted treatments for Asian patients with NSCLC. Expert Opinion on Pharmacotherapy, 2015, 16, 1167-1176.	0.9	16
1586	Physiologic Responsiveness Should Guide Entry into Randomized Controlled Trials. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1416-1419.	2.5	45
1587	Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial. Journal of Clinical Oncology, 2015, 33, 1000-1007.	0.8	206
1588	Anisamide-Decorated pH-Sensitive Degradable Chimaeric Polymersomes Mediate Potent and Targeted Protein Delivery to Lung Cancer Cells. Biomacromolecules, 2015, 16, 1726-1735.	2.6	73
1589	Histologic Classification and Its Need for Treatment of Lung Cancer. , 2015, , 1-14.		0
1590	Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. Future Oncology, 2015, 11, 385-397.	1.1	29
1591	Lâ€™afatinib, un nouveau mÃ©dicament dans le cancer bronchique. Actualites Pharmaceutiques, 2015, 54, 42-45.	0.0	0
1592	Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Nonâ€“Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR. Clinical Cancer Research, 2015, 21, 3552-3560.	3.2	201
1593	Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling. Cancer Cell, 2015, 27, 574-588.	7.7	485
1594	EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells. Biochemical and Biophysical Research Communications, 2015, 461, 28-34.	1.0	54

#	Article	IF	Citations
1595	PET in the management of locally advanced and metastatic NSCLC. Nature Reviews Clinical Oncology, 2015, 12, 395-407.	12.5	75
1596	2-Methoxy-1,4-naphthoquinone (MNQ) induces apoptosis of A549 lung adenocarcinoma cells via oxidation-triggered JNK and p38 MAPK signaling pathways. Life Sciences, 2015, 135, 158-164.	2.0	37
1597	Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations. Journal of Thoracic Oncology, 2015, 10, 59-66.	0.5	13
1598	Molecularly Targeted Therapies in Nonâ€“Small-Cell Lung Cancer Annual Update 2014. Journal of Thoracic Oncology, 2015, 10, S1-S63.	0.5	119
1599	Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncology, The, 2015, 16, e165-e172.	5.1	685
1600	Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer. Current Opinion in Oncology, 2015, 27, 102-107.	1.1	11
1601	Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 665-672.	0.5	28
1602	EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey. Journal of Thoracic Oncology, 2015, 10, 438-445.	0.5	156
1603	Inhibition of Î²-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Nonâ€“small-cell Lung Cancer with a T790M Mutation. Journal of Thoracic Oncology, 2015, 10, 93-101.	0.5	44
1604	Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)â€“Pretreated Nonâ€“Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease. Journal of Thoracic Oncology, 2015, 10, 156-163.	0.5	238
1605	Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Nonâ€“Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001. Journal of Thoracic Oncology, 2015, 10, 486-491.	0.5	93
1606	Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Nonâ€“Small-Cell Lung Cancer (INFORM; C-TONG 0804). Journal of Thoracic Oncology, 2015, 10, 655-664.	0.5	36
1607	Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer. Anti-Cancer Drugs, 2015, 26, 456-463.	0.7	6
1608	Hepatocyte growth factor and Met in drug discovery. Journal of Biochemistry, 2015, 157, 271-284.	0.9	67
1609	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2015, 27, 94-101.	1.1	126
1610	Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians. Journal of the American Board of Family Medicine, 2015, 28, 124-133.	0.8	28
1611	Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. Future Oncology, 2015, 11, 1245-1257.	1.1	66
1612	Molecular targeted therapy in the treatment of advanced stage nonâ€small cell lung cancer (<scp>NSCLC</scp>). Respirology, 2015, 20, 370-378.	1.3	119

#	Article	IF	Citations
1613	Management of EGFR mutated nonsmall cell lung carcinoma patients. European Respiratory Journal, 2015, 45, 1132-1141.	3.1	36
1614	Targeted therapy in cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 1113-1132.	1.1	139
1615	Predictive biomarkers in precision medicine and drug development against lung cancer. Chinese Journal of Cancer, 2015, 34, 295-309.	4.9	34
1617	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncology, The, 2015, 16, e447-e459.	5.1	325
1618	Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. Therapeutic Advances in Medical Oncology, 2015, 7, 263-273.	1.4	47
1619	Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer, 2015, 90, 307-313.	0.9	23
1620	Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. Journal of Structural Biology, 2015, 192, 539-544.	1.3	106
1621	Next-generation sequencing and empowering personalised cancer medicine. Drug Discovery Today, 2015, 20, 1470-1475.	3.2	22
1622	A Novel and Efficient Synthesis of Anti-Cancer Agent, Mereletinib. Journal of Chemical Research, 2015, 39, 318-320.	0.6	4
1623	Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor. Lung Cancer, 2015, 90, 364-368.	0.9	26
1624	Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer. BMC Cancer, 2015, 15, 241.	1.1	16
1625	Precision medicine in oncology drug development: a pharma perspective. Drug Discovery Today, 2015, 20, 1455-1463.	3.2	24
1626	Survival outcomes for oligometastasis in resected non-small cell lung cancer. Asian Cardiovascular and Thoracic Annals, 2015, 23, 937-944.	0.2	24
1627	WT1 Enhances Proliferation and Impedes Apoptosis in KRAS Mutant NSCLC via Targeting cMyc. Cellular Physiology and Biochemistry, 2015, 35, 647-662.	1.1	16
1628	Feasibility and Accuracy of Molecular Testing in Specimens Obtained with Small Biopsy Forceps: Comparison with the Results of Surgical Specimens. Respiration, 2015, 89, 235-242.	1.2	14
1629	Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. Pharmacogenomics, 2015, 16, 1135-1148.	0.6	26
1630	Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drugâ€“drug interaction. Cancer Chemotherapy and Pharmacology, 2015, 76, 713-721.	1.1	2
1632	Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1284-1291.	0.7	7

#	Article	IF	Citations
1633	Advances in molecularâ€based personalized nonâ€smallâ€cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Cancer Medicine, 2015, 4, 1621-1632.	1.3	48
1634	Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress. Current Treatment Options in Oncology, 2015, 16, 51.	1.3	9
1635	Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. Drugs and Aging, 2015, 32, 907-916.	1.3	9
1636	Patient-centric trials for therapeutic development in precision oncology. Nature, 2015, 526, 361-370.	13.7	251
1637	Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. British Journal of Cancer, 2015, 113, 1519-1528.	2.9	94
1638	Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. Future Oncology, 2015, 11, 489-500.	1.1	20
1639	Considerations on the management of EGF receptor-TKIs for brain metastases in EGFR-mutant lung carcinoma patients. Lung Cancer Management, 2015, 4, 43-49.	1.5	1
1640	Lung cancer: Biology and treatment options. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1856, 189-210.	3.3	526
1641	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2015, 1, 238.	3.4	44
1642	Systemic Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2015, 33, 3488-3515.	0.8	606
1643	Inhibition of ABCB1 Overcomes Cancer Stem Cellâ€“like Properties and Acquired Resistance to MET Inhibitors in Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2015, 14, 2433-2440.	1.9	51
1644	Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer, 2015, 89, 287-293.	0.9	29
1645	Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. Lung Cancer, 2015, 90, 71-77.	0.9	29
1646	EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 835-841.	1.1	40
1647	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. Lung Cancer, 2015, 90, 261-266.	0.9	4
1648	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 1324-1334.	5.1	897
1649	Development of a Center for Personalized Cancer Care at a Regional Cancer Center. Journal of Molecular Diagnostics, 2015, 17, 695-704.	1.2	14
1650	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Therapeutic Advances in Medical Oncology, 2015, 7, 274-290.	1.4	20

#	Article	IF	Citations
1651	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. Expert Opinion on Biological Therapy, 2015, 15, 1553-1566.	1.4	22
1652	Reengineered tricyclic anti-cancer agents. Bioorganic and Medicinal Chemistry, 2015, 23, 6528-6534.	1.4	58
1653	Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer, 2015, 90, 128-134.	0.9	80
1654	Low-frequency KRAS mutations are prevalent in lung adenocarcinomas. Personalized Medicine, 2015, 12, 83-98.	0.8	19
1655	Should Tyrosine Kinase Inhibitors Be Considered for Advanced Nonâ€“Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials. Clinical Lung Cancer, 2015, 16, 173-182.e4.	1.1	20
1656	Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptorâ€“Mutated Nonâ€“Small-Cell Lung Cancer With T790M Mutations. Clinical Lung Cancer, 2015, 16, e97-e99.	1.1	3
1657	Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 385-390.	1.1	115
1658	Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation. Lung Cancer, 2015, 88, 181-186.	0.9	29
1659	A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?. Clinical Lung Cancer, 2015, 16, e173-e181.	1.1	23
1660	Pharmacokinetics of Gefitinib in a Patient with Non-Small Cell Lung Cancer Undergoing Continuous Ambulatory Peritoneal Dialysis. Case Reports in Oncology, 2015, 8, 78-82.	0.3	9
1661	RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Lung Cancer, 2015, 90, 477-483.	0.9	43
1662	MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. Lung Cancer, 2015, 90, 590-597.	0.9	32
1663	Downregulation of the microRNA-1/133a cluster enhances cancer cell migration and invasion in lung-squamous cell carcinoma via regulation of Coronin1C. Journal of Human Genetics, 2015, 60, 53-61.	1.1	61
1664	Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Lung Cancer, 2015, 87, 122-129.	0.9	54
1665	Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro-Oncology, 2015, 17, 296-302.	0.6	72
1666	Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials. Current Medical Research and Opinion, 2015, 31, 25-33.	0.9	9
1667	Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. Journal of Chemotherapy, 2015, 27, 40-51.	0.7	56
1668	Outcomes by Tumor Histology and KRAS Mutation Status After Lung Stereotactic BodyÂRadiation Therapy for Early-Stage Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 24-32.	1.1	67

#	Article	IF	Citations
1669	Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment. Clinical Lung Cancer, 2015, 16, 60-66.	1.1	13
1670	Epidermal Growth Factor Receptor Mutation IsÂAssociated With Longer Local Control After Definitive Chemoradiotherapy in Patients WithÂStage III Nonsquamous Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 140-148.	0.4	53
1671	Optimizing the Sequence of Anti-EGFRâ€“Targeted Therapy in EGFR-Mutant Lung Cancer. Molecular Cancer Therapeutics, 2015, 14, 542-552.	1.9	28
1672	Pharmacogenomic biomarkers for personalized cancer treatment. Journal of Internal Medicine, 2015, 277, 201-217.	2.7	57
1673	Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. , 2015, , .		7
1675	Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics. Gut, 2015, 64, 627-635.	6.1	27
1676	Circulating tumour cells go green. Gut, 2015, 64, 528-530.	6.1	3
1677	Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. Intensive Care Medicine, 2015, 41, 164-165.	3.9	28
1679	Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene, 2015, 34, 3215-3225.	2.6	130
1680	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British Journal of Cancer, 2015, 112, 95-102.	2.9	515
1681	Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery, 2015, 47, 550-555.	0.6	29
1683	Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer. CardioVascular and Interventional Radiology, 2015, 38, 135-142.	0.9	46
1684	Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 182-192.	0.8	26
1685	Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer. Chinese Medical Journal, 2016, 129, 332-340.	0.9	18
1686	Analysis of the EGFR gene mutation in patients with nonsmall cell lung cancer in a Chinese population. Tropical Journal of Pharmaceutical Research, 2016, 15, 1637.	0.2	2
1687	FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget, 2016, 7, 55924-55938.	0.8	103
1688	The steady progress of targeted therapies, promising advances for lung cancer. Ecancermedicalscience, 2016, 10, 638.	0.6	6
1689	Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. Oncotarget, 2016, 7, 69450-69465.	0.8	60

#	Article	IF	Citations
1690	Quantification of DNA Extracted from Formalin Fixed Paraffin-Embeded Tissue Comparison of Three Techniques: Effect on PCR Efficiency. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, BC01-BC03.	0.8	3
1691	Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature. OncoTargets and Therapy, 2016, Volume 9, 4301-4305.	1.0	21
1692	Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor. OncoTargets and Therapy, 2016, 9, 1511.	1.0	11
1693	Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations. OncoTargets and Therapy, 2016, 9, 355.	1.0	4
1694	Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. OncoTargets and Therapy, 2016, 9, 929.	1.0	13
1695	Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR) Tj ETQq1 1 0.784314 rgBT /Ove		
1696	Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment. Oncotarget, 2016, 7, 71782-71789.	0.8	16
1697	Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations. Oncotarget, 2016, 7, 54965-54972.	0.8	6
1698	Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience, 2016, 10, 648.	0.6	29
1699	New targeted treatments for non-small-cell lung cancer – role of nivolumab. Biologics: Targets and Therapy, 2016, Volume 10, 103-117.	3.0	23
1700	Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Design, Development and Therapy, 2016, 10, 873.	2.0	33
1701	Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation. Molecular and Clinical Oncology, 2016, 5, 265-268.	0.4	12
1702	Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1. OncoTargets and Therapy, 2016, Volume 9, 5287-5295.	1.0	2
1703	Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients. OncoTargets and Therapy, 2016, Volume 9, 4671-4679.	1.0	2
1704	The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. OncoTargets and Therapy, 2016, 9, 833.	1.0	38
1705	EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy. OncoTargets and Therapy, 2016, Volume 9, 5153-5162.	1.0	11
1706	Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma. Tuberculosis and Respiratory Diseases, 2016, 79, 248.	0.7	41
1707	The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. Journal of Cancer, 2016, 7, 1901-1906.	1.2	5

#	Article	IF	Citations
1708	Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1194-1203.	0.5	9
1709	Quality in the Age of Precision Medicine: The Clinician Perspective. Journal of Oncology Practice, 2016, 12, 839-843.	2.5	8
1710	Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report. Translational Lung Cancer Research, 2016, 5, 532-537.	1.3	5
1711	Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget, 2016, 7, 3884-3896.	0.8	34
1712	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Translational Lung Cancer Research, 2016, 5, 563-578.	1.3	30
1713	A heterochronic genetic change from an EGFR mutation to an ALK rearrangement in a patient with lung adenocarcinoma: a case report. Journal of Thoracic Disease, 2016, 8, E345-E348.	0.6	2
1714	The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Journal of Thoracic Disease, 2016, 8, 3175-3186.	0.6	4
1715	A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting. Journal of Thoracic Disease, 2016, 8, E1520-E1524.	0.6	0
1716	Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?. Translational Lung Cancer Research, 2016, 5, 446-449.	1.3	6
1717	Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. Translational Lung Cancer Research, 2016, 5, 401-412.	1.3	56
1718	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?â€”current evidence and future perspectives. Translational Lung Cancer Research, 2016, 5, 628-636.	1.3	15
1719	Metastatic lung cancer in the age of targeted therapy: improving long-term survival. Translational Lung Cancer Research, 2016, 5, 727-730.	1.3	14
1720	Non-Small-Cell Lung Cancer Treatment. Juntendo Medical Journal, 2016, 62, 7-12.	0.1	1
1721	Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites?. Journal of Thoracic Disease, 2016, 8, E1517-E1519.	0.6	1
1722	Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations. Journal of Thoracic Disease, 2016, 8, E1293-E1295.	0.6	1
1723	The expression of SALL4 is significantly associated with EGFR, but not KRAS or EML4-ALK mutations in lung cancer. Journal of Thoracic Disease, 2016, 8, 2682-2688.	0.6	4
1724	Approach to Biomarker Testing: Perspectives from Various Specialties. Current Oncology, 2016, 23, 178-183.	0.9	5
1725	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget, 2016, 7, 20810-20824.	0.8	73

#	Article	IF	Citations
1726	Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. Translational Lung Cancer Research, 2016, 5, 525-531.	1.3	22
1727	Advances in targeted therapy and immunotherapy for treatment of lung cancer. Annals of Cancer Research and Therapy, 2016, 24, 1-6.	0.1	1
1728	EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method. Canadian Respiratory Journal, 2016, 2016, 1-7.	0.8	28
1729	Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. International Journal of Molecular Sciences, 2016, 17, 1186.	1.8	20
1730	Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. OncoTargets and Therapy, 2016, Volume 9, 5461-5473.	1.0	41
1731	The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget, 2016, 7, 78985-78993.	0.8	500
1732	EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP) Tj ETQq0 0 0 rgBT /Overlock 10	0.9	15
1733	Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions. International Journal of Molecular Sciences, 2016, 17, 1074.	1.8	26
1734	Pharmacogenomics in Pediatric Oncology: Review of Geneâ€"Drug Associations for Clinical Use. International Journal of Molecular Sciences, 2016, 17, 1502.	1.8	27
1735	Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer, 2016, 16, 593.	1.1	15
1736	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. Respiratory Research, 2016, 17, 105.	1.4	10
1737	Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report. World Journal of Surgical Oncology, 2016, 14, 175.	0.8	40
1738	Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. PLoS ONE, 2016, 11, e0154293.	1.1	11
1739	Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China. PLoS ONE, 2016, 11, e0151846.	1.1	17
1740	Gene Therapy for Human Lung Adenocarcinoma Using a Suicide Gene Driven by a Lung-Specific Promoter Delivered by JC Virus-Like Particles. PLoS ONE, 2016, 11, e0157865.	1.1	23
1741	Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis. PLoS ONE, 2016, 11, e0160148.	1.1	12
1742	Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-NaÃ¯ve Patients with Advanced Lung Adenocarcinoma. PLoS ONE, 2016, 11, e0161081.	1.1	34
1743	Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment. OncoTargets and Therapy, 2016, 9, 1579.	1.0	22

#	Article	IF	Citations
1744	Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. OncoTargets and Therapy, 2016, 9, 3711.	1.0	98
1745	Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis. OncoTargets and Therapy, 2016, 9, 1135.	1.0	17
1746	Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway. Theranostics, 2016, 6, 1232-1243.	4.6	42
1747	Overcoming Resistance to EGFR Inhibitors in NSCLC. Reviews on Recent Clinical Trials, 2016, 11, 99-105.	0.4	15
1748	The Current Situation and Problems of Re-biopsy in Non-small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations. Japanese Journal of Lung Cancer, 2016, 56, 331-336.	0.0	0
1749	Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. Oncotarget, 2016, 7, 49948-49960.	0.8	95
1750	Evaluation of Scoring Systems and Prognostic Factors in Patients With Spinal Metastases From Lung Cancer. Spine, 2016, 41, 638-644.	1.0	23
1751	Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 556-562.	0.6	3
1754	Bevacizumab beyond disease progression after firstâ€line treatment with bevacizumab plus chemotherapy in advanced nonsquamous nonâ€“small cell lung cancer (<scp>W</scp>est) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 422 T trial. Cancer, 2016, 122, 1050-1059.	2.0	35
1755	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2016, 99, 31-37.	0.9	31
1756	Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Lung Cancer, 2016, 101, 1-8.	0.9	118
1757	Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2016, 28, 115-121.	1.1	21
1758	Impact of the Bim Deletion Polymorphism on Survival Among Patients With Completely Resected Nonâ€“Small-Cell Lung Carcinoma. Journal of Global Oncology, 2016, 2, 15-25.	0.5	8
1759	Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2016, 34, 3233-3234.	0.8	0
1760	Targeted therapies for treatment of nonâ€small cell lung cancerâ€"Recent advances and future perspectives. International Journal of Cancer, 2016, 138, 2549-2561.	2.3	155
1761	Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells. Molecular Carcinogenesis, 2016, 55, 991-1001.	1.3	54
1762	Precision Oncology Medicine: The Clinical Relevance of Patientâ€Specific Biomarkers Used to Optimize Cancer Treatment. Journal of Clinical Pharmacology, 2016, 56, 1484-1499.	1.0	75
1763	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Supportive Care in Cancer, 2016, 24, 4057-4074.	1.0	21

#	Article	IF	Citations
1764	Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. Expert Opinion on Pharmacotherapy, 2016, 17, 1693-1701.	0.9	16
1765	Increased FLI-1 Expression is Associated With Poor Prognosis in Nonâ€“Small Cell Lung Cancers. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 556-561.	0.6	8
1766	Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Supportive and Palliative Care, 2016, 10, 152-156.	0.5	6
1767	Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with nonâ€smallâ€cell lung cancer. Biomedical Chromatography, 2016, 30, 1150-1154.	0.8	33
1768	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. The Cochrane Library, 2016, , CD010383.	1.5	146
1769	The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials. Chemotherapy, 2016, 61, 179-189.	0.8	5
1770	Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. Scientific Reports, 2016, 6, 37997.	1.6	31
1774	Relationship between miR-7 expression and treatment outcomes with gefitinib in non-small cell lung cancer. Oncology Letters, 2016, 12, 4613-4617.	0.8	7
1775	Inhibition wirkstoffresistenter Mutationsvarianten der Rezeptortyrosinkinase EGFR. Angewandte Chemie, 2016, 128, 11069-11073.	1.6	4
1776	Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma. Open Medicine (Poland), 2016, 11, 68-77.	0.6	10
1777	Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biology, 2016, 6, 160254.	1.5	21
1778	Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells. Cancer Science, 2016, 107, 1919-1928.	1.7	14
1779	Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression. Journal of Ethnopharmacology, 2016, 194, 918-929.	2.0	20
1780	Emerging therapeutic agents for lung cancer. Journal of Hematology and Oncology, 2016, 9, 138.	6.9	77
1781	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Biomedical Science, 2016, 23, 86.	2.6	41
1782	Indications de rÃ©animation en oncologie thoracique. Revue Des Maladies Respiratoires Actualites, 2016, 8, 506-514.	0.0	0
1783	Les cancers bronchiques non Ã petites cellules EGFR-mutÃ©s. Revue Des Maladies Respiratoires Actualites, 2016, 8, 373-381.	0.0	1
1784	Firstâ€line epidermal growth factor receptor (EGFR)â€“tyrosine kinase inhibitor alone or with wholeâ€brain radiotherapy for brain metastases in patients with EGFR â€mutated lung adenocarcinoma. Cancer Science, 2016, 107, 1800-1805.	1.7	53

#	Article	IF	Citations
1785	Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer. Oncology Letters, 2016, 12, 4598-4604.	0.8	49
1786	Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. Expert Opinion on Drug Safety, 2016, 15, 837-851.	1.0	14
1787	Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 1011-1018.	1.1	2
1788	Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational study. Cancer Treatment Communications, 2016, 5, 1-10.	0.4	1
1790	Clinical Reasoning: Stepwise paralysis in a patient with adenocarcinoma of lung. Neurology, 2016, 86, e122-e127.	1.5	2
1791	Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. Journal of Clinical Oncology, 2016, 34, 3248-3257.	0.8	130
1792	Development and validation of a UHPLCâ€“MS/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1025, 119-125.	1.2	0
1793	Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer. Oncology Letters, 2016, 11, 3-8.	0.8	10
1794	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer: Status in 2016. Journal of Thoracic Oncology, 2016, 11, 946-963.	0.5	173
1795	Molecular Targets in Advanced Therapeutics of Cancers: The Role of Pharmacogenetics. Oncology, 2016, 91, 3-12.	0.9	14
1796	Epidermal Growth Factor Receptor Activating Mutations in Squamous Histology of Lung Cancer Patients of Southern Bulgaria. Folia Medica, 2016, 57, 191-199.	0.2	2
1797	The Current and Evolving Role of PET in Personalized Management of Lung Cancer. PET Clinics, 2016, 11, 243-259.	1.5	7
1798	Integrin Î²1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway. Oncology Letters, 2016, 11, 535-542.	0.8	19
1799	Treatment ofEGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors. JAMA Oncology, 2016, 2, 948.	3.4	30
1800	Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase IIIÂRandomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Nonâ€“Small Cell Lung Carcinoma. Journal of Thoracic Oncology, 2016, 11, 1574-1585.	0.5	22
1801	Hepatotoxicity of targeted therapy for cancer. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 789-802.	1.5	16
1802	Amplification of FGFR1 gene and expression of FGFR1 protein is found in different histological types of lung carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 173-182.	1.4	17
1803	Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. Future Medicinal Chemistry, 2016, 8, 853-878.	1.1	15

#	Article	IF	Citations
1804	Safety of gefitinib in non-small cell lung cancer treatment. Expert Opinion on Drug Safety, 2016, 15, 993-1000.	1.0	14
1805	Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor. Cancer Chemotherapy and Pharmacology, 2016, 77, 1019-1029.	1.1	8
1806	Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer, 2016, 94, 68-73.	0.9	67
1807	Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. Therapeutic Advances in Respiratory Disease, 2016, 10, 256-264.	1.0	17
1808	Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter?. Journal of Clinical Oncology, 2016, 34, 774-776.	0.8	0
1809	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncology, The, 2016, 17, 577-589.	5.1	950
1810	The Conundrum of Genetic â€œDriversâ€•in Benign Conditions. Journal of the National Cancer Institute, 2016, 108, djw036.	3.0	113
1812	Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer. Journal of the Chinese Medical Association, 2016, 79, 248-255.	0.6	32
1813	NF-ÎºBâ€“driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2526-35.	3.3	71
1814	Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. Current Treatment Options in Oncology, 2016, 17, 25.	1.3	15
1815	Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 642-650.	5.1	352
1816	Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discovery, 2016, 6, 714-726.	7.7	139
1817	Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma. Oncology, 2016, 90, 289-298.	0.9	9
1818	Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of China. Molecular and Clinical Oncology, 2016, 4, 749-755.	0.4	15
1819	Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations. Oncology Reports, 2016, 35, 3460-3470.	1.2	8
1820	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Human Vaccines and Immunotherapeutics, 2016, 12, 2219-2231.	1.4	49
1821	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. Drugs, 2016, 76, 831-840.	4.9	13
1822	Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 2673-2680.	1.4	19

#	Article	IF	Citations
1823	Tyrosine kinase inhibitors as first-line treatment in NSCLC. Lancet Oncology, The, 2016, 17, 541-543.	5.1	6
1824	Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation. Pathology and Oncology Research, 2016, 22, 763-768.	0.9	25
1825	Gender Differences in Long-Term Survival after Surgery for Non-Small Cell Lung Cancer. Thoracic and Cardiovascular Surgeon, 2016, 64, 507-514.	0.4	13
1826	Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinibâ€effective patients with advanced <scp>NSCLC</scp>. Thoracic Cancer, 2016, 7, 422-427.	0.8	6
1827	PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. BMC Cancer, 2016, 16, 627.	1.1	40
1828	Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 2016, 99, 1-3.	0.9	12
1829	Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Annals of Oncology, 2016, 27, 2103-2110.	0.6	159
1830	Critical parameters in targeted drug development: the pharmacological audit trail. Seminars in Oncology, 2016, 43, 436-445.	0.8	64
1831	Resisting Resistance: Targeted Therapies in Lung Cancer. Trends in Cancer, 2016, 2, 350-364.	3.8	162
1833	Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study. Respiratory Investigation, 2016, 54, 462-467.	0.9	7
1835	Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials. Seminars in Oncology, 2016, 43, 446-452.	0.8	8
1836	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer Chemotherapy and Pharmacology, 2016, 78, 941-947.	1.1	6
1837	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. Expert Opinion on Pharmacotherapy, 2016, 17, 2253-2266.	0.9	26
1838	Quantification of epidermal growth factor receptor (<scp>EGFR</scp>) mutation may be a predictor of <scp>EGFR</scp>â€tyrosine kinase inhibitor treatment response. Thoracic Cancer, 2016, 7, 639-647.	0.8	6
1839	A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors. Pharmacological Reports, 2016, 68, 1140-1148.	1.5	13
1840	Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer. British Journal of Cancer, 2016, 115, 549-552.	2.9	11
1841	Clinical outcome of reflex EGFR mutation and ALK fusion testing in patients with non-squamous non-small cell lung cancer. Cancer Treatment and Research Communications, 2016, 9, 75-80.	0.7	0
1843	EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends in Pharmacological Sciences, 2016, 37, 887-903.	4.0	76

#	Article	IF	Citations
1844	The Emerging Role and Promise of Long Noncoding RNAs in Lung Cancer Treatment. Cellular Physiology and Biochemistry, 2016, 38, 2194-2206.	1.1	32
1845	Divide and Conquer to Treat Lung Cancer. New England Journal of Medicine, 2016, 375, 1892-1893.	13.9	17
1846	Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). Cancer Treatment and Research Communications, 2016, 9, 48-55.	0.7	7
1847	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in nonâ€“small cell lung cancer. Lung Cancer, 2016, 99, 79-87.	0.9	108
1848	Insight into the Inhibition of Drugâ€Resistant Mutants of the Receptor Tyrosine Kinase EGFR. Angewandte Chemie - International Edition, 2016, 55, 10909-10912.	7.2	54
1849	Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. Journal of Clinical Oncology, 2016, 34, 3258-3266.	0.8	153
1850	Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients. Oncology Letters, 2016, 11, 1413-1417.	0.8	10
1851	Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Nonâ€“Small Cell Lung Cancer Patients Treated with Antiâ€“PD-1/PD-L1 Antibodies. Journal of Thoracic Oncology, 2016, 11, 1927-1939.	0.5	63
1853	MEK inhibitor can reverse the resistance to bevacizumab in A 549 cells harboring Kirsten rat sarcoma oncogene homolog mutation. Thoracic Cancer, 2016, 7, 279-287.	0.8	7
1854	Small activating ribonucleic acid reverses tyrosine kinase inhibitor resistance in epidermal growth factor receptorâ€mutant lung cancer by increasing the expression of phosphatase and tensin homolog. Thoracic Cancer, 2016, 7, 481-485.	0.8	6
1855	Enhanced gefitinibâ€induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasiaâ€mutated kinase inhibition in nonâ€smallâ€cell lung cancer cells. Cancer Science, 2016, 107, 444-451.	1.7	7
1856	Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptorâ€tyrosine kinase inhibitor in lung cancer. Cancer Science, 2016, 107, 461-468.	1.7	31
1857	Combined inhibition of <scp>EZH</scp>2 and histone deacetylases as a potential epigenetic therapy for nonâ€smallâ€cell lung cancer cells. Cancer Science, 2016, 107, 955-962.	1.7	45
1858	Rebiopsy for patients with nonâ€smallâ€cell lung cancer after epidermal growth factor receptorâ€tyrosine kinase inhibitor failure. Cancer Science, 2016, 107, 1001-1005.	1.7	78
1859	R ad51 in regulating the radiosensitivity of nonâ€small cell lung cancer with different epidermal growth factor receptor mutation status. Thoracic Cancer, 2016, 7, 50-60.	0.8	24
1860	Pretreatment neutrophilâ€lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptorâ€mutant nonâ€small cell lung cancer patients treated with tyrosine kinase inhibitors. Thoracic Cancer, 2016, 7, 161-166.	0.8	16
1861	Synergistic antitumor activity of proâ€apoptotic agent <scp><scp>PACâ€1</scp></scp> with cisplatinum by the activation of <scp><scp>CASP3</scp></scp> in pulmonary adenocarcinoma cell line H1299. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 41-51.	0.7	4
1862	Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Science, 2016, 107, 713-720.	1.7	174

#	Article	IF	Citations
1863	Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Science, 2016, 107, 1179-1186.	1.7	305
1864	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. Investigational New Drugs, 2016, 34, 794-796.	1.2	17
1865	Phase II trial of weekly nab-paclitaxel for previously treated advanced nonâ€“small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. Lung Cancer, 2016, 99, 41-45.	0.9	28
1866	Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open, 2016, 1, e000060.	2.0	325
1867	Study of efficacy and safety of pulsatile administration of highâ€dose gefitinib or erlotinib for advanced nonâ€small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial. Thoracic Cancer, 2016, 7, 663-669.	0.8	19
1868	New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet, The, 2016, 388, 1012-1024.	6.3	381
1869	MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2209-2216.	1.2	9
1870	Standardized uptake value on 18 F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs. Lung Cancer, 2016, 100, 14-19.	0.9	20
1871	Pancreatic Cancer. Gastroenterology Clinics of North America, 2016, 45, 429-445.	1.0	73
1872	Protein Kinase G facilitates EGFR-mediated cell death in MDA-MB-468 cells. Experimental Cell Research, 2016, 346, 224-232.	1.2	13
1873	Management of Lung Cancer in the Elderly. Cancer Treatment and Research, 2016, 170, 251-284.	0.2	10
1874	Development of the Theta Comparative Cell Scoring Method to Quantify Diverse Phenotypic Responses Between Distinct Cell Types. Assay and Drug Development Technologies, 2016, 14, 395-406.	0.6	17
1875	Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis. Future Oncology, 2016, 12, 2741-2753.	1.1	8
1876	Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity. Investigational New Drugs, 2016, 34, 797-799.	1.2	12
1877	Colossolactone H, a new Ganoderma triterpenoid exhibits cytotoxicity and potentiates drug efficacy of gefitinib in lung cancer. FÃ¬toterapÃ¬Ã¢, 2016, 114, 81-91.	1.1	14
1878	The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. SpringerPlus, 2016, 5, 1244.	1.2	12
1879	Targeted Therapies for Lung Cancer. Cancer Treatment and Research, 2016, 170, 165-182.	0.2	10
1880	Stratified Treatment in Lung Cancer. Oncology Research and Treatment, 2016, 39, 760-766.	0.8	13

#	Article	IF	Citations
1881	Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies. BMC Cancer, 2016, 16, 908.	1.1	18
1882	Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. British Journal of Cancer, 2016, 115, 1504-1512.	2.9	55
1883	MEK inhibitors against MET-amplified non-small cell lung cancer. International Journal of Oncology, 2016, 49, 2236-2244.	1.4	24
1884	Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. Expert Review of Clinical Pharmacology, 2016, 9, 1283-1288.	1.3	2
1885	Molecular Evolution Patterns in Metastatic Lymph Nodes Reflect the Differential Treatment Response of Advanced Primary Lung Cancer. Cancer Research, 2016, 76, 6568-6576.	0.4	18
1886	Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. Journal of Hematology and Oncology, 2016, 9, 86.	6.9	41
1887	An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Medicine, 2016, 5, 2641-2648.	1.3	25
1888	Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. International Journal of Oncology, 2016, 49, 1576-1588.	1.4	38
1889	Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Medical Oncology, 2016, 33, 97.	1.2	39
1890	Gefitinib for asymptomatic brain metastasis from advanced nonâ€small cell lung cancer: Report of a favourable outcome. Thoracic Cancer, 2016, 7, 498-502.	0.8	1
1891	Management of non-small cell lung cancer in the era of personalized medicine. International Journal of Biochemistry and Cell Biology, 2016, 78, 173-179.	1.2	25
1892	Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib. Molecular and Clinical Oncology, 2016, 4, 774-778.	0.4	20
1893	Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2016, 46, 928-934.	0.6	10
1895	The prospect of patritumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 1549-1555.	1.4	5
1896	Profile of the therascreenÂ® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1251-1257.	1.5	17
1897	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15â€...years of clinical evidence. ESMO Open, 2016, 1, e000088.	2.0	85
1898	Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. BMC Cancer, 2016, 16, 864.	1.1	41
1899	Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro. Journal of Ethnopharmacology, 2016, 194, 1043-1050.	2.0	25

#	Article	IF	Citations
1900	ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma. Scientific Reports, 2016, 6, 36447.	1.6	52
1901	Delivering on the promise of precision cancer medicine. Genome Medicine, 2016, 8, 110.	3.6	7
1902	EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation. Scientific Reports, 2016, 6, 36371.	1.6	6
1903	Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. Scientific Reports, 2016, 6, 36458.	1.6	75
1904	Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with <scp>I</scp>cotinib. Thoracic Cancer, 2016, 7, 681-683.	0.8	4
1905	Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations. Thoracic Cancer, 2016, 7, 543-548.	0.8	10
1906	Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study. Oncology Letters, 2016, 11, 2757-2762.	0.8	3
1908	EGFR targeted delivery of paclitaxel and parthenolide co-loaded in PEG-Phospholipid micelles enhance cytotoxicity and cellular uptake in non-small cell lung cancer cells. Journal of Drug Delivery Science and Technology, 2016, 36, 150-155.	1.4	18
1909	Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics. Proteome Science, 2016, 14, 12.	0.7	13
1910	Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case. Thoracic Cancer, 2016, 7, 676-680.	0.8	4
1911	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 2016, 7, 11815.	5.8	520
1913	Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells. Journal of Proteome Research, 2016, 15, 4490-4504.	1.8	18
1914	Individualisierte Medizin bei ausgewÃhlten Krebserkrankungen. Public Health Forum, 2016, 24, 131-134.	0.1	1
1915	Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Scientific Reports, 2016, 6, 20913.	1.6	197
1916	A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma. Scientific Reports, 2016, 6, 22338.	1.6	49
1917	Mapping lung tumor cell drug responses as a function of matrix context and genotype using cell microarrays. Integrative Biology (United Kingdom), 2016, 8, 1221-1231.	0.6	10
1918	Predictive significance of thyroid transcription factor-1 expression in patients with non-squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib. Molecular and Clinical Oncology, 2016, 5, 14-18.	0.4	8
1919	SUV_{max} and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. Oncology Research and Treatment, 2016, 39, 681-686.	0.8	6

#	Article	IF	Citations
1920	A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds. Journal of Visualized Experiments, 2016, , e53885.	0.2	20
1921	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v1-v27.	0.6	1,351
1922	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer. Oncology, 2016, 91, 26-34.	0.9	13
1923	Sharpening the attack on nonâ€“small cell lung cancer. JAAPA: Official Journal of the American Academy of Physician Assistants, 2016, 29, 1-5.	0.1	0
1924	Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment. Medicine (United States), 2016, 95, e3998.	0.4	30
1925	Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy. Medicine (United States), 2016, 95, e4176.	0.4	7
1926	18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	19
1927	EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Over	0.4	10
1928	Impact of bevacizumab in combination with erlotinib on <scp>EGFR</scp>â€mutated nonâ€“small cell lung cancer xenograft models with <scp>T790M</scp> mutation or <scp>MET</scp> amplification. International Journal of Cancer, 2016, 138, 1024-1032.	2.3	35
1929	Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncology, The, 2016, 17, 984-993.	5.1	689
1930	Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer. BMC Cancer, 2016, 16, 354.	1.1	10
1931	Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 216-222.	0.5	13
1932	Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. Cancer Chemotherapy and Pharmacology, 2016, 78, 377-382.	1.1	13
1933	Targeting EGFR and ALK in NSCLC: current evidence and future perspective. Lung Cancer Management, 2016, 5, 79-90.	1.5	1
1934	PKIB promotes cell proliferation and the invasion-metastasis cascade through the PI3K/Akt pathway in NSCLC cells. Experimental Biology and Medicine, 2016, 241, 1911-1918.	1.1	24
1935	Clinicopathologic Features of Advanced Squamous NSCLC. Journal of Thoracic Oncology, 2016, 11, 1411-1422.	0.5	101
1936	Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. Cancer Chemotherapy and Pharmacology, 2016, 77, 1005-1009.	1.1	14
1937	Pharmacologic Costs of Tyrosine Kinase InhibitorsÂin First-Line Therapy for Advanced Nonâ€“Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: AÂReview of Pivotal Phase III Randomized Controlled Trials. Clinical Lung Cancer, 2016, 17, 91-94.	1.1	6

#	Article	IF	Citations
1938	The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC. Journal of Thoracic Oncology, 2016, 11, 1503-1510.	0.5	61
1939	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2016, 8, 176-187.	1.4	25
1940	Classification and Pathology of Lung Cancer. Surgical Oncology Clinics of North America, 2016, 25, 447-468.	0.6	237
1941	Targeted Therapy and Immunotherapy for Lung Cancer. Surgical Oncology Clinics of North America, 2016, 25, 601-609.	0.6	99
1942	Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. BMC Cancer, 2016, 16, 147.	1.1	12
1943	Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. Chinese Journal of Cancer, 2016, 35, 30.	4.9	42
1944	Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back. Trends in Pharmacological Sciences, 2016, 37, 789-806.	4.0	59
1945	Continuation maintenance therapy with S-1 in chemotherapy-naÃ¯ve patients with advanced squamous cell lung cancer. Investigational New Drugs, 2016, 34, 490-496.	1.2	8
1946	Neoadjuvant Therapy in Nonâ€“Small Cell Lung Cancer. Surgical Oncology Clinics of North America, 2016, 25, 567-584.	0.6	23
1947	Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer. OncoImmunology, 2016, 5, e947175.	2.1	1
1948	Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). Surgery Today, 2016, 46, 25-37.	0.7	30
1949	miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. International Journal of Oncology, 2016, 48, 937-944.	1.4	66
1950	Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLCâ€“MS/MS and its application to a pharmacokinetics study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1011, 215-222.	1.2	36
1951	Clinical trial designs incorporating predictive biomarkers. Cancer Treatment Reviews, 2016, 43, 74-82.	3.4	61
1952	Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR. Expert Opinion on Pharmacotherapy, 2016, 17, 193-203.	0.9	1
1953	Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancerâ˜†. Lung Cancer, 2016, 92, 29-34.	0.9	44
1954	Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. Journal of Clinical Oncology, 2016, 34, 91-101.	0.8	146
1955	Target Therapy in Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 893, 127-136.	0.8	18

#	Article	IF	Citations
1956	Health Disparities in Respiratory Medicine. Respiratory Medicine, 2016, , .	0.1	2
1957	Drugâ€“diagnostic co-development: challenges and issues. Expert Review of Molecular Diagnostics, 2016, 16, 187-204.	1.5	4
1958	Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. Lung Cancer, 2016, 91, 36-40.	0.9	38
1959	Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 2167-2176.	3.2	16
1960	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Therapeutic Advances in Respiratory Disease, 2016, 10, 113-129.	1.0	125
1961	Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer. Future Oncology, 2016, 12, 59-70.	1.1	34
1962	Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. European Journal of Clinical Pharmacology, 2016, 72, 1-11.	0.8	72
1963	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 263-270.e2.	1.1	107
1964	Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer. , 2016, 161, 97-110.		60
1965	FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 1307-1312.	3.2	173
1966	Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Japanese Journal of Clinical Oncology, 2016, 46, 462-467.	0.6	54
1967	Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas. Clinical Lung Cancer, 2016, 17, 441-448.e6.	1.1	264
1969	Clinical outcome of epidermal growth factor receptorâ€tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations. Thoracic Cancer, 2016, 7, 24-31.	0.8	3
1970	Epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 <scp>L858R</scp> mutation in nonâ€smallâ€cell lung cancer: Systematic review and meta analysis. Thoracic Cancer, 2016, 7, 406-414.	0.8	22
1971	Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutationâ€positive nonâ€small cell lung cancer. Thoracic Cancer, 2016, 7, 61-65.	0.8	7
1972	From fighting depression to conquering tumors: a novel tricyclic thiazepine compound as a tubulin polymerization inhibitor. Cell Death and Disease, 2016, 7, e2143-e2143.	2.7	5
1973	Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer. Medicine (United States), 2016, 95, e3008.	0.4	26
1974	Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis. Chemotherapy, 2016, 61, 41-50.	0.8	9

#	Article	IF	Citations
1975	A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Nonâ€“Small Cell Lung Cancer Cells. Neoplasia, 2016, 18, 199-212.	2.3	17
1976	EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Lung Cancer, 2016, 96, 87-92.	0.9	81
1977	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer, 2016, 93, 59-68.	0.9	103
1978	Skin problems and EGFR-tyrosine kinase inhibitor. Japanese Journal of Clinical Oncology, 2016, 46, 291-298.	0.6	82
1979	First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. Journal of Thoracic Oncology, 2016, 11, 370-379.	0.5	21
1980	Strategies to Improve Outcomes of Patients with EGFR-Mutant Nonâ€“Small Cell Lung Cancer: Review of the Literature. Journal of Thoracic Oncology, 2016, 11, 174-186.	0.5	77
1981	Quantitative and Simplified Analysis of ¹¹C-Erlotinib Studies. Journal of Nuclear Medicine, 2016, 57, 861-866.	2.8	22
1984	Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer. Future Oncology, 2016, 12, 815-825.	1.1	4
1985	Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer. Lung Cancer, 2016, 93, 43-46.	0.9	47
1986	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Nonâ€“Small Cell Lung Cancer: Double-Edged Sword of DDR2. Clinical Cancer Research, 2016, 22, 3663-3671.	3.2	14
1987	Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). Journal of Chemotherapy, 2016, 28, 50-58.	0.7	9
1988	Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung Cancer, 2016, 93, 69-76.	0.9	37
1989	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine, 2016, 22, 262-269.	15.2	768
1990	miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma. Tumor Biology, 2016, 37, 5193-5202.	0.8	43
1991	Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: A case report and literature review. Molecular and Clinical Oncology, 2016, 4, 203-205.	0.4	8
1992	Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling. International Journal of Oncology, 2016, 48, 945-952.	1.4	26
1994	Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer. Anti-Cancer Drugs, 2016, 27, 245-250.	0.7	18
1995	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemotherapy and Pharmacology, 2016, 77, 767-776.	1.1	118

#	Article	IF	Citations
1996	Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib andÂGefitinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring EGFRÂMutations. Clinical Lung Cancer, 2016, 17, 412-418.	1.1	36
1997	The safety and efficacy of osimertinib for the treatment ofEGFRT790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2016, 16, 383-390.	1.1	58
1998	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1325-1330.	1.2	20
1999	Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. British Journal of Cancer, 2016, 114, 616-622.	2.9	17
2000	Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. Journal of Thoracic Oncology, 2016, 11, 556-565.	0.5	268
2001	Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Academic Radiology, 2016, 23, 329-336.	1.3	33
2002	Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer. Expert Review of Respiratory Medicine, 2016, 10, 547-556.	1.0	9
2003	Erlotinib for the treatment of brain metastases in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1013-1021.	0.9	26
2004	Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations. Lung Cancer, 2016, 91, 7-14.	0.9	33
2005	First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 305.	3.4	201
2006	MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer, 2016, 19, 687-695.	2.7	37
2007	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 309-314.	1.1	13
2008	Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatinâ€“paclitaxel. European Journal of Health Economics, 2016, 17, 855-863.	1.4	22
2009	Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clinical Cancer Research, 2016, 22, 2386-2395.	3.2	169
2010	Mutations of the EGFR, K-ras, EML4â€“ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma. Surgery Today, 2016, 46, 1091-1098.	0.7	22
2011	Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Nonâ€“Small Cell Lung Cancers In Vitro and In Vivo. Clinical Cancer Research, 2016, 22, 122-133.	3.2	83
2012	Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. Advances in Experimental Medicine and Biology, 2016, 890, 1-23.	0.8	7
2013	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Nonâ€“Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Clinical Cancer Research, 2016, 22, 2139-2145.	3.2	30

#	Article	IF	Citations
2014	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Supportive Care in Cancer, 2016, 24, 301-309.	1.0	11
2015	Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis. Expert Review of Respiratory Medicine, 2016, 10, 223-234.	1.0	8
2016	Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Annals of Oncology, 2016, 27, 373-378.	0.6	50
2017	Safety and efficacy of targeted agents monotherapy in advanced NSCLC. Expert Review of Clinical Pharmacology, 2016, 9, 143-155.	1.3	1
2018	Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery. Journal of Neuro-Oncology, 2016, 126, 483-491.	1.4	15
2019	Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Tumor Biology, 2016, 37, 1061-1069.	0.8	16
2020	Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 167-173.	0.2	9
2021	Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Nonâ€“Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol. Clinical Lung Cancer, 2016, 17, 75-79.	1.1	13
2022	Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clinical Pharmacokinetics, 2016, 55, 297-311.	1.6	44
2023	EGFR mutation testing of lung cancer patients â€“ Experiences from Vestfold Hospital Trust. Acta OncolÃ³gica, 2016, 55, 149-155.	0.8	9
2024	Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Targeted Oncology, 2016, 11, 41-47.	1.7	15
2026	Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutationâ€“positive non-small cell lung cancers: an update for recent advances in therapeutics. Journal of Oncology Pharmacy Practice, 2016, 22, 461-476.	0.5	26
2027	Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer. Journal of Oncology Pharmacy Practice, 2017, 23, 203-214.	0.5	10
2028	Precision oncology: A new era of cancer clinical trials. Cancer Letters, 2017, 387, 121-126.	3.2	53
2029	Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation. Journal of Drug Targeting, 2017, 25, 119-124.	2.1	16
2030	Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. Cancer Letters, 2017, 387, 25-31.	3.2	24
2031	Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer, 2017, 107, 100-107.	0.9	128
2032	Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenomics Journal, 2017, 17, 325-330.	0.9	31

#	Article	IF	Citations
2033	Principles of Kinase Inhibitor Therapy for Solid Tumors. Annals of Surgery, 2017, 265, 311-319.	2.1	10
2034	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. British Journal of Cancer, 2017, 116, 568-574.	2.9	155
2035	The Emerging Role of â€œLiquid Biopsies,â€•Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. Current Oncology Reports, 2017, 19, 1.	1.8	53
2036	Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Reports, 2017, 18, 601-610.	2.9	125
2037	Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer, 2017, 104, 119-125.	0.9	41
2038	Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. Lung Cancer, 2017, 104, 85-90.	0.9	39
2039	LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer. Biochemistry and Biophysics Reports, 2017, 9, 86-94.	0.7	7
2040	Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. Clinical Lung Cancer, 2017, 18, 388-395.e4.	1.1	23
2041	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	3.4	80
2042	Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 151-163.	0.9	10
2043	Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. Cancer Treatment Reviews, 2017, 53, 111-119.	3.4	134
2044	Polymeric mixed micelles as nanomedicines: Achievements and perspectives. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 113, 211-228.	2.0	287
2045	Mechanism of Resistance to Targeted Molecular Therapy. , 2017, , 213-225.		0
2046	Targeting Epithelial-Mesenchymal Transition and Cancer Stem Cell. , 2017, , 295-307.		0
2047	MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 506-515.	1.9	52
2048	Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma. Clinical Lung Cancer, 2017, 18, e215-e217.	1.1	5
2049	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. , 2017, 174, 1-21.		123
2050	Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features. Scientific Reports, 2017, 7, 40847.	1.6	54

#	Article	IF	Citations
2051	Whole genome sequencing analysis of lung adenocarcinoma in <scp>X</scp>uanwei, <scp>C</scp>hina. Thoracic Cancer, 2017, 8, 88-96.	0.8	11
2052	Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy. BMJ Open Respiratory Research, 2017, 4, e000163.	1.2	7
2053	The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. Scientific Reports, 2017, 7, 40374.	1.6	43
2054	CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis. BMC Medical Imaging, 2017, 17, 5.	1.4	43
2055	Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to <scp>EGFR</scp>â€<scp>TKI</scp> treatment. FEBS Open Bio, 2017, 7, 35-43.	1.0	8
2056	Osimertinib for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 225-231.	0.9	4
2057	Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 304-313.	0.7	13
2058	Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy-naÃ¯ve patients with advanced or metastatic non-small-cell lung cancer: Long-term follow-up results. Molecular and Clinical Oncology, 2017, 6, 56-62.	0.4	2
2059	Nonâ€“Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Nonâ€“Small-cell Lung Cancer Favor Adenocarcinoma. Clinical Lung Cancer, 2017, 18, 316-323.e1.	1.1	7
2060	Osimertinib in Pretreated T790M-Positive Advanced Nonâ€“Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of Clinical Oncology, 2017, 35, 1288-1296.	0.8	470
2061	Clinical value of the new <scp>I</scp>nternational <scp>A</scp>ssociation for the <scp>S</scp>tudy of <scp>L</scp>ung <scp>C</scp>ancer/<scp>A</scp>merican <scp>T</scp>horacic <scp>S</scp>ociety<scp>/E</scp>uropean <scp>R</scp>espiratory <scp>S</scp>ociety classification of lung adenocarcinoma. Thoracic Cancer, 2017, 8, 159-169.	0.8	2
2062	Pulsatile Erlotinib in EGFR-Positive Nonâ€“Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: ReviewÂofÂthe Literature. Clinical Lung Cancer, 2017, 18, 354-363.	1.1	44
2063	Evaluating the effectiveness of <scp>RNA </scp>inâ€situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement. Histopathology, 2017, 71, 143-149.	1.6	16
2064	Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026781.	2.9	278
2065	Amplification of EGFR Wild-Type Alleles in Nonâ€“Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2017, 77, 2078-2089.	0.4	126
2066	Accuracy of nextâ€generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma. Cancer Cytopathology, 2017, 125, 398-406.	1.4	35
2067	EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opinion on Drug Safety, 2017, 16, 465-469.	1.0	156
2069	A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo. Drug Delivery, 2017, 24, 471-481.	2.5	38

#	Article	IF	Citations
2070	EGFR inhibition in NSCLC: New findingsâ€¦. and opened questions?. Critical Reviews in Oncology/Hematology, 2017, 112, 126-135.	2.0	22
2071	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) Tj ETQq1 1 0.784314 rgBT /Ove	0.7	34
2073	Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease. Cancer Chemotherapy and Pharmacology, 2017, 79, 705-710.	1.1	28
2074	Most T790M mutations are present on the same EGFR allele as activating mutations in patients with nonâ€“small cell lung cancer. Lung Cancer, 2017, 108, 75-82.	0.9	37
2075	Extracellular vesicles in lung cancerâ€”From bench to bedside. Seminars in Cell and Developmental Biology, 2017, 67, 39-47.	2.3	47
2076	Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. Targeted Oncology, 2017, 12, 153-161.	1.7	31
2077	Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution. Oncology Reports, 2017, 37, 1347-1358.	1.2	63
2078	Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival. Cancer Chemotherapy and Pharmacology, 2017, 79, 1013-1020.	1.1	11
2079	Prognostic impact of stathmin 1 expression in patients with lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1406-1417.e3.	0.4	12
2081	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. European Journal of Cancer, 2017, 78, 16-23.	1.3	108
2082	Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. Pancreas, 2017, 46, 335-340.	0.5	75
2083	Detection of EGFR mutations in patients with non-small cell lung cancer by high resolution melting. Comparison with other methods. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1970-1978.	1.4	10
2084	EGFR-mediated apoptosis via STAT3. Experimental Cell Research, 2017, 356, 93-103.	1.2	41
2085	CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors. Scientific Reports, 2017, 7, 46662.	1.6	36
2086	Analyzing epidermal growth factor receptor mutation status changes in advanced nonâ€smallâ€cell lung cancer at different sampling timeâ€points of blood within oneâ€‰day. Thoracic Cancer, 2017, 8, 312-319.	0.8	12
2087	Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Nonâ€“Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older. Clinical Lung Cancer, 2017, 18, 460-471.	1.1	25
2088	Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations. Oncology Research and Treatment, 2017, 40, 7-13.	0.8	9
2089	Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine. Journal of Nuclear Medicine, 2017, 58, 689-696.	2.8	15

#	Article	IF	Citations
2090	Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. Radiology, 2017, 283, 314-340.	3.6	19
2091	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Research, 2017, 77, 2990-3000.	0.4	106
2092	Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Nonâ€“small-cell Lung Cancer Harboring Epidermal Growth FactorÂReceptor Mutation. Clinical Lung Cancer, 2017, 18, e369-e373.	1.1	43
2093	Plasma ctDNA Analysis for Detection of the EGFR ÂT790M Mutation in Patients with Advanced Nonâ€“SmallÂCell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1061-1070.	0.5	240
2094	Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. European Journal of Medicinal Chemistry, 2017, 142, 32-47.	2.6	119
2095	The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis. Clinical Oncology, 2017, 29, 568-575.	0.6	42
2096	Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy. Journal of Controlled Release, 2017, 258, 43-55.	4.8	95
2097	Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clinical Radiology, 2017, 72, 521-533.	0.5	42
2098	TP53 gene status is a critical determinant of phenotypes induced by ALKBH3 knockdown in non-small cell lung cancers. Biochemical and Biophysical Research Communications, 2017, 488, 285-290.	1.0	9
2099	Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Clinical Lung Cancer, 2017, 18, 698-705.e2.	1.1	29
2100	Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway. Tumor Biology, 2017, 39, 101042831769756.	0.8	61
2101	Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer, 2017, 109, 137-144.	0.9	120
2102	Preclinical models for translational sarcoma research. Current Opinion in Oncology, 2017, 29, 275-285.	1.1	11
2103	Efficacy and safety of osimertinib in a Japanese compassionate use program. Japanese Journal of Clinical Oncology, 2017, 47, 625-629.	0.6	12
2104	Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Medical Oncology, 2017, 34, 105.	1.2	47
2105	Dynamic Contrast-enhanced MR Imaging Parameters in Bone Metastases from Nonâ€“Small Cell Lung Cancer: Comparison between Lesions with and Lesions without Epidermal Growth Factor Receptor Mutation in Primary Lung Cancer. Radiology, 2017, 284, 815-823.	3.6	14
2106	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open, 2017, 2, e000168.	2.0	48
2107	EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. Journal of Thoracic Oncology, 2017, 12, 529-538.	0.5	57

#	Article	IF	Citations
2108	Epidermal Growth Factor Receptor Mutated Advanced Nonâ€“Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 2017, 31, 83-99.	0.9	10
2109	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 357-364.	1.9	65
2110	Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. Expert Review of Anticancer Therapy, 2017, 17, 143-155.	1.1	26
2111	Precision Medicine for Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	9
2112	Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer, 2017, 110, 7-13.	0.9	40
2113	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. Targeted Oncology, 2017, 12, 563-569.	1.7	71
2114	Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy. Oncologist, 2017, 22, 786-796.	1.9	95
2116	Identifying â€œsuper respondersâ€•in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 300-311.	0.8	19
2117	AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier. Oncology Reports, 2017, 37, 3261-3269.	1.2	18
2118	Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR. EBioMedicine, 2017, 21, 86-93.	2.7	14
2119	Lung cancer samples preserved in liquid medium: One step beyond cytology. Diagnostic Cytopathology, 2017, 45, 915-921.	0.5	1
2120	Highly Sensitive and Reliable Detection of EGFR Exon 19 Deletions by Droplet Digital Polymerase Chain Reaction. Molecular Diagnosis and Therapy, 2017, 21, 555-562.	1.6	5
2121	Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. BMC Cancer, 2017, 17, 281.	1.1	31
2122	Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge. Oncology Letters, 2017, 13, 4939-4946.	0.8	1
2123	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies ofÂOsimertinib. Journal of Thoracic Oncology, 2017, 12, 1247-1256.	0.5	48
2124	Plasma genotyping in patients with non-small-cell lung cancer: simplifying or confusing the diagnosis?. Lung Cancer Management, 2017, 6, 29-37.	1.5	0
2125	MiR-424 Promotes Non-Small Cell Lung Cancer Progression and Metastasis through Regulating the Tumor Suppressor Gene TNFAIP1. Cellular Physiology and Biochemistry, 2017, 42, 211-221.	1.1	35
2126	Urgent Chemotherapy for Life-Threatening Complications Related to Solid Neoplasms. Critical Care Medicine, 2017, 45, e640-e648.	0.4	25

#	Article	IF	Citations
2127	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1376-1387.	0.5	39
2128	Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. International Journal of Cancer, 2017, 141, 1249-1256.	2.3	96
2129	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. Medical Oncology, 2017, 34, 121.	1.2	12
2130	Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. Oncology Letters, 2017, 13, 4433-4444.	0.8	53
2131	Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance. Oncology Letters, 2017, 13, 4549-4557.	0.8	21
2132	Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients. Clinica Chimica Acta, 2017, 471, 177-184.	0.5	24
2133	Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma. Laboratory Investigation, 2017, 97, 1332-1342.	1.7	23
2134	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. Journal of the National Cancer Institute, 2017, 109, .	3.0	196
2135	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 387-404.	1.4	30
2136	Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. Journal of the Formosan Medical Association, 2017, 116, 413-423.	0.8	21
2137	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Research, 2017, 77, 2712-2721.	0.4	110
2138	An LCâ€“MS/MS method for quantification of AC0010, a novel mutant-selective epidermal growth factor receptor (EGFR) inhibitor, and its metabolites in human plasma and the application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2017, 141, 9-18.	1.4	4
2139	A path to precision in the ICU. Critical Care, 2017, 21, 79.	2.5	77
2140	A large, singleâ€center, realâ€world study of clinicopathological characteristics and treatment in advanced <scp>ALK</scp>â€positive nonâ€smallâ€cell lung cancer. Cancer Medicine, 2017, 6, 953-961.	1.3	15
2141	Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1449-1459.	1.2	17
2142	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs, 2017, 77, 813-827.	4.9	42
2143	Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC. Cancer Treatment and Research Communications, 2017, 11, 10-16.	0.7	1
2144	Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer, 2017, 108, 109-114.	0.9	36

#	Article	IF	Citations
2145	Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases. Scientific Reports, 2017, 7, 45193.	1.6	37
2146	Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring <i>EGFR</i> Exon 19 Deletion and Exon 21 L858R Substitution. Chemotherapy, 2017, 62, 151-158.	0.8	21
2147	Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma. Scientific Reports, 2017, 7, 364.	1.6	22
2148	Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Molecular and Cellular Proteomics, 2017, 16, 891-910.	2.5	42
2149	Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition. Cancer Research, 2017, 77, 3013-3026.	0.4	42
2150	Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer. Bone and Joint Journal, 2017, 99-B, 516-521.	1.9	7
2151	A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens. Oncology Reports, 2017, 37, 1020-1026.	1.2	6
2152	Individual Biomarkers Using Molecular Personalized Medicine Approaches. Orl, 2017, 79, 7-13.	0.6	6
2153	Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790MinÂvivo. Molecular Oncology, 2017, 11, 670-681.	2.1	14
2154	Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer. Molecular and Clinical Oncology, 2017, 6, 3-6.	0.4	24
2155	Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology, 2017, 9, 201-216.	1.4	30
2156	Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. Clinical Pharmacology in Drug Development, 2017, 6, 517-523.	0.8	13
2157	Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy. Patient, 2017, 10, 593-603.	1.1	9
2158	Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Respiratory Investigation, 2017, 55, 181-183.	0.9	4
2159	Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nature Communications, 2017, 8, 14768.	5.8	306
2160	Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer. Lung Cancer, 2017, 106, 138-144.	0.9	15
2161	Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Molecular Cancer Research, 2017, 15, 915-928.	1.5	37
2162	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89

#	Article	IF	Citations
2163	Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement. Oncology Research and Treatment, 2017, 40, 27-33.	0.8	1
2164	Osimertinib or Platinumâ€“Pemetrexed in EGFR T790Mâ€“Positive Lung Cancer. New England Journal of Medicine, 2017, 376, 629-640.	13.9	2,631
2165	A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients withÂacquired EGFRâ€TKI resistance. Cancer Medicine, 2017, 6, 154-162.	1.3	82
2166	Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 633-643.	0.5	122
2167	Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 612-623.	0.5	203
2168	Systemic therapy of brain metastases: nonâ€“small cell lung cancer, breast cancer, and melanoma. Neuro-Oncology, 2017, 19, i1-i24.	0.6	171
2169	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
2170	Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK -Rearranged Nonâ€“Small-Cell Lung Cancer: AÀRetrospective Analysis. Clinical Lung Cancer, 2017, 18, e251-e258.	1.1	15
2171	Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. Cancer Chemotherapy and Pharmacology, 2017, 79, 209-213.	1.1	13
2172	New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. Expert Review of Respiratory Medicine, 2017, 11, 51-55.	1.0	16
2173	Unconvincing Benefit of Combination Therapy With Gefitinib and Pemetrexed in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017, 35, 691-692.	0.8	3
2174	Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer â€“ A multicenter retrospective SEQUENCE study. Lung Cancer, 2017, 104, 58-64.	0.9	22
2175	Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. Journal of Clinical Oncology, 2017, 35, 243-252.	0.8	19
2176	Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFRâ€mutant (Exon18:G719S) lung adenocarcinoma as a secondâ€line chemotherapy. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e531-e533.	0.7	6
2177	Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability inÂAdvanced Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 663-672.	0.5	100
2178	Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphismâ€“Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 2017, 23, 3139-3149.	3.2	69
2179	Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics, 2017, 18, 1525-1539.	0.6	21
2180	Klotho expression is correlated to molecules associated with epithelialâ€mesenchymal transition in lung squamous cell carcinoma. Oncology Letters, 2017, 14, 5526-5532.	0.8	13

#	Article	IF	Citations
2181	Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. Oncology Letters, 2017, 14, 5611-5618.	0.8	7
2182	Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy. Molecular Pharmaceutics, 2017, 14, 4551-4559.	2.3	30
2183	Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). Lung Cancer, 2017, 113, 79-84.	0.9	12
2184	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 1454-1466.	5.1	877
2185	In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer. Drug Delivery, 2017, 24, 1501-1512.	2.5	47
2186	Ex vivo model of nonâ€'small cell lung cancer using mouse lung epithelial cells. Oncology Letters, 2017, 14, 6863-6868.	0.8	20
2187	STAP-2 protein promotes prostate cancer growth by enhancing epidermal growth factor receptor stabilization. Journal of Biological Chemistry, 2017, 292, 19392-19399.	1.6	22
2188	Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 136-140.	0.3	5
2189	Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open, 2017, 2, e000214.	2.0	30
2190	Gefitinib: an â€œorphanâ€•drug for non-small cell lung cancer. Expert Opinion on Orphan Drugs, 2017, 5, 899-906.	0.5	2
2191	Structureâ€“Activity Relationship Study of 2,4â€Đianilinopyrimidine Containing Methanesulfonamide (TREâ€069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment. Bulletin of the Korean Chemical Society, 2017, 38, 1353-1357.	1.0	6
2192	A TERT-CLPTM1 locus polymorphism (rs401681) is associated with EGFR mutation in non-small cell lung cancer. Pathology Research and Practice, 2017, 213, 1340-1343.	1.0	9
2194	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nature Communications, 2017, 8, 1050.	5.8	115
2195	Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 1179-1187.	1.1	24
2196	Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?. Expert Review of Molecular Diagnostics, 2017, 17, 1089-1096.	1.5	16
2197	Targeted Therapy and Imaging Findings. Journal of Thoracic Imaging, 2017, 32, 313-322.	0.8	10
2198	Prognostic significance of the <scp>I</scp>nternational <scp>A</scp>ssociation for the <scp>S</scp>tudy of <scp>L</scp>ung <scp>C</scp>ancer/<scp>A</scp>merican <scp>T</scp>horacic <scp>S</scp>ociety/<scp>E</scp>uropean <scp>R</scp>espiratory <scp>S</scp>ociety classification of stage <scp>I</scp> lung adenocarcinoma: <scp>A</scp> retrospective study based on analysis of 110 <scp>C</scp>hinese patients. Thoracic Cancer, 2017, 8, 565-571.	0.8	8
2199	First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Annals of Oncology, 2017, 28, 2443-2450.	0.6	236

#	Article	IF	Citations
2200	Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. Cancer Treatment Reviews, 2017, 60, 1-11.	3.4	29
2201	Bevacizumab in advanced lung cancer: state of the art. Future Oncology, 2017, 13, 2515-2535.	1.1	53
2202	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2017, 60, 7725-7744.	2.9	24
2203	Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment. Medical Oncology, 2017, 34, 178.	1.2	7
2204	Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 1307-1316.	5.1	889
2205	External quality assessment for EGFR mutations in Italy: improvements in performances over the time. ESMO Open, 2017, 2, e000160.	2.0	8
2206	Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lung Cancer, 2017, 113, 106-114.	0.9	48
2207	Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer. Medical Oncology, 2017, 34, 169.	1.2	7
2208	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer, 2017, 113, 51-58.	0.9	16
2209	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. Scientific Reports, 2017, 7, 8483.	1.6	6
2210	EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. Medical Oncology, 2017, 34, 175.	1.2	5
2211	Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respiratory Medicine,the, 2017, 5, 707-716.	5.2	159
2212	Stable Property Clusters and Their Grounds. Philosophy of Science, 2017, 84, 944-955.	0.5	5
2213	DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Annals of Oncology, 2017, 28, 2451-2457.	0.6	58
2214	Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas Â® EGFR mutation test. Lung Cancer, 2017, 111, 190-194.	0.9	13
2215	Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. Surgical Oncology, 2017, 26, 278-285.	0.8	20
2216	Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL-6/JAK1/STAT3 signaling pathway. Molecular Medicine Reports, 2017, 16, 2733-2739.	1.1	24
2217	Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients. Oncogene, 2017, 36, 6432-6445.	2.6	29

#	Article	IF	Citations
2218	Clinical outcomes in patients with advanced epidermal growth factor receptorâ€•mutated nonâ€•smallâ€•cell lung cancer in South Western Sydney Local Health District. Internal Medicine Journal, 2017, 47, 1405-1411.	0.5	14
2219	Targeting ornithine decarboxylase (ODC) inhibits esophageal squamous cell carcinoma progression. Npj Precision Oncology, 2017, 1, 13.	2.3	17
2220	Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Letters, 2017, 405, 100-110.	3.2	90
2221	Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. Cancer Treatment Reviews, 2017, 59, 117-122.	3.4	61
2222	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations â€“ Still a daily challenge. European Journal of Cancer, 2017, 83, 266-278.	1.3	22
2223	Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden. Journal of Medical Economics, 2017, 20, 1136-1147.	1.0	21
2224	Endobronchial ultrasound guided transbronchial needle aspiration combining with immunohistochemistry and genotype in lung cancer: A single-center, 55 cases retrospective study. Annals of Medicine and Surgery, 2017, 23, 1-7.	0.5	6
2225	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. Journal of Thoracic Oncology, 2017, 12, 1588-1594.	0.5	21
2226	First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC). Cancer Investigation, 2017, 35, 541-546.	0.6	5
2227	Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?. Current Opinion in Oncology, 2017, 29, 89-96.	1.1	13
2228	Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1979-1986.	1.4	10
2229	3Dâ€Printed Polypropylene Continuousâ€Flow Column Reactors: Exploration of Reactor Utility in S_NAr Reactions and the Synthesis of Bicyclic and Tetracyclic Heterocycles. European Journal of Organic Chemistry, 2017, 2017, 6499-6504.	1.2	41
2230	Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. Expert Review of Respiratory Medicine, 2017, 11, 791-805.	1.0	4
2231	Lung cancer requires multidisciplinary treatment to improve patient survival: A case report. Oncology Letters, 2017, 14, 3035-3038.	0.8	26
2232	Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report. Molecular and Clinical Oncology, 2017, 7, 383-385.	0.4	19
2233	Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and Î±-glucosidase. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4309-4313.	1.0	29
2234	Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. Scientific Reports, 2017, 7, 6595.	1.6	29
2235	Ultrasound-Guided Needle Biopsy of Neck Lymph Nodes in Patients With Suspected Lung Cancer. Ultrasound Quarterly, 2017, 33, 133-138.	0.3	3

#	Article	IF	Citations
2236	Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers. Oncogene, 2017, 36, 6581-6591.	2.6	31
2237	Personalised medicine for nonsmall cell lung cancer. European Respiratory Review, 2017, 26, 170066.	3.0	37
2238	Reprogramming Tumor-Associated Macrophages To Reverse EGFR^{T790M} Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat. Nano Letters, 2017, 17, 7684-7690.	4.5	90
2240	Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma. Lung Cancer, 2017, 114, 23-30.	0.9	12
2241	A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer, 2017, 114, 96-102.	0.9	146
2242	Impact of metastatic status on the prognosis of EGFR mutationâ€'positive nonâ€'small cell lung cancer patients treated with firstâ€'generation EGFRâ€'tyrosine kinase inhibitors. Oncology Letters, 2017, 14, 7589-7596.	0.8	25
2243	Glucose metabolismâ€targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitorâ€induced drugâ€tolerant persisters. Cancer Science, 2017, 108, 1368-1377.	1.7	28
2244	Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. Journal of Thoracic Oncology, 2017, 12, 1388-1397.	0.5	49
2245	Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). Lung Cancer, 2017, 111, 23-29.	0.9	160
2246	Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 497-505.	1.1	16
2247	The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsm. Biomedical Reports, 2017, 7, 61-66.	0.9	5
2248	Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC. Oncology Letters, 2017, 14, 2573-2579.	0.8	20
2249	Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer. Oncology Research and Treatment, 2017, 40, 409-416.	0.8	30
2250	Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type. Oncology Letters, 2017, 14, 306-312.	0.8	11
2251	Prognostic significance of ABCB1 in stage I lung adenocarcinoma. Oncology Letters, 2017, 14, 313-321.	0.8	10
2252	Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status. Oncology Letters, 2017, 14, 885-890.	0.8	15
2253	EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. Targeted Oncology, 2017, 12, 663-675.	1.7	12
2254	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. Expert Review of Anticancer Therapy, 2017, 17, 779-786.	1.1	27

#	Article	IF	Citations
2255	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology, 2017, 28, 270-277.	0.6	425
2256	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. Cancer Letters, 2017, 405, 29-37.	3.2	93
2257	Detection of EGFR mutation in plasma using multiplex allele-specific PCR (MAS-PCR) and surface enhanced Raman spectroscopy. Scientific Reports, 2017, 7, 4771.	1.6	17
2258	Recent advances in targeted advanced lung cancer therapy in the elderly. Expert Review of Anticancer Therapy, 2017, 17, 787-797.	1.1	13
2259	DeSigN: connecting gene expression with therapeutics for drug repurposing and development. BMC Genomics, 2017, 18, 934.	1.2	62
2260	The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients. BMC Cancer, 2017, 17, 96.	1.1	47
2261	The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy. BMC Pharmacology & Toxicology, 2017, 18, 21.	1.0	17
2262	Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Nonâ€“Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. Clinical Lung Cancer, 2017, 18, e333-e340.	1.1	14
2263	Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study. Chinese Journal of Integrative Medicine, 2017, 23, 733-739.	0.7	17
2264	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 5-8.	0.7	5
2265	Targeting Oncoproteins for Molecular Cancer Therapy. , 2017, , 727-756.		0
2266	Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung CancerÂPatients. Annals of Thoracic Surgery, 2017, 103, 1594-1599.	0.7	14
2267	Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. European Journal of Cancer, 2017, 70, 12-21.	1.3	36
2268	Development of crizotinib, a rationally designed tyrosine kinase inhibitor for nonâ€small cell lung cancer. International Journal of Cancer, 2017, 140, 1945-1954.	2.3	19
2269	Addressing heterogeneity of individual blood cancers: the need for single cell analysis. Cell Biology and Toxicology, 2017, 33, 83-97.	2.4	27
2270	Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2017, 23, 2195-2202.	3.2	208
2271	Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 42-50.	5.2	252
2272	Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 60-67.	1.1	6

#	Article	IF	Citations
2273	Combined antitumor effect of Î³-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer. International Journal of Clinical Oncology, 2017, 22, 257-268.	1.0	12
2274	Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutationâ€"Positive Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 618-622.	3.2	35
2275	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. Clinical Lung Cancer, 2017, 18, 241-244.	1.1	9
2276	Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clinical Pharmacokinetics, 2017, 56, 235-250.	1.6	138
2277	Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 663-673.	2.5	24
2279	Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy. Clinical Lung Cancer, 2017, 18, e35-e40.	1.1	3
2280	First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner isâ€¦. Clinical Oncology, 2017, 29, e1-e4.	0.6	4
2281	Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Nonâ€"Small Cell Lung Cancer. Journal of Nuclear Medicine, 2017, 58, 569-576.	2.8	131
2282	Clinical Response to Everolimus of EGFRâ€"Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs. Clinical Lung Cancer, 2017, 18, e85-e87.	1.1	2
2283	Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. Journal of Medical Economics, 2017, 20, 1-7.	1.0	32
2284	Advanced non small cell lung cancer: response to microwave ablation and EGFR Status. European Radiology, 2017, 27, 1685-1694.	2.3	18
2285	Lung Adenocarcinoma: Predictive Value ofKRASMutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation. Radiology, 2017, 282, 251-258.	3.6	25
2286	Wâ€˜ALKâ€™ Into the Next Stage. Clinical Lung Cancer, 2017, 18, 122-126.	1.1	6
2287	Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2017, 10, 31-38.	1.3	23
2288	Risk factors for bone metastasis in completely resected non-small-cell lung cancer. Future Oncology, 2017, 13, 695-704.	1.1	20
2289	The End of Nihilism: Systemic Therapy of Advanced Nonâ€"Small Cell Lung Cancer. Annual Review of Medicine, 2017, 68, 153-168.	5.0	24
2290	Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. Cancer Biology and Therapy, 2017, 18, 883-887.	1.5	14
2291	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: ProposalÂfrom the Bench. Journal of Thoracic Oncology, 2017, 12, 27-35.	0.5	24

#	Article	IF	Citations
2292	K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives. European Journal of Medicinal Chemistry, 2017, 125, 299-314.	2.6	39
2293	Gene expression of MAGEâ€A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese nonâ€“small cell lung cancer patients. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e212-e223.	0.7	16
2294	Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report. Oncology Letters, 2017, 14, 5947-5951.	0.8	16
2295	EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient-derived xenografts with cetuximab. Oncology Reports, 2017, 38, 2387-2393.	1.2	12
2296	Les cancers bronchiques non Ã petites cellules EGFR-mutÃ©s. Revue Des Maladies Respiratoires Actualites, 2017, 9, 213-223.	0.0	0
2297	Characterization of Tumor Cells Using a Medical Wire for Capturing Circulating Tumor Cells: A 3D Approach Based on Immunofluorescence and DNA FISH. Journal of Visualized Experiments, 2017, , .	0.2	4
2298	Molecular Testing in Lung Cancer. , 2017, , 287-303.		2
2299	Utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients: Comparison between cell pellets, cell blocks and matching tissue specimens. Oncology Letters, 2017, 15, 1469-1474.	0.8	8
2300	P3.01-018 Mutation Abundance Affects the Therapeutic Efficacy of EGFR-TKI in Patients with Advanced Lung Adenocarcinoma: A Retrospective Analysis. Journal of Thoracic Oncology, 2017, 12, S2206-S2207.	0.5	0
2301	AltÃ©rations molÃ©culaires anciennes et Ã©mergentes : quand les rechercher ?. Revue Des Maladies Respiratoires Actualites, 2017, 9, 202-212.	0.0	1
2302	Prise en charge du CBNPC chez les sujets Ã¢gÃ©s. Revue Des Maladies Respiratoires Actualites, 2017, 9, 299-307.	0.0	0
2303	Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. Current Medical Science, 2017, 37, 864-872.	0.7	4
2304	Efficacy of osimertinib in a patient with nonâ€‘small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status. Molecular and Clinical Oncology, 2017, 8, 246-249.	0.4	6
2305	The ATS/ERS/JRS/ALAT Statement â€œIPF by HRCTâ€•could Predict Acute Exacerbation of Interstitial Lung Disease in Non-small Cell Lung Cancer. Tumori, 2017, 103, 60-65.	0.6	14
2306	Phase I/II study of alectinib in lung cancer with <i>RET</i> fusion gene: study protocol. Journal of Medical Investigation, 2017, 64, 317-320.	0.2	16
2307	Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Annals of Oncology, 2017, 28, 2715-2724.	0.6	72
2308	Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction. Oncotarget, 2017, 8, 106901-106912.	0.8	20
2310	Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000270.	0.2	5

#	Article	IF	Citations
2311	Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. Experimental Hematology and Oncology, 2017, 6, 29.	2.0	12
2312	Concurrent T790M and L858R mutations in treatment-naÃ¯ve metastatic non-small-cell lung cancer: A therapeutic challenge â€“ Current treatment strategies and promising therapies of the future in a nutshell. Asian Journal of Oncology, 0, 03, 087-091.	0.2	0
2313	Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine. Internal Medicine, 2017, 56, 2367-2371.	0.3	3
2314	Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. Journal of Thoracic Disease, 2017, 9, 2923-2934.	0.6	23
2315	Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment. OncoTargets and Therapy, 2017, Volume 10, 2903-2908.	1.0	29
2316	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. Ecancermedicalscience, 2017, 11, 787.	0.6	34
2317	The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer. OncoTargets and Therapy, 2017, Volume 10, 2335-2340.	1.0	21
2318	Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database. Oncotarget, 2017, 8, 25323-25333.	0.8	12
2319	Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. OncoTargets and Therapy, 2017, Volume 10, 2473-2482.	1.0	42
2320	Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib. The Application of Clinical Genetics, 2017, Volume 10, 49-56.	1.4	25
2321	Beyond chemotherapy for advanced diseaseâ€"the role of EGFR and PD-1 inhibitors. Translational Andrology and Urology, 2017, 6, 848-854.	0.6	12
2322	Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan. Lung Cancer: Targets and Therapy, 2017, Volume 8, 191-206.	1.3	14
2323	The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer. Journal of Cancer, 2017, 8, 1865-1871.	1.2	8
2324	Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors. Oncotarget, 2017, 8, 105103-105114.	0.8	27
2325	Medicinal Chemistry Case History: Osimertinib (AZD9291). , 2017, , 1-32.		0
2327	Circulating DNA in EGFR-mutated lung cancer. Annals of Translational Medicine, 2017, 5, 379-379.	0.7	24
2328	Redox-Responsive Manganese Dioxide Nanoparticles for Enhanced MR Imaging and Radiotherapy of Lung Cancer. Frontiers in Chemistry, 2017, 5, 109.	1.8	53
2329	Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Frontiers in Medicine, 2016, 3, 76.	1.2	74

#	Article	IF	Citations
2330	Second-Line Treatment of NSCLCâ€"The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. Frontiers in Medicine, 2017, 4, 9.	1.2	14
2331	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Frontiers in Medicine, 2017, 4, 39.	1.2	18
2332	Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. Frontiers in Oncology, 2017, 7, 38.	1.3	14
2333	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. Frontiers in Oncology, 2017, 7, 50.	1.3	30
2334	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Frontiers in Oncology, 2017, 7, 97.	1.3	12
2335	Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 113.	1.3	46
2336	Resources for Interpreting Variants in Precision Genomic Oncology Applications. Frontiers in Oncology, 2017, 7, 214.	1.3	18
2337	Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 222.	1.3	5
2338	Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer. Internal Medicine, 2017, 56, 2325-2328.	0.3	12
2339	Phase I study of combined therapy with vorinostat and gefitinib to treat <i>BIM</i> deletion polymorphism-associated resistance in <i>EGFR</i>-mutant lung cancer (VICTROY-J): a study protocol. Journal of Medical Investigation, 2017, 64, 321-325.	0.2	7
2340	Yin-Cold or Yang-Heat Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-7.	0.5	24
2341	Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?. Chemotherapy Research and Practice, 2017, 2017, 1-4.	1.6	1
2342	Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay. Oncotarget, 2017, 8, 72127-72132.	0.8	14
2343	Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection. OncoTargets and Therapy, 2017, Volume 10, 239-245.	1.0	18
2344	Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations. Journal of Cancer, 2017, 8, 597-605.	1.2	6
2345	Four-miRNA signature as a prognostic tool for lung adenocarcinoma. OncoTargets and Therapy, 2018, Volume 11, 29-36.	1.0	19
2346	AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?. Annals of Translational Medicine, 2017, 5, S14-S14.	0.7	5
2347	EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?. OncoTargets and Therapy, 2017, Volume 10, 1859-1863.	1.0	44

#	Article	IF	Citations
2348	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer: Targets and Therapy, 2017, Volume 8, 109-125.	1.3	49
2349	Frequency and clinical relevance of EGFR mutations and EML4–ALK translocations in octogenarians with non-small cell lung cancer. OncoTargets and Therapy, 2017, Volume 10, 5179-5186.	1.0	7
2350	Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma. Oncology Letters, 2017, 15, 3295-3304.	0.8	9
2351	Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. Oncotarget, 2017, 8, 66491-66503.	0.8	2
2352	Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation. Cancer Management and Research, 2017, Volume 9, 243-248.	0.9	10
2353	A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer. PLoS ONE, 2017, 12, e0176525.	1.1	11
2354	Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma. PLoS ONE, 2017, 12, e0185321.	1.1	17
2355	Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. PLoS ONE, 2017, 12, e0175622.	1.1	20
2356	Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients. Oncology Research, 2017, 25, 1601-1606.	0.6	26
2357	Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms. Tumori, 2017, 103, 325-337.	0.6	12
2358	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications, 2017, 8, 410.	5.8	117
2359	Addressing the challenges of applying precision oncology. Npj Precision Oncology, 2017, 1, 28.	2.3	43
2360	Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations. BMC Cancer, 2017, 17, 484.	1.1	34
2361	Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies. BMC Pulmonary Medicine, 2017, 17, 175.	0.8	14
2362	Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study. World Journal of Surgical Oncology, 2017, 15, 197.	0.8	11
2363	The clinical efficacy of Afatinib 30Âmg daily as starting dose may not be inferior to Afatinib 40Âmg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations. BMC Pharmacology & Toxicology, 2017, 18, 82.	1.0	34
2364	Significance of Neutrophil-to-lymphocyte Ratio in Western Advanced EGFR-mutated Non-small Cell Lung Cancer Receiving a Targeted Therapy. Tumori, 2017, 103, 443-448.	0.6	18
2365	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexedâ€“carboplatin chemotherapy. Ecancermedicalscience, 2017, 11, 776.	0.6	2

#	Article	IF	Citations
2366	The combination of checkpoint immunotherapy and targeted therapy in cancer. Annals of Translational Medicine, 2017, 5, 388-388.	0.7	54
2367	First and Best Treatments for EGFR and PD-L1 - Competition for First Line Therapy in Adenocarcinoma. Oncomedicine, 2017, 2, 138-141.	1.1	0
2368	Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget, 2017, 8, 73312-73328.	0.8	130
2369	Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration. Oncotarget, 2017, 8, 109818-109835.	0.8	5
2370	Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinoma. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 690-695.	0.5	4
2371	EGFR T790M: revealing the secrets of a gatekeeper. Lung Cancer: Targets and Therapy, 2017, Volume 8, 147-159.	1.3	23
2372	Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer. International Journal of Medical Sciences, 2017, 14, 1410-1417.	1.1	5
2373	Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway. Molecular Medicine Reports, 2017, 16, 3475-3481.	1.1	36
2374	Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy. International Journal of COPD, 2017, Volume 12, 3541-3547.	0.9	16
2375	Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer. OncoTargets and Therapy, 2017, Volume 10, 5107-5113.	1.0	17
2376	Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations. OncoTargets and Therapy, 2017, Volume 10, 3119-3122.	1.0	5
2377	5. New Development of the Lung Cancer Treatment. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 534-539.	0.0	0
2378	Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. OncoTargets and Therapy, 2017, Volume 10, 1955-1967.	1.0	7
2379	Survival significance of epidermal growth factor receptor tyrosine kinase inhibitors and current staging system for survival after recurrence in patients with completely resected lung adenocarcinoma. OncoTargets and Therapy, 2017, Volume 10, 4135-4141.	1.0	1
2380	Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget, 2017, 8, 9996-10006.	0.8	47
2381	Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 553-560.	0.7	13
2382	Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2017, 80, 187.	0.7	4
2383	Molecular Testing of Lung Cancers. Journal of Pathology and Translational Medicine, 2017, 51, 242-254.	0.4	26

#	Article	IF	Citations
2384	EGFR G796D mutation mediates resistance to osimertinib. Oncotarget, 2017, 8, 49671-49679.	0.8	90
2385	Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?. Korean Journal of Internal Medicine, 2017, 32, 422-428.	0.7	5
2386	Managing Resistance to EFGR- and ALK-Targeted Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 607-618.	1.8	16
2387	Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways. BMB Reports, 2017, 50, 150-155.	1.1	13
2388	Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al. Journal of Clinical Oncology, 2017, 35, 694-695.	0.8	0
2389	Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. Journal of Clinical Oncology, 2017, 35, 2279-2287.	0.8	100
2390	Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung. Journal of Oncology Practice, 2017, 13, 221-227.	2.5	15
2391	Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naÃ¯ve patients with nonâ€“small cell lung cancer harboring EGFR mutations. Oncotarget, 2017, 8, 68123-68130.	0.8	63
2392	Rapid response in a critical lung adenocarcinoma presenting as large airway stenoses after receiving stent implantation and sequential rebiopsy guided ALK inhibitor therapy: a case report. Journal of Thoracic Disease, 2017, 9, E230-E235.	0.6	2
2393	The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis. Journal of Thoracic Disease, 2017, 9, 1980-1987.	0.6	7
2394	Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 5278-5287.	0.6	15
2395	Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI. Journal of Thoracic Disease, 2017, 9, 470-473.	0.6	2
2396	Identification of genetic risk factors of aggressive periodontitis in a Japanese population by exome sequencing. Journal of Japanese Society of Periodontology, 2017, 59, 1-9.	0.1	0
2397	Urine test for EGFR analysis in patients with non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, S1323-S1331.	0.6	19
2398	Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. Translational Lung Cancer Research, 2017, 6, S21-S34.	1.3	9
2399	Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401875507.	1.4	13
2400	Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Nonâ€“Small-cell Lung Cancer Patients. Clinical Lung Cancer, 2018, 19, e361-e372.	1.1	17
2401	Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treatment Reviews, 2018, 65, 1-10.	3.4	225

#	Article	IF	Citations
2402	Overview of current systemic management of EGFR-mutant NSCLC. Annals of Oncology, 2018, 29, i3-i9.	0.6	229
2403	Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40Âyears or younger. Clinical and Translational Oncology, 2018, 20, 1168-1174.	1.2	18
2404	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 740-750.	1.9	27
2406	Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. Human Pathology, 2018, 75, 167-178.	1.1	13
2407	The role of the ground-glass opacity ratio in resected lung adenocarcinoma. European Journal of Cardio-thoracic Surgery, 2018, 54, 229-234.	0.6	28
2408	Discrete dynamic network modeling of oncogenic signaling: Mechanistic insights for personalized treatment of cancer. Current Opinion in Systems Biology, 2018, 9, 1-10.	1.3	52
2409	Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma. European Journal of Radiology, 2018, 101, 118-123.	1.2	17
2410	A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. Medical Oncology, 2018, 35, 34.	1.2	10
2411	Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Cancer Letters, 2018, 423, 9-15.	3.2	38
2412	Clinicopathological features of younger (aged â‰¤ 50 years) lung adenocarcinoma patients harboring the <scp>EML4â€“ALK</scp> fusion gene. Thoracic Cancer, 2018, 9, 563-570.	0.8	8
2413	Osimertinib in patients with epidermal growth factor receptor T790M advanced nonâ€small cell lung cancer selected using cytology samples. Cancer Science, 2018, 109, 1177-1184.	1.7	10
2414	Cell-Free Plasma DNA-Guided Treatment WithÂOsimertinib in Patients With Advanced EGFR-Mutated NSCLC. Journal of Thoracic Oncology, 2018, 13, 821-830.	0.5	53
2415	Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs. Lung Cancer, 2018, 118, 173-175.	0.9	9
2416	Adjuvant vinorelbine and cisplatin after complete resection of stage II and III non-small cell lung cancer: long-term follow-up of our study of Japanese patients. Surgery Today, 2018, 48, 687-694.	0.7	2
2417	Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma. Annals of Thoracic Surgery, 2018, 105, 1648-1654.	0.7	18
2418	Clinicopathologic Features and Immune Microenvironment of Nonâ€“Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2018, 19, 352-359.e1.	1.1	15
2419	Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Nonâ€“Small Cell Lung Cancer Patients. Clinical Cancer Research, 2018, 24, 3097-3107.	3.2	357
2420	Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nature Reviews Cancer, 2018, 18, 341-358.	12.8	248

#	Article	IF	Citations
2421	Epithelialâ€toâ€mesenchymal transition in the context of epidermal growth factor receptor inhibition in nonâ€smallâ€cell lung cancer. Biological Reviews, 2018, 93, 1735-1746.	4.7	23
2422	A comprehensive review on Brigatinib â€“ A wonder drug for targeted cancer therapy in non-small cell lung cancer. Saudi Pharmaceutical Journal, 2018, 26, 755-763.	1.2	30
2423	First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Nonâ€“Small CellÂLung Cancer: Safety, Efficacy, and PotentialÂMechanism of Resistance. Journal of Thoracic Oncology, 2018, 13, 968-977.	0.5	50
2424	Mechanisms and clinical activity of an EGFR and HER2 exon 20â€“selective kinase inhibitor in nonâ€“small cell lung cancer. Nature Medicine, 2018, 24, 638-646.	15.2	351
2425	Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFRâ€TKIs. Thoracic Cancer, 2018, 9, 754-757.	0.8	3
2426	Combination TSâ€1 plus EGFRâ€tyrosine kinase inhibitors (TKIs) for the treatment of nonâ€small cell lung cancer after progression on firstâ€line or further EGFRâ€TKIs: A phase II, singleâ€arm trial. Thoracic Cancer, 2018, 9, 693-698.	0.8	3
2427	BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer. Archives of Pathology and Laboratory Medicine, 2018, 142, 796-797.	1.2	10
2428	Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. Thoracic Cancer, 2018, 9, 656-661.	0.8	5
2429	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene, 2018, 37, 3740-3752.	2.6	89
2430	EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. Lung Cancer, 2018, 120, 82-87.	0.9	11
2431	Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. Oncologist, 2018, 23, 891-899.	1.9	36
2432	Target switching catalytic hairpin assembly and gold nanoparticle colorimetric for EGFR mutant detection. Sensors and Actuators B: Chemical, 2018, 261, 497-504.	4.0	30
2434	Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. Lung Cancer, 2018, 118, 1-5.	0.9	63
2435	Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. Critical Reviews in Oncology/Hematology, 2018, 123, 149-161.	2.0	50
2436	Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annals of Oncology, 2018, 29, i10-i19.	0.6	449
2437	Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI. Oncology, 2018, 94, 306-310.	0.9	5
2438	Targeting EGFR^{L858R/T790M} and EGFR^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry. Medicinal Research Reviews, 2018, 38, 1550-1581.	5.0	113
2439	Cell death-based treatment of lung adenocarcinoma. Cell Death and Disease, 2018, 9, 117.	2.7	434

#	Article	IF	Citations
2440	Targeting minimal residual disease: a path to cure?. Nature Reviews Cancer, 2018, 18, 255-263.	12.8	106
2441	The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. British Journal of Clinical Pharmacology, 2018, 84, 1156-1169.	1.1	47
2442	Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401775333.	1.4	41
2443	Estrogen receptor Î²1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer. Oncology Reports, 2018, 39, 1313-1321.	1.2	12
2444	Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma. Medical Oncology, 2018, 35, 22.	1.2	17
2445	Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer. Oncology Letters, 2018, 15, 3726-3734.	0.8	6
2446	Gefitinib for advanced non-small cell lung cancer. The Cochrane Library, 2018, 2018, CD006847.	1.5	44
2447	Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?. Future Oncology, 2018, 14, 1117-1132.	1.1	89
2448	Established, emerging and elusive molecular targets in the treatment of lung cancer. Journal of Pathology, 2018, 244, 565-577.	2.1	15
2449	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. Scientific Reports, 2018, 8, 1955.	1.6	34
2450	Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer. Targeted Oncology, 2018, 13, 141-156.	1.7	17
2451	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors) Tj ETQq1 1 0.784314 rgBT /Ove	2.8	28
2452	Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung Cancer, 2018, 117, 14-19.	0.9	63
2453	Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo. Anti-Cancer Drugs, 2018, 29, 262-270.	0.7	8
2454	The biology and management of non-small cell lung cancer. Nature, 2018, 553, 446-454.	13.7	2,877
2455	Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for nonâ€“small cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 267-276.	1.1	14
2456	Survival analysis of patients with advanced nonâ€small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multiâ€center retrospective study. Thoracic Cancer, 2018, 9, 278-283.	0.8	5
2457	MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7. Biochemical and Biophysical Research Communications, 2018, 495, 2482-2489.	1.0	41

#	Article	IF	Citations
2458	Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma. Clinical Lung Cancer, 2018, 19, e313-e322.	1.1	21
2459	Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. Genes Chromosomes and Cancer, 2018, 57, 211-220.	1.5	24
2460	Controllable extension of hairpin-structured flaps to allow low-background cascade invasive reaction for a sensitive DNA logic sensor for mutation detection. Chemical Science, 2018, 9, 1666-1673.	3.7	20
2461	Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 793-803.	1.8	94
2462	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	7.7	275
2463	Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clinical Drug Investigation, 2018, 38, 319-331.	1.1	14
2464	Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer. Translational Oncology, 2018, 11, 94-101.	1.7	101
2465	Lung Cancer Radiogenomics. Journal of Thoracic Imaging, 2018, 33, 17-25.	0.8	9
2466	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774501.	1.4	101
2467	Tissue Acquisition in Patients with Suspected Lung Cancer: Techniques Available to the Pulmonologist. , 2018, , 299-312.		0
2468	High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. Lung Cancer, 2018, 117, 1-6.	0.9	46
2469	Drug development and clinical trial design in pancreatico-biliary malignancies. Current Problems in Cancer, 2018, 42, 73-94.	1.0	5
2470	Droplet digital PCR-based EGFR mutation detection with an internal quality control index to determine the quality of DNA. Scientific Reports, 2018, 8, 543.	1.6	16
2471	A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting. Cancer Chemotherapy and Pharmacology, 2018, 81, 339-345.	1.1	3
2472	Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling. Cancer Letters, 2018, 417, 152-160.	3.2	69
2473	Multiple single cell screening and DNA MDA amplification chip for oncogenic mutation profiling. Lab on A Chip, 2018, 18, 723-734.	3.1	6
2474	Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach. Bioinformatics, 2018, 34, 1353-1362.	1.8	56
2475	First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?. Cancer Chemotherapy and Pharmacology, 2018, 81, 443-453.	1.1	10

#	Article	IF	Citations
2476	A blood biomarker for monitoring response to anti-EGFR therapy. Cancer Biomarkers, 2018, 22, 333-344.	0.8	3
2477	Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis. BMC Bioinformatics, 2018, 19, 88.	1.2	20
2478	The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. BMC Cancer, 2018, 18, 191.	1.1	14
2479	Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma. Journal of Proteomics, 2018, 189, 48-59.	1.2	8
2480	Populationâ€based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. Cancer Medicine, 2018, 7, 1211-1220.	1.3	22
2481	Relevance of a molecular tumour board (MTB) for patientsâ€™ enrolment in clinical trials: experience of the Institut Curie. ESMO Open, 2018, 3, e000339.	2.0	37
2482	A bicenter study on adjuvant surgery following treatment with tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 598-601.	0.5	4
2483	EGFR mutations subset in Chinese lung squamous cell carcinoma patients. Molecular Medicine Reports, 2018, 17, 7575-7584.	1.1	9
2484	Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib. Medicine (United States), 2018, 97, e0650.	0.4	13
2485	EGFR mutations in earlyâ€stage and advancedâ€stage lung adenocarcinoma: Analysis based on largeâ€scale data from China. Thoracic Cancer, 2018, 9, 814-819.	0.8	42
2486	Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib. Lung Cancer, 2018, 121, 101-104.	0.9	2
2487	Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. Lung Cancer, 2018, 121, 12-17.	0.9	23
2488	Recent advances in the management of lung cancer. Clinical Medicine, 2018, 18, s41-s46.	0.8	274
2489	Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring <i>EGFR</i> Mutations. Oncology, 2018, 95, 109-115.	0.9	10
2490	Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas. Cancer, 2018, 124, 2399-2406.	2.0	19
2491	Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. ESMO Open, 2018, 3, e000313.	2.0	33
2492	The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease. Japanese Journal of Clinical Oncology, 2018, 48, 89-93.	0.6	27
2493	Longâ€term safety and survival with gefitinib in select patients with advanced nonâ€“small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). Cancer, 2018, 124, 2407-2414.	2.0	17

#	Article	IF	Citations
2494	Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2018, 4, 739.	3.4	144
2495	In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition. Computational Biology and Chemistry, 2018, 74, 167-189.	1.1	19
2496	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 792-800.	0.5	17
2497	Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity. Anti-Cancer Drugs, 2018, 29, 471-476.	0.7	4
2498	A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy. Clinical Cancer Research, 2018, 24, 3583-3592.	3.2	151
2499	Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis. Cancer Biology and Therapy, 2018, 19, 687-694.	1.5	19
2500	Construction of diagnosis system and gene regulatory networks based on microarray analysis. Journal of Biomedical Informatics, 2018, 81, 61-73.	2.5	2
2501	Fluorometric detection of EGFR exon 19 deletion mutation in lung cancer cells using graphene oxide. Analyst, The, 2018, 143, 1797-1804.	1.7	13
2502	Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation. Investigational New Drugs, 2018, 36, 715-717.	1.2	7
2503	Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR. Carcinogenesis, 2018, 39, 719-727.	1.3	22
2504	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
2505	Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis. American Journal of Roentgenology, 2018, 210, 1346-1351.	1.0	16
2506	Genomic Testing in Lung Cancer: Past, Present, and Future. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 323-334.	2.3	20
2507	Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib. Clinical Lung Cancer, 2018, 19, e431-e438.	1.1	14
2508	EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Nonâ€“Small Cell Lung Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 385-390.	0.6	38
2509	Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?. Clinical and Experimental Medicine, 2018, 18, 15-20.	1.9	43
2510	Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. Journal of Oncology Pharmacy Practice, 2018, 24, 379-388.	0.5	46
2511	An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. Clinical Lung Cancer, 2018, 19, 42-50.	1.1	6

#	Article	IF	Citations
2512	Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. Journal of the Formosan Medical Association, 2018, 117, 326-331.	0.8	10
2513	Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Clinical and Translational Oncology, 2018, 20, 243-252.	1.2	4
2514	Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Nonâ€“Small-Cell Lung CancerÂ(NSCLC). Clinical Lung Cancer, 2018, 19, e19-e28.	1.1	17
2515	Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. Journal of Medical Economics, 2018, 21, 192-200.	1.0	31
2516	Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. Neurosurgery, 2018, 82, E6-E14.	0.6	2
2517	Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review. Clinical Lung Cancer, 2018, 19, e63-e66.	1.1	50
2518	Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. Drug Safety, 2018, 41, 229-237.	1.4	48
2519	Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitor Therapy. American Journal of Roentgenology, 2018, 210, 43-51.	1.0	3
2520	Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 195-204.	1.7	469
2521	Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?. Journal of Cancer Research and Clinical Oncology, 2018, 144, 165-171.	1.2	6
2522	Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 209-216.	3.2	47
2523	Effects of Concomitant Medication Use on Gefitinibâ€Induced Hepatotoxicity. Journal of Clinical Pharmacology, 2018, 58, 263-268.	1.0	15
2524	On Enrichment Strategies for Biomarker Stratified Clinical Trials. Journal of Biopharmaceutical Statistics, 2018, 28, 292-308.	0.4	14
2525	Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790ÂM Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment. Pathology and Oncology Research, 2018, 24, 843-851.	0.9	15
2526	Copy Number Abnormalities and Gene Fusions in Lung Cancer. , 2018, , 82-94.e4.		0
2527	Clinical Presentation and Prognostic Factors in Lung Cancer. , 2018, , 186-198.e6.		0
2528	Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer. , 2018, , 418-433.e6.		0
2529	How to Promote and Organize Clinical Research in Lung Cancer. , 2018, , 628-634.e2.		0

#	Article	IF	Citations
2530	Lung cancer epigenetics: From knowledge to applications. Seminars in Cancer Biology, 2018, 51, 116-128.	4.3	202
2531	Molecular Testing in Lung Cancer. , 2018, , 164-177.e5.		0
2532	Lung cancer's real adjuvant EGFR targeted therapy questions. Lancet Oncology, The, 2018, 19, 15-17.	5.1	20
2533	Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nature Reviews Clinical Oncology, 2018, 15, 151-167.	12.5	247
2534	Precision Medicine from a Public Health Perspective. Annual Review of Public Health, 2018, 39, 153-168.	7.6	95
2535	Molecular Diagnosis and Targeting for Lung Cancer. Current Human Cell Research and Applications, 2018, , 1-32.	0.1	0
2536	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient, 2018, 11, 131-141.	1.1	20
2537	Pharmacogenomic Biomarkers for Improved Drug Therapyâ€"Recent Progress and Future Developments. AAPS Journal, 2018, 20, 4.	2.2	106
2539	MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opinion on Investigational Drugs, 2018, 27, 17-30.	1.9	63
2540	Comparison of therapeutic effects of EGFRâ€tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function. Thoracic Cancer, 2018, 9, 228-233.	0.8	19
2541	Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma. International Journal of Clinical Oncology, 2018, 23, 249-257.	1.0	7
2542	Navigating the â€œNo Man's Landâ€•of TKI-Failed EGFR-Mutated Nonâ€“Small Cell Lung Cancer (NSCLC): A Review. Neoplasia, 2018, 20, 92-98.	2.3	24
2543	NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy. Respiration, 2018, 95, 169-176.	1.2	14
2544	Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. Journal of Clinical Pharmacology, 2018, 58, 485-493.	1.0	14
2545	The miR-875-5p inhibits SATB2 to promote the invasion of lung cancer cells. Gene, 2018, 644, 13-19.	1.0	22
2546	A phase I trial of afatinib and bevacizumab in chemo-naÃ¯ve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. Lung Cancer, 2018, 115, 103-108.	0.9	25
2547	Drug development in the era of precision medicine. Nature Reviews Drug Discovery, 2018, 17, 183-196.	21.5	294
2548	The RA-MAP Consortium: a working model for academiaâ€“industry collaboration. Nature Reviews Rheumatology, 2018, 14, 53-60.	3.5	15

#	Article	IF	Citations
2549	Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naÃ¯ve advanced non-squamous non-small cell lung cancer with EGFR mutations. Investigational New Drugs, 2018, 36, 608-614.	1.2	2
2550	Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. Biochemical and Biophysical Research Communications, 2018, 495, 360-367.	1.0	15
2551	Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Nonâ€“Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice. Clinical Lung Cancer, 2018, 19, 181-190.	1.1	16
2552	Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 81-87.	1.1	6
2553	Osimertinib in UntreatedEGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 113-125.	13.9	3,530
2554	Accuracy of the cobas EGFR Mutation Assay in Nonâ€“small-cell Lung Cancer Compared With Three Laboratory-developed Tests. Clinical Lung Cancer, 2018, 19, 170-174.	1.1	10
2555	Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. Lung Cancer, 2018, 115, 12-20.	0.9	131
2556	Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2018, 61, 4290-4300.	2.9	102
2557	Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Nonâ€“Small Cell Lung Cancer. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, e44-e51.	0.6	18
2558	Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e247-e252.	1.1	41
2559	Gefitinib plus Fuzheng Kangâ€™ai Formula (æ‰¶æ£ŠçŒæ–¹) in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial. Chinese Journal of Integrative Medicine, 2018, 24, 734-740.	0.7	23
2560	Design and synthesis of novel 2,4-disubstituted aminopyrimidines: reversible non-covalent T790M EGFR inhibitors. Journal of Receptor and Signal Transduction Research, 2018, 38, 393-412.	1.3	21
2561	Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer. Oncotarget, 2018, 9, 37520-37533.	0.8	7
2562	Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Nonâ€“Small-Cell Lung Cancer: A Multicenter Case Series. JCO Precision Oncology, 2018, 2, 1-10.	1.5	7
2563	Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations. Oncotarget, 2018, 9, 24237-24247.	0.8	32
2564	Systemic Therapy for Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancers. Journal of Clinical Oncology, 2018, 36, 2571-2574.	0.8	6
2565	Complexity of Delivering Precision Medicine: Opportunities and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 998-1007.	1.8	22
2566	Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology, 2018, 36, 2244-2250.	0.8	361

#	Article	IF	Citations
2567	Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance. Journal of Thoracic Disease, 2018, 10, 1431-1439.	0.6	9
2568	Lung cancer in never smokersâ€"the East Asian experience. Translational Lung Cancer Research, 2018, 7, 450-463.	1.3	104
2569	Inherited lung cancer syndromes targeting never smokers. Translational Lung Cancer Research, 2018, 7, 498-504.	1.3	31
2570	Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances. Journal of Thoracic Disease, 2018, 10, S2451-S2464.	0.6	41
2571	Circulating tumor DNA analysis in patients with EGFR mutant lung cancer. Journal of Thoracic Disease, 2018, 10, S4061-S4064.	0.6	2
2572	Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation. Journal of Thoracic Disease, 2018, 10, 2166-2178.	0.6	14
2573	ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real-world setting. Journal of Thoracic Disease, 2018, 10, 4169-4177.	0.6	12
2574	Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients. Journal of Thoracic Disease, 2018, 10, 5904-5912.	0.6	17
2575	Ablative therapy in oligometastatic non-small cell lung cancerâ€"an editorial on recent evidence. Journal of Thoracic Disease, 2018, 10, 138-140.	0.6	1
2576	Oncogene-addicted non-small cell lung cancer and immunotherapy. Journal of Thoracic Disease, 2018, 10, S1547-S1555.	0.6	25
2577	Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited. Journal of Thoracic Disease, 2018, 10, 1696-1702.	0.6	8
2578	Moving osimertinib to first-line: the right â€œstrategyâ€•in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?. Journal of Thoracic Disease, 2018, 10, S1076-S1080.	0.6	5
2579	Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens. Journal of Thoracic Disease, 2018, 10, 2631-2637.	0.6	37
2580	Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib. Journal of Thoracic Disease, 2018, 10, E359-E363.	0.6	14
2581	Vaccine and immune cell therapy in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S1602-S1614.	0.6	30
2582	Computed tomography characteristics of non-small cell lung cancers with EGFR T790M mutation: role of imaging in the era of precision medicine. Journal of Thoracic Disease, 2018, 10, S4126-S4129.	0.6	1
2583	Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S13-S18.	1.3	1
2584	Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 1788-1796.	0.6	13

#	Article	IF	Citations
2585	Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy. Journal of Thoracic Disease, 2018, 10, 1635-1647.	0.6	2
2586	Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. Journal of Thoracic Disease, 2018, 10, 2070-2078.	0.6	18
2587	Significance of testing for TP53 gene mutations in lung adenocarcinoma using targeted gene sequencing. Journal of Thoracic Disease, 2018, 10, S4147-S4150.	0.6	2
2588	Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitor. Asian Journal of Oncology, 2018, 04, 048-053.	0.2	1
2589	We should be done in such a way that patients with stage IV non-small cell lung cancer who would benefit from surgery are not overlooked. Journal of Thoracic Disease, 2018, 10, S3257-S3259.	0.6	3
2590	Choosing the Best EGFR TKI in the Era of Precision Medicine. Journal of Oncology Translational Research, 2018, 04, .	0.2	0
2591	What information could the main actors of liquid biopsy provide? Â°â„¢a representative case of non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 2018, 10, E570-E576.	0.6	9
2592	Upfront surgery in patients with clinical skip N2 lung cancer based on results of modern radiological examinations. Journal of Thoracic Disease, 2018, 10, 6828-6837.	0.6	13
2593	A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer. Medicine (United States), 2018, 97, e13112.	0.4	14
2594	Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancerâ€”the more specific, the better?. Journal of Thoracic Disease, 2018, 10, S3961-S3964.	0.6	1
2595	A leopard canâ€™t change its spots: can a T790M mutation-positive cancer change its spots after epidermal growth factor receptor-tyrosine kinase inhibitor therapy?. Journal of Thoracic Disease, 2018, 10, S4113-S4113.	0.6	1
2597	Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial. Journal of Thoracic Disease, 2018, 10, S3071-S3077.	0.6	4
2598	Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants. International Journal of Oncology, 2018, 52, 2110-2118.	1.4	6
2599	Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 494-502.	0.5	2
2600	Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines. Experimental and Therapeutic Medicine, 2019, 17, 953-959.	0.8	14
2601	MicroRNAâ€‘506â€‘3p reverses gefitinib resistance in nonâ€‘small cell lung cancer by targeting Yesâ€‘associated protein 1. Molecular Medicine Reports, 2018, 19, 1331-1339.	1.1	12
2602	Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells. JCI Insight, 2018, 3, .	2.3	26
2603	Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean Journal of Internal Medicine, 2018, 33, 168-175.	0.7	47

#	Article	IF	Citations
2604	Outcomes by EGFR, KRAS, and ALK Genotype After Combined Modality Therapy for Locally Advanced Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2018, 2, 1-18.	1.5	5
2605	EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Nonâ€“Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2018, 2, 1-13.	1.5	8
2606	What is the best drug as a front-line treatment for EGFR activating mutation?. Precision Cancer Medicine, 2018, 1, 16-16.	1.8	0
2607	Geranylgeranyl transferase 1 inhibitor GGTIâ€‘298 enhances the anticancer effect of gefitinib. Molecular Medicine Reports, 2018, 18, 4023-4029.	1.1	4
2608	Role of Cytokines in Combinatorial Immunotherapeutics of Non-Small Cell Lung Cancer Through Systems Perspective. SSRN Electronic Journal, 2018, , .	0.4	0
2609	Exploration of resistance mechanisms for epidermal growth factor receptorâ€tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and nextâ€generation sequencing. Cancer Science, 2018, 109, 3921-3933.	1.7	27
2610	Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors. Cancers, 2018, 10, 434.	1.7	11
2611	Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells, 2018, 7, 212.	1.8	190
2612	Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol. Kurume Medical Journal, 2018, 65, 77-81.	0.0	3
2613	Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States. Journal of Thoracic Oncology, 2018, 13, 1842-1850.	0.5	28
2614	Safety of osimertinib in EGFR-mutated non-small cell lung cancer. Expert Opinion on Drug Safety, 2018, 17, 1239-1248.	1.0	25
2615	Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors. Oncology Research and Treatment, 2018, 41, 755-761.	0.8	17
2616	Lessons Learned From Multi-regional Trials With Signals of Treatment Effect Heterogeneity. Therapeutic Innovation and Regulatory Science, 2018, , 216847901880542.	0.8	1
2617	Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. European Journal of Radiology, 2018, 109, 68-76.	1.2	8
2618	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	5.8	107
2619	Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. ESMO Open, 2018, 3, e000399.	2.0	6
2620	Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. OncoTargets and Therapy, 2018, Volume 11, 8575-8587.	1.0	21
2621	Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib. OncoTargets and Therapy, 2018, Volume 11, 7821-7825.	1.0	3

#	Article	IF	Citations
2622	Normalized Serum EGF Levels as a Potential Biomarker in Non-Small Cell Lung Cancer: The Role of Platelets. Journal of Molecular Biomarkers & Diagnosis, 2018, 09, .	0.4	3
2623	Comparative Transcriptomics Unravels Prodigiosin's Potential Cancer-Specific Activity Between Human Small Airway Epithelial Cells and Lung Adenocarcinoma Cells. Frontiers in Oncology, 2018, 8, 573.	1.3	11
2624	Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFRâ€'mutant Ba/F3 cells. Oncology Reports, 2018, 41, 1059-1066.	1.2	6
2625	Î²-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2. Frontiers in Pharmacology, 2018, 9, 1413.	1.6	37
2626	The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. BMC Cancer, 2018, 18, 1241.	1.1	1
2628	Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC Cancer, 2018, 18, 1231.	1.1	10
2629	Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance. Oncotarget, 2018, 9, 15418-15434.	0.8	21
2630	Prise en charge thÃ©rapeutique des cancers bronchiques non Ã petites cellules de stades avancÃ©s mutÃ©s pour lâ€™EGFR. Revue Des Maladies Respiratoires Actualites, 2018, 10, 425-439.	0.0	1
2632	Functional Gene Knockout of NRF2 Increases Chemosensitivity of Human Lung Cancer A549 Cells InÂVitro and in a Xenograft Mouse Model. Molecular Therapy - Oncolytics, 2018, 11, 75-89.	2.0	56
2633	Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas. Cancers, 2018, 10, 489.	1.7	18
2634	Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. Journal of Cancer, 2018, 9, 4279-4286.	1.2	38
2635	Systematic evaluation of the efficacyâ€"effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. European Respiratory Journal, 2018, 52, 1801100.	3.1	34
2636	Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer. Scientific Reports, 2018, 8, 14896.	1.6	31
2637	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. OncoTargets and Therapy, 2018, Volume 11, 6189-6196.	1.0	47
2638	Circular RNAs as Biomarkers for Cancer. Advances in Experimental Medicine and Biology, 2018, 1087, 171-187.	0.8	25
2639	Novel Systemic Treatments for Brain Metastases From Lung Cancer. Current Treatment Options in Neurology, 2018, 20, 48.	0.7	6
2640	Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2457-2463.	1.2	8
2641	Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment. DNA and Cell Biology, 2018, 37, 903-908.	0.9	2

#	Article	IF	Citations
2643	A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. Cancer Chemotherapy and Pharmacology, 2018, 82, 1031-1038.	1.1	18
2644	Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand. Cancer Epidemiology, 2018, 57, 24-32.	0.8	8
2645	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv192-iv237.	0.6	1,571
2646	Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations. BMC Cancer, 2018, 18, 1012.	1.1	8
2647	Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells. BMC Cancer, 2018, 18, 1028.	1.1	7
2648	Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. Lung Cancer, 2018, 126, 112-118.	0.9	14
2649	Structural insights into drug development strategy targeting EGFR T790M/C797S. Oncotarget, 2018, 9, 13652-13665.	0.8	31
2650	Factors affecting bacterial culture positivity in specimens from bronchoscopy in patients with suspected lung cancer. Respiratory Investigation, 2018, 56, 457-463.	0.9	2
2651	EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer, 2018, 126, 133-138.	0.9	33
2652	Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661880865.	1.0	22
2653	A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation. Medicine (United States), 2018, 97, e11569.	0.4	20
2654	Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death and Differentiation, 2018, 25, 1885-1904.	5.0	31
2655	The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. Journal of Cancer, 2018, 9, 1455-1465.	1.2	15
2656	Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis. Frontiers in Cellular and Infection Microbiology, 2018, 8, 332.	1.8	22
2657	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Lung Cancer, 2018, 126, 41-47.	0.9	39
2658	Reducing DNA damage by formaldehyde in liquidâ€based cytology preservation solutions to enable the molecular testing of lung cancer specimens. Cancer Cytopathology, 2018, 126, 1011-1021.	1.4	15
2659	Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results. Japanese Journal of Radiology, 2018, 36, 719-725.	1.0	17
2660	Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol. BMJ Open, 2018, 8, e022161.	0.8	4

#	Article	IF	Citations
2661	Cryptotanshinone Induces Cell Cycle Arrest and Apoptosis of NSCLC Cells through the PI3K/Akt/GSK-3Î² Pathway. International Journal of Molecular Sciences, 2018, 19, 2739.	1.8	32
2662	Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. Journal of Thoracic Oncology, 2018, 13, 1668-1675.	0.5	111
2663	Detection of Rare Mutations inEGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing. Yonsei Medical Journal, 2018, 59, 13.	0.9	10
2664	A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer. Oncology Research, 2018, 26, 1031-1036.	0.6	21
2665	Clinicopathological and genetic characteristics associated with brain metastases from lung adenocarcinoma and utility as prognostic factors. Oncology Letters, 2018, 16, 4243-4252.	0.8	6
2666	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. Scientific Reports, 2018, 8, 13379.	1.6	66
2667	Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining. Lung Cancer, 2018, 124, 241-247.	0.9	5
2668	MET amplification increases the metastatic spread of EGFR-mutated NSCLC. Lung Cancer, 2018, 125, 57-67.	0.9	25
2669	Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. Oncotarget, 2018, 9, 11805-11815.	0.8	9
2670	Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment. Anticancer Research, 2018, 38, 5231-5237.	0.5	20
2671	Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro. Anticancer Research, 2018, 38, 5165-5176.	0.5	14
2672	Master protocol trials in oncology: Review and new trial designs. Contemporary Clinical Trials Communications, 2018, 12, 1-8.	0.5	81
2673	Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan. Oncology and Therapy, 2018, 6, 203-215.	1.0	47
2674	Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 665-675.	1.0	10
2675	Identification of key genes and construction of microRNA-mRNA regulatory networks in non-small cell lung cancer. Cancer Genetics, 2018, 228-229, 47-54.	0.2	6
2676	BMP4ÂUpregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells. Molecular Therapy - Nucleic Acids, 2018, 12, 817-828.	2.3	39
2677	A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting. Cancers, 2018, 10, 290.	1.7	17
2678	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Cell Metabolism, 2018, 28, 848-865.e6.	7.2	184

#	Article	IF	Citations
2679	Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma. Journal of Thoracic Oncology, 2018, 13, e165-e168.	0.5	1
2680	An algorithm to evaluate the efficacy of detecting somatic mutations. Journal of Solid Tumors, 2018, 8, 25.	0.1	0
2681	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. CNS Drugs, 2018, 32, 527-542.	2.7	10
2682	Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation. Scientific Reports, 2018, 8, 8216.	1.6	27
2683	Feasibility of reâ€biopsy and EGFR mutation analysis in patients with nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 856-864.	0.8	21
2684	Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers. Oncologist, 2018, 23, 1054-1062.	1.9	14
2685	Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials. Lung Cancer, 2018, 122, 10-21.	0.9	22
2686	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. Pharmacogenomics, 2018, 19, 727-740.	0.6	20
2687	MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma. Journal of Neuro-Oncology, 2018, 139, 547-562.	1.4	34
2688	Antiâ€“Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells. Journal of Thoracic Oncology, 2018, 13, 1324-1337.	0.5	29
2689	Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Nonâ€“Small-Cell Lung Cancer Harboring Positive EGFR Mutations: AÂSingle-Center Retrospective Study. Clinical Lung Cancer, 2018, 19, 484-492.	1.1	18
2690	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1601-1611.	1.2	8
2691	Osimertinib in Japanese patients with <scp>EGFR</scp> T790M mutationâ€positive advanced nonâ€smallâ€cell lung cancer: <scp>AURA</scp>3 trial. Cancer Science, 2018, 109, 1930-1938.	1.7	53
2692	Functional cooperation between HIF-1Î± and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR. Lung Cancer, 2018, 121, 82-90.	0.9	21
2693	Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. Japanese Journal of Clinical Oncology, 2018, 48, 603-608.	0.6	24
2694	Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with nonâ€‘small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report. Oncology Letters, 2018, 16, 1046-1050.	0.8	3
2695	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. BioMed Research International, 2018, 2018, 1-8.	0.9	24
2696	Exosomeâ€‘mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miRâ€‘21. Oncology Letters, 2018, 15, 9811-9817.	0.8	32

#	Article	IF	Citations
2697	Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Current Oncology, 2018, 25, 73-82.	0.9	24
2698	Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients. Lung Cancer, 2018, 123, 60-69.	0.9	58
2699	Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations. BioMed Research International, 2018, 2018, 1-9.	0.9	6
2700	Nextâ€'generation sequencingâ€'based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Herâ€'2 and TP53 mutations in patients with nonâ€'small cell lung cancer. Molecular Medicine Reports, 2018, 18, 2191-2197.	1.1	37
2701	Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series. Lung Cancer, 2018, 122, 220-223.	0.9	23
2702	Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in nonâ€smallâ€cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. Thoracic Cancer, 2018, 9, 1012-1017.	0.8	14
2703	Resistance to gefitinib and crossâ€resistance to irreversible EGFRâ€TKIs mediated by disruption of the Keap1â€Nrf2 pathway in human lung cancer cells. FASEB Journal, 2018, 32, 5862-5873.	0.2	39
2704	Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Current Oncology, 2018, 25, 68-76.	0.9	11
2705	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. Cancers, 2018, 10, 245.	1.7	34
2706	Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 2018, 7, 192.	1.0	27
2707	Methodological comparison of the allele refractory mutation system and direct sequencing for detecting EGFR mutations in NSCLC, and the association of EGFR mutations with patient characteristics. Oncology Letters, 2018, 16, 1087-1094.	0.8	5
2708	Small Molecules in Oncology. Recent Results in Cancer Research, 2018, , .	1.8	5
2709	Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma. Molecular Cancer Therapeutics, 2018, 17, 2156-2163.	1.9	38
2710	PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma. Oncology Reports, 2018, 40, 331-338.	1.2	6
2711	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. Expert Opinion on Biological Therapy, 2018, 18, 937-945.	1.4	13
2712	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 1021-1030.	1.1	21
2713	mTOR signaling-related MicroRNAs and Cancer involvement. Journal of Cancer, 2018, 9, 667-673.	1.2	33
2714	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, T790M, and Clinical Trials. Current Oncology, 2018, 25, 28-37.	0.9	23

#	Article	IF	Citations
2715	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. Journal of Cancer, 2018, 9, 1813-1820.	1.2	41
2716	Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR nonâ€T790M mutations after progression on firstâ€line EGFRâ€tyrosine kinase inhibitors. Thoracic Cancer, 2018, 9, 1151-1155.	0.8	7
2717	Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma. Journal of Biomedical Science, 2018, 25, 53.	2.6	5
2718	Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation. Cancer Chemotherapy and Pharmacology, 2018, 82, 551-559.	1.1	6
2719	Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 3697-3703.	1.0	5
2720	Synthesis and antitumor evaluation of novel 4â€anilinoâ€7,8â€dihydropyrido[4,3â€d]pyrimidineâ€6(5H)â€carboxylate derivatives as potential EGFR inhibitors. Archiv Der Pharmazie, 2018, 351, e1800110.	2.1	10
2721	Tripartite motifâ€containing 37 (TRIM37) promotes the aggressiveness of nonâ€smallâ€cell lung cancer cells by activating the NFâ€ÎºB pathway. Journal of Pathology, 2018, 246, 366-378.	2.1	45
2722	Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. OncoTargets and Therapy, 2018, Volume 11, 2121-2129.	1.0	15
2723	Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. Cancers, 2018, 10, 35.	1.7	19
2724	The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients. OncoTargets and Therapy, 2018, Volume 11, 2637-2646.	1.0	8
2725	Gefitinib. Recent Results in Cancer Research, 2018, 211, 235-246.	1.8	68
2726	Precision medicine in COPD: where are we and where do we need to go?. European Respiratory Review, 2018, 27, 180022.	3.0	61
2727	Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs. Anticancer Research, 2018, 38, 4699-4704.	0.5	6
2728	Pituitary-Directed Therapies for Cushingâ€™s Disease. Frontiers in Endocrinology, 2018, 9, 164.	1.5	22
2729	First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?. Frontiers in Oncology, 2018, 8, 94.	1.3	20
2730	Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. Frontiers in Oncology, 2018, 8, 226.	1.3	56
2731	MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. Targeted Oncology, 2018, 13, 423-436.	1.7	5
2732	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. Cancer Science, 2018, 109, 2539-2548.	1.7	35

#	Article	IF	Citations
2733	Oncogene addicted non-small-cell lung cancer: current standard and hot topics. Future Oncology, 2018, 14, 3-17.	1.1	18
2734	Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in nonâ€small cell lung cancer progression during firstâ€generation tyrosine kinase inhibitor therapy: a prospective observational study. Cancer Communications, 2018, 38, 1-14.	3.7	29
2735	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. Oncology Letters, 2018, 15, 5671-5679.	0.8	4
2736	EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer?. Respiratory Disease Series, 2018, , 275-293.	0.1	0
2737	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respiratory Medicine,the, 2018, 6, 681-690.	5.2	166
2738	Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers. Lung Cancer, 2018, 123, 99-106.	0.9	20
2739	Nonâ€“Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutationâ€“positive Cancer. Radiology, 2018, 289, 227-237.	3.6	19
2740	Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma. Oncology Letters, 2018, 16, 2105-2112.	0.8	22
2741	CPNE1 is a target of miR-335-5p and plays an important role in the pathogenesis of non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2018, 37, 131.	3.5	57
2742	Identification of a novel BRAF Thr599dup mutation in lung adenocarcinoma. Open Medicine (Poland), 2018, 13, 278-280.	0.6	2
2743	A systematic review of targeted agents for non-small cell lung cancer. Acta OncolÃ³gica, 2018, 57, 176-186.	0.8	54
2744	Irreversible Tyrosine Kinase Inhibition of Epidermal Growth Factor Receptor with Afatinib in Egfr Activating Mutationâ€“Positive Advanced Non-Small-Cell Lung Cancer. Current Oncology, 2018, 25, 9-17.	0.9	15
2745	Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest. Respiratory Research, 2018, 19, 96.	1.4	11
2746	Third generation EGFR TKIs: current data and future directions. Molecular Cancer, 2018, 17, 29.	7.9	205
2747	Haploid genetic screens identify genetic vulnerabilities to microtubuleâ€targeting agents. Molecular Oncology, 2018, 12, 953-971.	2.1	12
2748	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. Clinical Lung Cancer, 2018, 19, e655-e665.	1.1	7
2750	TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Molecular Cancer Therapeutics, 2018, 17, 1648-1658.	1.9	64
2751	Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer, 2018, 18, 106.	1.1	9

#	Article	IF	Citations
2752	Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study. BMC Cancer, 2018, 18, 135.	1.1	11
2753	Frequency of the acquired resistant mutation T790ÂM in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis. BMC Cancer, 2018, 18, 148.	1.1	53
2754	Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer, 2018, 17, 58.	7.9	580
2755	mTOR up-regulation of BEX4 promotes lung adenocarcinoma cell proliferation by potentiating OCT4. Biochemical and Biophysical Research Communications, 2018, 500, 302-309.	1.0	12
2756	Xenograft tumors derived from malignant pleural effusion of the patients with nonâ€smallâ€cell lung cancer as models to explore drug resistance. Cancer Communications, 2018, 38, 1-12.	3.7	14
2757	Aldolase A promotes proliferation and G₁/S transition via the EGFR/MAPK pathway in nonâ€small cell lung cancer. Cancer Communications, 2018, 38, 1-15.	3.7	49
2758	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. Expert Opinion on Pharmacotherapy, 2018, 19, 851-864.	0.9	6
2759	Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. BMC Cancer, 2018, 18, 6.	1.1	7
2760	Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFRâ€“TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. Cancer Chemotherapy and Pharmacology, 2018, 82, 119-127.	1.1	5
2761	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. Cancer, 2018, 124, 3586-3595.	2.0	5
2762	Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review. Current Cancer Drug Targets, 2018, 18, 405-409.	0.8	4
2763	Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada. Current Oncology, 2018, 25, 163-169.	0.9	28
2764	Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Clinical Lung Cancer, 2018, 19, 518-530.e7.	1.1	48
2765	Label-free real-time ultrasensitive monitoring of non-small cell lung cancer cell interaction with drugs. Biomedical Optics Express, 2018, 9, 4149.	1.5	4
2766	Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. OncoTargets and Therapy, 2018, Volume 11, 3335-3343.	1.0	20
2767	Algorithm for the Treatment of Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Evidence-Based Overview. Current Oncology, 2018, 25, 77-85.	0.9	9
2768	Rise of Deep Learning for Genomic, Proteomic, and Metabolomic Data Integration in Precision Medicine. OMICS A Journal of Integrative Biology, 2018, 22, 630-636.	1.0	152
2769	No Therapeutic Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Retreatment Despite T790M Disappearance: Case Report of 3 Cases. Chemotherapy, 2018, 63, 198-202.	0.8	0

#	Article	IF	Citations
2770	Inhibiting Epidermal Growth Factor Receptor Dimerization and Signaling Through Targeted Delivery of a Juxtamembrane Domain Peptide Mimic. ACS Chemical Biology, 2018, 13, 2623-2632.	1.6	19
2771	Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. Clinical Lung Cancer, 2018, 19, e861-e864.	1.1	27
2772	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. Nature Reviews Clinical Oncology, 2018, 15, 694-708.	12.5	255
2773	Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors. Chemotherapy, 2018, 63, 181-189.	0.8	4
2774	Characterization of Factors Affecting the Detection Limit of EGFR p.T790M in Circulating Tumor DNA. Technology in Cancer Research and Treatment, 2018, 17, 153303381879365.	0.8	3
2775	The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. Drugs and Aging, 2018, 35, 819-834.	1.3	16
2776	Conventional treatment integrated with Chinese herbal medicine improves the survival rate of patients with advanced non-small cell lung cancer. Complementary Therapies in Medicine, 2018, 40, 29-36.	1.3	14
2777	Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients. PLoS ONE, 2018, 13, e0196350.	1.1	15
2778	Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Molecular and Clinical Oncology, 2018, 9, 201-206.	0.4	18
2779	Efficacy of icotinib in advanced lung squamous cell carcinoma. Cancer Medicine, 2018, 7, 4456-4466.	1.3	13
2780	Development and validation of a UPLCâ€“MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma. Biomedical Chromatography, 2018, 32, e4365.	0.8	19
2781	LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis. Cancer Management and Research, 2018, Volume 10, 1449-1459.	0.9	38
2782	Apatinib monotherapy for advanced nonâ€small cell lung cancer after the failure of chemotherapy or other targeted therapy. Thoracic Cancer, 2018, 9, 1285-1290.	0.8	26
2783	Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries. Current Cancer Therapy Reviews, 2018, 14, 120-136.	0.2	0
2784	Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway. Biologics: Targets and Therapy, 2018, Volume 12, 75-86.	3.0	26
2785	PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5766-E5775.	3.3	17
2786	Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy. Anticancer Research, 2018, 38, 3559-3566.	0.5	14
2787	Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. Expert Opinion on Pharmacotherapy, 2018, 19, 1049-1056.	0.9	0

#	Article	IF	Citations
2788	Allosteric Inhibitor TREAâ€0236 Containing Nonâ€hydrolysable Quinazolineâ€4â€one for EGFR T790M/C797S Mutants Inhibition. Bulletin of the Korean Chemical Society, 2018, 39, 895-898.	1.0	15
2789	Collagen type I induces <scp>EGFR</scp>â€<scp>TKI</scp> resistance in <scp>EGFR</scp>â€mutated cancer cells by <scp>mTOR</scp> activation through Aktâ€independent pathway. Cancer Science, 2018, 109, 2063-2073.	1.7	39
2790	Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer. Clinical Lung Cancer, 2018, 19, 435-440.e1.	1.1	5
2791	The Role of Osimertinib in Treatment NaÃ¯ve Epidermal Growth Factor Receptorâ€“Mutated Stage IIIB or IV Nonâ€“Small-Cell Lung Cancer Patients. Clinical Medicine Insights: Oncology, 2018, 12, 117955491877958.	0.6	1
2792	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. International Journal of Clinical Oncology, 2018, 23, 1052-1059.	1.0	27
2793	Targeting EGFR in Lung Cancer: Current Standards and Developments. Drugs, 2018, 78, 893-911.	4.9	61
2794	Suppressed expression of Cblâ€b by NFâ€ÎºB mediates icotinib resistance in EGFRâ€mutant nonâ€smallâ€cell lung cancer. Cell Biology International, 2019, 43, 98-107.	1.4	8
2795	Response to alectinib oil-based suspension in anaplastic lymphoma kinase-positive non-small cell lung cancer in a patient unable to swallow: A case report. Journal of Oncology Pharmacy Practice, 2019, 25, 1722-1725.	0.5	4
2796	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.		49
2797	Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR. International Journal of Molecular Sciences, 2019, 20, 4020.	1.8	7
2798	Osimertinib for Japanese patients with T790Mâ€positive advanced nonâ€smallâ€cell lung cancer: A pooled subgroup analysis. Cancer Science, 2019, 110, 2884-2893.	1.7	22
2799	An elderly woman with cervical lymphadenopathy and lung mass. Cytopathology, 2019, 30, 679-682.	0.4	1
2800	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology, 2019, 293, 15-29.	3.6	45
2801	Correlations Study Between 18F-FDG PET/CT Metabolic Parameters Predicting Epidermal Growth Factor Receptor Mutation Status and Prognosis in Lung Adenocarcinoma. Frontiers in Oncology, 2019, 9, 589.	1.3	13
2802	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences, 2019, 20, 3821.	1.8	116
2803	The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer, 2019, 138, 131-138.	0.9	6
2804	Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science Immunology, 2019, 4, .	5.6	30
2805	Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients. Cancer Science, 2019, 110, 3350-3357.	1.7	8

#	Article	IF	Citations
2806	Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs. Integrative Cancer Therapies, 2019, 18, 153473541986949.	0.8	11
2807	Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFRâ€mutated nonâ€“small cell lung cancer. Thoracic Cancer, 2019, 10, 1928-1935.	0.8	10
2808	Co-occurring genomic alterations inÂnon-small-cell lung cancer biology and therapy. Nature Reviews Cancer, 2019, 19, 495-509.	12.8	573
2809	Targeting an EGFR Water Network with 4â€Anilinoquin(az)oline Inhibitors for Chordoma. ChemMedChem, 2019, 14, 1693-1700.	1.6	27
2810	Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Translational Lung Cancer Research, 2019, 8, 302-316.	1.3	91
2811	Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Translational Lung Cancer Research, 2019, 8, 286-301.	1.3	69
2812	Radiomics for the prediction of EGFR mutation subtypes in nonâ€small cell lung cancer. Medical Physics, 2019, 46, 4545-4552.	1.6	62
2813	Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2019, 12, 831-840.	1.3	4
2814	Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Thoracic Disease, 2019, 11, 2350-2360.	0.6	34
2815	Systematic review and network meta-analysis of first-line therapy for advancedEGFR-positive non-small-cell lung cancer. Future Oncology, 2019, 15, 2857-2871.	1.1	17
2816	Nonâ€“Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings, 2019, 94, 1623-1640.	1.4	1,153
2817	Maximum allele frequency observed in plasma: A potential indicator of liquid biopsy sensitivity. Oncology Letters, 2019, 18, 2118-2124.	0.8	4
2818	Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury. International Journal of Molecular Sciences, 2019, 20, 4021.	1.8	24
2819	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. Journal of Clinical Medicine, 2019, 8, 998.	1.0	28
2820	Factors related to the quality of life in patients with bone metastases. Clinical and Experimental Metastasis, 2019, 36, 441-448.	1.7	19
2821	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene, 2019, 38, 6399-6413.	2.6	160
2822	Opportunities of circulating tumor DNA in lung cancer. Cancer Treatment Reviews, 2019, 78, 31-41.	3.4	16
2823	Treatment of Non-small Cell Lung Cancer with <i>EGFR</i>-mutations. Journal of UOEH, 2019, 41, 153-163.	0.3	65

#	Article	IF	Citations
2824	Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. Lung Cancer, 2019, 135, 92-96.	0.9	22
2825	Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer. Toxicology and Applied Pharmacology, 2019, 379, 114662.	1.3	27
2827	Gadolinium chloride promotes proliferation of HEK293 human embryonic kidney cells by activating EGFR/PI3K/Akt and MAPK pathways. BioMetals, 2019, 32, 683-693.	1.8	1
2828	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer, 2019, 135, 66-72.	0.9	22
2829	SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells. Oncogene, 2019, 38, 6196-6210.	2.6	32
2830	Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 1420-e1010.	1.9	4
2831	The canonical TGF-Î²/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer. Respiratory Research, 2019, 20, 164.	1.4	52
2832	Secretion of high amounts of hepatocyte growth factor is a characteristic feature of cancerâ€associated fibroblasts with EGFRâ€TKI resistanceâ€promoting phenotype: A study of 18 cases of cancerâ€associated fibroblasts. Pathology International, 2019, 69, 472-480.	0.6	15
2833	The biological functions and clinical applications of exosomes in lung cancer. Cellular and Molecular Life Sciences, 2019, 76, 4613-4633.	2.4	90
2834	Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance. BioMed Research International, 2019, 2019, 1-10.	0.9	14
2835	Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. Acta Neuropathologica Communications, 2019, 7, 119.	2.4	47
2836	Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC . Cancer Management and Research, 2019, Volume 11, 5665-5675.	0.9	48
2837	BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation. Cell and Bioscience, 2019, 9, 60.	2.1	9
2838	Comparative review of drugâ€“drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer . OncoTargets and Therapy, 2019, Volume 12, 5467-5484.	1.0	36
2839	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respiratory Investigation, 2019, 57, 512-533.	0.9	36
2840	Prognostic value of the expression of epithelial cell adhesion molecules in head and neck squamous cell carcinoma treated by definitive radiotherapy. Journal of Radiation Research, 2019, 60, 803-811.	0.8	9
2841	Exo-miRNAs as a New Tool for Liquid Biopsy in Lung Cancer. Cancers, 2019, 11, 888.	1.7	56
2842	Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. Molecular Cancer Therapeutics, 2019, 18, 1593-1601.	1.9	4

#	Article	IF	Citations
2843	Effectiveness of Treatments for Advanced Nonâ€“Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 2019, 20, e620-e630.	1.1	39
2844	The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer. Lung Cancer, 2019, 134, 218-224.	0.9	16
2845	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). Tumori, 2019, 105, 3-14.	0.6	9
2846	The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens. Journal of Experimental and Clinical Cancer Research, 2019, 38, 282.	3.5	29
2847	Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?. Anticancer Research, 2019, 39, 3923-3929.	0.5	24
2848	Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations. Journal of Vascular and Interventional Radiology, 2019, 30, 1004-1012.	0.2	7
2849	Functioning Pituitary Adenomas â€“ Current Treatment Options and Emerging Medical Therapies. European Endocrinology, 2019, 15, 30.	0.8	42
2850	Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort. Experimental Hematology and Oncology, 2019, 8, 24.	2.0	14
2851	Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Nonâ€“Small Cell Lung Cancer in China. Clinical Therapeutics, 2019, 41, 2308-2320.e11.	1.1	25
2852	First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. Annals of Oncology, 2019, 30, 1852-1855.	0.6	13
2853	STS-NLSP: A Network-Based Label Space Partition Method for Predicting the Specificity of Membrane Transporter Substrates Using a Hybrid Feature of Structural and Semantic Similarity. Frontiers in Bioengineering and Biotechnology, 2019, 7, 306.	2.0	17
2854	miR-134-5p Promotes Stage I Lung Adenocarcinoma Metastasis and Chemoresistance by Targeting DAB2. Molecular Therapy - Nucleic Acids, 2019, 18, 627-637.	2.3	29
2855	Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ: British Medical Journal, 2019, 367, l5460.	2.4	108
2856	Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer. Journal of Thoracic Disease, 2019, 11, S1831-S1834.	0.6	5
2857	FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. Biomolecules, 2019, 9, 668.	1.8	80
2858	How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study. Journal of Global Health, 2019, 9, 020702.	1.2	35
2859	Phase II study of nabâ€paclitaxelÂ+Âcarboplatin for patients with nonâ€smallâ€cell lung cancer and interstitial lung disease. Cancer Science, 2019, 110, 3738-3745.	1.7	49
2860	Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets. European Journal of Cancer, 2019, 121, 202-209.	1.3	11

#	Article	IF	Citations
2861	Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study. Targeted Oncology, 2019, 14, 719-728.	1.7	3
2862	Pemetrexed Plus Platinum for Patients With Advanced Non-small Cell Lung Cancer and Interstitial Lung Disease. In Vivo, 2019, 33, 2059-2064.	0.6	13
2863	Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicology and Applied Pharmacology, 2019, 383, 114761.	1.3	11
2864	The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). Cancer Communications, 2019, 39, 69.	3.7	19
2865	Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma. Molecular Diagnosis and Therapy, 2019, 23, 773-779.	1.6	10
2866	Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium. Respiratory Medicine Case Reports, 2019, 28, 100954.	0.2	1
2867	Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR Mutations . Cancer Management and Research, 2019, Volume 11, 9017-9024.	0.9	2
2868	The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients. Immunotherapy, 2019, 11, 1481-1490.	1.0	14
2869	Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. Frontiers in Medicine, 2019, 6, 233.	1.2	8
2870	Realâ€world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced nonâ€small cell lung cancer. Cancer Medicine, 2019, 8, 7542-7555.	1.3	14
2871	Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning. European Respiratory Journal, 2019, 53, 1800986.	3.1	298
2872	Efficacy of EGFRâ€TKIs with or without upfront brain radiotherapy for EGFRâ€mutant NSCLC patients with central nervous system metastases. Thoracic Cancer, 2019, 10, 2106-2116.	0.8	11
2873	Postâ€progression survival is highly linked to overall survival in patients with nonâ€smallâ€cell lung cancer harboring sensitive EGFR mutations treated with firstâ€line epidermal growth factor receptorâ€tyrosine kinase inhibitors. Thoracic Cancer, 2019, 10, 2200-2208.	0.8	8
2874	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptorâ€tyrosine kinase inhibitors in patients with <scp>EGFR</scp>â€mutant nonâ€small cell lung cancer. Cancer Science, 2019, 110, 3244-3254.	1.7	32
2875	Efficacy and safety of microwave ablation in the treatment of patients with oligometastatic non-small-cell lung cancer: a retrospective study. International Journal of Hyperthermia, 2019, 36, 826-833.	1.1	21
2876	Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates. Future Oncology, 2019, 15, 2983-2997.	1.1	27
2877	Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review. Frontiers in Oncology, 2019, 9, 715.	1.3	13
2878	Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. European Journal of Cancer, 2019, 119, 77-86.	1.3	23

#	Article	IF	Citations
2879	Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. PLoS ONE, 2019, 14, e0221575.	1.1	11
2880	Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations . OncoTargets and Therapy, 2019, Volume 12, 6045-6052.	1.0	6
2881	EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of nonâ€small cell lung cancer. Clinical and Translational Medicine, 2019, 8, 4.	1.7	15
2882	Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer . OncoTargets and Therapy, 2019, Volume 12, 6535-6548.	1.0	26
2883	PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma. BMC Pulmonary Medicine, 2019, 19, 169.	0.8	4
2884	A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology, 2019, 84, 1065-1071.	1.1	1
2885	Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients. Journal of Thoracic Disease, 2019, 11, 3004-3014.	0.6	22
2886	A pH-sensitive polymer based precise tumor targeting strategy with reduced uptake of nanoparticles by non-cancerous cells. Journal of Materials Chemistry B, 2019, 7, 5983-5991.	2.9	6
2887	An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer, 2019, 136, 74-79.	0.9	14
2888	Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer, 2019, 19, 896.	1.1	33
2889	Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population. Journal of Thoracic Oncology, 2019, 14, 2003-2008.	0.5	52
2890	Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. Future Oncology, 2019, 15, 2769-2777.	1.1	8
2891	Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. Journal of Personalized Medicine, 2019, 9, 42.	1.1	2
2892	Prognostic value of EGFR 19â€‘del and 21â€‘L858R mutations in patients with nonâ€‘small cell lung cancer. Oncology Letters, 2019, 18, 3887-3895.	0.8	26
2893	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Seminars in Oncology, 2019, 46, 271-283.	0.8	61
2894	Optimization of Cancer Treatment in the Frequency Domain. AAPS Journal, 2019, 21, 106.	2.2	2
2895	Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1978-1984.	0.6	75
2896	Predisposition to Lung Adenocarcinoma in a Family Harboring the Germline EGFR V843I Mutation. JCO Precision Oncology, 2019, 3, 1-4.	1.5	2

#	Article	IF	Citations
2897	Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives . Drug Design, Development and Therapy, 2019, Volume 13, 3187-3198.	2.0	39
2898	High-grade non-small cell lung carcinoma: a comparative analysis of the phenotypic profile in small biopsies with the corresponding postoperative material. Polish Journal of Pathology, 2019, 70, 100-108.	0.1	5
2899	Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies. , 2019, , .		3
2900	First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis. PLoS ONE, 2019, 14, e0223530.	1.1	11
2901	Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice. Lung Cancer, 2019, 137, 85-93.	0.9	24
2902	Fabrication of Furan-Functionalized Quinazoline Hybrids: Their Antibacterial Evaluation, Quantitative Proteomics, and Induced Phytopathogen Morphological Variation Studies. Journal of Agricultural and Food Chemistry, 2019, 67, 11005-11017.	2.4	29
2903	Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy. Lung Cancer, 2019, 137, 76-84.	0.9	30
2905	Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. , 2019, , 45-128.		0
2906	Incorporating Pharmacogenomics in Drug Development. , 2019, , 81-101.		1
2907	Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib. Internal Medicine, 2019, 58, 101-104.	0.3	3
2908	Oxidized Vitamin C (DHA) Overcomes Resistance to EGFR-targeted Therapy of Lung Cancer through Disturbing Energy Homeostasis. Journal of Cancer, 2019, 10, 757-764.	1.2	7
2909	miR-449a Suppresses Tumor Growth, Migration, and Invasion in Non-Small Cell Lung Cancer by Targeting a HMGB1-Mediated NF-ÎºB Signaling Pathway. Oncology Research, 2019, 27, 227-235.	0.6	46
2910	Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. Clinical Lung Cancer, 2019, 20, e309-e316.	1.1	11
2911	Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	74
2912	Prognostic impact of pleural effusion in EGFRâ€mutant nonâ€small cell lung cancer patients without brain metastasis. Thoracic Cancer, 2019, 10, 557-563.	0.8	8
2913	Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma. Tuberculosis and Respiratory Diseases, 2019, 82, 62.	0.7	9
2914	Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibodyâ€“positive Polymyositis/dermatomyositisâ€“associated Interstitial Lung Disease: A Propensity Scoreâ€“matched Analysis. Journal of Rheumatology, 2019, 46, 509-517.	1.0	18
2915	Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncology, 2019, 15, 805-816.	1.1	32

#	Article	IF	Citations
2916	Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial . Cancer Management and Research, 2019, Volume 11, 4449-4459.	0.9	5
2917	Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer . Therapeutics and Clinical Risk Management, 2019, Volume 15, 605-612.	0.9	2
2918	A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. Journal of Experimental and Clinical Cancer Research, 2019, 38, 211.	3.5	10
2919	A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the thirdâ€generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 370-381.	1.2	9
2920	Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) Biopolyester Based Nanoparticles as NVP-BEZ235 Delivery Vehicle for Tumor Targeting Therapy. Biomacromolecules, 2019, 20, 3313-3323.	2.6	8
2921	Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treatment and Research, 2019, 178, 3-43.	0.2	16
2922	EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1311-1320.	0.6	249
2923	First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting. JNCI Cancer Spectrum, 2019, 3, pkz020.	1.4	12
2924	CT imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma. Cancer Imaging, 2019, 19, 34.	1.2	28
2925	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Pharmacological Research, 2019, 146, 104297.	3.1	29
2926	The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 6382-6391.	3.2	39
2927	De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors. Cancer Biology and Therapy, 2019, 20, 1183-1186.	1.5	7
2928	Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with nonâ€‘small cell lung cancer. Oncology Letters, 2019, 17, 5125-5131.	0.8	6
2929	Transformation to small cell lung cancer and activation of KRAS during longâ€‘term erlotinib maintenance in a patient with nonâ€‘small cell lung cancer: A case report. Oncology Letters, 2019, 17, 5219-5223.	0.8	5
2931	Biomarkers of Lung Cancer: Liquid Biopsy Comes of Age. , 2019, , 105-113.		0
2932	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Medicine, 2019, 45, 988-997.	3.9	18
2933	Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo. Bioorganic and Medicinal Chemistry, 2019, 27, 114938.	1.4	11
2934	A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. Lung Cancer, 2019, 134, 46-51.	0.9	24

#	Article	IF	Citations
2935	Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report. Cancer Biology and Therapy, 2019, 20, 1172-1175.	1.5	10
2936	Response to First-Line Osimertinib Treatment in Nonâ€“Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 2019, 20, e531-e533.	1.1	1
2937	High-affinity peptide ligand LXY30 for targeting Î±3Î²1 integrin in non-small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 56.	6.9	28
2938	Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives. Cancer Letters, 2019, 459, 240-247.	3.2	19
2939	Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective study. Journal of Thoracic Disease, 2019, 11, 1347-1354.	0.6	3
2940	Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients. Lung Cancer, 2019, 134, 225-232.	0.9	10
2941	Network-based cancer precision medicine: A new emerging paradigm. Cancer Letters, 2019, 458, 39-45.	3.2	28
2942	Advances in the relationship between glycosyltransferases and multidrug resistance in cancer. Clinica Chimica Acta, 2019, 495, 417-421.	0.5	25
2943	Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer. Clinica Chimica Acta, 2019, 495, 331-337.	0.5	41
2944	Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. Drugs, 2019, 79, 823-831.	4.9	35
2945	Adding Nanotechnology to the Metastasis Treatment Arsenal. Trends in Pharmacological Sciences, 2019, 40, 403-418.	4.0	32
2946	Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling. Cells, 2019, 8, 442.	1.8	27
2947	Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort. Clinical Lung Cancer, 2019, 20, e576-e583.	1.1	32
2948	Toward automatic prediction of EGFR mutation status in pulmonary adenocarcinoma with 3D deep learning. Cancer Medicine, 2019, 8, 3532-3543.	1.3	87
2949	Determination of BPI15086 and its metabolite in human plasma by ultra-high performance liquid chromatographyâ€“MS/MS and its application to a pharmacokinetic study. Bioanalysis, 2019, 11, 773-784.	0.6	0
2950	Computed Tomography Imaging Characteristics of Nonâ€“Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis. Clinical Lung Cancer, 2019, 20, 339-349.	1.1	24
2951	An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 2483-2491.	0.5	3
2952	Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer. Medical Oncology, 2019, 36, 57.	1.2	18

#	Article	IF	Citations
2953	Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon. Diagnostic Cytopathology, 2019, 47, 845-850.	0.5	2
2954	Preparative isolation and purification of steroidal glycoalkaloid from the ripe berries of Solanum nigrum L. by preparative HPLCâ€“MS and UHPLCâ€“TOFâ€MS/MS and its antiâ€nonâ€small cell lung tumors effects in vitro and in vivo. Journal of Separation Science, 2019, 42, 2471-2481.	1.3	17
2955	Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. BMC Cancer, 2019, 19, 369.	1.1	13
2956	Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance. Memo - Magazine of European Medical Oncology, 2019, 12, 128-135.	0.3	1
2957	Role of cytokines in combinatorial immunotherapeutics of nonâ€small cell lung cancer through systems perspective. Cancer Medicine, 2019, 8, 1976-1995.	1.3	14
2958	Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients. Mutation Research - Reviews in Mutation Research, 2019, 781, 63-70.	2.4	10
2959	AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nature Communications, 2019, 10, 1812.	5.8	98
2960	Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives. Journal of Thoracic Disease, 2019, 11, S249-S252.	0.6	2
2961	Clinical analysis ofEGFRâ€positive nonâ€small cell lung cancer patients treated with firstâ€line afatinib: A Nagano Lung Cancer Research Group. Thoracic Cancer, 2019, 10, 1078-1085.	0.8	5
2962	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. International Journal of Clinical Oncology, 2019, 24, 731-770.	1.0	100
2963	Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors. PLoS ONE, 2019, 14, e0215923.	1.1	2
2964	Molecular and Morphological Profiling of Lung Cancer: A Foundation for â€œNext-Generationâ€• Pathologists and Oncologists. Cancers, 2019, 11, 599.	1.7	41
2965	The efficacy of immune checkpoint inhibitors in advanced nonâ€‘small cell lung cancer harboring driver mutations. Molecular and Clinical Oncology, 2019, 10, 610-614.	0.4	4
2966	Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis . Cancer Management and Research, 2019, Volume 11, 2677-2690.	0.9	10
2967	Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer. Clinical Lung Cancer, 2019, 20, 270-277.e1.	1.1	39
2968	Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma. Thoracic Cancer, 2019, 10, 1220-1228.	0.8	13
2969	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the â€˜real-worldâ€™ clinical setting. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983637.	1.4	25
2970	Emerging therapies for non-small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 45.	6.9	111

#	Article	IF	Citations
2971	Bio-Inspired NanoVilli Chips for Enhanced Capture of Tumor-Derived Extracellular Vesicles: Toward Non-Invasive Detection of Gene Alterations in Non-Small Cell Lung Cancer. ACS Applied Materials & Interfaces, 2019, 11, 13973-13983.	4.0	55
2972	Leptomeningeal Disease in Solid Cancers. , 2019, , 1-19.		0
2973	Redefining Treatment Paradigms in First-line Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 4881-4887.	3.2	10
2974	Survival benefit of first-generation epidermal growth factor receptorâ€“tyrosine kinase inhibitors in female with advanced lung cancer. Tumori, 2019, 105, 216-224.	0.6	1
2975	Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study. BMJ Open, 2019, 9, e022293.	0.8	9
2976	Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-Independent and Calcium-Mediated Repression of SKP2 Transcription. Cancer Research, 2019, 79, 2195-2207.	0.4	19
2977	Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. Cancers, 2019, 11, 365.	1.7	8
2978	LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC. Molecular Therapy - Nucleic Acids, 2019, 16, 155-161.	2.3	94
2979	Targeting Molecular Pathways in Intracranial Metastatic Disease. Frontiers in Oncology, 2019, 9, 99.	1.3	10
2980	Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?. Cancers, 2019, 11, 366.	1.7	50
2981	Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. Future Oncology, 2019, 15, 1493-1504.	1.1	6
2982	Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer. , 2019, , 115-131.		0
2983	Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study. Integrative Cancer Therapies, 2019, 18, 153473541982707.	0.8	13
2984	Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. International Journal of Clinical Oncology, 2019, 24, 461-467.	1.0	7
2985	Clinical and computed tomography characteristics of nonâ€small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFRâ€negative lung cancer. Thoracic Cancer, 2019, 10, 872-879.	0.8	9
2986	Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial). Japanese Journal of Clinical Oncology, 2019, 49, 554-558.	0.6	14
2987	Identification of genetic alterations associated with primary resistance to EGFRâ€TKIs in advanced nonâ€smallâ€cell lung cancer patients with EGFR sensitive mutations. Cancer Communications, 2019, 39, 1-15.	3.7	53
2988	Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. International Journal of Molecular Sciences, 2019, 20, 1431.	1.8	77

#	Article	IF	Citations
2989	Predictive importance of galectin-3 for recurrence of non-small cell lung cancer. General Thoracic and Cardiovascular Surgery, 2019, 67, 704-711.	0.4	12
2990	Biological Evaluation and Molecular Dynamics Simulation of Chalcone Derivatives as Epidermal Growth Factor-Tyrosine Kinase Inhibitors. Molecules, 2019, 24, 1092.	1.7	22
2991	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2019, 19, 547-559.	1.1	22
2992	A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). Lung Cancer, 2019, 135, 175-180.	0.9	24
2993	Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. Current Oncology, 2019, 26, 81-93.	0.9	38
2994	Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Clinical and Translational Oncology, 2019, 21, 1287-1301.	1.2	73
2995	Treatment of stage IIIAâ€“N2 EGFR-mutant non-small cell lung adenocarcinoma. Journal of Thoracic Disease, 2019, 11, 263-265.	0.6	1
2996	The superstars of precision medicineâ€”EGFR inhibitors in adjuvant treatment of lung cancer. Journal of Thoracic Disease, 2019, 11, E11-E13.	0.6	0
2997	Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib . OncoTargets and Therapy, 2019, Volume 12, 1521-1538.	1.0	3
2998	First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis . OncoTargets and Therapy, 2019, Volume 12, 1413-1421.	1.0	51
2999	Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer. Anticancer Research, 2019, 39, 1317-1328.	0.5	2
3000	De Novo HER2 S310Y mutation associates with poor response to EGFR tyrosine kinase inhibitor in activating EGFR-mutant NSCLC patient: A case report. European Journal of Inflammation, 2019, 17, 205873921982716.	0.2	0
3001	Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1â€‘positive nonâ€‘small cell lung cancer. Oncology Letters, 2019, 17, 3466-3474.	0.8	11
3002	Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFRâ€Mutated Nonâ€“Small Cell Lung Cancer. Journal of Clinical Pharmacology, 2019, 59, 1099-1109.	1.0	6
3003	Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. EBioMedicine, 2019, 42, 304-310.	2.7	51
3004	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	1.5	17
3005	Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 1767-1775.	0.5	10
3006	Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncology, The, 2019, 20, 625-635.	5.1	470

#	Article	IF	Citations
3007	LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR. BMC Cancer, 2019, 19, 293.	1.1	10
3008	The Diagnostic Value of Quantitative CT Analysis of Ground-Glass Volume Percentage in Differentiating Epidermal Growth Factor Receptor Mutation and Subtypes in Lung Adenocarcinoma. BioMed Research International, 2019, 2019, 1-8.	0.9	4
3009	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. Clinical Lung Cancer, 2019, 20, e442-e451.	1.1	15
3010	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer, 2019, 133, 10-19.	0.9	25
3011	CuS Nanoparticles as a Photodynamic Nanoswitch for Abrogating Bypass Signaling To Overcome Gefitinib Resistance. Nano Letters, 2019, 19, 3344-3352.	4.5	42
3012	Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations. PLoS ONE, 2019, 14, e0215292.	1.1	12
3013	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	3.5	170
3014	Osimertinib for patients with EGFR T790M mutation-positive nonâ€“small-cell lung cancer and a poor performance status. Japanese Journal of Clinical Oncology, 2019, 49, 671-675.	0.6	17
3015	A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 195.	1.3	48
3016	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respiratory Medicine,the, 2019, 7, 387-401.	5.2	704
3017	Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 39-41.	0.6	1
3018	Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing. Frontiers in Pharmacology, 2019, 10, 230.	1.6	89
3019	Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study . Cancer Management and Research, 2019, Volume 11, 2129-2138.	0.9	29
3020	CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor. Cancers, 2019, 11, 455.	1.7	18
3021	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2019, 393, 1819-1830.	6.3	2,347
3022	Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). Lung Cancer, 2019, 131, 128-133.	0.9	18
3023	Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. Lung Cancer, 2019, 132, 54-58.	0.9	15
3024	Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway. Journal of Experimental and Clinical Cancer Research, 2019, 38, 96.	3.5	22

#	Article	IF	Citations
3025	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFRâ€mutated nonâ€small cell lung cancer. Cancer Medicine, 2019, 8, 1521-1529.	1.3	82
3026	Detection of EGFR mutations using target capture sequencing in plasma of patients with non-small-cell lung cancer. Journal of Clinical Pathology, 2019, 72, 379-385.	1.0	3
3027	Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. Investigational New Drugs, 2019, 37, 1207-1217.	1.2	6
3028	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Clinical Cancer Research, 2019, 25, 3341-3351.	3.2	80
3029	Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Current Oncology Reports, 2019, 21, 21.	1.8	82
3030	First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. Journal of Cancer, 2019, 10, 522-529.	1.2	43
3031	Correlation of Thyroid Transcription Factor-1 Expression with EGFR Mutations in Non-Small-Cell Lung Cancer: A Meta-Analysis. Medicina (Lithuania), 2019, 55, 41.	0.8	8
3032	K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. Journal of Thoracic Oncology, 2019, 14, 606-616.	0.5	178
3033	The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis. Postgraduate Medicine, 2019, 131, 199-206.	0.9	21
3034	Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer. In Vivo, 2019, 33, 477-482.	0.6	22
3035	Comparison of PNA Clamping-assisted Fluorescence Melting Curve Analysis and PNA Clamping in Detecting EGFR Mutations in Matched Tumor Tissue, Cell Block, Pleural Effusion and Blood of Lung Cancer Patients With Malignant Pleural Effusion. In Vivo, 2019, 33, 595-603.	0.6	5
3036	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Seminars in Radiation Oncology, 2019, 29, 111-125.	1.0	4
3037	Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping. Cancer Biology and Therapy, 2019, 20, 837-842.	1.5	13
3038	Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. Cancer Chemotherapy and Pharmacology, 2019, 83, 817-825.	1.1	13
3039	How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study. Journal of Global Health, 2019, 9, 020702.	1.2	15
3040	Utilization of combined PD-L1 expression and neutrophil-to-lymphocyte ratio prior to surgery as a prognostic factor in non-small cell lung cancer with brain metastasis. Translational Cancer Research, 2019, 8, 2864-2877.	0.4	12
3041	The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. Translational Lung Cancer Research, 2019, 8, 1134-1151.	1.3	3
3042	Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series. CNS Oncology, 2019, 8, CNS42.	1.2	3

#	Article	IF	Citations
3043	For a better adjuvant strategy for resected lung cancerâ€"lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104). Translational Lung Cancer Research, 2019, 8, S395-S399.	1.3	4
3044	EGFR^{vIII}: An Oncogene with Ambiguous Role. Journal of Oncology, 2019, 2019, 1-20.	0.6	45
3045	Silence of S1 RNA binding domain 1 represses cell growth and promotes apoptosis in human non-small cell lung cancer cells. Translational Lung Cancer Research, 2019, 8, 760-774.	1.3	5
3046	Excellent platinum dependent response to chemotherapy after relapse under TKI treatment in NSCLC with sensitizing EGFR mutations and no detectable resistance mutations: three case studies. AME Case Reports, 2019, 3, 36-36.	0.2	1
3047	Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer . Cancer Management and Research, 2019, Volume 11, 9621-9630.	0.9	6
3048	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications, 2019, 10, 5157.	5.8	46
3050	Pemetrexed plus cisplatin versus docetaxel plus cisplatin for stage IV lung adenocarcinoma based on propensity score matching. Anti-Cancer Drugs, 2019, 30, 295-301.	0.7	2
3051	Uso de inhibidores del receptor del factor de crecimiento epidÃ©rmico en estadio precoz: nuestra experiencia clÃnica. Open Respiratory Archives, 2019, 1, 14-15.	0.0	0
3052	Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Scientific Reports, 2019, 9, 19501.	1.6	12
3053	Osimertinib-Induced Cardiotoxicity. JACC: CardioOncology, 2019, 1, 172-178.	1.7	66
3054	Enhanced anticancer effect of cetuximab combined with stabilized silver ion solution in EGFR-positive lung cancer cells. Turkish Journal of Biochemistry, 2019, 44, 426-437.	0.3	2
3055	Durvalumab for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2019, 19, 1009-1016.	1.1	20
3056	Distribution Of Brain Metastasis From Lung Cancer . Cancer Management and Research, 2019, Volume 11, 9331-9338.	0.9	24
3057	In vivo drug screening method of radiosensitizers using tumor-bearing chick embryo. The Enzymes, 2019, 46, 113-127.	0.7	2
3058	Treatment of atypical pulmonary carcinoid with combination ipilimumab and nivolumab. BMJ Case Reports, 2019, 12, e231029.	0.2	7
3059	FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma. Journal of Molecular Medicine, 2019, 97, 1657-1668.	1.7	7
3060	Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. Respiratory Research, 2019, 20, 263.	1.4	5
3061	Modified score based on revised Tokuhashi score is needed for the determination of surgical intervention in patients with lung cancer metastases to the spine. World Journal of Surgical Oncology, 2019, 17, 194.	0.8	8

#	Article	IF	Citations
3062	Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989028.	1.4	28
3063	Treatment of oncogene-driven non-small cell lung cancer. Current Opinion in Pulmonary Medicine, 2019, 25, 300-307.	1.2	7
3064	Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro. Anti-Cancer Drugs, 2019, 30, 495-500.	0.7	14
3065	Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer. Medicine (United States), 2019, 98, e13726.	0.4	7
3066	Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials. Medicine (United States), 2019, 98, e16427.	0.4	2
3067	Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. Translational Lung Cancer Research, 2019, 8, S235-S246.	1.3	8
3068	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S265-S279.	1.3	17
3069	Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. Cancers, 2019, 11, 2033.	1.7	26
3071	The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduction and Targeted Therapy, 2019, 4, 61.	7.1	436
3072	Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients. PLoS ONE, 2019, 14, e0226193.	1.1	18
3073	Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer. Chinese Medical Journal, 2019, 132, 1115-1116.	0.9	6
3074	Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 432-439.	0.6	21
3075	Patient-Defined Treatment Success: Perspectives of Patients With Advanced-Stage Lung Cancer. Journal of Oncology Practice, 2019, 15, e758-e768.	2.5	4
3076	BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer. Medicine (United States), 2019, 98, e14568.	0.4	14
3077	Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of Hematology and Oncology, 2019, 12, 134.	6.9	296
3078	Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a costâ€“effectiveness analysis. Journal of Comparative Effectiveness Research, 2019, 8, 853-863.	0.6	15
3079	Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors . OncoTargets and Therapy, 2019, Volume 12, 9495-9504.	1.0	5
3080	Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. Chemical Science, 2019, 10, 10789-10801.	3.7	25

#	Article	IF	Citations
3081	Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients. International Journal of Cancer, 2019, 144, 290-296.	2.3	13
3082	Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. Oncologist, 2019, 24, 157-e64.	1.9	79
3083	Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. Molecular Cancer Research, 2019, 17, 212-224.	1.5	41
3084	Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma. Journal of Bronchology and Interventional Pulmonology, 2019, 26, 96-101.	0.8	18
3085	Paving the way for precision medicine v2.0 in intensive care by profiling necroinflammation in biofluids. Cell Death and Differentiation, 2019, 26, 83-98.	5.0	10
3086	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. Clinical Lung Cancer, 2019, 20, e39-e51.	1.1	11
3087	Covalent vs. Nonâ€Covalent Inhibition: Tackling Drug Resistance in EGFR â€“ A Thorough Dynamic Perspective. Chemistry and Biodiversity, 2019, 16, e1800518.	1.0	8
3088	EGFR Mutation Testing: Changing Patterns of Molecular Testing in Brazil. Oncologist, 2019, 24, e137-e141.	1.9	13
3089	Evolution of Cancer Progression in the Context of Darwinism. Anticancer Research, 2019, 39, 1-16.	0.5	23
3090	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). Lung Cancer, 2019, 129, 63-71.	0.9	25
3091	miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs. Laboratory Investigation, 2019, 99, 568-576.	1.7	30
3092	Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. Japanese Journal of Clinical Oncology, 2019, 49, 174-182.	0.6	4
3093	Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Japanese Journal of Clinical Oncology, 2019, 49, 29-36.	0.6	101
3094	ALK testing methods: is there a winner or loser?. Expert Review of Anticancer Therapy, 2019, 19, 237-244.	1.1	10
3095	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCOâ€“ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Annals of Oncology, 2019, 30, 171-210.	0.6	214
3096	Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncology, 2019, 15, 637-652.	1.1	80
3097	EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 29-39.	3.3	137
3098	EGFR Mutations. , 2019, , 477-486.		2

#	Article	IF	Citations
3099	The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma. Clinical Lung Cancer, 2019, 20, e195-e207.	1.1	11
3100	Recommendations for Ancillary Testing. , 2019, , 125-142.		0
3101	The Papanicolaou Society of Cytopathology System for Reporting Respiratory Cytology. , 2019, , .		9
3102	Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. Clinical Lung Cancer, 2019, 20, 134-138.	1.1	19
3103	High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naÃ¯ve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer, 2019, 127, 37-43.	0.9	60
3104	Hospital Volume and Mortality following Diagnostic Bronchoscopy in Lung Cancer Patients: Data from a National Inpatient Database in Japan. Respiration, 2019, 97, 264-272.	1.2	2
3105	Phase II trial of a nonâ€platinum triplet for patients with advanced nonâ€small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA. Thoracic Cancer, 2019, 10, 452-458.	0.8	8
3106	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clinical Lung Cancer, 2019, 20, e407-e412.	1.1	12
3107	Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive nonâ€“small-cell lung cancer in the USA. PLoS ONE, 2019, 14, e0209709.	1.1	41
3108	First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?. International Journal of Molecular Sciences, 2019, 20, 146.	1.8	118
3109	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nature Communications, 2019, 10, 259.	5.8	223
3110	Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. Lung Cancer, 2019, 127, 25-33.	0.9	13
3111	Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. Lung Cancer, 2019, 127, 146-152.	0.9	42
3112	The Modern Hospital. , 2019, , .		8
3113	ZWINT is the next potential target for lung cancer therapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 661-673.	1.2	23
3114	Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors. Bioorganic Chemistry, 2019, 83, 186-197.	2.0	48
3115	Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas. International Journal of Cancer, 2019, 144, 1061-1072.	2.3	22
3116	Identification of epidermal growth factor receptor mutations in pulmonary adenocarcinoma using dual-energy spectral computed tomography. European Radiology, 2019, 29, 2989-2997.	2.3	25

#	Article	IF	Citations
3118	Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program. Oncology, 2019, 96, 51-58.	0.9	6
3119	Clinicopathologic characteristics and outcome of patients with different EGFR mutations. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 166-171.	0.7	7
3120	KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR. Molecular Cancer Therapeutics, 2019, 18, 112-126.	1.9	39
3122	Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy?. Current Opinion in Oncology, 2019, 31, 1-7.	1.1	19
3123	Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 1775-1781.	0.6	1
3124	Predictive value of oncogenic driver subtype, programmed deathâ€1 ligand (PDâ€L1) score, and smoking status on the efficacy of PDâ€1/PDâ€L1 inhibitors in patients with oncogeneâ€driven nonâ€“small cell lung cancer. Cancer, 2019, 125, 1038-1049.	2.0	66
3125	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. Clinical Lung Cancer, 2019, 20, e186-e194.	1.1	40
3126	Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2. Neoplasia, 2019, 21, 41-51.	2.3	19
3127	Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors. European Journal of Medicinal Chemistry, 2019, 163, 367-380.	2.6	28
3128	Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respiratory Investigation, 2019, 57, 20-26.	0.9	46
3129	A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Nonâ€“small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L). Clinical Lung Cancer, 2019, 20, e25-e27.	1.1	21
3130	New revisions and current issues in the eighth edition of the TNM classification for non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2019, 49, 3-11.	0.6	34
3131	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Seminars in Cancer Biology, 2019, 54, 14-28.	4.3	51
3132	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. Pathology and Oncology Research, 2019, 25, 513-520.	0.9	5
3133	Absolute Bioavailability of Osimertinib in Healthy Adults. Clinical Pharmacology in Drug Development, 2019, 8, 198-207.	0.8	22
3134	Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics Journal, 2019, 19, 164-177.	0.9	28
3135	The effects of switching EGFRâ€TKI treatments for nonâ€small cell lung cancer because of adverse events. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e113-e117.	0.7	10
3136	Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation. Investigational New Drugs, 2020, 38, 194-201.	1.2	5

#	Article	IF	Citations
3137	The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis. Pathology and Oncology Research, 2020, 26, 1137-1143.	0.9	1
3138	Intracellular Signaling. , 2020, , 24-46.e12.		0
3139	Stem Cells, Cell Differentiation, and Cancer. , 2020, , 97-107.e5.		2
3140	Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. European Journal of Health Economics, 2020, 21, 153-164.	1.4	30
3141	Longitudinal monitoring of somatic genetic alterations in circulating cellâ€free DNA during treatment with epidermal growth factor receptorâ€“tyrosine kinase inhibitors. Cancer, 2020, 126, 219-227.	2.0	20
3142	Tumor Liquid Biopsies. Recent Results in Cancer Research, 2020, , .	1.8	11
3143	Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA. Oncology, 2020, 98, 23-28.	0.9	5
3144	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. Clinical Oncology, 2020, 32, e1-e9.	0.6	6
3145	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Nonâ€“small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer, 2020, 21, 1-14.e3.	1.1	19
3146	Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. Journal of Clinical Oncology, 2020, 38, 124-136.	0.8	295
3147	Cancer of the Lung. , 2020, , 1108-1158.e16.		11
3148	Designing clinical studies for biomarker discovery: The Design criteria. , 2020, , 441-466.		0
3149	Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 2020, 139, 80-88.	0.9	9
3150	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. Annals of Palliative Medicine, 2020, 9, 4430-4445.	0.5	0
3151	Additional bevacizumab in EGFR-mutant lung adenocarcinoma patients who had oligo-progression after the failure of EGFR-TKI: A single-institute retrospective study. Cancer Treatment and Research Communications, 2020, 22, 100163.	0.7	5
3152	Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer. International Journal of Clinical Oncology, 2020, 25, 274-281.	1.0	7
3153	Impact of coexisting gene mutations in EGFR-mutated nonâ€“small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. Lung Cancer, 2020, 139, 28-34.	0.9	5
3154	Polymorphisms of NF-Î²B pathway genes influence adverse drug reactions of gefitinib in NSCLC patients. Pharmacogenomics Journal, 2020, 20, 285-293.	0.9	6

#	Article	IF	Citations
3155	A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer. Neuro-Oncology, 2020, 22, 675-683.	0.6	39
3156	Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Nonâ€“Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. Journal of Clinical Oncology, 2020, 38, 115-123.	0.8	327
3157	Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy. International Journal of Pharmaceutics, 2020, 573, 118785.	2.6	21
3158	Synthetic lethality as an engine for cancer drug target discovery. Nature Reviews Drug Discovery, 2020, 19, 23-38.	21.5	295
3159	Integrated evaluation of targeted and nonâ€targeted therapies in a network metaâ€analysis. Biometrical Journal, 2020, 62, 777-789.	0.6	2
3160	Systematic evaluation of PAXgeneÂ® tissue fixation for the histopathological and molecular study of lung cancer. Journal of Pathology: Clinical Research, 2020, 6, 40-54.	1.3	8
3161	Therapies after first-line afatinib in patients with EGFRm⁺ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Future Oncology, 2020, 16, 49-60.	1.1	4
3162	Tumor-educated platelet as liquid biopsy in lung cancer patients. Critical Reviews in Oncology/Hematology, 2020, 146, 102863.	2.0	27
3163	YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nature Communications, 2020, 11, 74.	5.8	49
3164	Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor. Thoracic Cancer, 2020, 11, 436-442.	0.8	8
3165	Dual-target kinase drug design: Current strategies and future directions in cancer therapy. European Journal of Medicinal Chemistry, 2020, 188, 112025.	2.6	42
3166	DACT2 modulated by TFAP2A-mediated allelic transcription promotes EGFR-TKIs efficiency in advanced lung adenocarcinoma. Biochemical Pharmacology, 2020, 172, 113772.	2.0	17
3167	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	39
3168	Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI. Lung Cancer, 2020, 140, 65-70.	0.9	15
3169	Bone Metastasis: Current State of Play. Translational Oncology, 2020, 13, 308-320.	1.7	30
3170	Epidermal Growth Factor Receptor Gene Mutation Status in Primary Lung Adenocarcinoma and Corresponding Bone Metastases. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 49-56.	0.6	2
3171	Lathyrane diterpenes from Euphorbia lathyris and the potential mechanism to reverse the multi-drug resistance in HepG2/ADR cells. Biomedicine and Pharmacotherapy, 2020, 121, 109663.	2.5	17
3172	Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced EGFR-Mutated Nonâ€“Small-Cell Lung Cancer in the First-Line Setting?. Journal of Clinical Oncology, 2020, 38, 843-844.	0.8	4

#	Article	IF	Citations
3173	Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer, 2020, 141, 37-43.	0.9	24
3174	Studies on interaction potency model based on drug synergy and therapeutic potential of triple stimuli-responsive delivery of doxorubicin and 5-fluoro-2-deoxyuridine against lymphoma using disulfide-bridged cysteine over mesoporous silica nanoparticles. Journal of Materials Chemistry B, 2020, 8, 1411-1421.	2.9	17
3175	Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Nonâ€“Small-Cell Lung Cancer: A Clash of the Generations. Clinical Lung Cancer, 2020, 21, e216-e228.	1.1	89
3176	Improved survival among patients enrolled in oncology phase 1 trials in recent decades. Cancer Chemotherapy and Pharmacology, 2020, 85, 449-459.	1.1	1
3177	Diagnostic test accuracy of droplet digital PCR for the detection of EGFR mutation (T790M) in plasma: Systematic review and meta-analysis. Clinica Chimica Acta, 2020, 503, 190-196.	0.5	7
3178	Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. European Journal of Cancer, 2020, 125, 49-57.	1.3	45
3179	Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expert Review of Respiratory Medicine, 2020, 14, 125-136.	1.0	51
3180	Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases. Journal of Cancer Research and Clinical Oncology, 2020, 146, 137-152.	1.2	17
3181	Osimertinib for Patients With Nonâ€“Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). Journal of Clinical Oncology, 2020, 38, 488-495.	0.8	233
3182	Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. Lung Cancer, 2020, 139, 133-139.	0.9	16
3183	Methods and resources to access mutation-dependent effects on cancer drug treatment. Briefings in Bioinformatics, 2020, 21, 1886-1903.	3.2	5
3184	A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy. Journal of Radiotherapy in Practice, 2020, 19, 370-384.	0.2	3
3185	Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects. Biochemical Pharmacology, 2020, 171, 113735.	2.0	6
3186	Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis. Cell Death and Differentiation, 2020, 27, 1795-1806.	5.0	31
3187	Mechanism research of miRâ€34a regulates Axl in nonâ€smallâ€cell lung cancer with gefitinibâ€acquired resistance. Thoracic Cancer, 2020, 11, 156-165.	0.8	9
3188	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e191-e204.	1.1	26
3189	Activation of insulinâ€like growth factorâ€1 receptor confers acquired resistance to osimertinib in nonâ€small cell lung cancer withEGFRT790M mutation. Thoracic Cancer, 2020, 11, 140-149.	0.8	34
3190	mPRÎ± mediates P4/Org OD02â€0 to improve the sensitivity of lung adenocarcinoma to EGFRâ€TKIs via the EGFRâ€SRCâ€ERK1/2 pathway. Molecular Carcinogenesis, 2020, 59, 179-192.	1.3	10

#	Article	IF	Citations
3191	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: COMPASS (WJOG5610L). Journal of Clinical Oncology, 2020, 38, 793-803.	0.8	28
3192	Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands. European Journal of Cancer Care, 2020, 29, e13210.	0.7	3
3193	Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation. Case Reports in Oncology, 2020, 12, 918-921.	0.3	1
3194	Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations. Immunotherapy, 2020, 12, 1195-1207.	1.0	2
3195	MicroRNA â€200b is a potential biomarker of the expression of PDâ€L1 in patients with lung cancer. Thoracic Cancer, 2020, 11, 2975-2982.	0.8	12
3196	Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data. Future Oncology, 2020, 16, 2569-2586.	1.1	2
3197	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nature Communications, 2020, 11, 4878.	5.8	27
3198	Realâ€life effectiveness of firstâ€line anticancer treatments in stage <scp>IIIB</scp>/<scp>IV NSCLC</scp> patients: Data from the <scp>C</scp>zech <scp>TULUNG R</scp>egistry. Thoracic Cancer, 2020, 11, 3346-3356.	0.8	8
3199	Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. Lung Cancer, 2020, 150, 83-89.	0.9	9
3200	Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage IIâ€“IIIA (N1â€“N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study. Lung Cancer, 2020, 150, 164-171.	0.9	5
3201	Chemotherapy should be performed in epidermal growth factor receptor mutation-positive lung adenocarcinoma patients who had progressive disease to the first epidermal growth factor receptor-tyrosine kinase inhibitor. Anti-Cancer Drugs, 2020, 31, 959-965.	0.7	0
3202	Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?. Biology, 2020, 9, 326.	1.3	6
3203	Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutationâ€”Positive Lung Cancer Cells. Pharmaceutics, 2020, 12, 939.	2.0	15
3204	Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India. Lung Cancer, 2020, 149, 53-60.	0.9	8
3205	Traitement des cancers bronchiques non Ã petites cellules de stades avancÃ©s mutÃ©s EGFR : quels inhibiteurs ? Quelles sÃ©quences thÃ©rapeutiques ?. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S195-2S211.	0.0	2
3206	Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy. Frontiers in Oncology, 2020, 10, 1145.	1.3	0
3207	Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. Targeted Oncology, 2020, 15, 503-512.	1.7	12
3208	Tumor organoids to study gastroesophageal cancer: a primer. Journal of Molecular Cell Biology, 2020, 12, 593-606.	1.5	7

#	Article	IF	Citations
3209	Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR â€mutated nonâ€small cell lung cancer patient: A case report. Thoracic Cancer, 2020, 11, 2717-2722.	0.8	7
3210	Management of medically inoperable and tyrosine kinase inhibitor-naÃ¯ve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis. BMC Cancer, 2020, 20, 646.	1.1	3
3211	Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand. BMC Cancer, 2020, 20, 658.	1.1	8
3212	ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib. Translational Lung Cancer Research, 2020, 9, 532-540.	1.3	17
3213	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. BMC Cancer, 2020, 20, 666.	1.1	22
3214	Erlotinib for Nonâ€Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101) Tj ETQq1 1 0.784314 rgBT	1.9	10
3215	Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3323-3332.	1.2	13
3216	Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096725.	1.4	6
3217	In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-resistant Human Non-small Cell Lung Cancer. Journal of Cancer, 2020, 11, 7216-7223.	1.2	1
3218	Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study. Journal of Thoracic Disease, 2020, 12, 5324-5335.	0.6	11
3219	Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib. Translational Lung Cancer Research, 2020, 9, 1952-1962.	1.3	10
3220	Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study. Frontiers in Oncology, 2020, 10, 587849.	1.3	2
3221	Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors . Cancer Management and Research, 2020, Volume 12, 11761-11772.	0.9	1
3222	Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report. Frontiers in Oncology, 2020, 10, 542277.	1.3	8
3223	Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. Cancer Treatment and Research Communications, 2020, 25, 100249.	0.7	1
3224	Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy. Diagnostics, 2020, 10, 1006.	1.3	7
3225	Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way. Annals of Translational Medicine, 2020, 8, 1111-1111.	0.7	2
3226	Itâ€™s Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC?. Cancers, 2020, 12, 3223.	1.7	0

#	Article	IF	Citations
3227	First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals, 2020, 13, 373.	1.7	49
3228	Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis. Journal of Cancer, 2020, 11, 7283-7290.	1.2	5
3229	Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis. Future Oncology, 2020, 16, 1585-1595.	1.1	5
3230	FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respiratory Research, 2020, 21, 210.	1.4	53
3231	Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases. Annals of Palliative Medicine, 2020, 9, 2062-2071.	0.5	10
3232	CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas. Cancer Imaging, 2020, 20, 51.	1.2	18
3233	Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer. BMC Cancer, 2020, 20, 699.	1.1	6
3234	Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors. EBioMedicine, 2020, 56, 102796.	2.7	7
3235	Huayu Wan Prevents Lewis Lung Cancer Metastasis in Mice via the Platelet Pathway. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-7.	0.5	4
3236	Prediction of pathological fracture in patients with lower limb bone metastasis using computed tomography imaging. Clinical and Experimental Metastasis, 2020, 37, 607-616.	1.7	4
3237	Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study. EBioMedicine, 2020, 57, 102861.	2.7	21
3238	Molecular mechanisms of interplay between autophagy and metabolism in cancer. Life Sciences, 2020, 259, 118184.	2.0	8
3239	Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Technology in Cancer Research and Treatment, 2020, 19, 153303382094042.	0.8	1
3240	Human genetic diversity in health and disease. , 2020, , 123-136.		1
3241	Prognostic role of targeted therapy in patients with multiple-site metastases from non-small- cell lung cancer. Future Oncology, 2020, 16, 1957-1967.	1.1	5
3242	Propensity score analysis of overall survival between firstâ€•and secondâ€generation EGFRâ€TKIs using realâ€world data. Cancer Science, 2020, 111, 3705-3713.	1.7	10
3243	A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity . Lung Cancer: Targets and Therapy, 2020, Volume 11, 73-103.	1.3	4
3244	Predicting therapy response by analysis of metastasis founder cells: emerging perspectives for personalized tumor therapy. Expert Review of Precision Medicine and Drug Development, 2020, 5, 413-420.	0.4	1

#	Article	IF	Citations
3245	Assessing consistency in clinical trials with two subgroups and binary endpoints: A new test within the logistic regression model. Statistics in Medicine, 2020, 39, 4551-4573.	0.8	1
3246	The role of viruses in adenocarcinoma development. Infection, Genetics and Evolution, 2020, 86, 104603.	1.0	6
3247	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Science Translational Medicine, 2020, 12, .	5.8	101
3248	PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. Translational Lung Cancer Research, 2020, 9, 1258-1267.	1.3	47
3249	Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. BMC Cancer, 2020, 20, 829.	1.1	11
3250	Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival. Future Oncology, 2020, 16, 3107-3116.	1.1	5
3251	Menin-mediated Repression of Glycolysis in Combination with Autophagy Protects Colon Cancer Against Small-molecule EGFR Inhibitors. Molecular Cancer Therapeutics, 2020, 19, 2319-2329.	1.9	3
3252	Optimal sequencing strategies in the treatment of EGFR mutationâ€“positive nonâ€“small cell lung cancer: Clinical benefits and cost-effectiveness. American Journal of Health-System Pharmacy, 2020, 77, 1466-1476.	0.5	10
3253	EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Nonâ€“Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectrum, 2020, 4, pkaa064.	1.4	4
3254	Transgenic zebrafish for modeling hepatocellular carcinoma. MedComm, 2020, 1, 140-156.	3.1	9
3255	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. Journal of Thoracic Oncology, 2020, 15, 1857-1870.	0.5	19
3256	Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. Cancer Chemotherapy and Pharmacology, 2020, 86, 517-525.	1.1	3
3257	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. Journal of Thoracic Oncology, 2020, 15, 1907-1918.	0.5	85
3258	Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations. Frontiers in Oncology, 2020, 10, 1455.	1.3	9
3259	Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment. PLoS ONE, 2020, 15, e0238120.	1.1	6
3261	CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation. Molecular Cancer Therapeutics, 2020, 19, 2288-2297.	1.9	89
3262	Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival. Frontiers in Immunology, 2020, 11, 1933.	2.2	6
3263	Successful use of extracorporeal membrane oxygenation for airwayâ€obstructing lung adenocarcinoma. Thoracic Cancer, 2020, 11, 3024-3028.	0.8	10

#	Article	IF	Citations
3264	<scp>EGF+61 A>G</scp> polymorphism does not predict response to firstâ€generation <scp>EGFR</scp> tyrosine kinase inhibitors in lung cancer patients. Thoracic Cancer, 2020, 11, 2987-2992.	0.8	2
3265	A combined â€œeat me/don't eat meâ€•strategy based on extracellular vesicles for anticancer nanomedicine. Journal of Extracellular Vesicles, 2020, 9, 1806444.	5.5	121
3266	Cross-talk between SOX2 and TGFÎ² Signaling Regulates EGFRâ€“TKI Tolerance and Lung Cancer Dissemination. Cancer Research, 2020, 80, 4426-4438.	0.4	29
3267	erbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open, 2020, 5, e000724.	2.0	22
3268	JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells . OncoTargets and Therapy, 2020, Volume 13, 7585-7598.	1.0	1
3269	Oncogene HSPH1 modulated by the rs2280059 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma. Carcinogenesis, 2020, 41, 1195-1202.	1.3	12
3270	Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program . OncoTargets and Therapy, 2020, Volume 13, 12539-12547.	1.0	3
3271	Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review. Frontiers in Oncology, 2020, 10, 610923.	1.3	61
3272	Clinical impact of a cancer genomic profiling test using an inâ€house comprehensive targeted sequencing system. Cancer Science, 2020, 111, 3926-3937.	1.7	20
3273	Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report. BMC Cancer, 2020, 20, 1177.	1.1	3
3274	KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity. Cell and Bioscience, 2020, 10, 139.	2.1	9
3275	Factors associated with overall survival in a population-based cohort of non- squamous NSCLC patients from northern New Zealand: A comparative analysis by EGFR mutation status. Cancer Epidemiology, 2020, 69, 101847.	0.8	2
3276	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges. Tumori, 2020, 107, 030089162096813.	0.6	2
3277	miR-1262 Transcriptionally Modulated by an Enhancer Genetic Variant Improves Efficiency of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Advanced Lung Adenocarcinoma. DNA and Cell Biology, 2020, 39, 1111-1118.	0.9	7
3278	A validated ultra-performance LCâ€“MS/MS method for quantifying a novel oral EGFR inhibitor FCN-411 in human plasma. Bioanalysis, 2020, 12, 295-304.	0.6	0
3279	Detailed identification of epidermal growth factor receptor mutations in lung adenocarcinoma: Combining radiomics with machine learning. Medical Physics, 2020, 47, 3458-3466.	1.6	20
3280	Circular RNA ABCB10 promotes non-small cell lung cancer progression by increasing E2F5 expression through sponging miR-584-5p. Cell Cycle, 2020, 19, 1611-1620.	1.3	24
3281	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. Investigational New Drugs, 2020, 38, 1854-1861.	1.2	18

#	Article	IF	Citations
3282	The influence of uncertainty and uncertainty tolerance on attitudes and self-efficacy about genomic tumor testing. Psychology, Health and Medicine, 2021, 26, 805-817.	1.3	12
3283	Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. Molecular Cancer Therapeutics, 2020, 19, 1562-1571.	1.9	17
3284	Osimertinib in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 2020, 382, 1863-1865.	13.9	7
3285	Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. BMJ Open, 2020, 10, e033427.	0.8	14
3286	Long-term survival with targeted therapy in an advanced non-small cell lung cancer patient based on genetic profiling. Translational Lung Cancer Research, 2020, 9, 373-378.	1.3	6
3287	Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors. BMC Cancer, 2020, 20, 408.	1.1	14
3288	The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 153-155.	0.6	2
3289	The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel. Oncology, 2020, 98, 661-668.	0.9	7
3290	An <scp>EGFR</scp> signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors. International Journal of Cancer, 2020, 147, 2621-2633.	2.3	13
3291	Epidermal growth factor receptor mutations in nonâ€“small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reactionâ€“based assays. Journal of the Chinese Medical Association, 2020, 83, 345-349.	0.6	2
3292	Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, e201250.	3.4	36
3293	Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer. Lung Cancer, 2020, 145, 48-57.	0.9	3
3294	PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 1385-1392.	0.6	12
3295	Current Landscape of Personalized Therapy. Thoracic Surgery Clinics, 2020, 30, 121-125.	0.4	2
3296	Combination of KRAS and SMAD4 mutations in formalinâ€fixed paraffinâ€embedded tissues as a biomarker for pancreatic cancer. Cancer Science, 2020, 111, 2174-2182.	1.7	16
3297	Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptorâ€“Mutated Non-Small Cell Lung Cancer Patients. Frontiers in Pharmacology, 2020, 11, 664.	1.6	3
3298	Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report. Clinical Lung Cancer, 2020, 21, e493-e496.	1.1	1
3299	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers. JAMA Oncology, 2020, 6, 1048.	3.4	96

#	Article	IF	Citations
3300	Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab. Translational Cancer Research, 2020, 9, 1307-1310.	0.4	0
3301	Ultra-sensitive and multiplex digital-PCR for quantifying the mutants in cell free DNA by employing invasive reaction as identifier. Sensors and Actuators B: Chemical, 2020, 320, 128362.	4.0	8
3302	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. Journal of Clinical Medicine, 2020, 9, 1762.	1.0	10
3303	Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment. Anti-Cancer Drugs, 2020, 31, 310-313.	0.7	2
3304	Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. Diagnostics, 2020, 10, 359.	1.3	51
3305	Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Current Oncology, 2020, 27, 146-155.	0.9	14
3306	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced nonâ€small cell lung cancer receiving EGFRâ€TKI treatment. Thoracic Cancer, 2020, 11, 2188-2195.	0.8	11
3307	Targeted Therapy for Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 409-434.	0.8	11
3308	Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database. Lung Cancer, 2020, 146, 236-243.	0.9	7
3309	Multiplex-invasive reaction-assisted qPCR for quantitatively detecting the abundance of EGFR exon 19 deletions in cfDNA. Analytical Methods, 2020, 12, 3344-3350.	1.3	2
3310	Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601). Oncologist, 2020, 25, e1451-e1456.	1.9	5
3311	Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a firstâ€line treatment for advanced EGFRâ€mutant nonâ€small cell lung cancer. Clinical and Translational Medicine, 2020, 10, e33.	1.7	13
3312	The top 100 cited articles in lung cancer â€“ a bibliometric analysis. Wspolczesna Onkologia, 2020, 24, 17-28.	0.7	7
3313	Lymecycline reverses acquired EGFR-TKI resistance in nonâ€“small-cell lung cancer by targeting GRB2. Pharmacological Research, 2020, 159, 105007.	3.1	15
3314	Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of Oncology Pharmacy Practice, 2020, 26, 1461-1474.	0.5	61
3315	Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Thoracic Disease, 2020, 12, 2859-2876.	0.6	11
3316	Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study. Targeted Oncology, 2020, 15, 175-184.	1.7	13
3317	Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System. Scientific Reports, 2020, 10, 4803.	1.6	48

#	Article	IF	Citations
3318	Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer. Medical Oncology, 2020, 37, 30.	1.2	11
3319	Isoliquiritigenin Suppressed Esophageal Squamous Carcinoma Growth by Blocking EGFR Activation and Inducing Cell Cycle Arrest. BioMed Research International, 2020, 2020, 1-11.	0.9	6
3320	Genomic landscape of acquired resistance to thirdâ€generation EGFR tyrosine kinase inhibitors in EGFR T790Mâ€mutant nonâ€“small cell lung cancer. Cancer, 2020, 126, 2704-2712.	2.0	26
3321	Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. , 2020, 210, 107522.		56
3322	Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer. BMC Cancer, 2020, 20, 150.	1.1	47
3323	Subtyping and EGFR mutation testing from blocks of cytological materials, based on liquidâ€based cytology for lung cancer at bronchoscopic examinations. Diagnostic Cytopathology, 2020, 48, 516-523.	0.5	11
3324	Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127045.	1.0	14
3325	A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers. Cancer Biology and Therapy, 2020, 21, 549-559.	1.5	10
3326	Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer: A Meta-Analysis. Frontiers in Oncology, 2020, 10, 290.	1.3	25
3327	EGFRPolymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis. Journal of Oncology, 2020, 2020, 1-14.	0.6	42
3328	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Translational Lung Cancer Research, 2020, 9, 111-138.	1.3	27
3329	Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. Expert Review of Respiratory Medicine, 2020, 14, 565-576.	1.0	9
3330	The lncRNA NORAD/miR-520a-3p Facilitates Malignancy in Non-Small Cell Lung Cancer via PI3k/Akt/mTOR Signaling Pathway . OncoTargets and Therapy, 2020, Volume 13, 1533-1544.	1.0	37
3331	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Frontiers in Immunology, 2020, 11, 159.	2.2	73
3332	Osimertinib, a thirdâ€generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its realâ€world efficacy and safety in advanced/recurrent nonâ€small cell lung carcinoma. Thoracic Cancer, 2020, 11, 935-942.	0.8	24
3333	Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial . Cancer Management and Research, 2020, Volume 12, 4633-4643.	0.9	8
3334	Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma. Clinical Lung Cancer, 2020, 21, 437-442.	1.1	26
3335	Budget Impact Analysis of EGFR Mutation Liquid Biopsy for First- and Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer in Greece. Diagnostics, 2020, 10, 429.	1.3	4

#	Article	IF	Citations
3336	Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Nonâ€“small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). Clinical Lung Cancer, 2020, 21, e592-e596.	1.1	5
3337	Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancerâ€"The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol. Diagnostics, 2020, 10, 459.	1.3	3
3338	Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy. Cancers, 2020, 12, 1609.	1.7	27
3339	Lung adenocarcinoma in a patient with Liâ€“Fraumeni syndrome bearing a novel germ-line mutation, TP53R333Vfs*12. Japanese Journal of Clinical Oncology, 2020, 50, 1214-1217.	0.6	1
3340	Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the <i>EGFR</i> T790M Mutation. Internal Medicine, 2020, 59, 2161-2164.	0.3	4
3341	Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using nextâ€generation sequencing technique. Thoracic Cancer, 2020, 11, 2262-2269.	0.8	5
3342	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Advances in Cancer Research, 2020, 147, 1-57.	1.9	32
3343	Molecular Dynamics Analysis of Binding Sites of Epidermal Growth Factor Receptor Kinase Inhibitors. ACS Omega, 2020, 5, 16307-16314.	1.6	22
3344	The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa064.	0.4	9
3345	High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy. Annals of Translational Medicine, 2020, 8, 685-685.	0.7	6
3346	Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells . Cancer Management and Research, 2020, Volume 12, 4453-4460.	0.9	6
3347	Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma. Scientific Reports, 2020, 10, 10881.	1.6	9
3348	MET targeting: time for a rematch. Oncogene, 2020, 39, 2845-2862.	2.6	40
3349	Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study. BMC Cancer, 2020, 20, 104.	1.1	1
3350	Molecular Analysis of Liquid-Based Cytological Specimen Using Virtually Positive Sputum with Adenocarcinoma Cells. Diagnostics, 2020, 10, 84.	1.3	10
3351	Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. BMC Cancer, 2020, 20, 156.	1.1	6
3352	The associations among quantitative spectral CT parameters, Ki-67 expression levels and EGFR mutation status in NSCLC. Scientific Reports, 2020, 10, 3436.	1.6	15
3353	Lessons Learned From Multi-regional Trials With Signals of Treatment Effect Heterogeneity. Therapeutic Innovation and Regulatory Science, 2020, 54, 21-31.	0.8	1

#	Article	IF	Citations
3354	The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. Critical Reviews in Oncology/Hematology, 2020, 148, 102894.	2.0	27
3355	The paradox of cancer genes in non-malignant conditions: implications for precision medicine. Genome Medicine, 2020, 12, 16.	3.6	33
3356	Spectrum of EGFR aberrations and potential clinical implications: insights from integrative panâ€cancer analysis. Cancer Communications, 2020, 40, 43-59.	3.7	45
3357	Number of metastatic organs negatively affects the treatment sequence in patients with EGFRâ€TKI failure. Thoracic Cancer, 2020, 11, 1038-1044.	0.8	0
3358	Use of a plasma test for verifying epidermal growth factor receptor gene (EGFR) mutations in fluid samples from non-small cell lung cancer patients. Respiratory Medicine Case Reports, 2020, 29, 101007.	0.2	0
3359	Definitive Local Therapy for Oligo-recurrence in Patients With Completely Resected Nonâ€“small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 210-217.	0.6	16
3360	Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. Cancer Chemotherapy and Pharmacology, 2020, 85, 605-614.	1.1	3
3361	Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells. Surgery Today, 2020, 50, 1099-1106.	0.7	20
3362	Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. PLoS ONE, 2020, 15, e0228925.	1.1	31
3363	In-silico activity prediction and docking studies of some 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9h-purine derivatives as Anti-proliferative agents. Heliyon, 2020, 6, e03158.	1.4	34
3364	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Journal of Thoracic Oncology, 2020, 15, 803-815.	0.5	178
3365	Successful lung cancer EGFR sequencing from DNA extracted from TTF-1 immunohistochemistry slides: a new means to extend insufficient tissue. Human Pathology, 2020, 97, 52-59.	1.1	3
3366	Front-line Therapy in Advanced Nonâ€“Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis. Clinical Therapeutics, 2020, 42, 338-350.e4.	1.1	13
3367	High CXCR4 Expression Predicts a Poor Prognosis in Resected Lung Adenosquamous Carcinoma. Journal of Cancer, 2020, 11, 810-818.	1.2	12
3368	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment inEGFR-Mutated Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 2244-2256.	3.2	75
3369	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. Supportive Care in Cancer, 2020, 28, 4825-4831.	1.0	8
3370	Precision Management of Advanced Nonâ€“Small Cell Lung Cancer. Annual Review of Medicine, 2020, 71, 117-136.	5.0	101
3371	IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Molecular Cancer Research, 2020, 18, 549-559.	1.5	34

#	Article	IF	Citations
3372	Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4. Cancer Letters, 2020, 475, 2-13.	3.2	64
3373	Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFRâ€mutated lung adenocarcinoma: a report of two cases. Respirology Case Reports, 2020, 8, e00521.	0.3	13
3374	Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib. Scientific Reports, 2020, 10, 691.	1.6	8
3375	Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. Medicine (United States), 2020, 99, e18726.	0.4	23
3376	Impact of somatic mutations on prognosis in resected nonâ€smallâ€cell lung cancer: The Japan Molecular Epidemiology for lung cancer study. Cancer Medicine, 2020, 9, 2343-2351.	1.3	10
3377	Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790Mâ€“positive nonâ€“small cell lung cancer: West Japan Oncology Group 8815L/LPS study. Cancer, 2020, 126, 1940-1948.	2.0	18
3378	Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists. American Journal of Neuroradiology, 2020, 41, 738-750.	1.2	8
3379	Clinical Activity of Afatinib in Patients With Nonâ€“Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. Clinical Lung Cancer, 2020, 21, 428-436.e2.	1.1	14
3380	Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors. Infectious Disease Clinics of North America, 2020, 34, 257-270.	1.9	0
3381	Epidermal Growth Factor Receptor Mutations. Thoracic Surgery Clinics, 2020, 30, 127-136.	0.4	14
3382	Wait-and-See Treatment Strategy Could be Considered for Lung Adenocarcinoma with Special Pleural Dissemination Lesions, and Low Genomic Instability Correlates with Better Survival. Annals of Surgical Oncology, 2020, 27, 3808-3818.	0.7	10
3383	A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorganic Chemistry, 2020, 99, 103811.	2.0	203
3384	Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Nonâ€“Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. Clinical Lung Cancer, 2020, 21, e464-e473.	1.1	24
3385	Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188363.	3.3	14
3386	Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. Lung Cancer, 2020, 143, 67-72.	0.9	17
3387	Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 589-599.	1.0	13
3388	Biopsy on Progression in Patients with EGFR Mutationâ€“Positive Advanced Non-Small-Cell Lung Cancerâ€”A Canadian Experience. Current Oncology, 2020, 27, 27-33.	0.9	6
3389	Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis. Journal of Cancer, 2020, 11, 3667-3674.	1.2	14

#	Article	IF	Citations
3390	Profiling of subcellular EGFR interactome reveals hnRNP A3 modulates nuclear EGFR localization. Oncogenesis, 2020, 9, 40.	2.1	13
3391	Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 998.	1.7	23
3392	Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. European Journal of Health Economics, 2020, 21, 931-943.	1.4	7
3393	Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. Trials, 2020, 21, 298.	0.7	6
3394	Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India. Current Problems in Cancer, 2020, 44, 100570.	1.0	14
3395	EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy. Expert Review of Anticancer Therapy, 2020, 20, 365-372.	1.1	6
3396	All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells. BMC Cancer, 2020, 20, 315.	1.1	24
3397	Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. Journal of Thoracic Disease, 2020, 12, 639-650.	0.6	6
3398	BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC). Journal of Biomolecular Structure and Dynamics, 2021, 39, 2838-2856.	2.0	24
3399	HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells. Acta Pharmacologica Sinica, 2021, 42, 115-119.	2.8	10
3400	Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)â€"development and in-vitro efficacy. Drug Delivery and Translational Research, 2021, 11, 927-943.	3.0	34
3401	Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. Investigational New Drugs, 2021, 39, 232-236.	1.2	5
3402	Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data. Acta Clinica Belgica, 2021, 76, 224-231.	0.5	1
3403	Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer. Journal of Clinical Pathology, 2021, 74, 116-122.	1.0	5
3404	In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics, 2021, 39, 1491-1505.	2.0	31
3405	The impact of smoking status on the progressionâ€free survival of nonâ€small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 256-266.	0.7	15
3406	Biomarkers for predicting the outcome of various cancer immunotherapies. Critical Reviews in Oncology/Hematology, 2021, 157, 103161.	2.0	10
3407	Massive Spondylectomy for Metastatic Spinal Cord Compression From Nonâ€“Small-Cell Lung Cancer With Local Failure After Radiotherapy. Global Spine Journal, 2021, 11, 549-555.	1.2	5

#	Article	IF	Citations
3408	A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. British Journal of Cancer, 2021, 124, 383-390.	2.9	54
3409	Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in nonâ€“smallâ€cell lung cancer patients: A network metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 310-318.	0.7	6
3410	Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. European Journal of Clinical Pharmacology, 2021, 77, 381-388.	0.8	5
3411	Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1169-1178.	1.2	11
3412	Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib. Journal of Ethnopharmacology, 2021, 265, 113302.	2.0	30
3413	Clinical and Imaging Features of Nonâ€“Small-Cell Lung Cancer in Young Patients. Clinical Lung Cancer, 2021, 22, 23-31.	1.1	14
3414	A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Nonâ€“Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). Clinical Lung Cancer, 2021, 22, 147-151.	1.1	16
3415	Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis. Clinical Lung Cancer, 2021, 22, e70-e83.	1.1	10
3416	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 992-1002.	3.2	36
3417	Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer. European Journal of Medicinal Chemistry, 2021, 211, 113022.	2.6	13
3418	Bioactive dihydroagarofuran sesquiterpenes from the twigs of Tripterygium hypoglaucum. Phytochemistry Letters, 2021, 41, 92-100.	0.6	8
3419	Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. Future Oncology, 2021, 17, 103-115.	1.1	1
3420	Comparison of adequacy between transbronchial lung cryobiopsy samples and endobronchial ultrasoundâ€guided transbronchial needle aspiration samples for nextâ€generation sequencing analysis. Thoracic Cancer, 2021, 12, 251-258.	0.8	13
3422	Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. Trends in Cancer, 2021, 7, 410-429.	3.8	13
3423	Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS. Xenobiotica, 2021, 51, 434-446.	0.5	8
3424	Preâ€existing interstitial lung disease does not affect prognosis in nonâ€small cell lung cancer patients with <scp>PDâ€L1</scp> expression â‰¥50% on firstâ€line pembrolizumab. Thoracic Cancer, 2021, 12, 304-313.	0.8	17
3425	PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer, 2021, 151, 69-75.	0.9	12
3426	Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer. Translational Oncology, 2021, 14, 100951.	1.7	9

#	Article	IF	Citations
3427	Impact of the generation of <scp>EGFRâ€TKIs</scp> administered as prior therapy on the efficacy of osimertinib in patients with nonâ€small cell lung cancer harboring <scp>EGFR T790M</scp> mutation. Thoracic Cancer, 2021, 12, 329-338.	0.8	2
3428	Celastrol acts synergistically with afatinib to suppress nonâ€small cell lung cancer cell proliferation by inducing paraptosis. Journal of Cellular Physiology, 2021, 236, 4538-4554.	2.0	21
3429	Predictive and Prognostic Potential of TP53 in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). Clinical Lung Cancer, 2021, 22, 100-109.e3.	1.1	31
3430	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest, 2021, 159, 1256-1264.	0.4	14
3431	2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist, 2021, 26, e454-e472.	1.9	17
3432	Suppression of tumor immune microenvironment via microRNAâ€1 after epidermal growth factor receptorâ€tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma. Cancer Medicine, 2021, 10, 718-727.	1.3	11
3433	Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model. Biochemical and Biophysical Research Communications, 2021, 534, 1-7.	1.0	2
3434	Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs, 2021, 81, 257-266.	4.9	57
3435	Long term follow-up of EGFR mutated NSCLC cases. Translational Oncology, 2021, 14, 100934.	1.7	6
3436	Dabrafenib and trametinib therapy in an elderly patient with nonâ€small cell lung cancer harboring the BRAF V600E mutation. Thoracic Cancer, 2021, 12, 272-276.	0.8	3
3437	SHOC2 Is a Critical Modulator of Sensitivity to EGFRâ€“TKIs in Nonâ€“Small Cell Lung Cancer Cells. Molecular Cancer Research, 2021, 19, 317-328.	1.5	12
3438	Effectiveness of <scp>EGFR</scp> tyrosine kinase inhibitors in advanced nonâ€small cell lung cancer patients with uncommon <scp>EGFR</scp> mutations: A multicenter observational study. Thoracic Cancer, 2021, 12, 90-96.	0.8	5
3439	NORAD, a critical long non-coding RNA in human cancers. Life Sciences, 2021, 264, 118665.	2.0	48
3440	Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e98-e111.	1.1	6
3441	Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells. Translational Oncology, 2021, 14, 100887.	1.7	10
3442	Predicting osimertinibâ€treatment outcomes through EGFR mutantâ€fraction monitoring in the circulating tumor DNA of EGFR T790Mâ€positive patients with nonâ€small cell lung cancer (WJOG8815L). Molecular Oncology, 2021, 15, 126-137.	2.1	12
3443	Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). Supportive Care in Cancer, 2021, 29, 2327-2334.	1.0	2
3444	FoundationOneÂ® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Surgery Today, 2021, 51, 619-626.	0.7	9

#	Article	IF	Citations
3445	Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. Investigational New Drugs, 2021, 39, 571-577.	1.2	20
3446	Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelialâ€“mesenchymal transition through targeting major vault protein (MVP). Cellular Oncology (Dordrecht), 2021, 44, 109-133.	2.1	9
3447	Method for preservation of DNA stability of liquid-based cytology specimens from a lung adenocarcinoma cell line. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 507-516.	1.4	4
3448	Outcomes of gefitinib therapy for disease recurrence in medically inoperable stage I lung adenocarcinoma patients with active EGFR mutations receiving stereotactic body radiotherapy: a single-institute retrospective study. International Journal of Surgery Oncology, 2021, 4, 72.	0.2	0
3449	Prevalence and Significance of Potential Pharmacokinetic Drugâ€“Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials. Clinical Drug Investigation, 2021, 41, 161-167.	1.1	8
3450	Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. BMC Cancer, 2021, 21, 57.	1.1	3
3451	Adverse event profiles of epidermal growth factor receptorâ€tyrosine kinase inhibitors in cancer patients: A systematic review and metaâ€analysis. Clinical and Translational Science, 2021, 14, 919-933.	1.5	8
3452	Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer. Journal of Cancer, 2021, 12, 5286-5295.	1.2	10
3453	An integrated epigenomic-transcriptomic landscape of lung cancer reveals novel methylation driver genes of diagnostic and therapeutic relevance. Theranostics, 2021, 11, 5346-5364.	4.6	23
3454	Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199297.	1.4	1
3455	Gefitinib initiates sterile inflammation by promoting IL-1Î² and HMGB1 release via two distinct mechanisms. Cell Death and Disease, 2021, 12, 49.	2.7	29
3456	Olmutinib in T790Mâ€positive nonâ€“small cell lung cancer after failure of firstâ€line epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer, 2021, 127, 1407-1416.	2.0	17
3457	Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 612.	1.8	79
3458	Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO Clinical and Research Reports, 2021, 2, 100107.	0.6	15
3459	Trends in Phase II Trials for Cancer Therapies. Cancers, 2021, 13, 178.	1.7	4
3460	Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway. Acta Biochimica Et Biophysica Sinica, 2021, 53, 1670-1680.	0.9	10
3461	Molecular Therapeutics of Non-Small Cell Lung Cancer (NSCLC) and Challenges in Repeat Tissue Biopsy. Advances in Lung Cancer (Irvine), 2021, 10, 21-39.	0.2	2
3462	Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib. Cureus, 2021, 13, e12451.	0.2	0

#	Article	IF	Citations
3463	MRI Texture Analysis for the Prediction of Stereotactic Radiosurgery Outcomes in Brain Metastases from Lung Cancer. Journal of Clinical Medicine, 2021, 10, 237.	1.0	3
3464	Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with nonâ€“small-cell lung cancer. Bioengineered, 2021, 12, 791-802.	1.4	15
3465	Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A postâ€authorization safety cohort study conducted in Europe and in the United States. Pharmacoepidemiology and Drug Safety, 2021, 30, 758-769.	0.9	4
3466	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2021, 5, 93-102.	1.5	31
3467	Pulmonary complications of tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with non-small cell lung cancer. Cancer Treatment and Research Communications, 2021, 28, 100439.	0.7	1
3468	Experimental and bioinformatics considerations in cancer application of single cell genomics. Computational and Structural Biotechnology Journal, 2021, 19, 343-354.	1.9	3
3469	Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2020, 10, 607840.	1.3	10
3470	<scp>HSP90</scp> inhibition overcomes <scp>EGFR</scp> amplificationâ€induced resistance to thirdâ€generation <scp>EGFRâ€TKIs</scp>. Thoracic Cancer, 2021, 12, 631-642.	0.8	14
3471	Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study. Clinics, 2021, 76, e2251.	0.6	2
3472	Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer. , 2021, 4, 740-744.		1
3473	SMOKING CARCINOGENS AND LUNG CANCER â€“ A REVIEW. Asian Journal of Pharmaceutical and Clinical Research, 0, , 5-12.	0.3	1
3474	Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer. Acta Pharmacologica Sinica, 2021, 42, 648-654.	2.8	11
3475	Effectiveness of EGFRâ€TKI rechallenge immediately after PD â€1 blockade failure. Thoracic Cancer, 2021, 12, 864-873.	0.8	10
3476	RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma. Journal of Cellular and Molecular Medicine, 2021, 25, 2418-2425.	1.6	16
3477	Almonertinib-induced interstitial lung disease. Medicine (United States), 2021, 100, e24393.	0.4	10
3478	A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. Cancer Treatment and Research Communications, 2021, 28, 100416.	0.7	0
3479	Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer. Journal of Evidence-based Integrative Medicine, 2021, 26, 2515690X2110107.	1.4	1
3480	Automated TTF-1 Immunohistochemistry Assay for the Differentiation of Lung Adenocarcinoma Versus Lung Squamous Cell Carcinoma. Methods in Molecular Biology, 2021, 2279, 1-12.	0.4	0

#	Article	IF	Citations
3481	Predictive factors for dental inflammation with exacerbation during cancer therapy with FDG-PET/CT imaging. Supportive Care in Cancer, 2021, 29, 4277-4284.	1.0	0
3482	Small-Cell Lung Cancer: Is the Black Box Finally Opening Up?. Cancers, 2021, 13, 236.	1.7	0
3483	Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Frontiers in Pharmacology, 2021, 12, 636324.	1.6	2
3484	Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis. Translational Lung Cancer Research, 2021, 10, 914-925.	1.3	9
3485	Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma. Medicine (United States), 2021, 100, e24640.	0.4	11
3486	Precision treatment for metastatic nonâ€“small cell lung cancer: A conceptual overview. Cleveland Clinic Journal of Medicine, 2021, 88, 117-127.	0.6	3
3487	Longâ€term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutationâ€positive lung adenocarcinoma. Thoracic Cancer, 2021, 12, 989-992.	0.8	1
3488	Bioinformatics and integrated analyses of prognosis-associated key genes in lung adenocarcinoma. Journal of Thoracic Disease, 2021, 13, 1172-1186.	0.6	3
3489	EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study. Translational Lung Cancer Research, 2021, 10, 662-674.	1.3	17
3490	Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Journal of Comparative Effectiveness Research, 2021, 10, 193-206.	0.6	5
3491	Comparative study of the loop-mediated isothermal amplification method and the QIAGEN therascreen PCR kit for the detection of EGFR mutations in non-small cell lung cancer. Journal of Thoracic Disease, 2021, 13, 743-753.	0.6	2
3492	Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study. Translational Lung Cancer Research, 2021, 10, 839-854.	1.3	4
3493	Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing. Diagnostics, 2021, 11, 391.	1.3	20
3494	Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Annals of Translational Medicine, 2021, 9, 206-206.	0.7	4
3495	Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses. JCO Precision Oncology, 2021, 5, 418-431.	1.5	9
3496	Deep CNN Model Using CT Radiomics Feature Mapping Recognizes EGFR Gene Mutation Status of Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 598721.	1.3	26
3497	Allosteric Inhibition of the Epidermal Growth Factor Receptor. Biochemistry, 2021, 60, 500-512.	1.2	1
3498	Extensive functional evaluation of exon 20 insertion mutations of EGFR. Lung Cancer, 2021, 152, 135-142.	0.9	15

#	Article	IF	Citations
3499	Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways. Biomedicine and Pharmacotherapy, 2021, 134, 111144.	2.5	11
3500	Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer. Cancer Management and Research, 2021, Volume 13, 2025-2032.	0.9	4
3501	Understanding barriers to the introduction of precision medicine in non-small cell lung cancer: a qualitative interview study. Wellcome Open Research, 0, 6, 25.	0.9	2
3502	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer. BMJ Open, 2021, 11, e041345.	0.8	3
3503	First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence. Cancer Management and Research, 2021, Volume 13, 1667-1672.	0.9	1
3504	Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy. Frontiers in Oncology, 2021, 11, 621992.	1.3	13
3505	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers, 2021, 13, 804.	1.7	76
3506	Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study. Cancer Management and Research, 2021, Volume 13, 2033-2039.	0.9	8
3507	Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism. Journal of Clinical Oncology, 2021, 39, 697-700.	0.8	3
3508	Anti-Lung Cancer Targets of Radix Paeoniae Rubra and Biological Molecular Mechanism: Network Pharmacological Analyses and Experimental Validation. OncoTargets and Therapy, 2021, Volume 14, 1925-1936.	1.0	3
3509	CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 1231-1242.	0.5	16
3510	High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma. Journal of Thoracic Disease, 2021, 13, 1476-1484.	0.6	4
3511	N â€glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC. Cancer Science, 2021, 112, 1911-1923.	1.7	10
3512	Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma. Scientific Reports, 2021, 11, 5679.	1.6	9
3513	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 2021, 39, 1040-1091.	0.8	192
3514	The histological diagnosis and molecular testing of lung cancer by surgical biopsy for intrathoracic lesions. General Thoracic and Cardiovascular Surgery, 2021, 69, 1185-1191.	0.4	0
3515	Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment NaÃ¯ve Advanced EGFR-Mutant Lung Adenocarcinoma Patients. OncoTargets and Therapy, 2021, Volume 14, 2139-2148.	1.0	7
3516	EGFR â€mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib. Thoracic Cancer, 2021, 12, 1441-1444.	0.8	3

#	Article	IF	Citations
3517	Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada. Pharmacoeconomics, 2021, 39, 537-548.	1.7	6
3518	Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation. Journal of the Formosan Medical Association, 2022, 121, 170-180.	0.8	7
3519	Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial. Trials, 2021, 22, 214.	0.7	1
3520	Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Cancer Science, 2021, 112, 1963-1974.	1.7	13
3521	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clinical Cancer Research, 2021, 27, 2920-2927.	3.2	42
3522	Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Advances in Therapy, 2021, 38, 2038-2053.	1.3	8
3523	Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study. Drugs - Real World Outcomes, 2021, 8, 141-152.	0.7	6
3524	Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Diagnostics, 2021, 11, 469.	1.3	2
3525	A novel protein ubiquitination-related five-gene signature predicts overall survival in patients with lung adenocarcinoma. Aging, 2021, 13, 8510-8523.	1.4	2
3526	Lentivirusâ€'mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelialâ€'mesenchymal transition in lung adenocarcinoma A549 cells. Oncology Letters, 2021, 21, 433.	0.8	0
3527	Identification of <scp>NTRK</scp> gene fusions in lung adenocarcinomas in the Chinese population. Journal of Pathology: Clinical Research, 2021, 7, 375-384.	1.3	17
3528	Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: aÂcostâ€"effectiveness analysis. Journal of Comparative Effectiveness Research, 2021, 10, 325-335.	0.6	4
3529	Impacts of anticancer drug parity laws on mortality rates. Social Science and Medicine, 2021, 272, 113714.	1.8	0
3530	Proteomics in aging research: A roadmap to clinical, translational research. Aging Cell, 2021, 20, e13325.	3.0	59
3531	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogeneâ€driven nonâ€smallâ€cell lung cancers. Cancer Science, 2021, 112, 1853-1864.	1.7	29
3532	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. The Cochrane Library, 2021, 2021, CD010383.	1.5	28
3533	Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small-cell lung cancer. Pharmacological Research, 2021, 165, 105442.	3.1	28
3534	Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer. Expert Review of Precision Medicine and Drug Development, 2021, 6, 161-171.	0.4	5

#	Article	IF	Citations
3535	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer, 2021, 154, 176-185.	0.9	18
3536	Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer. JCO Global Oncology, 2021, 7, 639-645.	0.8	10
3537	Trans-Ancestry Mutation Landscape of Hepatoblastoma Genomes in Children. Frontiers in Oncology, 2021, 11, 669560.	1.3	2
3538	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Critical Reviews in Oncology/Hematology, 2021, 160, 103299.	2.0	5
3539	Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 4618.	1.8	30
3540	Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients. Frontiers in Oncology, 2021, 11, 629394.	1.3	19
3541	Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies. Molecules, 2021, 26, 2211.	1.7	23
3542	Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 160, 103305.	2.0	25
3543	Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer. Annals of Translational Medicine, 2021, 9, 635-635.	0.7	7
3544	Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model. International Journal of Pharmaceutics, 2021, 598, 120350.	2.6	8
3545	Abnormal spindle-like microcephaly-associated protein enhances cell invasion through Wnt/Î²-catenin-dependent regulation of epithelial-mesenchymal transition in non-small cell lung cancer cells. Journal of Thoracic Disease, 2021, 13, 2460-2474.	0.6	5
3546	High-risk-pattern lung adenocarcinoma with epidermal growth factor receptor mutation is associated with distant metastasis risk and may benefit from adjuvant targeted therapy. Interactive Cardiovascular and Thoracic Surgery, 2021, 33, 395-401.	0.5	2
3547	Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations. Cancer Management and Research, 2021, Volume 13, 3293-3301.	0.9	5
3548	Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling. International Journal of Molecular Sciences, 2021, 22, 4005.	1.8	24
3549	Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively. BMC Cancer, 2021, 21, 445.	1.1	2
3550	Efficacy and dose of afatinib in patients with nonâ€small cell lung cancer after failure of prior gefitinib or erlotinib treatment. Thoracic Cancer, 2021, 12, 1598-1604.	0.8	2
3551	Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer. Current Pharmaceutical Biotechnology, 2021, 22, 389-399.	0.9	5
3552	A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD). Annals of Translational Medicine, 2021, 9, 545-545.	0.7	6

#	Article	IF	Citations
3553	Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review. Molecular Biology Reports, 2021, 48, 3593-3604.	1.0	12
3554	Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. Translational Lung Cancer Research, 2021, 10, 1623-1634.	1.3	5
3555	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. Japanese Journal of Clinical Oncology, 2021, 51, 956-965.	0.6	6
3556	Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multiâ€CDx system in lung cancer. Cancer Cytopathology, 2021, 129, 729-738.	1.4	10
3557	First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 598265.	1.3	15
3558	Mesoporous organosilica nanoparticles: Degradation strategies and application in tumor therapy. View, 2021, 2, 20200117.	2.7	21
3559	Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-10.	0.5	0
3560	Management of brain metastases in elderly patients with lung cancer. Journal of Thoracic Disease, 2021, 13, 3295-3307.	0.6	1
3561	Targeted PD-L1 PLGA/liposomes-mediated luteolin therapy for effective liver cancer cell treatment. Journal of Biomaterials Applications, 2021, 36, 843-850.	1.2	16
3562	VATS right upper lobectomy after alectinib administration for ALK-positive lung adenocarcinoma. The Journal of the Japanese Association for Chest Surgery, 2021, 35, 297-302.	0.0	0
3563	EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2301-2307.	1.2	0
3564	The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. Scientific Reports, 2021, 11, 9629.	1.6	3
3565	Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. Lung Cancer: Targets and Therapy, 2021, Volume 12, 35-50.	1.3	25
3566	Characteristics of central nervous system progression in nonâ€small cell lung cancer treated with crizotinib or alectinib. Cancer Reports, 2021, , e1414.	0.6	4
3567	The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2239-2248.	1.2	1
3568	Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells. Respiratory Research, 2021, 22, 146.	1.4	10
3569	Preclinical models and technologies to advance nanovaccine development. Advanced Drug Delivery Reviews, 2021, 172, 148-182.	6.6	18
3570	Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 108-116.	0.8	2

#	Article	IF	Citations
3571	Absorption, metabolism, excretion, and safety of [14C]almonertinib in healthy Chinese subjects. Annals of Translational Medicine, 2021, 9, 867-867.	0.7	9
3572	Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations. Medicina (Lithuania), 2021, 57, 508.	0.8	2
3573	Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. Cells, 2021, 10, 1206.	1.8	17
3574	Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma. OncoTargets and Therapy, 2021, Volume 14, 2953-2965.	1.0	6
3575	Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors. Scientific Reports, 2021, 11, 9984.	1.6	13
3577	Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. Cancers, 2021, 13, 2736.	1.7	19
3578	The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations. Frontiers in Oncology, 2021, 11, 659065.	1.3	3
3579	Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer. Nucleic Acid Therapeutics, 2021, 31, 364-374.	2.0	25
3580	First-Line Afatinib plus Cetuximab for EGFR-Mutant Nonâ€“Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study. Clinical Cancer Research, 2021, 27, 4168-4176.	3.2	9
3581	mTOR modulates resistance to gemcitabine in lung cancer in an MTORC2 dependent mechanism. Cellular Signalling, 2021, 81, 109934.	1.7	6
3582	Efficacy and Safety of EGFR Inhibitors in the Treatment of EGFRPositive NSCLC Patients: A Meta-Analysis. Reviews on Recent Clinical Trials, 2021, 16, 193-201.	0.4	3
3583	Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET/CT imaging. Lung Cancer, 2021, 155, 156-162.	0.9	11
3584	Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. BMC Cancer, 2021, 21, 495.	1.1	8
3585	Boolean dynamic modeling of cancer signaling networks: Prognosis, progression, and therapeutics. Computational and Systems Oncology, 2021, 1, e1017.	1.1	24
3586	Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer. Cell Death and Disease, 2021, 12, 561.	2.7	19
3587	Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 608608.	1.3	5
3588	Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting. BMC Cancer, 2021, 21, 602.	1.1	7
3589	Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. Clinical Lung Cancer, 2021, 22, e870-e877.	1.1	6

#	Article	IF	Citations
3590	Precision Oncology. Advances in Oncology, 2021, 1, 97-112.	0.1	0
3591	Kinase drug discovery 20 years after imatinib: progress and future directions. Nature Reviews Drug Discovery, 2021, 20, 551-569.	21.5	497
3592	The Root Extract of Scutellaria baicalensis Induces Apoptosis in EGFR TKI-Resistant Human Lung Cancer Cells by Inactivation of STAT3. International Journal of Molecular Sciences, 2021, 22, 5181.	1.8	15
3593	Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer. ELife, 2021, 10, .	2.8	16
3594	Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer. , 0, , .		0
3595	Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma. International Journal of Molecular Sciences, 2021, 22, 6727.	1.8	11
3596	Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. BMC Cancer, 2021, 21, 731.	1.1	4
3597	The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. Expert Opinion on Drug Discovery, 2021, 16, 1091-1103.	2.5	6
3598	Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. Current Treatment Options in Oncology, 2021, 22, 71.	1.3	3
3599	A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. ESMO Open, 2021, 6, 100115.	2.0	30
3600	Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis. Medicine (United States), 2021, 100, e26450.	0.4	2
3601	Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 1521-1532.	1.1	3
3602	Value of radiomics model based on multi-parametric magnetic resonance imaging in predicting epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Journal of Thoracic Disease, 2021, 13, 3497-3508.	0.6	7
3603	A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer, 2021, 21, 672.	1.1	0
3604	The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLCâ€“IMâ€“MS Study. Metabolites, 2021, 11, 379.	1.3	6
3605	A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study. Journal of Oncology Pharmacy Practice, 2022, 28, 1140-1151.	0.5	7
3606	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers, 2021, 13, 3164.	1.7	35
3607	A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The â€˜LUNGFULâ€™ Study. Cancers, 2021, 13, 3172.	1.7	6

#	Article	IF	Citations
3608	Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib. Toxicology Letters, 2021, 343, 1-10.	0.4	14
3609	EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncology, 2021, 17, 2395-2408.	1.1	17
3610	The 2020 Edition of the Clinical Guidelines for Lung Cancer: Challenges and Future Perspectives. Japanese Journal of Lung Cancer, 2021, 61, 163-170.	0.0	0
3611	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. Frontiers in Medicine, 2021, 8, 570921.	1.2	2
3612	Concurrent chemotherapy and firstâ€generation epidermal growth factor receptor (EGFR)â€tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as firstâ€line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. Thoracic Cancer, 2021, 12, 2233-2240.	0.8	1
3613	Mutation status and postresection survival of patients with nonâ€“small cell lung cancer brain metastasis: implications of biomarker-driven therapy. Journal of Neurosurgery, 2022, 136, 56-66.	0.9	3
3614	Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study. Translational Lung Cancer Research, 2021, 10, 2551-2561.	1.3	12
3615	MEX3A promotes development and progression of breast cancer through regulation of PIK3CA. Experimental Cell Research, 2021, 404, 112580.	1.2	8
3616	Icotinib alone or with bevacizumab as firstâ€line therapy in Chinese patients with advanced nonsquamous nonâ€small cell lung cancer and activating <scp>EGFR</scp> mutations: A retrospective study. Thoracic Cancer, 2021, 12, 2369-2374.	0.8	2
3617	Design of more potent quinazoline derivatives as EGFRWT inhibitors for the treatment of NSCLC: a computational approach. Future Journal of Pharmaceutical Sciences, 2021, 7, .	1.1	9
3618	Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage Iâ€“III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations. Translational Lung Cancer Research, 2021, 10, 3213-3225.	1.3	9
3619	A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer. BMC Cancer, 2021, 21, 877.	1.1	10
3620	Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated nonâ€“small cell lung cancer patients with asymptomatic brain metastases. Investigational New Drugs, 2021, 39, 1598-1603.	1.2	1
3621	Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors. Bioorganic Chemistry, 2021, 112, 104848.	2.0	6
3622	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. Pharmacological Research, 2021, 169, 105643.	3.1	13
3623	Review of chemotherapyâ€associated paronychia. International Journal of Dermatology, 2022, 61, 410-415.	0.5	5
3624	Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer. Respiratory Investigation, 2021, 59, 535-544.	0.9	5
3625	High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib. JTO Clinical and Research Reports, 2021, 2, 100191.	0.6	5

#	Article	IF	Citations
3626	2D-Quantitative structure activity relationship (QSAR) modeling, docking studies, synthesis and in-vitro evaluation of 1,3,4-thiadiazole tethered coumarin derivatives as antiproliferative agents. Journal of Saudi Chemical Society, 2021, 25, 101279.	2.4	7
3627	EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer, 2022, 23, e148-e153.	1.1	16
3628	ALCAP2 inhibits lung adenocarcinoma cell proliferation, migration and invasion via the ubiquitination of Î²-catenin by upregulating the E3 ligase NEDD4L. Cell Death and Disease, 2021, 12, 755.	2.7	13
3629	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. Future Oncology, 2021, 17, 2513-2527.	1.1	7
3630	Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes. Molecular Oncology, 2021, 15, 3299-3316.	2.1	5
3631	Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clinical and Translational Oncology, 2021, 23, 2560-2567.	1.2	7
3632	The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. Cancers, 2021, 13, 3656.	1.7	8
3633	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Cancer Research, 2021, 81, 4835-4848.	0.4	31
3634	Paradigm shift in the management of metastatic nonsmall cell lung cancer. International Journal of Clinical Practice, 2021, 75, e14533.	0.8	0
3635	Hypoxiaâ€related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PDâ€L1 squamous and adenocarcinoma NSCLC. Cancer Medicine, 2021, 10, 6099-6113.	1.3	4
3636	Dramatic response to alectinib in a patient with <scp>ALK</scp>â€rearranged squamous cell lung cancer. Thoracic Cancer, 2021, 12, 2420-2423.	0.8	4
3637	Brutonâ€™s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma. Oncogenesis, 2021, 10, 56.	2.1	5
3638	Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer, 2021, 21, 859.	1.1	15
3639	Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease. Translational Lung Cancer Research, 2021, 10, 3132-3143.	1.3	1
3640	Optimization of Solid Lipid Nanoparticles and Nanostructured Lipidic Carriers as Promising Delivery for Gefitinib: Characterization and Invitro Evaluation. Current Drug Therapy, 2021, 16, 170-183.	0.2	3
3641	Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 709137.	1.3	14
3642	Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation. Frontiers in Pharmacology, 2021, 12, 720687.	1.6	3
3643	Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respiratory Medicine,the, 2022, 10, 72-82.	5.2	62

#	Article	IF	Citations
3644	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. Scientific Reports, 2021, 11, 16122.	1.6	13
3645	EGFRâ€mutated stage IV nonâ€small cell lung cancer: What is the role of radiotherapy combined with TKI?. Cancer Medicine, 2021, 10, 6167-6188.	1.3	8
3646	Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. OncoTargets and Therapy, 2021, Volume 14, 4579-4597.	1.0	21
3647	Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study. ESMO Open, 2021, 6, 100191.	2.0	15
3648	An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. Lung Cancer: Targets and Therapy, 2021, Volume 12, 93-102.	1.3	1
3649	Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Nonâ€“Squamous Nonâ€“Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clinical Lung Cancer, 2021, 22, 587-595.	1.1	7
3650	Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors. Journal of Bone Oncology, 2021, 29, 100369.	1.0	5
3651	EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 8522.	1.8	7
3652	Clinical Outcomes in Nonâ€“Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precision Oncology, 2021, 5, 1241-1249.	1.5	11
3653	Molecular follow-up of first-line treatment by osimertinib in lung cancer: Importance of using appropriate tools for detecting EGFR resistance mutation C797S. Cancer Genetics, 2021, 256-257, 158-161.	0.2	4
3654	Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer. Cancer Cell International, 2021, 21, 428.	1.8	28
3655	Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis. Lung Cancer, 2021, 158, 74-84.	0.9	8
3656	EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 691915.	1.3	6
3657	Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC. Current Problems in Cancer, 2022, 46, 100787.	1.0	5
3659	Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptorâ€mutant nonâ€small cell lung cancer: A prospective, multicenter, doseâ€modification study. Geriatrics and Gerontology International, 2021, 21, 881-886.	0.7	3
3660	The Association of Annexin A1 and Chemosensitivity to Osimertinib in Lung Cancer Cells. Cancers, 2021, 13, 4106.	1.7	5
3661	The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutationsâ€”The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations. Frontiers in Oncology, 2021, 11, 646577.	1.3	12
3662	What management for epidermal growth factor receptor-mutated nonâ€“small-cell lung cancer, with squamous cell transformation and T790M-acquired resistance mechanisms? A Case report and review of literature. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	3

#	Article	IF	Citations
3663	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. Translational Lung Cancer Research, 2021, 10, 3582-3593.	1.3	12
3664	Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis. ESMO Open, 2021, 6, 100187.	2.0	2
3665	The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2021, 21, 1071-1080.	1.1	3
3666	Development and validation of an HPLCâ€“MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run. Biomedical Chromatography, 2021, 35, e5224.	0.8	9
3667	PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC. Scientific Reports, 2021, 11, 17522.	1.6	15
3668	Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from MycobacteriumÂtuberculosis: A case report. Molecular and Clinical Oncology, 2021, 15, 227.	0.4	3
3669	Outcomes of salvage lung resections in advanced <scp>EGFR</scp>â€mutant lung adenocarcinomas under <scp>EGFR TKIs</scp>. Thoracic Cancer, 2021, 12, 2655-2665.	0.8	10
3670	Updates in the molecular pathology of non-small cell lung cancer. Seminars in Diagnostic Pathology, 2021, 38, 54-61.	1.0	10
3671	Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Antitumor Immunosuppression of EGFR Wild Type Lung Cancers With Low PD-L1 Expression. Frontiers in Oncology, 2021, 11, 643503.	1.3	2
3672	Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations. Medicina (Lithuania), 2021, 57, 929.	0.8	3
3673	Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Scientific Reports, 2021, 11, 18762.	1.6	13
3674	Aidi injection, a traditional Chinese medicine extract, reverses Gefitinib resistance in non-small cell lung cancer cells. European Journal of Integrative Medicine, 2021, 46, 101368.	0.8	3
3675	Patients' Expectations of Benefits From Large-Panel Genomic Tumor Testing in Rural Community Oncology Practices. JCO Precision Oncology, 2021, 5, 1554-1562.	1.5	4
3676	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist, 2022, 27, 87-e115.	1.9	25
3677	Development and Validation of a Gene Mutation-Associated Nomogram for Hepatocellular Carcinoma Patients From Four Countries. Frontiers in Genetics, 2021, 12, 714639.	1.1	5
3678	Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 4215-4228.	0.5	7
3679	Fascin as a useful marker for cancer-associated fibroblasts in invasive lung adenocarcinoma. Medicine (United States), 2021, 100, e27162.	0.4	2
3680	Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell, 2021, 39, 1279-1291.e3.	7.7	99

#	Article	IF	Citations
3681	TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. Translational Oncology, 2021, 14, 101163.	1.7	11
3682	A Comprehensive Review of Current Perspectives on Novel Drug Delivery Systems and Approaches for Lung Cancer Management. Journal of Pharmaceutical Innovation, 2022, 17, 1530-1553.	1.1	4
3683	Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. Translational Lung Cancer Research, 2021, 10, 3823-3839.	1.3	13
3684	Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Imaging, 2021, Publish Ahead of Print, .	0.8	0
3685	Cardiovascular Complications by EGFR Tyrosine Kinase Inhibitors in Patients with Lung Cancer. International Heart Journal, 2021, 62, 949-951.	0.5	1
3686	Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Nonâ€“small-cell Lung Cancer Treated in the Real-World. Clinical Lung Cancer, 2021, 22, e723-e733.	1.1	7
3687	Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer. Pharmaceutics, 2021, 13, 1478.	2.0	9
3689	Alternate dosage formulations of oral targeted anticancer agents. Journal of Oncology Pharmacy Practice, 2021, 27, 1963-1981.	0.5	3
3690	Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 732841.	1.3	1
3691	A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1. Molecular Cancer Research, 2022, 20, 127-138.	1.5	6
3692	A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer. Biochemical Pharmacology, 2021, 193, 114792.	2.0	4
3693	Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC). Bioorganic Chemistry, 2021, 115, 105234.	2.0	33
3694	Hype or hope â€“ Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. Critical Reviews in Oncology/Hematology, 2021, 166, 103454.	2.0	15
3695	The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study. Journal of Pharmaceutical Sciences, 2021, 110, 3507-3519.	1.6	6
3696	Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor. Cancer Management and Research, 2021, Volume 13, 7517-7526.	0.9	2
3697	The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC. Lung Cancer, 2021, 160, 118-126.	0.9	5
3698	Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. Journal of Thoracic Oncology, 2021, 16, 1745-1752.	0.5	19
3699	Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1291-1302.	0.4	0

#	Article	IF	Citations
3700	A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance. Frontiers in Oncology, 2021, 11, 722039.	1.3	12
3701	The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations. European Journal of Medicinal Chemistry, 2021, 224, 113711.	2.6	16
3702	Molecular Targetable Pathways â€“ EGFR. , 2022, , 844-852.		0
3703	Silencing of CASC8 inhibits non-small cell lung cancer cells function and promotes sensitivity to osimertinib via FOXM1. Journal of Cancer, 2021, 12, 387-396.	1.2	21
3704	The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small-cell lung cancer. Translational Cancer Research, 2021, 10, 0-0.	0.4	2
3705	Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). Translational Lung Cancer Research, 2021, 10, 314-325.	1.3	13
3706	Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. International Journal of Molecular Sciences, 2021, 22, 593.	1.8	35
3707	A Method for the Establishment of Human Lung Adenocarcinoma Patient-Derived Xenografts in Mice. Methods in Molecular Biology, 2021, 2279, 165-173.	0.4	1
3709	Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations. Translational Lung Cancer Research, 2021, 10, 183-192.	1.3	7
3710	Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury. International Journal of Molecular Sciences, 2021, 22, 792.	1.8	43
3711	Crizotinib for recurring nonâ€smallâ€cell lung cancer with EML4â€ALK fusion genes previously treated with alectinib: A phase II trial. Thoracic Cancer, 2021, 12, 643-649.	0.8	5
3712	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790Mâ€“Positive NSCLC. JTO Clinical and Research Reports, 2021, 2, 100099.	0.6	0
3713	Adenocarcinoma. Molecular Pathology Library, 2012, , 119-162.	0.1	1
3714	Role of Genetic Polymorphisms in the Angiogenesis Pathway and Non-small-Cell Lung Cancer Tumor Behavior: Implications in Risk Assessment and Clinical Outcome. , 2013, , 381-403.		3
3715	Targeting Receptor Tyrosine Kinases in Cancer. , 2015, , 225-278.		11
3716	Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations. Methods in Molecular Biology, 2017, 1636, 485-506.	0.4	11
3717	Clinical Interpretation. , 2019, , 33-48.		2
3718	Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling. Recent Results in Cancer Research, 2020, 215, 213-230.	1.8	15

#	Article	IF	Citations
3719	Molecular Pathology Laboratory Management. , 2016, , 945-973.		1
3721	Stratifying Cancer Therapies by Molecular Interactions and Imaging. , 2017, , 315-358.		1
3722	Precision Medicine in Lung Cancer. Molecular Pathology Library, 2018, , 3-13.	0.1	1
3724	Stem Cells, Cell Differentiation, and Cancer. , 2014, , 98-107.e3.		1
3725	Cancer of the Lung. , 2014, , 1143-1192.e13.		5
3726	Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. Cancer Epidemiology, 2020, 67, 101737.	0.8	15
3727	LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers. Cancer Letters, 2020, 486, 58-70.	3.2	55
3728	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. Lung Cancer, 2018, 115, 135-142.	0.9	27
3729	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2012, 58, 263-268.	0.3	4
3732	Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation doubleâ€positive lung cancer. Cancer Science, 2020, 111, 561-570.	1.7	31
3733	Glycogen synthase kinaseâ€3 inhibition overcomes epithelialâ€mesenchymal transitionâ€associated resistance to osimertinib in EGFRâ€mutant lung cancer. Cancer Science, 2020, 111, 2374-2384.	1.7	17
3734	Statins use and its impact in EGFRâ€TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan. Cancer Science, 2020, 111, 2965-2973.	1.7	17
3735	Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia. BMJ Case Reports, 2014, 2014, bcr2013202705-bcr2013202705.	0.2	4
3736	B7-H3-Induced Signaling in Lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth Factor Receptor Mutation Patterns. BioMed Research International, 2020, 2020, 1-8.	0.9	7
3737	Kinetics of Nuclear Uptake and Site-Specific DNA Cleavage during CRISPR-Directed Gene Editing in Solid Tumor Cells. Molecular Cancer Research, 2020, 18, 891-902.	1.5	9
3738	Personalized therapy for lung cancer: Striking a moving target. JCI Insight, 2018, 3, .	2.3	114
3739	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight, 2019, 4, .	2.3	42
3740	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. Journal of Clinical Investigation, 2014, 124, 3003-3015.	3.9	84

#	Article	IF	Citations
3741	Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Tumor Biology, 2017, 39, 101042831770534.	0.8	4
3742	Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989575.	1.4	39
3743	Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Medical Science Monitor, 2018, 24, 3193-3203.	0.5	10
3744	Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations. Medical Science Monitor, 2019, 25, 8430-8437.	0.5	20
3745	Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptorâ€“activating mutation-positive nonâ€“small-cell lung cancer patients in Hong Kong. Hong Kong Medical Journal, 2014, 20, 178-86.	0.1	17
3746	Customised , Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC) = Ø§Ù„Ø¹Ù„Ø§Ø¬ Ø§Ù„Ù…Ø±Ø¶ Ù Ø§ Sultan Qaboos University Medical Journal, 2013, 13, 202-217.	0.3	8
3747	Suppression of Expression of Heat Shock Protein 70 by Gefitinib and Its Contribution to Pulmonary Fibrosis. PLoS ONE, 2011, 6, e27296.	1.1	43
3748	Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. PLoS ONE, 2012, 7, e42164.	1.1	51
3749	The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience. PLoS ONE, 2012, 7, e48323.	1.1	36
3750	Eligibility for Bevacizumab as an Independent Prognostic Factor for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study. PLoS ONE, 2013, 8, e59700.	1.1	12
3751	EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy. PLoS ONE, 2013, 8, e61561.	1.1	61
3752	The Efficacy of Bevacizumab Compared with Other Targeted Drugs for Patients with Advanced NSCLC: A Meta-Analysis from 30 Randomized Controlled Clinical Trials. PLoS ONE, 2013, 8, e62038.	1.1	17
3753	Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e64816.	1.1	71
3754	Efficacy and Safety Profile of Combining Vandetanib with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS ONE, 2013, 8, e67929.	1.1	6
3755	Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy. PLoS ONE, 2013, 8, e71356.	1.1	22
3756	EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e72966.	1.1	11
3757	Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma. PLoS ONE, 2013, 8, e77731.	1.1	24
3758	EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation. PLoS ONE, 2013, 8, e78389.	1.1	29

#	Article	IF	Citations
3759	Upregulation of Cleavage and Polyadenylation Specific Factor 4 in Lung Adenocarcinoma and Its Critical Role for Cancer Cell Survival and Proliferation. PLoS ONE, 2013, 8, e82728.	1.1	25
3760	Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy). PLoS ONE, 2013, 8, e83607.	1.1	76
3761	Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients. PLoS ONE, 2014, 9, e85350.	1.1	51
3762	Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Nonâ€“Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial. PLoS ONE, 2014, 9, e89518.	1.1	32
3763	Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study. PLoS ONE, 2014, 9, e95897.	1.1	21
3764	DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations. PLoS ONE, 2014, 9, e111019.	1.1	21
3765	Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS ONE, 2015, 10, e0123587.	1.1	30
3766	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. PLoS ONE, 2015, 10, e0125232.	1.1	27
3767	High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood. PLoS ONE, 2015, 10, e0130418.	1.1	43
3768	Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations. PLoS ONE, 2015, 10, e0135393.	1.1	9
3769	Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy. PLoS ONE, 2015, 10, e0140794.	1.1	33
3770	Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon. PLoS ONE, 2016, 11, e0149628.	1.1	23
3771	Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules. PLoS ONE, 2016, 11, e0154316.	1.1	16
3772	Inferring RBP-Mediated Regulation in Lung Squamous Cell Carcinoma. PLoS ONE, 2016, 11, e0155354.	1.1	4
3773	Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells. PLoS ONE, 2016, 11, e0158395.	1.1	28
3774	Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0163652.	1.1	8
3775	Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS ONE, 2017, 12, e0171137.	1.1	60
3776	The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma. PLoS ONE, 2017, 12, e0177822.	1.1	5

#	Article	IF	Citations
3777	In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy. PLoS ONE, 2017, 12, e0180576.	1.1	8
3778	Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients. PLoS ONE, 2017, 12, e0181867.	1.1	9
3779	Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma. PLoS ONE, 2017, 12, e0186567.	1.1	19
3780	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE, 2018, 13, e0189766.	1.1	46
3781	Timeliness of Treatment Initiation and Associated Survival Following Diagnosis of Nonâ€“Small-Cell Lung Cancer in South Carolina. Southern Medical Journal, 2017, 110, 107-113.	0.3	16
3782	Genomic Landscape of Squamous Cell Carcinoma of the Lung. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 348-353.	1.8	6
3783	The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis. Cellular and Molecular Biology, 2019, 65, 89-93.	0.3	15
3784	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist, 2019, 24, e318-e326.	1.9	5
3785	Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis. Aging, 2020, 12, 7129-7162.	1.4	6
3786	Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. Aging, 2020, 12, 14244-14270.	1.4	23
3787	Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Genes and Cancer, 2016, 7, 301-308.	0.6	15
3788	Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naÃ¯ve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation. Genes and Cancer, 2017, 8, 559-565.	0.6	7
3789	ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes and Cancer, 2014, 5, 1-14.	0.6	54
3790	FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells. Oncoscience, 2015, 2, 419-427.	0.9	6
3791	Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience, 2014, 1, 522-528.	0.9	24
3792	Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer. Oncotarget, 2016, 7, 52862-52869.	0.8	9
3793	EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. Oncotarget, 2016, 7, 54137-54156.	0.8	27
3794	FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop. Oncotarget, 2016, 7, 59245-59259.	0.8	15

#	Article	IF	Citations
3795	A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer. Oncotarget, 2016, 7, 63924-63936.	0.8	9
3796	Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors. Oncotarget, 2016, 7, 68597-68613.	0.8	16
3797	Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations. Oncotarget, 2016, 7, 68442-68448.	0.8	13
3798	Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation. Oncotarget, 2016, 7, 70535-70545.	0.8	28
3799	BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. Oncotarget, 2016, 7, 68933-68942.	0.8	26
3800	A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. Oncotarget, 2017, 8, 15924-15933.	0.8	16
3801	Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. Oncotarget, 2017, 8, 1343-1353.	0.8	36
3802	KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 3519-3527.	0.8	11
3803	Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine. Oncotarget, 2017, 8, 48534-48544.	0.8	7
3804	Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs. Oncotarget, 2017, 8, 13195-13205.	0.8	19
3805	Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Oncotarget, 2017, 8, 29406-29415.	0.8	9
3806	Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?. Oncotarget, 2017, 8, 40594-40605.	0.8	2
3807	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget, 2017, 8, 43555-43570.	0.8	10
3808	WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas. Oncotarget, 2017, 8, 49033-49043.	0.8	18
3809	Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. Oncotarget, 2017, 8, 55760-55765.	0.8	1
3810	Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: a pooled analysis of 1665 patients. Oncotarget, 2017, 8, 60954-60961.	0.8	29
3811	Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. Oncotarget, 2017, 8, 65111-65122.	0.8	23
3812	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. Oncotarget, 2017, 8, 49680-49688.	0.8	17

#	Article	IF	Citations
3813	The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC. Oncotarget, 2017, 8, 49773-49782.	0.8	29
3814	Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations. Oncotarget, 2017, 8, 56714-56725.	0.8	6
3815	Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients. Oncotarget, 2017, 8, 75952-75967.	0.8	22
3816	FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. Oncotarget, 2014, 5, 5908-5919.	0.8	92
3817	Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. Oncotarget, 2017, 8, 100801-100818.	0.8	35
3818	Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget, 2014, 5, 2293-2304.	0.8	32
3819	Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients. Oncotarget, 2017, 8, 63846-63856.	0.8	21
3820	High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma. Oncotarget, 2017, 8, 59000-59007.	0.8	6
3821	The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells. Oncotarget, 2017, 8, 70736-70751.	0.8	26
3822	Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. Oncotarget, 2017, 8, 77897-77914.	0.8	19
3823	Lung cancer mutation testing: a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test. Oncotarget, 2017, 8, 101437-101451.	0.8	12
3824	Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget, 2014, 5, 10434-10445.	0.8	30
3825	Organotypic three-dimensional cancer cell cultures mirror drug responsesin vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 2017, 8, 107423-107440.	0.8	36
3826	Detection of EGFR and KRAS gene mutations using suspension liquid-based cytology specimens in metastatic lung adenocarcinoma. Oncotarget, 2017, 8, 106685-106692.	0.8	13
3827	Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. Oncotarget, 2017, 8, 107630-107639.	0.8	16
3828	Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget, 2018, 9, 5459-5472.	0.8	47
3829	Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy. Oncotarget, 2018, 9, 5435-5444.	0.8	6
3830	Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). Oncotarget, 2018, 9, 8253-8262.	0.8	25

#	Article	IF	Citations
3831	Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. Oncotarget, 2018, 9, 9480-9488.	0.8	23
3832	Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer. Oncotarget, 2011, 2, 165-177.	0.8	52
3833	T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer. Oncotarget, 2018, 9, 27929-27939.	0.8	16
3834	Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma. Oncotarget, 2018, 9, 29379-29391.	0.8	12
3835	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. Oncotarget, 2018, 9, 29525-29531.	0.8	28
3836	Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment. Oncotarget, 2020, 11, 982-991.	0.8	13
3837	A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget, 2015, 6, 4527-4536.	0.8	85
3838	Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget, 2015, 6, 5182-5194.	0.8	72
3839	Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer. Oncotarget, 2015, 6, 12481-12492.	0.8	10
3840	MLH1V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients withEGFRL858R-positive lung adenocarcinoma. Oncotarget, 2015, 6, 8407-8417.	0.8	17
3841	Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants. Oncotarget, 2015, 6, 8839-8850.	0.8	12
3842	Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib ofEGFRmutant advanced lung adenocarcinoma. Oncotarget, 2015, 6, 12783-12795.	0.8	58
3843	Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. Oncotarget, 2015, 6, 20466-20473.	0.8	32
3844	Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget, 2015, 6, 16725-16734.	0.8	26
3845	Putative effectors for prognosis in lung adenocarcinoma are ethnic and gender specific. Oncotarget, 2015, 6, 19483-19499.	0.8	4
3846	Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. Oncotarget, 2015, 6, 24904-24911.	0.8	22
3847	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget, 2015, 6, 30929-30938.	0.8	10
3848	Generation and characterization of a tetraspanin CD151/integrin Î±6Î²1-binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC. Oncotarget, 2016, 7, 6314-6322.	0.8	20

#	Article	IF	Citations
3849	KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Oncotarget, 2016, 7, 8373-8388.	0.8	73
3850	Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts. Oncotarget, 2016, 7, 35741-35752.	0.8	2
3851	PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. Oncotarget, 2012, 3, 1566-1575.	0.8	79
3852	Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis. Oncotarget, 2016, 7, 20093-20108.	0.8	31
3853	Nitrilase 1 modulates lung tumor progression in vitro and in vivo. Oncotarget, 2016, 7, 21381-21392.	0.8	5
3854	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. Oncotarget, 2016, 7, 25632-25639.	0.8	9
3855	Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer. Oncotarget, 2016, 7, 24860-24870.	0.8	25
3856	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Oncotarget, 2016, 7, 36311-36320.	0.8	44
3857	Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Oncotarget, 2016, 7, 39823-39833.	0.8	9
3858	Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?. Annals of Translational Medicine, 2016, 4, 225-225.	0.7	7
3859	The aftermath of LUX-Lung 7 studyâ€"what have we learnt from it?. Annals of Translational Medicine, 2016, 4, 294-294.	0.7	1
3860	Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance. Annals of Translational Medicine, 2017, 5, 377-377.	0.7	15
3861	Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. Annals of Translational Medicine, 2017, 5, 371-371.	0.7	2
3862	Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). Annals of Translational Medicine, 2018, 6, 140-140.	0.7	14
3863	Osimertinib in first-line treatmentâ€"is a comparison not proof?. Annals of Translational Medicine, 2018, 6, 57-57.	0.7	3
3864	First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer. Annals of Translational Medicine, 2018, 6, 62-62.	0.7	2
3865	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. Annals of Translational Medicine, 2018, 6, 143-143.	0.7	13
3866	The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. Annals of Translational Medicine, 2019, 7, 806-806.	0.7	11

#	Article	IF	Citations
3867	EGFR first- and second-generation TKIsâ€"there is still place for them in EGFR-mutant NSCLC patients. Translational Cancer Research, 2018, 8, S23-S47.	0.4	48
3868	Akt/mTOR and AMPK signaling pathways are responsible for liver X receptor agonist GW3965-enhanced gefitinib sensitivity in non-small cell lung cancer cell lines. Translational Cancer Research, 2019, 8, 66-76.	0.4	8
3869	Adjuvant TKI treatment of EGFR-mutant lung cancerâ€"already ripe for decision?. Translational Lung Cancer Research, 2020, 9, 964-966.	1.3	3
3870	Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 339-347.	0.7	9
3871	Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 543-552.	0.7	27
3872	Biomarkers for the targeted therapies of non-small cell lung cancer. Current Biomarker Findings, 0, , 7.	0.4	3
3873	Highly Sensitive Droplet Digital PCR Method for Detection of de novo EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer. OncoTargets and Therapy, 2020, Volume 13, 10621-10630.	1.0	12
3874	Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Betterâ€¦. Current Pharmaceutical Design, 2014, 20, 3901-3913.	0.9	7
3875	Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinibâ€™s Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach. Combinatorial Chemistry and High Throughput Screening, 2021, 25, 149-166.	0.6	25
3876	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2019, 19, 595-630.	0.8	61
3877	Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives. Current Cancer Therapy Reviews, 2013, 9, 97-110.	0.2	10
3878	Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond. Reviews on Recent Clinical Trials, 2019, 14, 120-128.	0.4	11
3879	â€œImpact of Smoking Cessation Treatmentâ€•on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study. Recent Patents on Anti-Cancer Drug Discovery, 2015, 10, 342-351.	0.8	8
3880	From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1235-1240.	0.9	9
3881	Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer. Anticancer Research, 2016, 36, 4951-4954.	0.5	4
3882	Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population. Anticancer Research, 2018, 38, 393-400.	0.5	10
3883	Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression. Anticancer Research, 2018, 38, 753-762.	0.5	12
3884	Phenethyl Isothiocyanate Induces Apoptotic Cell Death Through the Mitochondria-dependent Pathway in Gefitinibresistant NCI-H460 Human Lung Cancer Cells In Vitro. Anticancer Research, 2018, 38, 2137-2147.	0.5	13

#	Article	IF	Citations
3885	Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases. Anticancer Research, 2019, 39, 923-931.	0.5	6
3886	Association of BIM Deletion Polymorphism and BIM-Î³ RNA Expression in NSCLC with EGFR Mutation. Cancer Genomics and Proteomics, 2016, 13, 475-482.	1.0	9
3887	Mobile Phone Appâ€“Based Pulmonary Rehabilitation for Chemotherapy-Treated Patients With Advanced Lung Cancer: Pilot Study. JMIR MHealth and UHealth, 2019, 7, e11094.	1.8	37
3888	A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted Therapy for Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1761-1766.	0.5	5
3889	Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy. Immunotherapy, 2020, 12, 431-437.	1.0	4
3890	EML4-ALK in non-small-cell lung cancer: the breathtaking progress from benchtop to Phase III clinical trial. Therapy: Open Access in Clinical Medicine, 2011, 8, 55-61.	0.2	1
3891	Knockout of lncRNA UCA1 inhibits drug resistance to gefitinib via targeting STAT3 signaling in NSCLC. Minerva Medica, 2019, 110, 273-275.	0.3	14
3892	Image-guided adaptive radiotherapy in patients with locally advanced non-small cell lung cancer: the art of PET. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 369-384.	0.4	6
3894	A Case of Small-cell Lung Carcinoma with EGFR Gene Mutation. Japanese Journal of Lung Cancer, 2011, 51, 798-802.	0.0	1
3895	Mechanisms and Overcome of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Japanese Journal of Lung Cancer, 2012, 52, 131-135.	0.0	1
3896	A Case of Small Cell Lung Cancer with an Epidermal Growth Factor Receptor T790M Mutation That Responded to Osimertinib. Japanese Journal of Lung Cancer, 2019, 59, 151-157.	0.0	1
3897	Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3581-3589.	0.5	6
3898	Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2014, 18, 1-166.	1.3	42
3899	The Influence of Biomarker Mutations and Systemic Treatment on Cerebral Metastases from NSCLC Treated with Radiosurgery. Journal of Korean Neurosurgical Society, 2017, 60, 21-29.	0.5	2
3900	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. Frontiers in Oncology, 2019, 9, 263.	1.3	62
3901	Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 593831.	1.3	25
3902	Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images. Journal of Clinical Medicine, 2021, 10, 118.	1.0	14
3903	Efficacy and Predictors of EGFR Tyrosine Kinase Inhibitors in Chinese Advanced Lung Adenocarcinoma: Analyses of 253 Cases From a Single Institute. Oncology Research, 2014, 21, 237-246.	0.6	6

#	Article	IF	Citations
3909	Decreased human antigenï¿½R expression confers resistance toï¿½tyrosine kinase inhibitors in epidermal growth factor receptor-mutant lung cancer by inhibiting Bim expression. International Journal of Molecular Medicine, 2018, 42, 2930-2942.	1.8	4
3910	Clinical importance of long nonâ€‘coding RNA LINC00460 expression in EGFRâ€‘mutant lung adenocarcinoma. International Journal of Oncology, 2020, 56, 243-257.	1.4	19
3911	Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients. Oncology Letters, 2020, 19, 3495-3505.	0.8	9
3912	Predictive value of tumor genetic alteration profiling for chemotherapy and EGFRâ€‘TKI treatment in advanced NSCLC. Oncology Letters, 2020, 19, 3859-3870.	0.8	1
3913	The effect of TKI therapy and chemotherapy treatment delivery sequence on total progressionâ€‘free survival in patients with advanced EGFRâ€‘mutated NSCLC. Oncology Letters, 2020, 20, 391-400.	0.8	4
3914	¹⁸Fâ€‘FDG PET/CT SUV_{max} and serum CEA levels as predictors for EGFR mutation state in Chinese patients with nonâ€‘small cell lung cancer. Oncology Letters, 2020, 20, 61.	0.8	12
3915	Zoledronic acid reâ€‘sensitises gefitinibâ€‘resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelialâ€‘mesenchymal transition. Oncology Reports, 2020, 45, 459-468.	1.2	7
3916	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Korean Journal of Internal Medicine, 2015, 30, 891-898.	0.7	10
3917	Anti-Cancer Therapy of Advanced Lung Cancer in Elderly Patients. Korean Journal of Medicine, 2014, 87, 537.	0.1	1
3918	Targeted Therapy for Non-Small Cell Lung Cancer. Korean Journal of Medicine, 2020, 95, 78-88.	0.1	3
3919	The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. Journal of Thoracic Disease, 2010, 2, 144-53.	0.6	10
3920	Treatment of advanced non small cell lung cancer. Journal of Thoracic Disease, 2011, 3, 122-33.	0.6	99
3921	The pivotal role of pathology in the management of lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S463-78.	0.6	99
3922	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S579-92.	0.6	37
3923	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. Journal of Thoracic Disease, 2013, 5, 585-92.	0.6	23
3924	Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. Journal of Thoracic Disease, 2014, 6, S502-25.	0.6	13
3925	Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status. Journal of Thoracic Disease, 2014, 6, 958-64.	0.6	9
3926	The lung adenocarcinoma guidelines: what to be considered by surgeons. Journal of Thoracic Disease, 2014, 6, S561-7.	0.6	9

#	Article	IF	Citations
3927	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). Journal of Thoracic Disease, 2015, 7, E468-72.	0.6	6
3928	Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. Journal of Gastrointestinal Oncology, 2014, 5, 57-66.	0.6	5
3929	Irreversible EGFR-TKIs: dreaming perfection. Translational Lung Cancer Research, 2013, 2, 40-9.	1.3	20
3930	Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2013, 2, 128-41.	1.3	16
3931	Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2013, 2, 160-71.	1.3	11
3932	Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. Translational Lung Cancer Research, 2013, 2, 226-37.	1.3	35
3933	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Translational Lung Cancer Research, 2015, 4, 36-54.	1.3	499
3934	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Translational Lung Cancer Research, 2015, 4, 67-81.	1.3	241
3935	Treatment of advanced squamous cell carcinoma of the lung: a review. Translational Lung Cancer Research, 2015, 4, 524-32.	1.3	74
3936	Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. Translational Lung Cancer Research, 2015, 4, 465-74.	1.3	21
3937	Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR-mutated non-small-cell lung cancer?. Translational Lung Cancer Research, 2016, 5, 98-101.	1.3	4
3938	Cranial irradiation in patients with EGFR-mutant non-small cell lung cancer brain metastases. Translational Lung Cancer Research, 2016, 5, 134-7.	1.3	6
3939	Somatic DNA mutation analysis in targeted therapy of solid tumours. Translational Pediatrics, 2015, 4, 125-38.	0.5	19
3940	The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Annals of Translational Medicine, 2015, 3, 96.	0.7	20
3941	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). Annals of Translational Medicine, 2015, 3, 260.	0.7	9
3943	From the Bench to Bedside: Biological and Methodology Considerations for the Future of Companion Diagnostics in Nonsmall Cell Lung Cancer. Pathology Research International, 2011, 2011, 1-8.	1.4	15
3944	Epidermal growth factor receptor positive lung cancer: The nontrial scenario. Indian Journal of Cancer, 2017, 54, 132.	0.2	5
3945	A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia. Indian Journal of Cancer, 2017, 54, 104.	0.2	3

#	Article	IF	Citations
3946	Anaplastic lymphoma kinase immunohistochemistry in lung adenocarcinomas: Evaluation of performance of standard manual method using D5F3 antibody. Indian Journal of Cancer, 2017, 54, 209.	0.2	1
3947	Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients. Lung India, 2015, 32, 561.	0.3	13
3948	Role of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present era. Journal of Cytology, 2015, 32, 217.	0.2	11
3949	Differential toxicities of tyrosine kinase inhibitors in the management of metastatic lung cancer. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 15.	0.1	3
3950	Successful treatment of non-small cell lung cancer with gefitinib after erlotinib-induced severe eyelid erosion: Two case reports. Journal of Cancer Research and Therapeutics, 2015, 11, 653.	0.3	4
3951	Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. Journal of Natural Science, Biology and Medicine, 2016, 7, 119.	1.0	31
3952	Targeted therapies in development for non-small cell lung cancer. Journal of Carcinogenesis, 2013, 12, 22.	2.5	67
3953	Role of Crizotinib in previously treated non-small-cell lung cancer. South Asian Journal of Cancer, 2014, 03, 138-140.	0.2	4
3954	Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study. Biomedical Journal, 2015, 38, 221.	1.4	7
3955	Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management. Cancer Research Statistics and Treatment, 2019, 2, 36.	0.1	23
3956	Targeted therapy in nonsmall cell lung cancer. Indian Journal of Cancer, 2017, 54, 83.	0.2	6
3957	T790M mutation and clinical outcomes with osimertinib in patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 73-78.	0.1	3
3958	T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Lung India, 2020, 37, 13.	0.3	8
3959	Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. Lung India, 2018, 35, 27.	0.3	3
3960	Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital. Lung India, 2018, 35, 390.	0.3	9
3961	Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey. Journal of Pathology and Translational Medicine, 2015, 49, 481-488.	0.4	24
3962	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancer Research and Treatment, 2014, 46, 323-330.	1.3	21
3963	Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. Cancer Research and Treatment, 2015, 47, 266-273.	1.3	9

#	Article	IF	Citations
3964	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2015, 47, 182-188.	1.3	3
3965	Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Cancer Research and Treatment, 2013, 45, 79-85.	1.3	21
3966	How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution. Cancer Research and Treatment, 2013, 45, 178-185.	1.3	11
3967	Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. Cancer Research and Treatment, 2016, 48, 88-97.	1.3	19
3968	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. Cancer Research and Treatment, 2015, 47, 630-637.	1.3	21
3969	Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of <i>EGFR</i> Gene Mutation in Patients with Non-small Cell Lung Cancer. Cancer Research and Treatment, 2015, 47, 661-669.	1.3	23
3970	Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned. Cancer Research and Treatment, 2015, 47, 549-554.	1.3	8
3971	Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in <i>EGFR</i>-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis. Cancer Research and Treatment, 2016, 48, 1110-1119.	1.3	11
3972	A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (<i>EGFR</i>)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFRâ€“Tyrosine Kinase Inhibitors. Cancer Research and Treatment, 2017, 49, 10-19.	1.3	35
3973	Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer Research and Treatment, 2017, 49, 1001-1011.	1.3	43
3974	Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment. Cancer Research and Treatment, 2018, 50, 1164-1174.	1.3	5
3975	The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. Cancer Research and Treatment, 2018, 50, 1294-1303.	1.3	49
3976	Treatment Guideline for Advanced NSCLC Based on Driver Gene Mutations. Journal of Genetic Syndromes & Gene Therapy, 2014, 05, .	0.2	1
3977	Current Algorithm for Treatment of Advanced NSCLC Patients: How to Include Active Immunotherapy?. Journal of Cancer Therapy, 2013, 04, 59-75.	0.1	1
3978	Successful treatment of carcinomatous meningitis with erlotinib and whole brain radiotherapy. Annals of Cancer Research and Therapy, 2012, 20, 58-62.	0.1	2
3979	Carcinomatous meningitis and EGFR mutation. Annals of Cancer Research and Therapy, 2015, 23, 14-18.	0.1	2
3980	PNA-mediated Real-Time PCR Clamping for Detection of EGFR Mutations. Bulletin of the Korean Chemical Society, 2010, 31, 3525-3529.	1.0	12
3981	Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer. Archives of Medical Science, 2015, 1, 164-168.	0.4	13

#	Article	IF	Citations
3982	TARGETED THERAPIES IN NON-SMALL CELL LUNG CANCER: WHICH IMPLICATION IN ROUTINE PRACTICE. Toraks Cerrahisi Bulteni, 2012, 3, 167-172.	0.0	1
3983	Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World Journal of Clinical Oncology, 2011, 2, 367.	0.9	39
3984	Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World Journal of Clinical Oncology, 2013, 4, 29.	0.9	11
3985	Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation. World Journal of Clinical Oncology, 2014, 5, 560.	0.9	16
3986	Individualized Systemic Treatment of Lung Cancer. Disease and Molecular Medicine, 2013, 1, 15.	0.1	1
3987	UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells. BMB Reports, 2018, 51, 642-647.	1.1	25
3988	Studies Regarding Quality Enhancement of Affairs by Pharmacist and Clinical Evaluation of Cancer Chemotherapy. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2015, 41, 289-310.	0.0	2
3989	Reflex Testing for Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Fluorescence In Situ Hybridization in Nonâ€“Small Cell Lung Cancer. Archives of Pathology and Laboratory Medicine, 2011, 135, 655-664.	1.2	30
3990	Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 228.	2.3	343
3991	Selection of Luteolin as a potential antagonist from molecular docking analysis of EGFR mutant. Bioinformation, 2018, 14, 241-247.	0.2	12
3992	EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. International Journal of Medical Sciences, 2013, 10, 320-330.	1.1	106
3993	High Resolution Melting Analysis for Epidermal Growth Factor Receptor Mutations in Formalin-fixed Paraffin-embedded Tissue and Plasma Free DNA from Non-small Cell Lung Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6619-6623.	0.5	39
3994	Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4485-4494.	0.5	16
3995	Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3927-3932.	0.5	16
3996	Roles of Immunohistochemical Staining in Diagnosing Pulmonary Squamous Cell Carcinoma. Asian Pacific Journal of Cancer Prevention, 2015, 16, 551-557.	0.5	4
3997	Clinical Efficacy and Possible Applications of Genomics in Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1693-1698.	0.5	3
3998	Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area. Asian Pacific Journal of Cancer Prevention, 2016, 17, 785-789.	0.5	8
3999	Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI. Cancer Biology and Medicine, 2014, 11, 270-6.	1.4	14

#	Article	IF	Citations
4000	Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. ELife, 2016, 5, .	2.8	11
4001	Efficacy of Paclitaxel plus TS1 against previously treatedEGFRmutated non-small cell lung cancer. PeerJ, 2019, 7, e7767.	0.9	1
4002	Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Cureus, 2020, 12, e12128.	0.2	14
4003	Pyruvate dehydrogenase E1Î± represents a reliable prognostic predictor for patients with non-small cell lung cancer resected via curative operation. Journal of Thoracic Disease, 2021, 13, 5691-5700.	0.6	1
4006	EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nature Reviews Clinical Oncology, 2022, 19, 51-69.	12.5	101
4007	An Anti-EGFR/anti- HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells. Protein and Peptide Letters, 2021, 28, 1290-1297.	0.4	2
4008	Qing-Kai-Ling Injection Acts Better Than Shen-Fu Injection in Enhancing the Antitumor Effect of Gefitinib in Resistant Non-Small Cell Lung Cancer Models. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-14.	0.5	4
4009	A call to action: molecular pathology in Brazil. Surgical and Experimental Pathology, 2021, 4, .	0.2	5
4010	Conventional Transbronchial Needle Aspiration (cTBNA) and EBUS-Guided Transbronchial Needle Aspiration (EBUS-TBNA): A Retrospective Study on the Comparison of the Two Methods for Diagnostic Adequacy in Molecular Analysis. Journal of Molecular Pathology, 2021, 2, 296-305.	0.5	2
4011	Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer. Cancer Medicine, 2021, 10, 8595-8603.	1.3	3
4012	Possibility of brigatinibâ€based therapy, or chemotherapy plus antiâ€angiogenic treatment after resistance of osimertinib harboring EGFR T790Mâ€cisâ€C797S mutations in lung adenocarcinoma patients. Cancer Medicine, 2021, 10, 8328-8337.	1.3	9
4013	Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Nonâ€“Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2021, 5, 1603-1610.	1.5	4
4014	Diverse landscape of dermatologic toxicities from smallâ€molecule inhibitor cancer therapy. Journal of Cutaneous Pathology, 2022, 49, 61-81.	0.7	5
4015	Harnessing multimodal data integration to advance precision oncology. Nature Reviews Cancer, 2022, 22, 114-126.	12.8	168
4016	Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Clinical Lung Cancer, 2022, 23, e69-e82.	1.1	31
4017	Cost-effectiveness analysis of the firstâ€line EGFRâ€TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 637-646.	0.7	3
4018	EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. Cancers, 2021, 13, 5132.	1.7	9
4019	Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). International Journal of Clinical Oncology, 2022, 27, 112-120.	1.0	9

#	Article	IF	Citations
4020	Comparing survival and treatment response of patients with acquired <scp>T790M</scp> mutation secondâ€line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A realâ€world study. Thoracic Cancer, 2021, 12, 3263-3272.	0.8	2
4021	Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns. Journal of Cancer Research and Clinical Oncology, 2022, 148, 163-176.	1.2	4
4022	Î”CT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Nonâ€“Small-Cell Lung Cancer: A Multi-Center Retrospective Study. Frontiers in Molecular Biosciences, 2021, 8, 684661.	1.6	1
4023	Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors. Bioorganic and Medicinal Chemistry Letters, 2021, 52, 128406.	1.0	2
4024	EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 1793-1797.	0.5	5
4025	Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies. ESMO Open, 2021, 6, 100280.	2.0	29
4026	Detection of Epidermal Growth Factor Receptor Mutations in Circulating Tumor Cells in Blood Specimens in Non-Small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2011, 51, 689-693.	0.0	0
4027	Translational Research in Lung Cancer. Medical Radiology, 2011, , 793-808.	0.0	0
4030	Retrospective analysis of treatment and prognosis in recurrence patients after complete resection of p-N2 non-small cell lung cancer. The Journal of the Japanese Association for Chest Surgery, 2011, 25, 707-713.	0.0	0
4031	A Case of Advanced Lung Adenocarcinoma with Paranasal Sinus Metastases, in Which Gefitinib Was Effective as First-line Therapy and CyberknifeÂ® Was Efficacious for Local Control. Japanese Journal of Lung Cancer, 2011, 51, 5-10.	0.0	0
4032	Continuous treatment with EGFR-TKI in the terminal stage for non-small cell lung cancer patients who initially responded to EGFR-TKI. Palliative Care Research, 2011, 6, 119-125.	0.0	0
4033	A Retrospective Study of Feasibility of Third-line or Higher Chemotherapy Using Pemetrexed in Non-squamous, Non-small Cell Lung Cancer Patients. Japanese Journal of Lung Cancer, 2011, 51, 227-232.	0.0	0
4034	Genotyping non-small cell lung cancer (NSCLC) in Latin America (LATAM).. Journal of Clinical Oncology, 2011, 29, e21155-e21155.	0.8	0
4035	HIV and Lung Cancer. , 0, , .		0
4037	Maintenance Chemotherapy Use for Advanced Non-Small Cell Lung Cancer in an Australian Cancer Centre. World Journal of Oncology, 2012, 3, 264-270.	0.6	0
4038	A Strategy for the Lung Cancer Treatment in Elderly Patients. Nihon Kikan Shokudoka Gakkai Kaiho, 2012, 63, 374-382.	0.0	0
4039	Multiple Choice Questions with explanations. , 2012, , 1-196.		0
4040	Targeted Therapies for Non-small-Cell Lung Cancer. , 2012, , 93-114.		0

#	Article	IF	Citations
4041	Efficacy and Safety of Gefitinib or Platinum plus Taxane in Egfr-Mutant Advanced Non-Small Cell Lung Cancers: A Meta-Analysis of First-Line Randomized Controlled Trials. Journal of Cancer Therapy, 2012, 03, 467-476.	0.1	0
4042	Content Validity and Feasibility of the Care Notebook to Assess Cancer-Related Quality of Life in Hawaii. Annals of Cancer Research and Therapy, 2012, 20, 68-72.	0.1	0
4043	Early and Complete Response of Bone Metastases, Documented by FDG-PET/CT Scan, in a Patient With NSCLC. World Journal of Oncology, 2012, 3, 39-41.	0.6	0
4044	Treatment of non-small cell lung cancer in the era of targeted therapy. Advances in Lung Cancer (Irvine), 2012, 01, 1-4.	0.2	0
4045	Clinical Analysis of 17 Cases Beginning Treatment with Erlotinib the Day After Terminating Gefitinib for Advanced Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2012, 52, 871-877.	0.0	0
4046	Induction of Ski Protein Expression upon Luteinization in Rat Granulosa Cells without a Change in its mRNA Expression. Journal of Reproduction and Development, 2012, 58, 254-259.	0.5	0
4047	A case of advanced lung cancer treated by surgery followed by adjuvant combination therapy of gefitinib and interleukin-2 lymphokine-activated killer cell immunotherapy. Annals of Cancer Research and Therapy, 2012, 20, 11-16.	0.1	0
4048	How Should Targeting Agents Be Used?. Japanese Journal of Lung Cancer, 2012, 52, 142-152.	0.0	1
4050	EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence. Journal of Cancer Research Updates, 0, , .	0.3	0
4051	Correlation of anaplastic lymphoma kinase overexpression and the EML4-ALK fusion gene in non-small cell lung cancer by immunohistochemical study. Biomedical Journal, 2012, 35, 309.	1.4	6
4052	First-line therapy of advanced non-small cell lung cancer with activatingEGFRmutations. , 2012, , 75-84.		0
4053	Predictive Markers in Lung Cancer. , 2013, , 43-68.		0
4055	Molecular Pathology of Lung Cancers. , 2013, , 83-94.		1
4056	Tissue Acquisition in Patients with Suspected Lung Cancer: Techniques Available to the Pulmonologist. , 2013, , 261-270.		0
4057	First-Line Treatment and the New Paradigm of Histology-Based Treatment. , 2013, , 187-200.		0
4058	FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer. World Journal of Respirology, 2013, 3, 104.	0.5	0
4060	Hsp90 Inhibitors in Clinic. RSC Drug Discovery Series, 2013, , 336-378.	0.2	0
4061	A Case of Adenosquamous Lung Carcinoma with Dermatomyositis as a Paraneoplastic Syndrome. Japanese Journal of Lung Cancer, 2013, 53, 870-875.	0.0	4

#	Article	IF	Citations
4062	Six Cases of Lung Adenocarcinoma Successfully Treated Using Alternate Day Administration of Gefitinib. Japanese Journal of Lung Cancer, 2013, 53, 25-28.	0.0	1
4063	Gefitinib Treatment for Pulmonary Sarcomatoid Carcinoma Driven by an EGFR Mutation: Two Cases. Korean Journal of Medicine, 2013, 84, 446.	0.1	0
4064	Long-term survival of more than 3 years among patients with advanced non-small cell lung cancer treated with chemotherapy. World Journal of Respirology, 2013, 3, 110.	0.5	0
4065	Reanalysis of the EGFR Mutation Status in Non-small Cell Lung Cancer Patients Without an EGFR Mutation Treated with Erlotinib. Japanese Journal of Lung Cancer, 2013, 53, 324-328.	0.0	0
4066	Usefulness of PreservCyt^|^reg; Solution as a cytological sample preservation fluid for EGFR gene mutation analysis. The Journal of the Japanese Society of Clinical Cytology, 2013, 52, 411-414.	0.0	1
4067	Advances in Lung Cancer and Treatment Research. Journal of Cancer Therapy, 2013, 04, 36-43.	0.1	1
4068	Evolving Management with Molecular-Targeted and Bone-Targeted Medicine in Patients with Advanced Non?Small Cell Lung Cancer. General Medicine (Los Angeles, Calif), 2013, 01, .	0.2	0
4069	Current Status and Future Directions of Radiotherapy and Chemotherapy for Locally Advanced Non-small Cell Lung Cancer. Nihon Kikan Shokudoka Gakkai Kaiho, 2013, 64, 359-365.	0.0	0
4070	The Genotype-Oriented Therapy Changed the Therapy Mode of Metastatic NSCLC. Advances in Clinical Medicine, 2013, 03, 5-9.	0.0	0
4071	Assessment of Diagnostic Accuracy of Bronchoalveolar Lavage Cytology in the Diagnosis of Lung Tumors and Contribution to the Classification of Non-Small Cell Lung Cancer Entities: A Retrospective Clinocopathological Study. Open Journal of Pathology, 2013, 03, 107-112.	0.0	1
4072	Are Second- and Third-Line Treatments in the Elderly Feasible?. , 2013, , 213-220.		0
4073	TYPES OF DNA DAMAGE. , 2013, , 115-118.		0
4074	Systemic Therapy for Lung Cancer. , 2013, , 125-135.		0
4075	A Retrospective Survey of Implementation Status of Non-daily Administration of Gefitinib to Control Associated Adverse Reactions. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq1 1 0.784314 rgBT /Overlock		
4076	Reinforcement of Appropriate Use of Drugs by Developing Simple Genotyping Methods and Their Clinical Application. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2013, 39, 61-76.	0.0	0
4077	Abstract PL03-04: Using functional genetics to optimize the treatment of cancer.. , 2013, , .		0
4078	Alternative drug therapies are superior to epidermal growth factor receptor -targeted chemotherapeutic drug responses in non-small cell lung cancer. Tang [humanitas Medicine], 2013, 3, 10.1-10.8.	0.2	0
4082	Signal Transduction Inhibitors of the HER Family. , 2013, , 17-50.		0

#	Article	IF	Citations
4083	Longcarcinoom. , 2014, , 117-124.		0
4084	A Case of Favorable Responses after Gefitinib in a Patient with EGFR Mutated Adenosquamous Lung Carcinoma. Soonchunhyang Medical Science, 2013, 19, 123-127.	0.0	0
4085	A Phase II Study of Erlotinib in Patients with Previously Treated Non-Small Cell Lung Cancer. Advances in Lung Cancer (Irvine), 2014, 03, 10-20.	0.2	0
4086	Molecular Testing in Pulmonary Tumors. , 2014, , 211-228.		0
4087	Transitioning Diagnostic Molecular Pathology to the Genomic Era: Cancer Somatic Mutation Panel Testing. , 2014, , 3-13.		0
4089	Two Cases of Synchronous Multiple Lung Cancer Harboring Different Mutations; EGFR or ALK. Japanese Journal of Lung Cancer, 2014, 54, 146-152.	0.0	1
4090	Current status and perspectives of molecular target therapy for advanced lung cancer. Nihon Koku Geka Gakkai Zasshi, 2014, 60, 328-334.	0.0	0
4091	Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung. Journal of Cancer Therapy, 2014, 05, 1012-1020.	0.1	1
4092	EGFR-Targeted Therapies in Non-small Cell Lung Cancer. , 2014, , 31-66.		0
4093	PAÅ½ENGUSI AR METASTAZAVUSI PLAUÄŒIÅ² ADENOKARCINOMOS SU VYRAUJANÄŒIA EGFR MUTACIJA. GYDYMO PATIRTIS IR NEPAGEIDAUJAMI REIÅKINIAI. Health Sciences, 2014, 24, 35-38.	0.0	0
4094	Research Methods for Clinical Trials in Personalized Medicine: A Systematic Review. , 2014, , 659-684.		1
4095	Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line. Experimental and Therapeutic Medicine, 2019, 18, 3793-3800.	0.8	6
4098	Strategy on Patients with EGFR Mutation. , 2015, , 133-145.		0
4099	Advances in Radiotherapy for Locally Advanced NSCLC. , 2015, , 69-94.		0
4100	Distribution of EGFR Mutations Commonly Observed in Primary Lung Adenocarcinomas in Pakistan as Predictors for Targeted Therapy. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7125-7128.	0.5	3
4101	Management of Metastatic Bladder Tumours. , 2015, , 627-646.		0
4102	Development and Current Situation of Treatment for Patients with Acquired Resistance to EGFR-TKIs. Japanese Journal of Lung Cancer, 2015, 55, 932-935.	0.0	0
4104	Next-Generation Sequencing in the Era of Cancer-Targeted Therapies: Towards the Personalised Medicine. , 2015, , 39-55.		0

#	Article	IF	Citations
4105	Molecular targeted therapy of lung cancer. Tenri Medical Bulletin, 2015, 18, 75-79.	0.1	0
4106	Clinical Benefits Associated with First Line Treatment Using Afatinib. Japanese Journal of Lung Cancer, 2015, 55, 866-870.	0.0	0
4107	Evaluation of Patient Education System to Improve Their Understanding in Patients Treated with Erlotinib or Gefitinib. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2015, 41, 566-577.	0.0	0
4108	Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation. Journal of Cancer Therapy, 2015, 06, 1214-1222.	0.1	0
4109	Therapy options for advanced NSCLC. , 2015, , 5-25.		0
4110	Targeted Therapies for Non-Small Cell Lung Cancer. Current Clinical Pathology, 2015, , 89-101.	0.0	1
4111	Frequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia. Asian Pacific Journal of Cancer Prevention, 2015, 16, 689-692.	0.5	6
4112	Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. Oncotarget, 2015, 6, 25452-25465.	0.8	3
4113	Abstract 756: Inhibition of ABCB1 overcomes cancer stem cell-like properties and acquired resistance to MET inhibitor in non-small cell lung cancer. , 2015, , .		0
4114	14. Molecular Target Therapy for Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 128b-129a.	0.0	0
4115	ã‚¨ãƒ“ãƒ‡ãƒ³ã‚¹ã‚’ã‚‚ã¾ã¨ã‚ãŸEGFR-TKIã®ä½¿ã„æ–¹. Japanese Journal of Lung Cancer, 2016, 56, 985-987.	0.0	0
4116	Genetic Testing in Lung Cancer Treatment. Japanese Journal of Lung Cancer, 2016, 56, 242-245.	0.0	0
4117	14. Molecular Target Therapy for Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1840-1848.	0.0	0
4118	VII. Developments of Chemotherapy and Improvements of Prognosis in Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 997-1003.	0.0	0
4119	Disparities in Lung Cancer Outcomes. Respiratory Medicine, 2016, , 237-264.	0.1	1
4120	Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer. Korean Journal of Medicine, 2016, 90, 1-6.	0.1	1
4122	The Efficacy and Safety of Gefitinib in Elderly Patients with Epidermal Growth Factor Receptor Mutation-positive Advanced Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2016, 56, 177-182.	0.0	0
4123	Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 179-188.	0.1	0

#	Article	IF	Citations
4124	Hapten Improved Overall Survival Benefit in Late Stages of Non-Small Cell Lung Cancer (NSCLC) by Ultra-Minimum Incision Personalized Intratumoral Chemo Immunotherapy (UMIPIC) Therapy With and without Radiation Therapy. Journal of Cancer Prevention & Current Research, 2016, 4, .	0.1	0
4125	Strategies for power calculations in predictive biomarker studies in survival data. Oncotarget, 2016, 7, 80373-80381.	0.8	4
4126	Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 242-250.	0.1	3
4127	Management Strategies for Adverse Events Associated With EGFR TKIs in Nonâ€“Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.2	6
4128	EGFR-TKI Versus Chemotherapy for Previously Untreated Advanced Non-Small Cell Lung Cancer in Asians: A Meta-Analysis. The Showa University Journal of Medical Sciences, 2017, 29, 435-443.	0.1	0
4129	Effect of Coadministration of Gastric Acid-suppressing Drugs on the Safety and Efficacy of EGFR-TKIs in Patients with <i>EGFR</i> Mutation-positive Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2017, 57, 190-195.	0.0	0
4130	The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis. Open Journal of Genetics, 2017, 07, 117-129.	0.1	0
4131	The Role of Angiogenesis in Non-small Cell Lung Cancer Tumor Behavior. , 2017, , 217-239.		0
4132	Methods in Molecular Diagnosis. , 2017, , 63-77.		0
4133	Companion Diagnostics. , 2017, , 117-136.		0
4134	Gene Signature. , 2017, , 279-292.		1
4135	EGFR Mutant. , 2017, , 167-189.		0
4136	Saudi lung cancer management guidelines 2017: Improving lung cancer care in Saudi region. Annals of Thoracic Medicine, 2017, 12, 219.	0.7	0
4137	Minor-Driver Mutant. , 2017, , 199-212.		0
4138	Clinical outcome of posterior fixation surgery in patients with vertebral metastasis of lung cancer. Molecular and Clinical Oncology, 2017, 6, 770-774.	0.4	1
4139	Upfront radiation versus EGFR-TKI: which is the best approach for EGFR-mutated NSCLC patients with brain metastasis?. Translational Cancer Research, 2017, 6, S533-S536.	0.4	0
4140	2. State of the Art of EGFR-TKI and Future Perspectives. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1096-1100.	0.0	0
4141	I. Diagnosis of the Molecular Aberrations in Non-small Cell Cancer. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1082-1088.	0.0	0

#	Article	IF	Citations
4143	Analysis of Evolving Clinicopathological Features of Metastatic Brain Tumors Over 30 Years of Surgical Management. Anticancer Research, 2017, 37, 3969-3974.	0.5	0
4144	Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS). Molecular Pathology Library, 2018, , 93-108.	0.1	0
4145	5. Present State of Molecular Target Drug for Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1910-1915.	0.0	0
4146	Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs. , 2017, 37, 5771-5776.		11
4147	AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES. Meditsinskiy Sovet, 2017, , 46-55.	0.1	0
4148	Frameless stereotactic radiosurgery for brain metastases: a review of outcomes and prognostic scores evaluation. Hong Kong Medical Journal, 2017, 23, 599-608.	0.1	3
4149	Receptor Tyrosine Kinases in Human Platelets: A Review of Expression, Function and Inhibition in Relation to the Risk of Bleeding or Thrombocytopenia from Phase I through Phase III Trials. Journal of Cancer Prevention & Current Research, 2017, 8, .	0.1	1
4150	Pathology of Lung Cancer. , 2018, , 9-22.		0
4151	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493.	0.1	0
4152	Targeted therapy in cancer. Oncolog-Hematolog Ro, 2018, 3, 13.	0.0	0
4153	Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer. Anticancer Research, 2018, 38, 2385-2390.	0.5	1
4154	the Japanese Society of Internal Medicine, 2018, 107, 396-402.	0.0	0
4156	Transition Rate from EGFR-TKI to Cytotoxic Chemotherapy Patients with EGFR Mutation-positive Lung Adenocarcinoma. Anticancer Research, 2018, 38, 3127-3132.	0.5	1
4158	Detecting EGFR mutations in patients with non-small cell lung cancer. Balkan Journal of Medical Genetics, 2018, 21, 13-17.	0.5	3
4159	New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors. Journal of Modern Oncology, 2018, 20, 50-54.	0.1	0
4160	Tratamiento de cÃ¡ncer de pulmÃ³n metastÃ¡sico (estadio IV) de cÃ©lula no pequeÃ±a : consenso de expertos, AsociaciÃ³n Colombiana de HematologÃa y OncologÃa (ACHO).. Revista Colombiana De Hematologìa Y Oncologìa, 2018, 5, 61-71.	0.0	1
4161	Non-small-cell lung cancer (NSCLC) harboring driver mutation (EGFR mutation or ALK translocations) with clinical characteristics and management in a real-life setting: a retrospective observational multicenter case series study. OrtadoÄŸu TÄ±p Dergisi, 2018, 10, 361-367.	0.1	0
4162	The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Đ¢790Đœ mutation to anti-EGFR drugs in non-small cell lung cancer. Journal of Modern Oncology, 2018, 20, 10-18.	0.1	0

#	Article	IF	Citations
4163	Molecular Targeted Therapy of Lung Cancer. Nihon Ika Daigaku Igakkai Zasshi, 2018, 14, 177-179.	0.0	0
4164	The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice. Uspehi Molekularnoj Onkologii, 2018, 5, 17-24.	0.1	0
4165	Proteomics for Cancer: Approaches and Challenges. , 2019, , 343-368.		0
4166	Non small cell lung cancer with targetable driver alterations: Imaging perspective. Integrative Cancer Science and Therapeutics, 2019, 6, .	0.1	0
4167	Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma. Indian Journal of Pathology and Microbiology, 2019, 62, 566.	0.1	0
4168	Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland â€“ Real-World Data. Archives of Medical Science, 2019, 17, 1618-1627.	0.4	2
4169	Icotinib inhibits proliferation and epithelial-mesenchymal transition of non-small cell lung cancer A549 cells. Mathematical Biosciences and Engineering, 2019, 16, 7707-7718.	1.0	4
4171	Intensive Care Unit Model of Modern Hospital: Genomically Oriented and Biology-Based. , 2019, , 293-301.		0
4172	The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis. Mathematical Biosciences and Engineering, 2019, 16, 7921-7933.	1.0	2
4173	Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer. Cancer Research Statistics and Treatment, 2019, 2, 21.	0.1	0
4174	Cancer Clinical Trials Based on Master Protocol. Japanese Journal of Biometrics, 2019, 39, 85-101.	0.0	1
4175	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
4176	Possibilities of consistent targeted therapy for EGFR-positive NSCLC. Clinical case. Onkologiya Zhurnal Imeni P A Gertsena, 2019, 8, 289.	0.0	0
4178	Experiencia Con Erlotinib Y Gefitinib En Pacientes Con CÃ¡ncer De PulmÃ³n Avanzado Con MutaciÃ³n Positiva En El Receptor De Factor De Crecimiento EpidÃ©rmico.. Revista Medica De Panama, 2019, 38, .	0.0	0
4179	Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. Asian Pacific Journal of Cancer Prevention, 2019, 20, 2415-2420.	0.5	1
4180	Carcinoembryonic antigen in pleural effusion of patients with lung adenocarcinoma: a predictive marker for EGFR mutation. Translational Cancer Research, 2019, 8, 1027-1034.	0.4	1
4181	Menin: Expanding and dichotomous roles in cancer. Oncoscience, 2019, 6, 368-370.	0.9	3
4182	EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan. Oncology Letters, 2019, 18, 6090-6100.	0.8	3

#	Article	IF	Citations
4184	Tratamiento de cÃ¡ncer de pulmÃ³n metastÃ¡sico (estadio IV) : segundo consenso de expertos, AsociaciÃ³n Colombiana de HematologÃa y OncologÃa (ACHO), 2019.. Revista Colombiana De Hematologìa Y Oncologìa, 2019, 6, 10-22.	0.0	0
4185	Traitement des cancers bronchiques non Ã petites cellules de stades avancÃ©s mutÃ©s EGFR: quelle(s) sÃ©quence(s) ?. Revue Des Maladies Respiratoires Actualites, 2019, 11, 364-379.	0.0	0
4186	Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR. Translational Cancer Research, 2019, 8, 2858-2863.	0.4	5
4187	Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?. Translational Cancer Research, 2019, 8, S633-S635.	0.4	1
4188	Reviews on the Hepatotoxicity of Tyrosine Kinase Inhibitors. Korean Journal of Clinical Pharmacy, 2019, 29, 223-230.	0.0	0
4190	Exosomal Long NonCoding Rnas as Cancer Biomarkers and Therapeutic Targets. KreativnaÃ¢ HirurgiÃ¢ I OnkologiÃ¢, 2020, 9, 297-304.	0.1	2
4191	Systemic Therapy of Brain Metastases: Lung Cancer. , 2020, , 207-217.		0
4192	Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice. Journal of Toxicological Sciences, 2020, 45, 493-502.	0.7	1
4193	Next Generation of Advanced Non-Small Cell Lung Cancer Therapy: Targeted and Immuno-Therapies. International Journal of Medical Students, 2020, 8, 26-32.	0.2	0
4194	Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study. European Journal of Clinical Pharmacology, 2020, 76, 1183-1191.	0.8	6
4195	Developing Pathology Measures for the Quality Payment Programâ€"Part I: A Quest for Meaningful Measures. Archives of Pathology and Laboratory Medicine, 2020, 144, 686-696.	1.2	2
4196	Role of imaging biomarkers in mutation-driven non-small cell lung cancer. World Journal of Clinical Oncology, 2020, 11, 412-427.	0.9	4
4197	Progress in individualized treatment for <i>EGFR</i>-mutated advanced non-small cell lung cancer. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2020, 96, 266-272.	1.6	4
4198	Predictive factors of the 30-day mortality after surgery for spinal metastasis: Analysis of a nationwide database. Journal of Orthopaedic Science, 2021, 26, 666-671.	0.5	4
4200	Implications of the success of EGFR-targeted therapy in advanced nonâ€"small cell lung cancer for its application to the adjuvant setting. Journal of Thoracic Disease, 2020, 12, 4553-4555.	0.6	0
4201	Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study. EJNMMI Research, 2020, 10, 97.	1.1	11
4202	Efficacy of gefitinib in patients with advanced non-small cell carcinoma of the lung harboring common, uncommon and complex EGFR mutations. Clinical Cancer Drugs, 2021, 08, .	0.3	0
4203	Evaluation Expression of miR-146a and miR-155 in Non-Small-Cell Lung Cancer Patients. Frontiers in Oncology, 2021, 11, 715677.	1.3	7

#	Article	IF	Citations
4205	Testing for Driver Oncogenes is Essential for the Optimal Treatment of Advanced Non-small-cell Lung Cancer. Juntendo Medical Journal, 2020, 66, 403-409.	0.1	0
4206	Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma. Radiology and Oncology, 2020, 55, 66-76.	0.6	4
4208	OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS. Siberian Journal of Oncology, 2020, 19, 119-125.	0.1	0
4210	Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study. Translational Cancer Research, 2020, 9, 7562-7571.	0.4	0
4211	The Role of 18F-FDG-PET as Therapeutic Monitoring in Patients with Lung Cancer. , 2021, , 23-33.		0
4212	Development of Molecularly Targeted Agents in Early Phase Clinical Trials. , 2020, , 199-220.		0
4214	The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study. European Clinical Respiratory Journal, 2021, 8, 1984375.	0.7	0
4215	Tratamiento de cÃ¡ncer de pulmÃ³n metastÃ¡sico (estadio IV) : segundo consenso de expertos, AsociaciÃ³n Colombiana de HematologÃa y OncologÃa (ACHO), 2019.. Revista Colombiana De Hematologiıa Y Oncologiıa, 2019, 6, 10-22.	0.0	0
4216	Leptomeningeal Disease in Solid Cancers. , 2020, , 409-427.		0
4218	Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, <i>EGFR</i>-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study. SSRN Electronic Journal, 0, , .	0.4	3
4220	Experience with Large Panel Next-generation Sequencing in Patients with Advanced Solid Cancers at Juntendo University Hospital. Juntendo Medical Journal, 2020, 66, 392-402.	0.1	0
4221	Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with <i>BIM</i> deletion polymorphism. Journal of Medical Investigation, 2020, 67, 343-350.	0.2	3
4223	Critical Review of EGFR-Mutated NSCLC: What We Do and Do Not Know. Healthbook TIMES Oncology Hematology, 2020, , 20-35.	0.1	3
4224	Epidermal growth factor receptor variants in patients from Myanmar with lung adenocarcinoma. Asian Biomedicine, 2020, 14, 75-81.	0.2	1
4225	Updated Genomic Medicine for Lung Cancer: The Clinical Usefulness and Future Issues Associated with Analytical Technologies for Cell-free DNA in Peripheral Blood. Japanese Journal of Lung Cancer, 2020, 60, 90-98.	0.0	1
4226	Computer-aided molecular modeling studies of some 2, 3-dihydro-[1, 4] dioxino [2, 3-f] quinazoline derivatives as EGFRWT inhibitors. Beni-Suef University Journal of Basic and Applied Sciences, 2020, 9, .	0.8	5
4227	Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2589-2598.	1.2	9
4228	Advances in systemic therapy for non-small cell lung cancer. BMJ, The, 2021, 375, n2363.	3.0	134

#	Article	IF	Citations
4229	Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics. Acta Pharmacologica Sinica, 2022, 43, 1857-1864.	2.8	1
4230	Prognostic Value ofEGFRExon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 5625-5634.	0.5	1
4231	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Nonâ€“Small-Cell Lung Cancer With EGFR Mutation (IMPACT). Journal of Clinical Oncology, 2022, 40, 231-241.	0.8	61
4232	Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer, 2021, 162, 154-161.	0.9	24
4233	Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China. Cancer Management and Research, 2021, Volume 13, 8297-8306.	0.9	6
4234	Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutationâ€“positive nonâ€“small-cell lung cancer in a real-world setting (OSI-FACT). European Journal of Cancer, 2021, 159, 144-153.	1.3	33
4235	Sequencing Therapy for Patients With Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 945-948.	2.3	0
4236	Molecular pathology. , 0, , 95-118.		2
4237	Achievements in targeted therapies. , 0, , 215-233.		0
4238	Multiple Choice Questions with explanations. , 0, , 1-544.		0
4239	Question 180. , 0, , 373-374.		0
4240	Tyrosine kinase inhibitors in the treatment of advanced lung cancer from example of preferential medicine provision in Moscow city. Pulmonologiya, 2020, 30, 463-472.	0.2	1
4241	Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists. Current Respiratory Medicine Reviews, 2020, 16, 5-10.	0.1	0
4244	MiRNAs: A New Approach to Predict and Overcome Resistance to Anticancer Drugs. Clinical Cancer Drugs, 2020, 7, 65-77.	0.3	0
4245	Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer. Journal of Thoracic Disease, 2015, 7, 875-80.	0.6	10
4246	EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population. Journal of Thoracic Disease, 2012, 4, 219-20.	0.6	10
4247	A time to test, a time to treat. Journal of Thoracic Disease, 2012, 4, 223-5.	0.6	3
4249	First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?. Translational Lung Cancer Research, 2012, 1, 219-23.	1.3	5

#	Article	IF	Citations
4250	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. Annals of Translational Medicine, 2015, 3, 81.	0.7	9
4251	Biomarkers in the selection of maintenance therapy in non-small cell lung cancer. Translational Lung Cancer Research, 2012, 1, 96-8.	1.3	10
4252	Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. P and T, 2011, 36, 263-79.	1.0	21
4253	Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer. Journal of Thoracic Disease, 2011, 3, 141-3.	0.6	1
4255	Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ontario Health Technology Assessment Series, 2010, 10, 1-48.	3.0	23
4256	Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?. Journal of Thoracic Disease, 2012, 4, 226-8.	0.6	2
4257	Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts. , 2012, 3, 438-43.		4
4258	Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 90-4.	0.7	18
4259	Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. Cancer Biology and Medicine, 2012, 9, 38-43.	1.4	0
4261	EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2014, 7, 1967-78.	1.3	16
4262	Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition). Journal of Thoracic Disease, 2014, 6, 1489-98.	0.6	2
4263	Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines. International Journal of Clinical and Experimental Pathology, 2014, 7, 7304-11.	0.5	8
4264	Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies. International Journal of Clinical and Experimental Medicine, 2014, 7, 3833-42.	1.3	4
4265	Expanding options for EGFR targeting in lung cancer. Translational Lung Cancer Research, 2012, 1, 287-8.	1.3	3
4266	Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC. Translational Lung Cancer Research, 2012, 1, 224-6.	1.3	0
4267	Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. Translational Lung Cancer Research, 2012, 1, 227-9.	1.3	0
4268	EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMation. Translational Lung Cancer Research, 2012, 1, 160-2.	1.3	0
4269	Advances on EGFR mutation for lung cancer. Translational Lung Cancer Research, 2012, 1, 5-13.	1.3	46

#	Article	IF	Citations
4270	EGFR-TKIs in EGFR-mutated lung cancer: Setting the new standard for 1(st) line therapy. Translational Lung Cancer Research, 2012, 1, 3-4.	1.3	3
4271	Management of elderly patients. Translational Lung Cancer Research, 2013, 2, 200-7.	1.3	1
4272	Personalized maintenance therapy in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2013, 2, 452-6.	1.3	0
4273	Keeping our fingers crossed on 2(nd) generation EGFR TKIs: is better good enough?. Translational Lung Cancer Research, 2013, 2, 55-7.	1.3	0
4274	MET inhibition in lung cancer. Translational Lung Cancer Research, 2013, 2, 23-39.	1.3	11
4275	10(th) Congress on Lung Cancer-updates on clinical trials: goal. Translational Lung Cancer Research, 2014, 3, 66-9.	1.3	1
4276	Sarcomatous transformation of EGFR and TP53 mutation-positive metastatic adenocarcinoma of the lungs, masquerading as a primary pleomorphic sarcoma of the proximal femur. International Journal of Clinical and Experimental Pathology, 2015, 8, 3270-8.	0.5	4
4277	Mutation of the epidermal growth factor receptor gene and its impact on the efficacy of gefitinib in advanced non-small cell lung cance. International Journal of Clinical and Experimental Medicine, 2015, 8, 5397-405.	1.3	2
4278	Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. Cancer Biology and Medicine, 2015, 12, 126-39.	1.4	20
4279	Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. American Journal of Translational Research (discontinued), 2015, 7, 1126-39.	0.0	23
4280	Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 10330-9.	1.3	19
4281	Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells. International Journal of Clinical and Experimental Pathology, 2015, 8, 9010-20.	0.5	9
4282	Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 11278-86.	0.5	2
4283	Pemetrexed and cyclophosphamide combination therapy for the treatment of non-small cell lung cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 14693-700.	0.5	4
4284	Predictive potential role of GSTs gene polymorphisms in the treatment outcome of advanced non-small cell lung cancer patients. International Journal of Clinical and Experimental Medicine, 2015, 8, 20918-24.	1.3	4
4285	Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy. Journal of Thoracic Disease, 2016, 8, 116-23.	0.6	1
4286	Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysis. Journal of Thoracic Disease, 2016, 8, 98-115.	0.6	7
4287	Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Thoracic Disease, 2016, 8, 68-78.	0.6	6

#	Article	IF	Citations
4288	Afatinib in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2015, 6, 448-55.	0.2	6
4289	Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya Journal of Medical Science, 2012, 74, 133-40.	0.6	34
4290	Role of epidermal growth factor receptor in lung cancer and targeted therapies. American Journal of Cancer Research, 2017, 7, 187-202.	1.4	43
4291	DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair. Yonago Acta Medica, 2017, 60, 9-15.	0.3	20
4292	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?. Lung India, 2017, 34, 405-408.	0.3	1
4293	Molecular Targets in Non-Small Cell Lung Cancer. Ochsner Journal, 2017, 17, 388-392.	0.5	20
4294	Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, 723-735.	0.2	4
4336	Impaired Liver Function Implied Shorter Progression Free Survival for EGFR Tyrosine Kinase Inhibitors. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2177-2181.	0.5	1
4340	Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSF1A and GADD45Î² promoter. International Journal of Clinical and Experimental Pathology, 2019, 12, 4002-4010.	0.5	7
4342	Cell-Free Circulating Tumour DNA Blood Testing to Detect T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2020, 20, 1-176.	3.0	7
4344	Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells. Oncology Letters, 2020, 20, 206.	0.8	5
4346	Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status. Journal of Thoracic Disease, 2020, 12, 5505-5516.	0.6	0
4347	Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with sensitizing mutations. American Journal of Cancer Research, 2020, 10, 4266-4286.	1.4	4
4349	Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. American Journal of Cancer Research, 2021, 11, 3189-3200.	1.4	1
4350	Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant Brain Metastasis and Spinal Cord Metastasis Models. Frontiers in Pharmacology, 2021, 12, 750031.	1.6	2
4351	Metal Organic Framework Nanomaterial-Based Extraction and Proteome Analysis of Membrane and Membrane-Associated Proteins. Analytical Chemistry, 2021, 93, 15922-15930.	3.2	1
4352	DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. Cancers, 2021, 13, 5974.	1.7	9
4353	A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. Cancer Management and Research, 2021, Volume 13, 8695-8705.	0.9	8

#	Article	IF	Citations
4354	Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. BMC Cancer, 2021, 21, 1247.	1.1	3
4355	A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 105-115.	1.1	10
4356	First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002). Scientific Reports, 2021, 11, 23140.	1.6	15
4357	Identification of lncRNAâ€“miRNAâ€“mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor. Frontiers in Genetics, 2021, 12, 758591.	1.1	4
4358	Fracture Risk Evaluation of Bone Metastases: A Burning Issue. Cancers, 2021, 13, 5711.	1.7	10
4359	First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. Investigational New Drugs, 2022, 40, 430-437.	1.2	8
4360	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. Medicina (Lithuania), 2021, 57, 1252.	0.8	5
4361	Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation. European Journal of Medicinal Chemistry, 2022, 228, 113984.	2.6	8
4362	Advances in the diagnosis, evaluation, and management of leptomeningeal disease. Neuro-Oncology Advances, 2021, 3, v86-v95.	0.4	10
4363	Community oncologistsâ€™ perceptions and utilization of large-panel genomic tumor testing. BMC Cancer, 2021, 21, 1273.	1.1	6
4364	Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1â€“STAT1 loop in lung adenocarcinoma. Cancer Science, 2022, 113, 205-220.	1.7	10
4365	Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive nonâ€“small cell lung cancer. European Journal of Cancer, 2022, 160, 227-234.	1.3	5
4366	Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance. Cells, 2021, 10, 3192.	1.8	17
4367	MicroRNA-214 in Health and Disease. Cells, 2021, 10, 3274.	1.8	20
4368	First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status. Future Oncology, 2022, 18, 291-300.	1.1	4
4369	The Impact of Core Tissues on Successful Next-Generation Sequencing Analysis of Specimens Obtained through Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. Cancers, 2021, 13, 5879.	1.7	4
4370	Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model. Acta Pharmacologica Sinica, 2022, 43, 1865-1874.	2.8	3
4371	Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer. Cancers, 2021, 13, 5639.	1.7	13

#	Article	IF	Citations
4372	Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis. Journal of Modern Oncology, 2021, 23, 408-417.	0.1	0
4373	Patientâ€derived organoids as a preclinical platform for precision medicine in colorectal cancer. Molecular Oncology, 2022, 16, 2396-2412.	2.1	17
4374	Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations. Translational Lung Cancer Research, 2021, 10, 4120-4129.	1.3	6
4375	Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program. Cancer Discovery, 2022, 12, 938-948.	7.7	19
4376	Lungenkarzinom: Was bei Frauen anders ist. , 0, , .		1
4377	Trastuzumab emtansine for patients with nonâ€“small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. European Journal of Cancer, 2022, 162, 99-106.	1.3	30
4378	AIR-Net: A novel multi-task learning method with auxiliary image reconstruction for predicting EGFR mutation status on CT images of NSCLC patients. Computers in Biology and Medicine, 2022, 141, 105157.	3.9	4
4379	Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer. ESMO Open, 2022, 7, 100347.	2.0	4
4380	Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptorâ€tyrosine kinase inhibitor via the PI3K/AKT pathway in nonâ€small cell lung cancer cells in vitro. Oncology Letters, 2020, 20, 1-1.	0.8	6
4381	Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status. Journal of Thoracic Disease, 2020, 12, 5505-5516.	0.6	0
4383	Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations. Healthbook TIMES Oncology Hematology, 2020, , .	0.1	3
4384	Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma. Translational Cancer Research, 2020, 9, 6683-6690.	0.4	7
4385	Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report. Case Reports in Oncology, 2022, 14, 1447-1453.	0.3	1
4386	Treatment with immune checkpoint inhibitors after EGFRâ€TKIs in EGFR â€mutated lung cancer. Thoracic Cancer, 2022, 13, 386-393.	0.8	8
4387	Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Nonâ€“Small Cell Lung Cancer Patients Treated with Osimertinib. Tuberculosis and Respiratory Diseases, 2022, 85, 155-164.	0.7	5
4389	A Need for More Molecular Profiling in Brain Metastases. Frontiers in Oncology, 2021, 11, 785064.	1.3	1
4390	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFRâ€T790M mutation in nonâ€small cell lung cancer cells. Cancer Medicine, 2022, 11, 944-955.	1.3	5
4391	Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). Oncologist, 2022, 27, 255-265.	1.9	13

#	Article	IF	Citations
4392	Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study. BMJ Open, 2022, 12, e046451.	0.8	2
4393	Successful desensitization under antihistamine suppression in a case with urticaria due to osimertinib. Journal of Oncology Pharmacy Practice, 2022, , 107815522210758.	0.5	1
4394	Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer. Lung Cancer, 2022, 166, 9-16.	0.9	15
4395	New <scp>PET</scp>/<scp>CT</scp> criterion for predicting lymph node metastasis in resectable advanced (stage <scp>IBâ€‖</scp>) lung cancer: The standard uptake values ratio of ipsilateral/contralateral hilar nodes. Thoracic Cancer, 2022, 13, 708-715.	0.8	6
4396	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. Journal of Clinical Oncology, 2022, 40, 611-625.	0.8	242
4397	First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study. Japanese Journal of Clinical Oncology, 2022, 52, 405-410.	0.6	5
4398	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-NaÃ¯ve Patients withÂEGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. Targeted Oncology, 2022, 17, 1-13.	1.7	6
4399	Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study. Cancer Treatment and Research Communications, 2022, 31, 100526.	0.7	1
4400	Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma. Cancers, 2022, 14, 674.	1.7	10
4401	A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed. Anticancer Research, 2022, 42, 709-722.	0.5	6
4402	Cytologyâ€“Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Nonâ€“Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 810124.	1.3	2
4403	Clinical characteristics of nonâ€small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions. Clinical Respiratory Journal, 2022, 16, 216-225.	0.6	4
4404	Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell Reports, 2022, 38, 110291.	2.9	7
4405	Plasmodium Circumsporozoite Protein Enhances the Efficacy of Gefitinib in Lung Adenocarcinoma Cells by Inhibiting Autophagy via Proteasomal Degradation of LC3B. Frontiers in Cell and Developmental Biology, 2022, 10, 830046.	1.8	2
4406	Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 772770.	1.3	8
4407	Effects of Ethnicity on Outcomes of Patients With EGFR Mutationâ€“Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection. JTO Clinical and Research Reports, 2022, 3, 100259.	0.6	1
4408	Study on First-Generation TKIs in the Treatment of Patients with Unresectable EGFR-Mutation-Positive Non-Small-Cell Lung Cancer. Advances in Clinical Medicine, 2022, 12, 761-770.	0.0	0
4409	A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. Lung Cancer, 2022, 166, 98-106.	0.9	1

#	Article	IF	Citations
4410	Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resectedEGFR-mutated non-small-cell lung cancer: a meta-analysis. Future Oncology, 2022, 18, 1159-1169.	1.1	6
4411	The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2022, 12, 843299.	1.3	6
4412	Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis. PLoS ONE, 2022, 17, e0263629.	1.1	11
4413	Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/Î²-Catenin activity and cancer stemness. Cancer Letters, 2022, 531, 83-97.	3.2	27
4414	Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer. Scientific Reports, 2022, 12, 2167.	1.6	18
4415	Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 661-671.e4.	0.4	6
4416	A Randomized Phase II Study Comparing Nivolumab with Carboplatinâ€“Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical Cancer Research, 2022, 28, 893-902.	3.2	35
4417	â€œHow Long Have I Got?â€•in Stage IV NSCLC Patients With at Least 3ÂMonths Up to 10ÂYears Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question. Frontiers in Oncology, 2021, 11, 761042.	1.3	9
4422	Neurological complications of lung cancer. , 2022, , 243-276.		0
4423	Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial. Integrative Cancer Therapies, 2022, 21, 153473542210866.	0.8	4
4424	A Case of Advanced Gastric Cancer That Was Difficult to Treat During Chemotherapy for Advanced Lung Cancer. Journal of the Japanese Association of Rural Medicine, 2022, 70, 504-509.	0.0	0
4425	STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. Npj Precision Oncology, 2022, 6, 11.	2.3	8
4426	Imaging Biomarkers in Thoracic Oncology: Current Advances in the Use of Radiomics in Lung Cancer Patients and its Potential Use for Therapy Response Prediction and Monitoring. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2022, , .	0.7	0
4427	Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI. Cancers, 2022, 14, 977.	1.7	12
4428	The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib. Clinical Drug Investigation, 2022, 42, 221-235.	1.1	1
4429	Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study. Journal of Thoracic Oncology, 2022, 17, 708-717.	0.5	11
4430	FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy. Acta Pharmaceutica Sinica B, 2022, 12, 3639-3649.	5.7	4
4431	Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer. International Journal of Clinical Oncology, 2022, , 1.	1.0	0

#	Article	IF	Citations
4432	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. Molecular Cancer, 2022, 21, 61.	7.9	6
4433	Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib. Medical Journal of the Islamic Republic of Iran, 0, , .	0.9	0
4434	Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy. Current Oncology Reports, 2022, 24, 475-491.	1.8	4
4435	Saiseigakusha, the Predecessor of Nippon Medical School: Philosophy of Saisei-Kyumin and Associates of Tai Hasegawa. Nihon Ika Daigaku Igakkai Zasshi, 2022, 18, 86-97.	0.0	0
4436	Palliative Systemic Therapy Given near the End of Life for Metastatic Non-Small Cell Lung Cancer. Current Oncology, 2022, 29, 1316-1325.	0.9	3
4437	LIMK2 Is a Novel Prognostic Biomarker and Correlates With Tumor Immune Cell Infiltration in Lung Squamous Cell Carcinoma. Frontiers in Immunology, 2022, 13, 788375.	2.2	6
4438	A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma. Translational Lung Cancer Research, 2022, 11, 238-249.	1.3	7
4439	The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. Cancers, 2022, 14, 1143.	1.7	23
4440	Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation. European Radiology, 2022, 32, 5869-5879.	2.3	17
4441	Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial). Japanese Journal of Clinical Oncology, 2022, , .	0.6	2
4442	EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature. Translational Lung Cancer Research, 2022, 11, 497-503.	1.3	2
4443	Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib. Journal of International Medical Research, 2022, 50, 030006052110588.	0.4	5
4444	Real-world Afatinib Outcomes in Advanced Nonâ€“small Cell Lung Cancer Harboring EGFR Mutations. Anticancer Research, 2022, 42, 2145-2157.	0.5	10
4445	Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients. Cancer Management and Research, 2022, Volume 14, 863-873.	0.9	4
4446	Medical Affairs and Innovative Medicinal Product Strategy Development. Pharmaceutical Medicine, 2022, 36, 71.	1.0	1
4447	Potential treatment strategy for the rare osimertinib resistant EGFR L718Q mutation. Journal of Thoracic Disease, 2022, 14, 599-601.	0.6	0
4448	Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells. PLoS ONE, 2022, 17, e0264717.	1.1	9
4449	Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancerâ€”is there a â€œtail plateauâ€•in the survival curve of these patients?. BMC Cancer, 2022, 22, 323.	1.1	12

#	Article	IF	Citations
4450	Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated with First-Line EGFR-TKIs: A Large Population-Based Study and Literature Review. International Journal of General Medicine, 2022, Volume 15, 3405-3416.	0.8	3
4451	miRNAâ€˜218 targets multiple oncogenes and is a therapeutic target for osteosarcoma. Oncology Reports, 2022, 47, .	1.2	2
4452	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 869672.	1.3	30
4453	ORIENT-31 as the Sakigake â€œCharging Samuraiâ€•Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the â€œMeiji Modernizationâ€•of Post-3G EGFR TKI Progression?. Lung Cancer: Targets and Therapy, 2022, Volume 13, 13-21.	1.3	2
4454	Radiationâ€˜induced enterocolitis after combination therapy with palliative radiotherapy and immune checkpoint inhibitors in patients with metastatic lung cancer. Experimental and Therapeutic Medicine, 2022, 23, 336.	0.8	2
4455	MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells. Cell Communication and Signaling, 2022, 20, 27.	2.7	12
4456	Circular RNA ZNF609 promotes laryngeal squamous cell carcinoma progression by upregulating epidermal growth factor receptor via sponging microRNA-134-5p. Bioengineered, 2022, 13, 6929-6941.	1.4	8
4457	Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer. Egyptian Journal of Bronchology, 2022, 16, .	0.3	0
4458	Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer. Current Oncology, 2022, 29, 1902-1918.	0.9	5
4459	Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials. BMC Cancer, 2022, 22, 328.	1.1	16
4460	Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC. Cancers, 2022, 14, 1465.	1.7	0
4461	A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. European Journal of Cancer, 2022, 165, 195-204.	1.3	5
4462	Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis. JTO Clinical and Research Reports, 2022, 3, 100322.	0.6	3
4463	Role of NIMAâ€•related kinase 2 in lung cancer: Mechanisms and therapeutic prospects. Fundamental and Clinical Pharmacology, 2022, 36, 766-776.	1.0	2
4464	Novel targeted therapies for advanced non-small lung cancer. Seminars in Oncology, 2022, 49, 326-336.	0.8	9
4465	RELAY+: Exploratory Study of Ramucirumab PlusÂGefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC. JTO Clinical and Research Reports, 2022, 3, 100303.	0.6	1
4466	The Root Extract of Peucedanum praeruptorum Dunn Exerts Anticancer Effects in Human Non-Small-Cell Lung Cancer Cells with Different EGFR Mutation Statuses by Suppressing MET Activity. Molecules, 2022, 27, 2360.	1.7	4
4467	Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent Î²-Catenin Activating FOXO3a Signaling. Frontiers in Oncology, 2022, 12, 855603.	1.3	3

#	Article	IF	Citations
4468	Incidence and risk factors of drugâ€induced liver injury. Liver International, 2022, 42, 1999-2014.	1.9	35
4469	The RNA editing enzyme ADAR modulated by the rs1127317 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma. Life Sciences, 2022, 296, 120408.	2.0	6
4470	Histologic transformation of epidermal growth factor receptorâ€“mutated lung cancer. European Journal of Cancer, 2022, 166, 41-50.	1.3	10
4471	Investigation of the Effects of Vitamin C on Resistance to 5-FU in Colon Cancer Cells Line HT29. Majallah-i DÄ•nishgÄh-i â€™UlÅ«m-i PizishkÄ«-i Ä³lÄ•m, 2021, 29, 49-58.	0.1	0
4472	Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. Cancers, 2022, 14, 122.	1.7	16
4473	Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	14
4474	Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery. Journal of Medicinal Chemistry, 2021, 64, 17728-17743.	2.9	29
4475	Therapeutic advances in nonâ€small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm, 2021, 2, 692-729.	3.1	38
4476	Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer. Seminars in Cancer Biology, 2022, 86, 566-582.	4.3	33
4477	Limited-Stage Small-Cell Lung Cancer: Current Progress and the Next Frontier. Radiation, 2021, 1, 317-333.	0.6	0
4478	Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. Cancers, 2022, 14, 92.	1.7	3
4479	Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review. Annals of Translational Medicine, 2021, 9, 1805-1805.	0.7	3
4480	Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models. Frontiers in Pharmacology, 2021, 12, 750031.	1.6	26
4483	The spectrum of clinical trials aiming at personalizing medicine. Chinese Clinical Oncology, 2014, 3, 13.	0.4	15
4484	Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer. Frontiers in Chemistry, 2022, 10, 837987.	1.8	8
4485	Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC. Lung Cancer Management, 2022, 11, LMT54.	1.5	3
4486	Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC. Scientific Reports, 2022, 12, 6367.	1.6	7
4487	Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. Drugs, 2022, 82, 649-662.	4.9	15

#	Article	IF	Citations
4488	Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant nonâ€“small cell lung cancer: A multicenter retrospective analysis (<scp>TOPGAN2020</scp>â€02). Thoracic Cancer, 2022, 13, 1471-1478.	0.8	5
4489	EGFR signaling pathway as therapeutic target in human cancers. Seminars in Cancer Biology, 2022, 85, 253-275.	4.3	61
4490	Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Nonâ€“Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). Lung Cancer, 2022, 168, 38-45.	0.9	5
4491	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusionâ€“Positive Cholangiocarcinoma. Cancer Discovery, 2022, 12, 1378-1395.	7.7	33
4492	Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 870636.	1.3	14
4493	A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 780186.	1.3	8
4494	Targeting EGFR, RSK1, RAF1, PARP2 and LIN28B for several cancer type therapies with newly synthesized pyrazole derivatives via a computational study. Journal of Biomolecular Structure and Dynamics, 2023, 41, 4194-4218.	2.0	4
4495	An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nature Cancer, 2022, 3, 402-417.	5.7	65
4496	Impact of preâ€existing interstitial lung abnormal shadow on lung injury development and severity in patients of nonâ€small cell lung cancer treated with osimertinib. Cancer Medicine, 2022, , .	1.3	4
4497	Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report. Frontiers in Pharmacology, 2022, 13, 854277.	1.6	4
4498	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Nonâ€“Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Cancer Discovery, 2022, 12, 1676-1689.	7.7	30
4511	Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care. American Journal of the Medical Sciences, 2022, 364, 371-378.	0.4	2
4512	Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction. Scientific Reports, 2022, 12, 6693.	1.6	21
4513	New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib. Tumori, 2012, 98, e102-4.	0.6	2
4514	A case of lung adenocarcinoma with postoperative recurrence of multiple bone metastases that showed a gradual complete response to combined administration of erlotinib and zoledronic acid. Tumori, 2014, 100, e45-8.	0.6	0
4580	Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?. Annals of Palliative Medicine, 2014, 3, 19-21.	0.5	5
4581	Drifting EGFR mutation. Chinese Clinical Oncology, 2013, 2, 3.	0.4	5
4582	Can EGFR mutation status evolve with chemotherapy?. Chinese Clinical Oncology, 2013, 2, 1.	0.4	11

#	Article	IF	Citations
4583	Perspectives in drug development for cancer therapy in Asia. Chinese Clinical Oncology, 2012, 1, 17.	0.4	1
4584	EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy. Chinese Clinical Oncology, 2013, 2, 2.	0.4	16
4585	Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. Chinese Clinical Oncology, 2015, 4, 37.	0.4	12
4586	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as â€œROS1â€•as it appears?. Lung India, 2017, 34, 405.	0.3	3
4588	Decouple-Couple Network for Drug-Resistant EGFR Mutation Subtype Prediction with Lung Cancer CT Images. , 2022, , .		0
4589	Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer. Anticancer Research, 2022, 42, 2583-2590.	0.5	5
4590	Effects of cigarette smoking on metabolic activity of lung cancer on baseline ¹⁸F-FDG PET/CT. PeerJ, 2022, 10, e13352.	0.9	0
4591	Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study. International Journal of General Medicine, 2022, Volume 15, 4453-4464.	0.8	1
4592	Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 2157.	1.7	7
4593	Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors. Science Advances, 2022, 8, eabm6638.	4.7	17
4594	Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer. Ecancermedicalscience, 0, 16, .	0.6	3
4595	Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Cancer Diagnosis & Prognosis, 2022, 2, 324-329.	0.3	5
4596	A comparison of methods for enriching network metaâ€analyses in the absence of individual patient data. Research Synthesis Methods, 2022, , .	4.2	0
4597	Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report. Journal of Geriatric Oncology, 2022, 13, 1071-1083.	0.5	2
4598	The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy. BMC Cancer, 2022, 22, 491.	1.1	6
4599	Diagnosis and Clinical Aspects of Lung Cancer: A Special Emphasis on Drug Targeting to Cancer Cells Through Nanoparticles. Letters in Drug Design and Discovery, 2022, 19, .	0.4	0
4600	Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer. International Journal of Molecular Sciences, 2022, 23, 5346.	1.8	11
4601	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nature Reviews Clinical Oncology, 2022, 19, 499-514.	12.5	140

#	Article	IF	Citations
4602	Design, Synthesis and Molecular Docking of Novel Quinazolinone Hydrazide Derivatives as EGFR Inhibitors. Chemistry and Biodiversity, 2022, 19, .	1.0	5
4603	Annexin <scp>A2</scp>: The diversity of pathological effects in tumorigenesis and immune response. International Journal of Cancer, 2022, 151, 497-509.	2.3	15
4604	Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study. ESMO Open, 2022, 7, 100473.	2.0	0
4605	The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinomaâ€"successes and challenges. Journal of Thoracic Disease, 2021, .	0.6	0
4606	New pyrimidine-5-carbonitrile derivatives as EGFR inhibitors with anticancer and apoptotic activities: design, molecular modeling and synthesis. New Journal of Chemistry, 2022, 46, 11812-11827.	1.4	3
4607	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors. Cancers, 2022, 14, 2202.	1.7	3
4608	A randomized phase <scp>II</scp> study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with nonâ€small cell lung cancer harboring <scp>EGFR</scp> mutations (<scp>JMTO LC12</scp>â€01). Thoracic Cancer, 2022, 13, 1827-1836.	0.8	2
4610	B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors. World Journal of Surgical Oncology, 2022, 20, 159.	0.8	8
4611	Machine learning-based algorithm demonstrates differences in del19 and L858R EGFR subgroups in non-small cell lung cancer: a single center experience.. American Journal of Translational Research (discontinued), 2022, 14, 2677-2684.	0.0	0
4612	Effectiveness of Rehabilitation for Cancer Patients with Bone Metastasis. Progress in Rehabilitation Medicine, 2022, 7, n/a.	0.3	0
4613	Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. Cancers, 2022, 14, 2613.	1.7	8
4614	Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. Cancers, 2022, 14, 2519.	1.7	8
4615	Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent <i>EGFR</i> T790M Mutated NSCLC: A Phase IIb Study. SSRN Electronic Journal, 0, , .	0.4	0
4616	Improving the tolerability of osimertinib by identifying its toxic limit. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211032.	1.4	16
4617	Epidermal growth factor receptor tyrosine kinase inhibitors for de novo <scp>T790M</scp> mutation: A retrospective study of 44 patients. Thoracic Cancer, 2022, 13, 1888-1897.	0.8	8
4618	Prevalence of highly actionable mutations among Indian patients with advanced nonâ€small cell lung cancer: A systematic review and metaâ€analysis. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 158-171.	0.7	0
4619	Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib. BMC Cancer, 2022, 22, .	1.1	2
4620	Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study. Journal of Thoracic Oncology, 2022, 17, 1098-1108.	0.5	51

#	Article	IF	Citations
4621	Management of Patients With Resectable and Metastatic Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 1-5.	2.3	1
4623	Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression. Cancer Management and Research, 0, Volume 14, 1891-1902.	0.9	0
4624	Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study. Journal of Thoracic Oncology, 2022, 17, 1205-1215.	0.5	12
4625	Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate, 2022, 82, .	1.2	3
4626	A narrative review of deep learning applications in lung cancer research: from screening to prognostication. Translational Lung Cancer Research, 2022, 11, 1217-1229.	1.3	8
4627	Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211032.	0.6	2
4628	Are We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?. JCO Global Oncology, 2022, , .	0.8	2
4629	Platelet Activation in High D-Dimer Plasma Plays a Role in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Mutant Lung Adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	3
4630	Prolonged durability of extensive contiguous spinal metastasis stabilization in non-small cell lung cancer patients receiving targeted therapy: two case reports and a literature review. Journal of International Medical Research, 2022, 50, 030006052211050.	0.4	1
4631	Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3366.	1.0	2
4632	Cosuppression of NF-Î²B and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer. Cancers, 2022, 14, 2940.	1.7	5
4633	Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Nonâ€“Small Cell Lung Cancer. Frontiers in Pharmacology, 0, 13, .	1.6	3
4634	TÃ€ Dá»NG KHÃ”NG MONG MUá»N TRÃŠN DA TRONG Ä‘iá»€U TRá»Š THUá»€ á»¨C CHáº¾ TYROSINE KINASE Bá»†NH NHÂN UNG THƯ CÃ“ Äá»˜T Biáº¾N EGFR. Y Hoc Viet Nam, 2022, 515, .	0.0	0
4635	Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma. Micromachines, 2022, 13, 897.	1.4	2
4636	Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis. World Journal of Clinical Cases, 2022, 10, 6360-6369.	0.3	2
4637	Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors. European Journal of Medicinal Chemistry, 2022, 238, 114492.	2.6	5
4638	Rapid Intraoperative Ki-67 Immunocytochemistry for Lung Cancer Using Non-Contact Alternating Current Electric Field Mixing. SSRN Electronic Journal, 0, , .	0.4	0
4639	The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure. The Showa University Journal of Medical Sciences, 2022, 34, 64-77.	0.1	0

#	Article	IF	Citations
4641	Erlotinib with or without bevacizumab as a firstâ€line therapy for patients with advanced nonsquamous epidermal growth factor receptorâ€positive nonâ€small cell lung cancer: Exploratory subgroup analyses from the phase <scp>II JO25567</scp> study. Thoracic Cancer, 2022, 13, 2192-2200.	0.8	5
4642	EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors. Journal of Thoracic Disease, 2022, 14, 2254-2267.	0.6	4
4643	Clinical Experience on Use of Oral EGFR-TKIs as First-line Treatment of Advanced NSCLC from a Tertiary Care Centre in North India and Implications of Skin Rash. The Indian Journal of Chest Diseases & Allied Sciences, 2022, 56, 149-152.	0.1	5
4644	A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and GiotrifÂ® in healthy Chinese subjects. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
4645	The Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Predicting Treatment Response Before EGFR TKI Treatment in Patients with Advanced Lung Adenocarcinoma. Molecular Imaging and Radionuclide Therapy, 2022, 31, 104-113.	0.3	1
4646	Comparison of T790M Acquisition After Treatment With First- and Second-Generation Tyrosine-Kinase Inhibitors: A Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 0, 12, .	1.3	3
4648	Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Clinical Oncology, 2022, 34, e451-e462.	0.6	6
4649	Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis. Cancers, 2022, 14, 3362.	1.7	1
4650	Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Oncogene, 2022, 41, 3953-3968.	2.6	4
4651	Fbxo45â€mediated <scp>NPâ€STEP₄₆</scp> degradation via <scp>K6</scp>â€linked ubiquitination sustains <scp>ERK</scp> activity in lung cancer. Molecular Oncology, 2022, 16, 3017-3033.	2.1	2
4652	Clinically-meaningful improvements in therapy for unresectable NSCLC. Expert Review of Anticancer Therapy, 2022, 22, 927-937.	1.1	6
4653	MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential. Diagnostics, 2022, 12, 1610.	1.3	10
4654	Neuronal survival factor <scp>VGF</scp> promotes chemoresistance and predicts poor prognosis in lung cancers with neuroendocrine feature. International Journal of Cancer, 2022, 151, 1611-1625.	2.3	4
4655	Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitorsâ€”Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?. Cancers, 2022, 14, 3323.	1.7	0
4656	Gefitinib in patients with advanced non-small-cell lung cancer. Pneumonologia I Alergologia Polska, 2012, 80, 439-449.	0.6	1
4657	Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. Annals of the Academy of Medicine, Singapore, 2015, 44, 449-462.	0.2	2
4658	Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report. International Journal of Cancer Care and Delivery, 2022, 2, .	0.0	0
4659	Various recurrence dynamics for non-small cell lung cancer depending on pathological stage and histology after surgical resection. Translational Lung Cancer Research, 2022, 11, 1327-1336.	1.3	6

#	Article	IF	Citations
4660	Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease. Drugs in Context, 0, 11, 1-10.	1.0	1
4661	The story of EGFR: from signaling pathways to a potent anticancer target. Future Medicinal Chemistry, 2022, 14, 1267-1288.	1.1	11
4662	The clinical significance and function of EGFR mutation in TKI treatments of NSCLC patients. Cancer Biomarkers, 2022, 35, 119-125.	0.8	1
4663	MiR-21/Sonic Hedgehog (SHH)/PI3K/AKT Pathway is Associated with NSCLC of Primary EGFR-TKI Resistance. Oncologie, 2022, 24, 579-590.	0.2	3
4664	Lazertinib: on the Way to Its Throne. Yonsei Medical Journal, 2022, 63, 799.	0.9	7
4665	The predictive value of 18F-FDG PET/CT in an EGFR-mutated lung adenocarcinoma population. Translational Cancer Research, 2022, 11, 2338-2347.	0.4	2
4666	Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. Diagnostics, 2022, 12, 1799.	1.3	7
4667	The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia. F1000Research, 0, 11, 853.	0.8	0
4668	Non-small-cell lung cancer: how to manage EGFR-mutated disease. Drugs in Context, 0, 11, 1-17.	1.0	3
4669	Use of thyroid transcription factor 1 and napsin A to predict local failure and survival after Gamma Knife radiosurgery in patients with brain metastases from lung adenocarcinoma. Journal of Neurosurgery, 2023, 138, 663-673.	0.9	0
4670	Molecular modelling of antiproliferative inhibitors based on SMILES descriptors using Monte-Carlo method, docking, MD simulations and ADME/Tox studies. Molecular Simulation, 2022, 48, 1575-1591.	0.9	12
4671	18F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-small cell lung cancer. Clinical Lung Cancer, 2022, 23, 608-619.	1.1	5
4672	Identifying and characterizing drug sensitivity-related lncRNA-TF-gene regulatory triplets. Briefings in Bioinformatics, 0, , .	3.2	0
4673	Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies. Frontiers in Genetics, 0, 13, .	1.1	10
4674	Retrospective analysis of independent predictors of progressionâ€free survival in patients with <scp>EGFR mutationâ€positive</scp> advanced nonâ€small cell lung cancer receiving firstâ€line osimertinib. Thoracic Cancer, 2022, 13, 2741-2750.	0.8	5
4675	Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Nonâ€“Small-Cell Lung Cancer With Mutated EGFR. Journal of Clinical Oncology, 2022, 40, 3587-3592.	0.8	26
4676	Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities. Anti-Cancer Drugs, 2022, 33, 1139-1144.	0.7	3
4677	Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations. Cellular Oncology (Dordrecht), 2022, 45, 913-930.	2.1	1

#	Article	IF	Citations
4678	Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece. Future Oncology, 0, , .	1.1	0
4679	T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock		
4680	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. Frontiers in Oncology, 0, 12, .	1.3	4
4681	EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022. Expert Review of Anticancer Therapy, 2022, 22, 1115-1125.	1.1	2
4682	Current treatments for non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	1.3	18
4683	Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis. Future Oncology, 0, , .	1.1	1
4684	Pan-cancer efficacy of pralsetinib in patients with RET fusionâ€“positive solid tumors from the phase 1/2 ARROW trial. Nature Medicine, 2022, 28, 1640-1645.	15.2	83
4685	Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
4686	Label-free visualization of cellular response to molecularly targeted agents using multiplex CARS and THG (coherent anti-Stokes Raman scattering and third harmonic generation) microscopy. Applied Physics Express, 0, , .	1.1	0
4687	Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Frontiers in Immunology, 0, 13, .	2.2	19
4688	Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with inÂvitro antitumor activity towards non-small lung cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 2265-2282.	2.5	13
4689	P21-activated kinase 2-mediated Î²-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer. Oncogene, 0, , .	2.6	5
4690	An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	1.3	4
4691	PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug. Pathology Research and Practice, 2022, 237, 154065.	1.0	1
4692	Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients. Lung Cancer, 2022, 172, 86-93.	0.9	4
4693	Rapid intraoperative Ki-67 immunohistochemistry for lung cancer using non-contact alternating current electric field mixing. Lung Cancer, 2022, 173, 75-82.	0.9	1
4694	A High Number of Co-Occurring Genomic Alterations Detected by NGS is Associated with Worse Clinical Outcomes in Advanced EGFR-Mutant Lung Adenocarcinoma: Data from LATAM Population. SSRN Electronic Journal, 0, , .	0.4	0
4695	The Interface of Cancer, Their Microenvironment and Nanotechnology. Oncologie, 2022, 24, 371-411.	0.2	2

#	Article	IF	Citations
4696	Translational Research in Lung Cancer. Medical Radiology, 2022, , .	0.0	0
4697	Targeted Therapies in Non-small Cell Lung Cancer. Medical Radiology, 2022, , .	0.0	1
4698	Adverse Event Profiles of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Adenocarcinoma Lung Patients in North Sumatera Population. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 134-137.	0.1	0
4699	A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11). Clinical Lung Cancer, 2022, 23, e536-e539.	1.1	7
4700	Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer. Cancer Research and Treatment, 2023, 55, 112-122.	1.3	1
4701	Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors. Chemical and Pharmaceutical Bulletin, 2022, 70, 637-641.	0.6	3
4702	Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations. BMC Cancer, 2022, 22, .	1.1	0
4704	EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy. Investigational New Drugs, 2022, 40, 1342-1349.	1.2	3
4705	Prognostic Value of Combination of Controlling Nutritional Status and Tumor Marker in Patients with Radical Non-Small-Cell Lung Cancer. Disease Markers, 2022, 2022, 1-12.	0.6	1
4706	Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study. International Journal of Molecular Sciences, 2022, 23, 10661.	1.8	2
4707	KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma. BioMed Research International, 2022, 2022, 1-9.	0.9	3
4709	Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. Frontiers in Oncology, 0, 12, .	1.3	3
4711	Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis. Cancer Research, 2022, 82, 3751-3762.	0.4	0
4712	High levels of <scp>AXL</scp> expression in untreated <scp>EGFR</scp>â€mutated nonâ€small cell lung cancer negatively impacts the use of osimertinib. Cancer Science, 2023, 114, 606-618.	1.7	9
4713	Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature. European Radiology, 2023, 33, 825-835.	2.3	10
4714	Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. International Journal of Molecular Sciences, 2022, 23, 11353.	1.8	6
4715	Comparison of aprepitant versus desloratadine for EGFRâ€TKIâ€induced pruritus: A randomized phase 2 clinical trial. Cancer, 2022, 128, 3969-3976.	2.0	3
4716	Comparison of nextâ€generation sequencing and cobas <scp>EGFR</scp> mutation test v2 in detecting <scp>EGFR</scp> mutations. Thoracic Cancer, 2022, 13, 3217-3224.	0.8	6

#	Article	IF	Citations
4717	Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma. Journal of Oncology, 2022, 2022, 1-10.	0.6	4
4718	Histologic transformation in lung cancer: when one door shuts, another opens. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211305.	1.4	3
4719	Sequential treatment in advanced nonâ€“small cell lung cancer harboring EGFR mutations. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662211327.	1.0	6
4720	Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. , 2022, , 251-267.		0
4721	Emerging genetic biomarkers in lung adenocarcinoma. SAGE Open Medicine, 2022, 10, 205031212211323.	0.7	1
4722	Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. Acta OncolÃ³gica, 2022, 61, 1347-1353.	0.8	2
4723	New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. Current Treatment Options in Oncology, 2022, 23, 1626-1644.	1.3	10
4725	Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs, 2022, 36, 717-729.	2.2	3
4726	Integrated Tissue and Blood miRNA Expression Profiles Identify Novel Biomarkers for Accurate Non-Invasive Diagnosis of Breast Cancer: Preliminary Results and Future Clinical Implications. Genes, 2022, 13, 1931.	1.0	1
4727	<scp>TAS2940</scp>, a novel <scp>brainâ€penetrable panâ€ERBB</scp> inhibitor, for tumors with HER2 and EGFR aberrations. Cancer Science, 2023, 114, 654-664.	1.7	3
4729	Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients. Cancers, 2022, 14, 5095.	1.7	5
4731	Landscape of the clinical development of China innovative anti-lung cancer drugs. , 2023, 1, 67-75.		2
4732	Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis. Journal of Oncology, 2022, 2022, 1-9.	0.6	0
4733	Advanced Lung Cancer Patientsâ€™ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada. Current Oncology, 2022, 29, 8043-8073.	0.9	1
4734	Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients â€“ an overview. Frontiers in Oncology, 0, 12, .	1.3	2
4736	Multiple mutations in the EGFR gene in lung cancer: a systematic review. Translational Lung Cancer Research, 2022, 11, 2148-2163.	1.3	6
4737	Hazard Function Analysis of Recurrence in Patients with Curatively Resected Lung Cancer: Results from the Japanese Lung Cancer Registry in 2010. Cancers, 2022, 14, 5119.	1.7	0
4739	A novel RP-HPLC method development and validation for simultaneous quantification of gefitinib and resveratrol in polymeric hybrid lipid nanoparticles and glioma cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1212, 123483.	1.2	3

#	Article	IF	Citations
4740	The LCNetWork: An electronic representation of the mRNA-lncRNA-miRNA regulatory network underlying mechanisms of non-small cell lung cancer in humans, and its explorative analysis. Computational Biology and Chemistry, 2022, 101, 107781.	1.1	1
4741	Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review. Annals of Translational Medicine, 2022, .	0.7	0
4742	Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade. Annals of the Academy of Medicine, Singapore, 2017, 46, 333-338.	0.2	4
4743	The Latest Information on Chemotherapy for Patients with Advanced Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 2441-2448.	0.0	0
4745	Phenolic diterpenes from Rosemary supercritical extract inhibit non-small cell lung cancer lipid metabolism and synergise with therapeutic drugs in the clinic. Frontiers in Oncology, 0, 12, .	1.3	4
4746	3â€²,4â€²,5â€²-trimethoxy- and 3,4-dimethoxychalcones targeting A549 cells: Synthesis, cytotoxic activity, and molecular docking. Journal of Molecular Structure, 2023, 1275, 134572.	1.8	1
4747	Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2023, 165, 1682-1693.e3.	0.4	2
4748	Changes in survival of patients with nonâ€“small cell lung cancer in Japan: An interrupted time series study. Cancer Science, 2023, 114, 1154-1164.	1.7	3
4749	Chloroquine induces transitory attenuation of proliferation of human lung cancer cells through regulation of mutant P53 and YAP. Molecular Biology Reports, 0, , .	1.0	0
4750	A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations. Nature Communications, 2022, 13, .	5.8	10
4751	Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. Clinical Chemistry and Laboratory Medicine, 2023, 61, 906-920.	1.4	4
4752	A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population. Lung Cancer, 2022, 174, 133-140.	0.9	5
4753	Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges. , 2022, 13, 1615.		21
4754	Pseudogene DUXAP10 contributes to Gefitinib resistance in NSCLC via repressing OAS2 expression. Acta Biochimica Et Biophysica Sinica, 2022, , .	0.9	1
4755	A peptide derived from adaptor protein STAP-2 inhibits tumor progression by downregulating epidermal growth factor receptor signaling. Journal of Biological Chemistry, 2023, 299, 102724.	1.6	3
4756	Palliative External Beam Thoracic Radiation Therapy of Non-small Cell Lung Cancer. Medical Radiology, 2022, , .	0.0	0
4757	Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer. Integrative Cancer Therapies, 2022, 21, 153473542211443.	0.8	3
4758	Novel insights into histone lysine methyltransferases in cancer therapy: From epigenetic regulation to selective drugs. Journal of Pharmaceutical Analysis, 2023, 13, 127-141.	2.4	6

#	Article	IF	Citations
4759	Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. BMC Pulmonary Medicine, 2022, 22, .	0.8	2
4760	The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis. Journal of Modern Oncology, 2022, 24, 340-344.	0.1	0
4761	Epidermal growth factor receptor tyrosine kinase inhibitors for nonâ€small cell lung cancer harboring uncommon <scp>EGFR</scp> mutations: Realâ€world data from Taiwan. Thoracic Cancer, 2023, 14, 12-23.	0.8	8
4762	Immune micro-environment and drug analysis of peritoneal endometriosis based on epithelial-mesenchymal transition classification. Frontiers in Endocrinology, 0, 13, .	1.5	1
4763	Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer. Genes, 2022, 13, 2183.	1.0	3
4764	The bleeding risk and safety of repeated bronchoscopies with tissue sampling in patients with pulmonary lesions. Expert Review of Respiratory Medicine, 0, , 1-6.	1.0	0
4765	Side effects of tyrosine kinase inhibitors therapy in patients with nonâ€‘small cell lung cancer and associations with EGFR polymorphisms: A systematic review and metaâ€‘analysis. Oncology Letters, 2022, 25, .	0.8	10
4766	A systematic review of epidermal growth factor receptor tyrosine kinase inhibitor-induced heart failure and its management. The Egyptian Journal of Internal Medicine, 2022, 34, .	0.3	1
4767	Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 2023, 22, 213-234.	21.5	69
4769	Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights. Molecules, 2022, 27, 8901.	1.7	4
4770	Effect of EGFR amplification on the prognosis of EGFR-mutated advanced nonâ€“small-cell lung cancer patients: a prospective observational study. BMC Cancer, 2022, 22, .	1.1	0
4771	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Molecular Biomedicine, 2022, 3, .	1.7	8
4772	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. Journal of Hematology and Oncology, 2022, 15, .	6.9	46
4774	Nonâ€small cell lung cancer with <scp> EGFR </scp> (<scp>L858R</scp> and <scp>E709X</scp>) and <scp>CNNB1</scp> mutations responded to afatinib. Thoracic Cancer, 0, , .	0.8	1
4775	Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. International Journal of Molecular Sciences, 2022, 23, 15056.	1.8	32
4776	<scp>FBP1</scp> induced by Î²â€elemene enhances the sensitivity of gefitinib in lung cancer. Thoracic Cancer, 2023, 14, 371-380.	0.8	6
4777	Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. Journal of Clinical Investigation, 2023, 133, .	3.9	6
4778	Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2023, 72, 1699-1707.	2.0	2

#	Article	IF	Citations
4779	Traditional Herbal Medicine: A Potential Therapeutic Approach for Adjuvant Treatment of Non-small Cell Lung Cancer in the Future. Integrative Cancer Therapies, 2022, 21, 153473542211443.	0.8	6
4780	Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. Frontiers in Pharmacology, 0, 13, .	1.6	2
4781	Efficacy and safety of antiangiogenic agents or chemotherapy plus <scp>EGFRâ€TKIs</scp> in advanced nonâ€small cell lung cancer: A systematic review and network metaâ€analysis. Thoracic Cancer, 0, , .	0.8	2
4782	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nature Reviews Clinical Oncology, 2023, 20, 143-159.	12.5	29
4784	High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population. Journal of Thoracic Disease, 2023, 15, 101-111.	0.6	2
4785	Ten-year trends in the treatment and intervention timing for patients with metastatic spinal tumors: a retrospective observational study. Journal of Orthopaedic Surgery and Research, 2023, 18, .	0.9	1
4786	Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study. Journal of Clinical Medicine, 2023, 12, 236.	1.0	2
4787	Autocrine <scp>EGF</scp> and <scp>TGF</scp> â€Î± promote primary and acquired resistance to <scp>ALK</scp> / <scp>câ€Met</scp> kinase inhibitors in nonâ€smallâ€cell lung cancer. Pharmacology Research and Perspectives, 2023, 11, .	1.1	2
4788	Apoptosis signaling in EGFR inhibitor resistance in NSCLC. , 2023, , 71-88.		0
4789	Synthesis, Molecular Dynamics Simulation, and In-vitro Antitumor Activity of Quinazoline-2,4,6-triamine Derivatives as Novel EGFR Tyrosine Kinase Inhibitors. Iranian Journal of Pharmaceutical Research, 2023, 21, .	0.3	2
4790	Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer. Anticancer Research, 2023, 43, 725-732.	0.5	1
4791	Deep learning for predicting epidermal growth factor receptor mutations of non-small cell lung cancer on PET/CT images. Quantitative Imaging in Medicine and Surgery, 2023, 13, 1286-1299.	1.1	3
4792	The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review. Journal of Thoracic Disease, 2023, 15, 747-758.	0.6	2
4793	Survival benefit of thoracic radiotherapy plus EGFR-TKIs in patients with non-oligometastatic advanced non-small-cell lung cancer: a single-center retrospective study. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311614.	1.4	2
4794	Physical Sciences in Cancer: Recent Advances and Insights at the Interface. Current Cancer Research, 2023, , 301-328.	0.2	0
4795	Efficacy of combined transbronchial lung cryobiopsy and conventional forceps biopsy for lung malignancies: a prospective cohort study. Scientific Reports, 2023, 13, .	1.6	4
4796	Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST). International Journal of Molecular Sciences, 2023, 24, 5411.	1.8	2
4797	Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. European Journal of Cancer, 2023, 185, 83-93.	1.3	10

#	Article	IF	Citations
4798	Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients. Analytical Biochemistry, 2023, 669, 115115.	1.1	1
4799	Rare case of de novo EGFR L718V mutation-positive non-small cell lung cancer successfully treated with afatinib. Current Problems in Cancer Case Reports, 2023, 10, 100228.	0.1	0
4800	NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature. Current Problems in Cancer Case Reports, 2023, 10, 100232.	0.1	0
4801	Analysis of the in vitro function and internalization ability of a humanized EGFR antibody AE01 expressed by Chinese hamster ovary cells. Protein Expression and Purification, 2023, 206, 106243.	0.6	1
4802	EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis. International Immunopharmacology, 2023, 119, 110001.	1.7	3
4803	Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. Cancers, 2023, 15, 629.	1.7	7
4804	Novel 4-arylaminoquinazoline derivatives: design, synthesis, crystal structure and biological evaluation as potent antitumor agents. Molecular Crystals and Liquid Crystals, 0, , 1-19.	0.4	0
4805	Precision Oncology: Grundlagen und Klassifikationen. Springer Reference Medizin, 2022, , 1-7.	0.0	0
4807	Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Nonâ€“Small Cell Lung Cancer in Patients With Brain Metastases. JAMA Network Open, 2023, 6, e2255050.	2.8	8
4808	Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelialâ€“Mesenchymal Transition. Cancers, 2023, 15, 1092.	1.7	1
4809	GLUT1 and PKM2 may be useful prognostic predictors in patients with nonâ€‘small cell lung cancer following curative R0 resection. Oncology Letters, 2023, 25, .	0.8	0
4810	CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell, 2023, 41, 340-355.e6.	7.7	23
4811	The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study. Annals of Translational Medicine, 2023, 11, 157-157.	0.7	2
4812	Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward. OncoTargets and Therapy, 0, Volume 16, 99-108.	1.0	4
4813	Comparison of the radiomics-based predictive models using machine learning and nomogram for epidermal growth factor receptor mutation status and subtypes in lung adenocarcinoma. Physical and Engineering Sciences in Medicine, 2023, 46, 395-403.	1.3	1
4814	Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors. Neoplasia, 2023, 38, 100888.	2.3	2
4815	Machine Learning in Lung Cancer Radiomics. , 2023, 20, 753-782.		1
4816	Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC. International Journal of Molecular Sciences, 2023, 24, 4126.	1.8	3

#	Article	IF	Citations
4817	Rare molecular subtypes of lung cancer. Nature Reviews Clinical Oncology, 2023, 20, 229-249.	12.5	20
4818	Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement. Cancer Imaging, 2023, 23, .	1.2	0
4819	Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes. BMC Medicine, 2023, 21, .	2.3	1
4820	Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations. Thoracic and Cardiovascular Surgeon, 0, , .	0.4	0
4821	Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage IIIâ€“IV lung adenocarcinoma. Siberian Journal of Oncology, 2023, 22, 5-14.	0.1	0
4822	Uncommon EGFR-Mutant NSCLCâ€”One Drug Does Not Fit All. JTO Clinical and Research Reports, 2023, 4, 100477.	0.6	0
4823	Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. Current Medical Science, 2023, 43, 1-12.	0.7	1
4824	The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2023, 24, 4827.	1.8	1
4825	Intracranial efficacy and safety of furmonertinib 160â€‰mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy. BMC Cancer, 2023, 23, .	1.1	4
4826	Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. Critical Reviews in Oncology/Hematology, 2023, 184, 103954.	2.0	3
4827	Urban-Rural and Socioeconomic Differences in Patient Knowledge and Perceptions of Genomic Tumor Testing. JCO Precision Oncology, 2023, , .	1.5	2
4828	Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. BMC Cancer, 2023, 23, .	1.1	5
4829	Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. Cancers, 2023, 15, 1766.	1.7	6
4830	Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naÃ¯ve ALK-positive advanced lung adenocarcinoma. Frontiers in Oncology, 0, 13, .	1.3	0
4831	Next-generation sequencing of non-small cell lung cancer at a Quebec health care cancer centre. Cancer Treatment and Research Communications, 2023, 35, 100696.	0.7	2
4832	Safety analysis of antineoplastic drugs for lung cancer: a retrospective analysis based on Shaanxi Province in Western China. Expert Opinion on Drug Safety, 2024, 23, 99-105.	1.0	1
4833	Simultaneous and Rapid Determination of Plasma Concentrations of Four Tyrosine Kinase Inhibitors Using Liquid Chromatography/Tandem Mass Spectrometry in Patients with Nonâ€“Small Cell Lung Cancer. Chromatography, 2023, , .	0.8	1
4834	Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib. Cancers, 2023, 15, 2019.	1.7	1

#	Article	IF	Citations
4835	Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid <scp>cellâ€free DNA</scp> from <scp>nonâ€small</scp>â€cell lung cancer patients with leptomeningeal metastases. Thoracic Cancer, 2023, 14, 1251-1259.	0.8	5
4836	Prolonged response to firstâ€generation tyrosine kinase inhibitor in a metastatic nonâ€small cell lung cancer harbouring complex <scp>G719X</scp> and <scp>S768I</scp> mutations: A case report from Vietnam and literature review. Respirology Case Reports, 2023, 11, .	0.3	1
4837	Constructed Tumor-Targeted and MMP-2 Biocleavable Antibody Conjugated Silica Nanoparticles for Efficient Cancer Therapy. ACS Omega, 2023, 8, 12752-12760.	1.6	2
4838	Recent progress of biosensors for the detection of lung cancer markers. Journal of Materials Chemistry B, 2023, 11, 5715-5747.	2.9	6
4839	Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study. BMC Cancer, 2023, 23, .	1.1	0
4841	A systematic review of genetic ancestry as a risk factor for incidence of non-small cell lung cancer in the US. Frontiers in Genetics, 0, 14, .	1.1	3
4843	Global burden and trends of lung cancer incidence and mortality. Chinese Medical Journal, 2023, 136, 1583-1590.	0.9	11
4844	å'¼å¸å™¨å—çš'é˜åŸŸã«ãŠã'ã‚‹æ°—é•'ç‹ç‚„ã®æ²»ç™‚. Nihon Kikan Shokudoka Gakkai Kaiho, 2023, 74, 103-105.	0.0	0
4845	The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis. Disease Markers, 2023, 2023, 1-8.	0.6	2
4846	An 83â€yearâ€old patient with <scp>RET</scp> fusionâ€positive nonâ€small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration. Respirology Case Reports, 2023, 11, .	0.3	1
4847	Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer. Frontiers in Oncology, 0, 13, .	1.3	0
4848	Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations. Cancer Immunology, Immunotherapy, 0, , .	2.0	1
4849	Role of molecular testing for malignant pleural effusion in targeted therapy for advanced nonâ€small cell lung cancer. Diagnostic Cytopathology, 2023, 51, 397-405.	0.5	0
4850	Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer. European Journal of Cancer, 2023, 188, 81-89.	1.3	3
4851	Targeted therapy. , 2023, , 205-411.		0
4854	Genetic and Epigenetic Dysregulation in Environmental Disease. , 2024, , 465-492.		0
4855	Precision medicine-based cancer care. , 2024, , 272-283.		0
4907	Evaluation des Nutzens. , 2023, , 37-179.		0

#	Article	IF	Citations
4910	Precision Oncology: Grundlagen und Klassifikationen. Springer Reference Medizin, 2023, , 1321-1327.	0.0	0
4935	Molecular testing in lung cancer. , 2024, , 319-337.		0
4945	Precision clinical genomics and single subject studies of multi-omics data. , 2024, , 41-56.		0
4952	Epidermal growth factor receptorâ€“mutated nonâ€“small cell lung cancer: a clinical approach. , 2024, , 217-252.		0
4955	Treatment of Stage IV Non-small Cell Lung Cancer. Respiratory Medicine, 2023, , 165-186.	0.1	0
4983	Molecular Pathology of Lung Tumors. , 2023, , 231-245.		0
5030	Synergistic Potential of Antigen-Specific Vaccines and Immunomodulatory Agents for Lung Cancer Treatment. , 2024, , 317-330.		0